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SUMMARY
In Section 1, the effects of intraperitoneal administration
of the DA receptor agonist apomorphine, the DA releasing agent
amphetamine and the DA receptor antagonist haloperidol on DA
metabolism in the corpus striatum and the substantia nigra of the
rat brain are described. The concentrations of the main DA
metabolites, HVA and DOPAC, were determined in these regions at
various doses and time-intervals with the aim of elucidating the
mechanism of regulation of DA metabolism at the two ends of the
nigrostriatal DAergic pathway. On the basis of the observed
similarities and differences in the drug-induced changes of the
metabolite concentrations in the DA cell body area of substantia
nigra and the DA nerve terminal area of corpus striatum, the
hypothesis that DA released from the dendrites of DAergic neurons
in the substantia nigra acts on DA 'autoreceptors' located on the
same neurons to regulate the activity of the nigrostriatal DAergic
pathway was examined. Parallel to that,or alternative mechanisms
were proposed to exist and regulate locally and independently the
DAergic neuronal activity in the two areas.
In Section 2, the biochemical effects of lesions of the
substantia nigra caused by 6-hydroxy—dopamine injected stereo-
taxically into this area were analysed. The primary effects of the
lesion on DA concentration in the striatum were correlated with the
observed changes in HVA and DOPAC in the same region. Hyperactivity
r
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of the remaining intact neurons was suggested on the basis of the
finding that lesions decreasing over 90$ of striatal DA produced only
30-50$ reduction of the metabolite levels. Administration of
apomorphine did not alter the concentrations of HVA and DOPAC in the
denervated striatum, whereas haloperidol produced marked increases in
the metabolite levels on both sides, but higher percentage rise on the
intact side. These findings were suggestive of a presynaptic effect
of apomorphine on DA metabolism, whereas haloperidol could mainly be
acting at postsynaptic receptor sites to cause an increase in DA
turnover.
The effect of the lesion on the cholinergic system was
assessed by measuring the activity of the enzyme choline acetyl-
transferase (CAT) which synthesises Achj the effect on the
GABergic system was assessed by measuring the concentration of GABA
and the activity of its synthesising enzyme glutamic acid
decarboxylase (GAD)• The neuronal interconnections of the DAergic
with the other two systems were investigated after severing
selectively the nigrostriatal pathway. The lesions resulted in
increased GAD and GABA as well as CAT in the ipsilateral striatum}
a reduction of GAD, GABA and CAT was found in the lesioned
substantia nigra. An activation of the GABergic and cholinergic
neurons of the striatum seemed to result from the lesion,
suggesting an inhibitory influence of the intact DAergic input on
these neurons. Treatment of the animals with apomorphine or
haloperidol revealed a correlation between the activity of the
GABA-containing neurons in the lesioned side of the substantia nigra
and the supersensitive behavioural response of this side to DA
receptor stimulation. A model of the intranigral and intrastriatal
- 3 -
neuronal interrelations was proposed on the basis of the findings
of this study.
In Section 3, the acute and the chronic treatment of rats
with neuroleptic drugs were compared, in order to establish
biochemical correlates of the reported tolerance which develops
to some of their effects. The effects on the DA-, GABA- and
Ach-containing neurons were investigated and several points
regarding the neuronal interconnections in the striatum and the
substantia nigra were assessed. A comparison was attempted of
the biochemical findings accompanying the 6-OH-DA lesions of the
substantia nigra and chronic neuroleptic treatment of rats and
Parkinson's disease in humans; the similarities and differances
were outlined.
In Section 4t the effects of administration of L-tryptophan,
either alone or in combination with MAO inhibitors (given acutely or
chronically) on the metabolism of DA and NA in the rat brain are
described. The resulting marked increase in 5-HT seems to cause an
increase in the turnover of the catecholamines, probably as a
consequence of release by displacement caused by the 5-HT that
spills over their neurons. On the basis of comparison of these
effects with those of amphetamine, it was concluded that
Lr-tryptophan plus a MAO inhibitor may act like the catecholamine-
releasing agent to cause the reported beneficial effects in manio-
depressive illness.
In Section 5» the influence of the 5-HT system on the
nigrostriatal DAergic pathway was examined, using a different approach
than the one employed in Section 4» Selective asymmetric electrolytic
lesions of the median raphe (MR) and the dorsal raphe (DR) nuclei
of the rat brain were made. A combination of histological, biochemical
- 4 -
and behavioural studies were employed and the results suggested
that the two nuclei project to different sites of the nigro-
striatal DAergic pathway and, therefore, influence its function in
a different manner. It was concluded that the MR nucleus
unilaterally innervates the striatum, whereas the DR nucleus
unilaterally innervates the substantia nigra. The behavioural
studies suggested and the biochemical data demonstrated
convincingly that these innervations are inhibitory on the target
DAergic neuronB, since removal of either of these serotonergic
projections resulted in an increase of DA turnover in the
respective terminal area. A rat turning model was demonstrated
following asymmetric raphe lesions. Thus, lesions of the ICR
resulted in turning contralateral to the lesion upon the administration
of apomorphine or amphetamine} lesions of the DR resulted in
ipsilateral turning upon the administration of the same drugs.
Furthermore, administration of the 5-HT receptor agonist
5-methoxy-N,W-dimethyltryptamine caused turning in opposite
directions than apomorphine or amphetamine with both types of
lesion. Combinations of drugs thought to act specifically either
on the DAergic or on the serotonergic system were given and their
effect on turning behaviour assessed. A model was proposed
incorporating the serotonergic afferents to the substantia nigra
and the striatum, together with the other neuronal connections which
axe believed to exert an influence on the function of the nigro-
striatal DAergic pathway.
In the Appendix, the methodology of estimation of DA
metabolites (HVA and DOPAC) in brain tissue is described. The
original gas liquid chromatographic method of Pearson and Sharman
was modified, to improve its recovery, decrease its complexity and
- 5 -
increase its specifioity. The modified assay procedure enabled the
estimation of HVA and DOPAC in small discrete areas of the rat
brain.
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DOPAMINE METABOLISM IN CORPUS STRIATUM, SUBSTANTIA NIGRA
AND OTHER RAT BRAIN REGIONS
1.1 INTRODUCTION
1.1.1 Distribution of dopamine in brain
Dopamine (DA) has been biochemically demonstrated in various areas
of the brain (1,2) and this provided evidence for a possible DAergic
(that is, DA-containing) system in the brain. The Falck and Hi Harp
histochemical technique provided the first evidence of cellular local¬
isation of DA (3,4)- Subsequent work described the detailed local¬
isation of the DA cell bodies and nerve terminals (5,6).
The well known nigro-striatal DAergic (that is, DA-containing)
pathway originates from the area pars compacta of the substantia nigra
(cell group A9 according to Dahlstrom and Fuxe) (5), and from the
adjacent ventrolateral mesencephalic reticular formation (cell group A8)
(7,8). The DA-containing fibres ascend in the area ventralis tegmenti,
enter into the medial forebrain bundle, pass into the internal capsule
in mid—hypothalamus, and reach the striatum (nucleus caudatus-putamen)
through the globus pallidus (8).
The mesolimbic DA system originates from the A10 cell bodies,
located medial to the pars compacta, surrounding the nucleus interpedun-
cularis and mixed with the occulomotor nerve fibres. The axons ascend
more medially than the nigrostriatal fibres and terminate in the
nucleus accumbens, olfactory tubercle and the septal nuclei (8,9)«
The tubero-infundibular DA neuronal system originates mainly from
the cell bodies in the nucleus arcuatus (cell group A12) and the ventral
part of the anterior periventricular hypothalamic nucleus and innervates the
external layer of the median eminence (10). A number of catecholamine-
containing nerve cells (probably DA-containing) have also been found
throughout most of the rostral periventricular hypothalamic area (11),
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named A14» A retina DAr-containing neuronal system has also been demon-
strated (12), and by the use of a variety of methods DA-containing nerve
terminals have been observed in the cerebral cortex (13,14) as well as
the frontal and anterior limbic cortices of the rat brain (9).
Biochemical estimations of regional DA concentrations and tyro¬
sine hydroxylase activities (15) provided further evidence concerning
the distribution of DA in the rat brain.
A DA-sensitive adenylate cyclase, thought to be associated with the
DA receptors (16) has been localised in and isolated from various parts
of the rat brain, such as the oorpus striatum (17)» substantia nigra
(18), cerebral cortex (l9)» nucleus accumbens and olfactory tuberole
(20).
1.1.2 Dopamine metabolism
DA in the rat brain is metabolised by the action of the enzymes
monoamine oxidase (MAO), catechol-o-methyl transferase (COMT) and in¬
directly aldehyde dehydrogenase (ADH) (21). 3,4-Dihydroxyphenyl acetic
acid (DOPAC), horaovanillic acid (HVA) and 3~methoxytyramine are con¬
sidered as the three main products of DA degradation (2l). DOPAC is
only partially Q-methylated to HVA, whereas the formation of HVA through
methoxytyramine is unlikely (22), DOPAC turnover probably reflects DA
turnover (22), though HVA has been proposed for the same role (23). The
presence of both free and conjugated with sulphate or glucuronide HVA
and DOPAC in areas of the rat brain, Buch as the striatum, the olfactory
tubercle and the frontal cortex has been demonstrated (24).
Roth et al. (25) have suggested that short term changes in brain
levels of DOPAC provide a useful index of alterations in the functional
activity of central DAergic neurons, since drugs which increase impulse
- 9 -
flow in the nigrostriatal or mesolimbic DA neurons increase DOPAC
levels in the rat striatum and olfactory tubercle, and drugs which
reduce impulse flow lead to a reduction in DOPAC. According to this
model, during periods of increased impulse flow when more transmitter
is utilised, synthesis should be accelerated, and during periods of
decreased impulse flow transmitter synthesis should be retarded as a
result of decreased utilisation and a build up of transmitter. This
is consistent with results obtained in both peripheral (26) and cen¬
tral (27) noradrenergic neurons, where increases and decreases in
neuronal activity appear to be well correlated with increases or
decreases in noradrenaline metabolism and turnover. Recent studies have
shown that central dopaminergic neurons behave in a fashion very similar
to both peripheral and central noradrenergic neurons in their response to
increases in impulse flow (25).
DA metabolism can be studied in vivo by measuring concentrations
of DA and its major metabolites, HVA and DOPAC. Distinction between
effects of treatments on turnover or on release of DA can be made on
the basis of measurements of the concentration of DA. Release and up¬
take processes could be distinguished on the basis of the measured
changes in the concentrations of the metabolites, and of the assumption
that DOPAC is formed intraneuronally and HVA extraneuronally (38,39»40).
However, recent investigations by Korf et al, (33) suggest that DA released
from DAergic neurons is predominantly deaminated extraneuronally to form
DOPAC, and approximately half of the deaminated metabolite is then
methylated to form HVA. Other methods of studying DA metabolism and
turnover in vivo include the administration of a labelled precursor
and measurement of the rate of disappearance of the newly synthesised
amine by estimating the concentration of the labelled metabolites.
However, such methods suffer from the fact that what is measured are
the metabolites of exogenous DA.
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1.1.3 Nigrostriatal dopaminergic pathway
The association of DA with synaptic transmission in the nigro-
striatal pathway is well documented. Electrical stimulation in the
region of the substantia nigra causes release of DA (28,29) as well as
electrical responses in the corpus striatum (30). Bjorklund and
Lindvall (31) and Hajdu et al.(32) have demonstrated histologically
the presence of DA not only in the cell bodies, the nerve terminals
and the axons, but also in the dendritic processes which project
abundantly into the pars reticulata of the substantia nigra. The sim¬
ilarity of the storage and uptake properties of the nigral dendrites
to those of the axons and the cell bodies might suggest that DA ful¬
fills a role as a transmitter in dendro-dendritic synapses (31).
There are few reports on the influence of drugs on DA metabol¬
ism in the substantia nigra. Korf et al.(33) obtained evidence for
DA release in the substantia nigra following electrical stimulation
of the medial forebrain bundle. Geffen et al. (34) observed ^H-DA rel¬
ease after potassium stimulation of substantia nigra (mainly pars ret¬
iculata) slices prelabelled with "^H-DA. Javoy et al. (35) reported an
increased rate of synthesis of ^H-DA from "'H-tyrosine in both the
substantia nigra and the corpus striatum 3 hours after treating the
animals with the neuroleptic drug thioproperazine. Lienhart et al. (36)
demonstrated increased DA-derived fluorescence of the cell bodies of the
substantia nigra, 10 min after morphine treatment or after cold stress.
Periscic and Walters (37) demonstrated a different response of the DA cell
bodies in the substantia nigra and the axon terminals in the corpus striatum
following the inhibition of impulse flow by the administration of
^—butyrolactone, i.e. an increase of DA synthesis in the axon terminals
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but no increase in the nigral and ventral tegmental areas.
1.1.4 Purpose of the present study
There appears to exist a close relationship between functional
activity of DAergic neurons and the concentrations of both HVA and
DOPAC (33). However, although the regional distribution of DA and
tyrosine hydroxylase have been extensively studied, methodological
problems have hindered a study of the regional distribution of HVA and
DOPAC. Development of more sensitive techniques than the fluorimetric
methods facilitated the measurement of these metabolites in areas of
the rat brain not particularly rich in DA (e.g. 41»42). In the pres¬
ent study, measurements of HVA and DOPAC concentrations in various
areas of the rat brain have been carried out, using the modified sen¬
sitive gas-chromatographic method of Pearson and Sharman (41, Appen¬
dix of present Thesis). Particular emphasis was placed on the estim¬
ation of the metabolite levels in corpus striatum and substantia nigra.
A comparison was attempted of the changes induced by drug treatments
in both structures in order to clarify the similarities and differences
between the cell bodies and the nerve terminals in relation to DA met¬
abolism. This would give some insight into the function of the phys¬
iologically important nigrostriatal DAergic pathway and help elucidate
a possible regulatory system functioning in connection with it.
The DA receptor stimulant apomorphine, the DA-releasing agent
amphetamine and the DA receptor blocker haloperidol were used as tools
for the present study. Apomorphine is thought to directly stimulate
DA receptors in brain, thus leading to a feedback-mediated reduction
of DA synthesis and utilisation (63 ). Amphetamine has, possibly,
no direct action on DA receptors at physiological doses, but it is
12
believed to act by releasing DA from its presynaptic storage sites
(43)* Haloperidol is a drug that blocks the apomorphine- or amphet-
amine-induoed stimulation of DA receptors in brain. It is known to
produce an increase in DA turnover, thought to result from a second¬
ary activation of the enzyme tyrosine hydroxylase following a primary
blockade of DA receptors, probably at postsynaptic siies (44)• Var¬
ious other modes of action have, however, been proposed to explain
the effect of hsloperidol on DA turnover (Bee Review by Wright et ah,
45).
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1.2 MATERIALS AND METHODS
1.2.1 Animals and dissection
Male albino Wistar rats, 200-300 g were used. The animals were
killed by a blow on the head and decapitation, after which the brains
were quickly removed and transferred to a beaker containing chilled
saline solution (0.9$ NaCl). The brains were then placed on a glass-
plate kept on ice and the various brain areas were dissected out and
placed immediately into liquid nitrogen. The areas olfactory tubercle,
hypothalamus and cerebellum, were first removed. Two transversal cuts
were then made with a razor blade, one cut just rostral to the cerebellum
and the other one 2mm rostral to the caudal end of the hypothalamus
(Fig. 1.1). A part of the mesencephalic tissue was then disseoted, as
shown in the Figure; this included the substantia nigra and the ventral
tegmental area. The easily recognised hippocampus was also dissected
from the same section. Another coronal cut was made 2mm rostral to the
commencement of the optic ohiasma. The corpus striatum was then
dissected from the two pieces (2 and 3 in the Figure) and the septum,
lying between the two sides of the striatum was pinched out. Part of the
cerebral cortex of the area 2 was also dissected. Area 3 was cut
perpendicularly to the previous cut at the level of the anterior
coramisure and the small region of the nucleus accumbens was dissected
according to Horn et al, (20). A sample of part of the frontal cortex
lying at the rostral part of the brain was alBO obtained. Care was
always taken during the dissection of the striatum to distinguish the
caudateputamen (neostriatum, striatum) from the globus pallidus
Fig. 1.1
A diagram of tie rat brain illustrating (a) the levels of
coronal sections used in the biochemical analyses, and
(b) the substantia nigra, dissected from the tissue between
the levels A2970 and A1020 of Kbnig and Klippel (l40)
(area indicated by the dashed lines).
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(paleostriatum, pallidum).
Quoted estimates for the concentrations of HVA and DOPAC in the
corpus striatum, the substantia nigra, the nucleus accumbens, the
olfactory tubercle, the frontal cortex, the cerebral cortex, the
hippocampus and the hypothalamus are each the mean of the bilateral parts
of the dissected tissues pooled together. About 200 mg of the cerebral
cortex, the cerebellum and the frontal cortex were dissected out and
analysed.
1.2.2 Drug treatments
DL-Amphetamine sulphate (Sigma) and apomorphine hydrochloride
(Macfarlane & Smith) were administered intraperitoneally dissolved in
saline (0.9fo NaCl) solution. The doses were calculated as free base.
Haloperidol was used as a commercially available solution (Serenase,
Jansen). Dosage schedules are given in the RESULTS.
1.2.3 Statistics
Differences between control and experimental values were
analysed using Students t test for unpaired samples (two tailed).
A p value of less than 0.05 was considered significant.
1*2.4 Determination of HVA and DOPAC in brain samples
The concentrations of HVA and DOPAC in brain regions were
measured with the modified and improved gas chromatographic method of
Pearson and Sharman (41) as described in the Appendix. The original
method was used for the assay of the two metabolites in the whole
brain of rats, as described also in the Appendix.
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1.3 RESULTS
1.3.1 Regional concentrations of HVA and DOPAC
The HVA and DOPAC levels in rat whole brain (including
cerebellum) were 0.153 + 0.010 [Ag/g (n = 8) and 0.186 + 0.016 fJLg/g
(n = 8), respectively, as shown in Table 1.1. The ratio HVA/dOPAC
is 0.82.
The estimates of the concentrations of HVA and DOPAC in
several regions of the rat brain are shown in Table 1.1. The ratio
of HVA to DOPAC varies between 0.49 (nucleus accumbens) and 1.26
(frontal cortex). The highest HVA and DOPAC concentrations were found
in the olfactory tubercles, nucleus accumbens, substantia nigra and
corpus striatum. Other areas moderately rich in these metabolites were
the hypothalamus and the hippocampus. Areas such as the cerebral
cortex and the frontal cortex were also found to contain measurable
amounts of the two metabolites. The cerebellum had the lowest
concentrations but in sufficient amounts to be measured with the glc
method.
The weights of wet tissue analysed are shown in Table 1.1. The
weights for both sides of the substantia nigra, hypothalamus and
hippocampus are given.
1.3.2 Effect of drug treatments
The drug haloperidol, believed to be a DA receptor blocker, given
in various doses and according to different time schedules, caused
apparent changes in the concentrations of HVA and DOPAC in corpus
- IS -
Table 1.1
Whole rat brain and regional concentrations of HVA and DOPAC
1
I






Whole brain 1830 + 64(32) 0.15> + 0.10 (8) 0.19 + 0.02 (8) 0.82
Substantia
nigra* *




0.12 + 0.05 (9) 0.11 + 0.03 (9) 1.09
Hypothalamus* * 26.3 + 2.4 (6) 0.20 + 0.04 (6) 0.31 + o.o4 (6) 0.66
Frontal
cortex
0.18 + 0.02(21) 0.14 + 0.02(21) 1.26
Hippocampus** 84.5 + 12.3 (9) 0.23 + 0.03 (7) 0.24 + 0.02 (8) 0.96
Olfactory
tubercle*
18.5 + 3.4(27) 0.76 + 0.16(16) 1.4l + 0.20(18) 0.54
Nucleus
accumbens*
21.6 + 2.7 (43) 0.69 + 0.18(43) 1.40 + 0.22(43) 0.49
Cerebellum 0.05 + 0.01 (5) 0.05 + 0.01 (5) 0.96
Corpus
striatum*
37.4 + 4.1(13) 1.14 + 0.14(30)
1
1.18 + 0.14(32) 0.97
1
The concentrations of HVA and DOPAC were measured with the sensitive gas
chromatographic procedure described in the Appendix.
The weight of dissected tissue samples is quoted for some regions (* one side;
** both sides) whereas for cerebral cortex, frontal cortex and cerebellum
approximately 200 mg of tissue was used.
Figures represent means + s.d.; the number of animals is in parentheses.
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striatum and substantia nigra, as shown in Fig. 1.2 and 1.3. Control
animals were treated with 0.5 ml saline solution and immediately killed.
Haloperidol, given at doses 0.4-10 mg/kg i.p. caused a dose
related increase in HVA and DOPAC in the corpus striatum, but showed a
plateau at doses over 1 mg/kg, especially apparent in DOPAC levels
(Fig. 1.2). The concentrations of both metabolites were significantly
higher than controls with all doses of haloperidol used, but the
difference between the concentrations after 1 mg/kg and after
2 mg/kg was not statistically significant. A higher dose (10 mg/kg i.p.)
induced a further rise in the metabolite concentrations, which were
significantly higher than the concentrations after 1 mg/kg. A dose of
1 mg/kg i.p. caused a significant increase in HVA and DOPAC between
30 min and 3 hours after the injection, with a maximum effect between
1 and 2 hours (Fig. 1.3). Thereafter the DOPAC concentration showed
a decline and a return to normal levels after 5 hours, whereas the HVA
concentration was still significantly higher than the control at this
time.
A different dose and time-effect response with regard to HVA and
DOPAC was produced in the substantia nigra (Fig. 1.2 and 1.3). Doses
of 0.4 and 1 mg/kg caused a significant riBe in the concentrations of
both metabolites 1 hour after injection, but higher doses of 2 mg/kg
produced a lower percentage rise than the doses of 0.4 and 1 mg/kg,
although these concentrations were still higher than the controls.
The concentration of HVA was not significantly higher than control
when 5 or 10 mg/kg were injected 1 hour before decapitation of the
rats, whereas the DOPAC concentration was higher than controls with
both doses, but significantly lower than the maximum concentration
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1 mg/kg haloperidol i.p. on the concentrations of HVA and DOPAC in
the substantia nigra was different from that in the corpus striatum
(Pig. 1.3). A significant decrease in both metabolite concentrations
30 min after injection (to 70$ of control), was followed by a signif¬
icant increase to 251$ for HVA and 258$ for DOPAC 1 hour after inject¬
ion of this dose. This peak in the time-effect curve was followed by
a fall to 136$ of control for HVA and 122$ of control for DOPAC 2
hours after injection and then to 120$ and 76$ respectively, 3 hours
after injection. The concentration of HVA was still significantly
higher than controls 2 hours after injection, whereas DOPAC was not
different than control levels. 3 and 5 hours after administration of
1 mg/kg haloperidol, the HVA concentrations were not significantly
different than controls, whereas the DOPAC concentrations were signif¬
icantly lower than controls (70$ at 3 and 78$ at 5 hours).
Figure 1.4 summarises the effects of apomorphine (a DA receptor
stimulant) on HVA and DOPAC in the corpus striatum and the substantia
nigra. The concentrations of HVA and DOPAC in the corpus striatum at
10 and 20 min after the i.p. injection of 1 mg/kg apomorphine were
significantly reduced to 72$ and 81$ (HVA) and 62$ and 60$ (DOPAC) of
the control levels, respectively. At 20 min, the reduction following
a 2 mg/kg dose was not greater than that after a 1 mg/kg dose. In the
substantia nigra on the contrary, at 10 min after a dose of 1 mg/kg was
given, there was a significant rise in the concentrations of both HVA
and DOPAC to 125$ and 129$ respectively, but at 20 min after this dose
there was a significant decrease in both metabolites to about the same
extent as in the corpus striatum (77$ a11^ 68$). In both brain areas,
a dose of 1 mg/kg of apomorphine caused the maximum effect and a dose
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Effect of apomorphine on the concentrations of HVA and DOPAC in the
substantia nigra and the corpus striatum
Vertical bars represent s.d. for the number of observations indicated.
Statistical significance (Student's t test, two-tailed):




DL-Amphetamine (Table 1.2), in a dose of 5 mg/kg i.p. 1 hour
before killing caused a significant reduction in both HVA and DOPAC in
the substantia nigra (p<^0.01 and p<^ 0.05, respectively). In the
corpus striatum, the DOPAC concentration was decreased significantly,
(p <("0.01), whereas HVA had not changed.
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Table 1.2
Effect of amphetamine on dopamine metabolite concentrations in
corpus striatum and substantia nigra
Corpus striatum substantia nigra














Rats were injected with DL-amphetamine (5mg/kg i.p.), sacrificed 1 hour
later and the concentrations of HVA and DOPAC measured in corpus striatum
and substantia nigra.
Control animals received saline solution.
Results are expressed as ftg/g tissue, wet weight.
Values represent means + s.d.; the number of animals is in parentheses.




Biy comparison with earlier measurements of the concentrations of
HVA and DOPAC in rat whole brain and in brain areas the values obtained
in this study were in good agreement, as shown in Table 1.3. The diff¬
erent dissection procedure, the strain of rats used and the different
recoveries of the various methods may account for the differences bet¬
ween the reported estimates of the two metabolites. With regard to
areas not clearly defined, such as the nucleus accumbens, frontal cor¬
tex, substantia nigra, the difference between the reported values may
result mainly from the dissection procedure used in each study. The
low recoveries of the fluorimetric procedures used for some assays (47)
may explain the generally low values obtained, compared to the results
of studies using the present and other gas chromatographic techniques.
The ratios HVA/DOPAC seem to suggest that DOPAC is the main DA
metabolite in certain areas of the brain, such as the nucleus accumb¬
ens and the olfactory tubercle (ratios 0.49 an4 0.54 respectively) and
probably the hypothalamus (ratio 0,66) in agreement with previous rep¬
orts (33,42). Several other areas, however, such as the striatum, the
cerebral cortex, the hippocampus and the cerebellum had ratios of about
1. Furthermore, areas such as the substantia nigra and the frontal
cortex had ratios of 1.23 and 1.26 respectively. Although the functional
significance of these variations is not known, HVA could be equally
suggested as the main metabolite reflecting DA metabolism in certain
areas with ratio HVA/DOPAC greater than 1, as it has been proposed by
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Table 1.3
Comparison of reported estimates of HVA and DOPAC concentrations
in the rat brain with those of the present study
Brain Area HVA (pg/g) DOPAC (pg/g) Procedure Reference
Whole brain 0.153 + 0.010 (8)
0.074 + 0.003(13)









0.67 + 0.06 (5)
1.02 + 0.09 (8)
0.80 + 0.05(10)
1.18 + 0.14(32)
0.97 + 0.06 (5)
1.23 + 0.15 (8)































O.52 + 0.14 (5)
1.41 + 0.20(18)
1.03 + 0.02(20)








- i . . .
0.20 + 0.04 (6)
0.09 + 0.01 (8)
0.31 + 0.04 (6)







0.12 + 0.05 (9)
0.02 + 0.02 (5)
0.12 + 0.01 (8)
0.11 + 0.03 (9)
0.06 + 0.01 (9)








0.23 + 0.03 (7)
0.16 + 0.01 (4)
0.24 + 0.02 (8)

















i.50 + 0.25(26) 1.22 + 0.27(26)






0.05 + 0.01 (5)
0.03 + 0.01 (5)
0.05 + 0.01 (5)





Results are the means + s.e.m. (s.d. in the present study) of values obtained










other workers (23). However, in order to clarify this noint, more complex
measurements must he carried out, which would inc1ude the tota1 HVA and
DOPAC content, free and conjugated (21,2A). The relative importance of the
two metabolites in the various brain regions can onl-"- be assessed if the
rates of synthesis, metabolism and transport for both free and conjugated
HVA and DOPAC are determined.
The results shown in Table 1.1 also indicate that DA metabolism is
not uniform in brain and furthermore that it is different in different
carts of a neuron. The presence of DA-containing cell bodies in substantia
nigra (5) and the presence of DA nerve termina1s in corpus striatum (3),
olfactory tubercle (3,9) and nucleus accumbens (3,9) is well documented.
The nresence of DA neurons in the hypothalamic area (lO), in the cerebral
(48,49) and in the frontal cortex (9,49) has also been established. There¬
fore, the finding of relatively high concentrations of DA metabolites in
these areas is not surprising. The DAergic cell bodies of the mesencephalic
brain areas seam to be the origin of the DAergic innervation of these reg¬
ions. The nerve terminals of the striatum are known to originate ^rom the
area A9 substantia nigra (8). The terminals in the nucleus accumbens and
olfactory tubercle originate from the area A10, medial to the substantia
nigra (8,9). Lesion studies indicate that the areas A9 and A10 probably
give rise to the projection to the frontal cortex and the cerebral cortex
(9,49). The tubero-infundibular DAergic pathway is more likely to be the
source of innervation of the hypothalamic area (A,10). The possibility
must be considered that HVA and DOPAC detected in areas not previously
associated wit1 DAergic innervation might derive from metabolism unrelated
to DAergic neurotransmission. This is probably the case in the cerebellum,
where there is apparently no DAergic innervation (3) or DA receptors (30);
the DA present in this structure might function as a precursor of noradrenaline.
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The presence of nerve terminals containing DA in tie hippooam^us() explains
the finding of moderate amounts of IIVA and DOPAC in this stricture. The
finding of high concentrations of HVA aid DOPAC in t e substantia nigra is
consistent with the high tyrosine hydroxylase activit lound in this
structure (8l). However, the functional, significance o! t be DA metabolites
in the cell bod area of substantia nigra cou"'d be assessed only after
pharmacological or other manipulations which could alter selectively their
concentration, and by comparison of these effects with the effects at the
nerve terminal areas.
y
1.4.2 Drug effects on DA metabolism in corpus striatum and substantia nigra
1.4.2.1 Support for a neuromodulator function of DA in the substantia
nigra
Research on central DA neurotransmission was, until very recently,
almost exclusively restricted to axon nerve terminals. The histological
studies of Rinvik and Grofova (51), of Ha.idu et al. (3?) and of Bjorkltmd
and Lindvall (3l) have, however, revealed the presence of DA in dendrites
of the substantia nigra, a region known to contain DAergic eel"1 bodies.
These dendrites contain relatively large amounts of DA, revealed by histo-
fluorescence, and vesicle-like strictures (32). DA seems to be stored in
reserpine-sensitive structures (31), which are also able to take up " H-DA
(31,51). Exogenous 3r-DA taken up in slices of rat substantia nigra was
shown to be released by potassium (30 mM) through a calcium-dependent pro¬
cess (34) • Furthermore, spontaneous and evoked in vivo re"1 ease of ^H-DA
has been demonstrated from the cat substantia nigra (p2). These observa¬
tions, toge^er with the presence of a DA-sensitive adenylate cyclase in
the substantia nigra with characteristics similar to that in the striatum
(18), where it is apparently associated with the DA-receptors (l6), suggest
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that DA may serve a neuromodulatory function in this structure. The
suggestion has been made that in the substantia nigra DA released from
dendrites or cell bodies may influence the activity of the nigrostri-
atal DAergic neurons by interacting with dendritic or somatic DA rec¬
eptors, which have been termed autoreceptors (53»F>4). However, the
finding that the DA-sensitive adenylate cyclase is apparently located
on the terminals of striato-nigral afferents containing either GABA or
substance P (56, 46), and the demonstrated in vitro release of GABA from
suoerfused slices of rat substantia nigra both by DA and by amphet¬
amine (17) suggest that the proposed local dendritic release of DA may
modify the excitability of DAergic neurons by stimulating the local
release of GABA. On the basis of these results, it has been concluded
that the activity of the DAergic neurons is inversely correlated to
the extent of the dendritic release of the transmitter.
1.4.2.2 Possible mechanisms of auto—inhibition of DAergic cells in
the substantia nigra
Westerink and Korf (54) have demonstrated that various treat¬
ments with drugs thought to affect primarily DA neurotransmission in
brain produce parallel changes in HVA and DOPAC levels in both substan¬
tia nigra and corpus striatum; the apomorohine- and halooeridol-induced
changes in the substantia nigra were thought to result from DA auto-
receptor stimulation or blockade, respectively.
The present study confirmed that parallel changes in the 1 eve1s
of the two acidic metabolites of DA may occur in both striatum and
substantia nigra. There was a significant decrease in the concentra.-
tions of the two metabolites in both structures at 20 min after i.p.
injection of apomorphine (l or 2 mg/kg), indicating the presence of
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DA receptors in striatum and substantia nigra and the existence of
similar mechanisms leading to a decrease in DA metabolism, induced as
a consemience of DA receptor stimulation. However, when the DA reo-
entor stimulant was administered to the rats 10 min "He-fore sacrifice,
significant increases in HVA and DOPAC were found in the substantia
nigra, in contrast to the significant decrease found in the striatum.
Thus the belief that DA recentor stimulation produces a marked inhibi¬
tion of activity in the DAergic neurona1 terminals and a degression of
firing of the cell bodies of the DAer^ic neurons, in the substantia
nigra (53) cannot be always supported by the findings of this study.
The initial inorea.se in DA metabolite concentrations in the substantia
nigra after apomorrhine ma-" indicate an initia1 stimu1 ation of firing
rate in this structure, resulting in increased dendritic release of
DA, which in turn mav act directly or through release of an inhibitors
transmitter (e.g. GABA), causing finally an inhibition of neuronal
firing. This sequence may em!ain the reduction of FVA and DOPAC that
follows the ranid initial inoresse in the substantia nigra.
An annarent disereranc-/- arises, however, between the previously
described inhibitor"- effects of DA reoentor agonists on the firing
rate of the cells in the substantia nigra and the hypothesised initial
stimulation of the firing rate by anomomhine. This discrepancy could
be resolved if any of severa1 other possibilities were assessed. First,
the proposed existence of two copulations of DA receptors in the stri¬
atum and the nucleus accumbens of the rat brain, termed excitation-
mediating DA receptors (DAe) and inhibition-mediating DA receptors
(DAi) (55) might be considered in relation to the DA autorecentors bel¬
ieved to exist in the substantia nigra. These autoreceptors may be
subdivided into two groups, DAe and DAi, of which DAe ma" be selectively
- 27 -
activated during the initial period and DAi during the subsequent
period. This explanation would be simpler than those involving den-
dritically released DA or DA-induced release of GABA as mediators of
the autoregulation of the DA cells, but there is no direct or indirect
evidence in favour of this hypothesis. Second, stimulation of the
release of an excitatory transmitter such as substance P or acetylcho¬
line from their neurons, mediated through stimulation of DA receptors
located on the respective neurons, might explain the initial stage of
the bihhasic effects of apomorohine. The existence of a DA-sensitive
aden.yl cyclase on nerve terminals containing substance P has been dem¬
onstrated in the substantia nigra (46). An initial stimulation of the
release of substance P or acetylcholine, known to be excitatory on cell
activity in substantia nigra (64) may be responsible for the demon¬
strated transient increase in HVA and DOPAC following apomorphine
administration. Subsequent stimulation of the DA autoreceotors may
surmount the effect of the excitatory transmitter. Third, two forms
of adenylate cyclase may existj one located on DA cell bodies or den¬
drites, and the other located on GABA- or substance P-containing neur¬
ons. Preferential stimulation of the DA receptors operating through
either of these adenylate cyclases may be followed by stimulation of
the other receptors resulting by an unknown mechanism to inhibition of
the cell firing. Fourth, the existence of two types of DA autorecentors,
one on the DA cell bodies and the other on the DAergic dendrites.
Initial stimulation of the 'dendritic' autorecectors may be responsible
for the release of DA and the observed initial increase in HVA and
DOPAC, whereas subsequent stimulation of the 'somatic' autorecectors
may be responsible for the prolonged cell inhibition and the parallel
fall in the concentrations of the metabolites of DA in the substantia
nigra.
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1.4*2.3 Different responses of the striatum
These and other possibilities, available for consideration, may
also be examined in order to interpret the biphasic effects of haloper-
idol on the concentrations of HVA and DOPAC in the substantia nigra,
which are in general the reverse of those following apomorphine (Fig.
1.2 and 1.3). On the other hand, the different responses of the sub¬
stantia nigra and the corpus striatum to apomorphine and haloperidol
indicate that local regulation of DA utilisation may occur in both
structures, rather than the regulatory system operating through a
neuronal striatonigral feedback loop proposed by Carlsson and
Lindquist (44)* In this case, different mechanisms may operate in the
two structures. However, the possibility exists that the cell body
area and the terminal area have the same regulatory mechanism, the
initial increase in DA metabolism, observed 10 min after apomorphine,
being a latency phenomenon with unknown physiological significance.
Support for this hypothesis comes from electrophysiological experiments
(M. Garcia-Munoz, personal communication) which showed that intraven¬
ous administration of apomorphine or amphetamine causes an initial
increase in firing rate of DA cells in the substantia nigra, rapidly
followed by a prolonged inhibition. This biphasic effect on firing
rate might be the reason for the biphasic effect on DA metabolite lev¬
els observed in the substantia nigra after apomorphine.
The question why changes in the firing rate of the DA cells in
the substantia nigra are not followed by appropriate changes in impulse
flow to the nerve terminals (implied by the differential effects of
apomorphine and haloperidol on HVA and DOPAC in the substantia nigra
and the colrpus striatum), may be answered (if the nigral regulation of
striatal DA metabolism is accepted) by the fact that a nerve impulse
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is generated only when the threshold of stimulus is exceeded. There¬
fore, subtle changes in cell firing rate may not result in changes in
the impulse flow to the nerve terminals. This idea could facilitate
the interpretation of results of our subsequent experiments (described
in other Sections) and also of reports in the literature providing
evidence that changes in DA metabolism in the substantia nigra are
followed by no changes or even by changes in the opposite direction in
the corpus striatum. As mentioned previously, iontophoretic applica¬
tion of DA in the substantia nigra causes a decrease in the firing
rate of the DA cells, thought to result from a direct action on DAergic
cell bodies (67) and to be mediated by presynaptic autoreceptors loc¬
alised on the DA cell bodies (53). Presynaptic DA autoreceptors have
also been postulated to exist on the striatal DAergic nerve terminals
(63). Further studies are needed in order to clarify whether DA
autoreceptors exist on DA cells or dendrites in the substantia nigra,
whether in addition to DA autoreceptors, GABA or other receptors exist
on DA cell bodies or dendrites mediating in part or totally the
inhibitory effect of DA on cell firing, or whether local neuromodulation
takes place and to what extent in the activity of the nigral neurons.
1.4.2.4 Effects of amphetamine on DA metabolism in the substantia
nigra and the striatum
Intraperitoneal administration of amphetamine produced a depression
of neuronal activity in the substantia nigra (53), possibly through a
mechanism intrinsic to this structure. Consistent with this is the
finding of a decrease in the levels of both HVA and DOPAC in the sub¬
stantia nigra 1 hour after the administration of amphetamine (Table 1.2).
In the striatum on the other hand, the same dose produced no effect on
HVA, but a significant decrease in DOPAC levels, confirming the suggested
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effects of this agent on DA release and reuptake (43) and the proposed
intraneuronal formation of DOPAC and extraneuronal formation of HVA
(38,39,40).
In behaviourally effective doses the primary action of ampheta¬
mine in brain appears to be that of increasing the release and block¬
ing the reuptake of catecholamines, thereby indirectly stimulating
postsynaptic DA receptors (43). In 1967 Corrodi and co-workers sugg¬
ested that this action of amphetamine on postsynaptic neurons causes
a compensatory decrease in the firing rate of DAergic (presynaptic)
neurons via a neuronal feedback pathway.
Intravenous injection of amphetamine in low doses inhibited DA
cell activity in the substantia nigra(53,59).Direct application of
amphetamine onto DA cell bodies and proximal dendrites as well as on
distal dendrites produced only a decrease of approximately 25$ in DA
cell activity (59) • The effect of amphetamine on cell firing in the
substantia nigra was reduced by lesions of the descending striatonigral
pathway (6l). The above evidence seems to support the hypothesis
first proposed by Corrodi et al. in 1967 that the depressant effect of
amphetamine (in pharmacologically relevant doses) on DAergic cells is
mediated primarily through its effect on a striatonigral feedback
pathway (60). The finding that the amphetamine-induced inhibition of
DAergic cells is reversed by an intravenous injection of picrotoxin
(59) suggestedthat such a pathway may contain a neuron which uses
GAM as its neurotransmitter.
1.4*2.5 GAM as possible mediator of auto-inhibition in the substantia
nigra
However, the idea of a GAMergic neuronal feedback loop regulat¬
ing the activity of the nigrostriatal DAergic pathway has been
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challenged (45) • Further reports seem to offer alternative inter¬
pretations of the ahove data, which do not depend on the existence of
a neuronal striatonigral feedback pathway. The finding that DA at
concentrations 5 x 10~^ - 5 x 10""4 m and amphetamine can selectively
release GABA from nigral slices in vitro by a neuroleptio-inhibited
process (57)t combined to the localisation of DA-sensitive adenylate
cyclase in non-DAergic neurons of the substantia nigra (l8,62), prob¬
ably GABA-containing in nature (56), may suggest that the inhibitory
effect of GABA on DA cells or dendrites follows the release of GABA
from its neurons by a DA-sensitive process. Our finding that amphet¬
amine increases the turnover of GABA (Section 3) while decreasing
(probably as a consequence) the DA turnover in the substantia nigra
provides further support for this hypothesis. The different effects
of various treatments with DA receptor agonists and antagonists on
the GABA turnover in the striatum and the substantia nigra seem to
support local links interrelating the DA and GABA systems, in both
structures. The functional integrity of the nigrostriatal or the
striatonigral pathways does not always appear to be critically in¬
volved in the action of DA receptor blockers or stimulants on the met¬
abolism of DA in the striatum or the substantia nigra (45)*
The presence of presynaptic DA receptors at the nerve terminals
which appear to regulate the rate of DA synthesis and turnover by a
local negative feedback mechanism (44) is supported by various pharm¬
acological or other treatments. Stimulation of these receptors by DA
agonists, such as apomorphine, caused a receptor-mediated reduction in
DA synthesis and blockade by DA antagonists, such as haloperidol, res-
ultedin an increase in DA synthesis (25). Parenteral or micro-
iontophoretic administration of DA agonists and antagonists produced
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physiological responses of DAergic neurons in the substantia nigra
(pars conrpacta) which paralleled the biochemical effects at the terminal
area (67).
DA receptor agonists seem, according to the proposed model, to
act in the substantia nigra as GABA-like agents, thereby reducing the
DAergic cell firing rate. The opposite appears to happen with DA reo-
eptor antagonists. The involvement of DA-DA interactions, as well as
the involvement of substance P or acetycholine at certain stages of the
nigral DA neuromodulation may also be proposed to occur in parallel
with the GABA-raediated control of DA neuronal activity. A combination
of these mechanisms might explain the finding of an inverse correla-
, *
tion between the activity of the DAergic nigrostriatal pathway (as
shown by changes in the turnover of DA in the striatum) and the extent
of the dendritic release of DA in the substantia nigra (as shown by
changes in the turnover of DA in the substantia nigra). The demon¬
strated similarities between the two structures can also be interpreted
on the basis of the proposed local regulation of DAergic neuronal activ¬
ity. The various possibilities are depicted in a generalised form in
Pig. 1.5.
1.4.2.6 Haloperidol treatment; support for local regulation of DA
neuronal activity
The time-effect curves as well as the dose-effect curves of the
haloperidol treatment, demonstrate striking differences in the
response of the striatum and the substantia nigra with respect to
changes in HVA and DOPAC concentrations. Haloperidol at a dose of
1 mg/kg produced within 30 min an initial significant decrease in the
levels of the metabolites in the substantia nigra, which was followed
by a sharp increase within the next 30 min. Within the subsequent
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2 hours the metabolite concentrations had fallen to control values.
The concentration of DOPAC was even significantly lowered 3 and 5
hours after injection, whereas the HVA concentration was not differ¬
ent from control at this time. On the other hand, in the striatum,
there was a rapid increase in the concentrations of HVA and DOPAC which
persisted for 2 hours and then declined to normal levels by 5 hours
after the injection. Thus, the finding that haloperidol increased
the activity of DAergic cells in the substantia nigra (e.g. 59) cannot
alone explain the difference in the HVA and DOPAC concentrations in
the two areas. Changes in impulse flow should result in parallel eff¬
ects on DA metabolism in the substantia nigra and the striatum, if
there is a single regulatory mechanism for DA metabolism. This sin>-
ilarity appear§donly at certain time^ and as the Pig. 1.2 shows, only
at certain doses. In contrast to the biochemical events in the stri¬
atum, where increasing increments in the concentrations of HVA and
DOPAC are obtained at 1 hour after increasing doses of haloperidol
within the range 0.4-10 mg/kg, in the substantia nigra the significant
increase of the acid metabolites observed with doses of 0.4-2 mg/kg
was less and insignificant at higher dose levels of >-10 mg/kg.
If the blockade of postsynaptic DA receptors in the striatum
was followed by the inactivatjon of the "feedback'* striatonigral path¬
way, leading to an increase in the activity of the DA cells in the
substantia nigra (44,60j)the striatal DA turnover would consequently
increase, but a parallel increase would be observed in the nigral DA
turnover. This sequence was not found in the present study. There¬
fore, an interpretation based on the existence of local regulatory
mechanisms in both structures seems to be supported by the differential
effects of haloperidol on HVA and DOPAC in the two areas. Blockade of
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postsynaptic DA receptors in the striatum may lead to an activation
of a local feedback mechanism resulting in increased DA synthesis and
turnover, as it was supported by previous studies (63). Blockade of
DA receptors in the substantia nigra, probably located on terminals of
striatonigral GABA-containing neurons (56) forming synapses with the
DA-containing dendrites, may prevent the release of GABA which norm¬
ally acts to inhibit the DA cells or the dendrites. Therefore, the
DA cells or the dendrites are released from the Inhibition during DA
receptor blockade and respond to this treatment with an increase in
DA turnover.
This mechanism does not explain either the initial fall in DA
turnover or release implied by the significant fall in HVA and DOPAC
after haloperidol or the reduction of the response with higher doses
of haloperidol. The latter may result from the activation of an alt¬
ernative mechanism, such as the proposed autorecer^ton-mediated reg-
(53)
ulatory system,/ which may obscure the increase in DA turnover.
Although there is no obvious explanation for the decrease in HVA and
DOPAC in the substantia nigra observed 30 rain after haloperidol, a
blockade of DA autoreceptors leading to a subtle decrease in the cell
firing rate cot evident in the striatum (contrary to an initial acti¬
vation by apomorphine leading to an increase in the cell firing rate),
seems to be a possible mechanism functioning in parallel with the
proposed GABA-raediated local regulatory system.
The various possibilities considered above in relation to the
effects of apomorphine on HVA and DOPAC in the substantia nigra may
also be proposed. Furthermore, the finding of Westerink and Korf
(47)» that haloperidol induced a rapid increase in HVA and DOPAC in
the substantia nigra 10 min after the injection, which within another
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5 min disappeared, may also be relevant to the decrease found in the
present study at 30 min. Thus, the increased release or turnover of
DA implied by the temporary rise in HVA and DOPAC at 10 min may result
in an inhibition of the cell firing rate and a subsequent reduction in
the release or turnover of DA reflected in the reduction of the concent¬
rations of the metabolites found in the present study at 30 min after
administration of haloperidol. Finally, the possibility that DA is met¬
abolised under certain circumstances via the 3-methoxytyramine pathway (44)
and therefore HVA and DOPAC do not always reflect the activity of DAergic
neurons cannot be excluded.
1.4.2.7 Alternative interpretations
Several other, rather remote, possibilities could be considered
in attempting to explain the different biochemical responses of the
substantia nigra and the corpus striatum after various treatments.
First, different distribution or access to the receptor sites may be
responsible for some of the observed different effects of drugs at
certain doses and time-intervals. The fact, however, that some of the
effects of DA receptor agonists are in the opposite direction that the
effects of DA recentor antagonists eliminates this possibility and suggests
that the main effects are mediated through a direct action on DA recept¬
ors. A study of the distribution of haloperidol, apomorphine and amphet¬
amine in the striatum and in the substantia nigra could clarify this point.
Second, a difference between the characteristics of the DA receptors
found in the two structures may account for the different responses.
A different affinity of the drugs for these receptors might imply that
DA receptors in the striatum are different from DA receptors in the
substantia nigra. Although the adenylate cyclase found in the substantia
nigra appears to have characteristics similar to that in the striatum,
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which is thought to be associated with DA receptors (16), it is poss¬
ible that the nigral DA—sensitive adenylate oyclase is not associated
with DA receptors, or that there are more than one adenylate cyclases
in the substantia nigra. Third, effects of these drugs on blood flow
(65) or glucose utilisation (66), which may affect the distribution or
the clearance of the drugs or the metabolic rate of the neurons, may
contribute to the effects of the "treatments on DA metabolism. Fourth,
the involvement of other neurotransmitter systems, such as the GABAergic,
the cholinergic and the serotonergic system, may critically determine
the response of the DAergic system in the two regions. These possible
mechanisms are examined in subsequent Sections of the present Thesis,
where the proposed model of regulation of DAergic neuronal activity is
tested by the use of other pharmacological or lesioning procedures.
1.4.2.8 Conclusions
Taken together the results reported in this section indicate that
changes of DA turnover in the rat substantia nigra are not, in general,
followed by changes in the same direction in the corpus striatum; at
certain time and dosage, the opposite effects of DA receptor agonists
and antagonists are seen in the two areas, i.e. an increase in DA turn¬
over in the corpus striatum is associated with a decrease in the sub¬
stantia and vice-versa.
The findings suggest that local independent mechanisms for the
regulation of DA metaboleim may exist in the substantia nigra and the
corpus striatum. The DA 'autoreceptor* theory does not explain suff¬
iciently these results, neither does the striatonigral 'neuronal feed¬
back loop* hypothesis. Modulation of DAergic cell activity and DA rel¬
ease from the dendrites of the substantia nigra, mediated by inhibitory
(e.g. GABA, 5-HT) or excitatory (e.g. substance P, Ach) transmitters,
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may be postulated to replace or accomplish the proposed DA autoregula-
tion. An embryonic model integrating the most probably mechanisms for
the modulation of DA cell activity in the substantia nigra is illust¬
rated in Pig. 1»5» It appears that the dendro-dendritic contacts and
the postulated DA-induced release of certain excitatory or inhibitory
transmitters may result in the appropriate effect on DA cell activity
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SECTION 2
SOME BIOCHEMICAL EFFECTS OF LESIONS IN THE SUBSTANTIA NIGRA
OF THE RAT BRAIN WITH 6-HYDROXIDOPAMINE
- 38 -
2.1 INTRODUCTION
2.1.1 Substantia nigra: anatomy, "biochemistry
The dopamine (DA)-containing cell bodies of the substantia nigra
are found densely aggregated throughout the pars compacta and scattered
in the pars reticulata (31,51). Their axons are known to leave the nig¬
ral cells and form the medially directed DA fibre-outflow of the sub¬
stantia nigra, ascending partly within the medial forebrain bundle
(7,8,9) and terminating within the corpus striatum, where they form a
dense terminal plexus (8,9,31). In Golgi and histofluorescence stud¬
ies (31,51), the nigral cells have also been shown to project abund¬
antly with several long processes which ramify within the pars reticu¬
lata. These processes fulfil the ultrastructural criteria for dendrites
(32,51).
It has been demonstrated that both the rxonal and dendritic ter¬
minals in the substantia nigra possess storage and uptake mechanisms
which are reserpine-sensitive (31). It has also been shown that DA
may be released from the cell-bodies and dendrites of the substantia
nigra as well as from the corpus striatum after electrical stim¬
ulation (33) or potassium depolarisation (34 ) • It seems that DA
released from the dendrites can be partly inactivated by a potent reup¬
take process as is observed in the nerve terminals. The DAergic den¬
drites contain tyrosine hydroxylase, the rate limiting step in the
synthesis of DA, as indicated by a recent imraunchistochemical study
(77). Other results suggest that the local synthesis rate of DA in
the dendrites is important and can efficiently supply the release process
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(52). When compared to the striatal axon terminals the dendrites show
a relatively much greater uptake and retention of ^H-DA (34)» probably
because of a lower endogenous DA content and a higher storage capacity
for exogenous DA in the vesicles of dendrites.
2.1.2 Physiological role of dopamine released in the substantia nigra
It has been postulated that the demonstrated release of DA from
dendrites in the substantia nigra has important physiological funct¬
ions. Firstly, DA may inhibit the neurons from which it is released
(self- or auto-inhibition). In microiontophoretic electrophysiolog¬
ical studies it has been found that DA-containing cells of the sub¬
stantia nigra are inhibited when the amine is applied to the pars
reticulata (67)> and it has also been postulated that DA acts on DA
autoreceptors on the cells, thus controlling the range of their firing
frequencies (53)• Secondly, DA released in the substantia nigra may
inhibit other neurons located near the dendrites releasing DA (lateral
inhibition). Dendro-dendritic contacts in the substantia nigra have
been revealed by electron microscopy (32), and it could be postulated
that an action of DA on receptors located either on the DA dendrites
or presynaptically on the axon terminals innervating them may take
place. A third regulatory function of the dendritic release of DA
could be the control of plastic regenerative sprouting of neuronal pro¬
cesses and the formation of new synapses (33).
The local application of DA or DA receptor agonists to the sub¬
stantia nigra produces an inhibition in the firing of neurons in the
pars compacta, which is blocked by DA antagonists (53,67)« This find¬
ing does not discriminate between the possible functions of DA released
from the dendrites.
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2.1.3 Striatal and nigral interneurons
Neurons containing ^-aminobutyric acid (GABA), substance P,
acetylcholine (Ach) and 5-hydroxytryptamine (5-HT) have been found in
the substantia nigra^but relatively little is known about the synaptic
interactions of these neurons (see review by Dray and Straughan,
ref. 64).
The veiy high concentration of GABA and its synthesizing enzyme
glutamic acid decarboxylase (GAD) in the substantia nigra is well
established (81,69)• The main projection to the substantia nigra app¬
ears to arise unilaterally from the corpus striatum (84,60), is mainly
inhibitory (81,82) and utilises GABA as its neurotransmitter (68).
The striatonigral projection also contains an excitatory pathway
which may utilise substance P as its neurotransmitter (58). Moreover,
GABA-containing striatal neurons which travel through the globus pall-
idus on their way to the substantia nigra have been described (84)•
Evidence has been presented that the striatonigral pathway terminates
mainly within the pars reticulata (85), where GAD activity is higher
than in the pars compacta (86).
Fibres arising from cell bodies in the raphe nuclei terminate
within the substantia nigra, and probably utilise 5-HT as their neuro¬
transmitter (73,37). Evidence has been presented for synaptic contacts
between the 5-HT-containing nerve terminals and the DAergic neurons in
the substantia nigra (73)•
It is well established that the nigrostriatal DAergic neurons
exert a tonic inhibition of certain striatal cells through the release
of DA as a neurotransmitter. Morphological evidence suggests that
synaptic boutons belonging, to the DAergic terminals exist in the stri¬
atum (88). In addition, stimulation of the nigrostriatal pathway causes
- 41 -
release of DA from the striatum (89). Electrical stimulation of the
substantia nigra induces mainly inhibition of the activity of certain
striatal cells, presumably by a direct monosynaptic process (90,9l)«
Moreover, local iontophoretic application of DA to the striatal cells,
which are inhibited after nigral stimulation, also causes a depression
of firing rate (90,92). The above observations lead to the view that
DAergic postsynaptic receptors are present on certain striatal neurons
and mediate the inhibitory effect of DA, which is released by the
DAergic terminals. The cells which form synapses with the DAergic ter¬
minals appear to be cholinergic (93)* Anatomical evidence has also
been presented, showing that the DAergic nerve endings make synaptic
contacts with cholinergic dendritic structures which contain the
Ach-synthesising enzyme choline acetyltransferase (CAT) (95> 96).
Lesioning studies suggest that the cholinergic system in the
striatum may also be primarily organised within this structure (97)
and that the described afferent from the ventral tegmentum (98) or the
efferents to the globus pallidus and the substantia nigra (99) nay not
be responsible for the cholinergic activity in the striatum. Choliner¬
gic neurons seem to have short axons within the striatum, with many
terminals which could contain most of the Ach and CAT activity. The
striatum contains the highest CAT activity in the brain (100,101),
mostly concentrated in nerve endings (101).
(IAD, the rate-limiting enzyme in the synthesis of GABA, is one
of the best available markers for GABAergic neurons. The activity of
GAD correlates well with the distribution of GABA (75*7^) and- during
ontogenesis parallel increases in GAD activity and GABA concentration
can be observed (102). GAD is found mainly in synaptosomes (76), which
suggests that GABA formation may occur in nerve endings in vivo.
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Furthermore, GAD, unlike GABA, is much less subject to post—mortem
changes (86). In many inhibitory nerves, both GAD and GABA are pres¬
ent and are distributed throughout the neuron, although the GAD is
somewhat more highly concentrated in the presynaptic endings than else¬
where. The GABA-transaminase is contained in the mitochondria of all
neuronal regions, but it seems to be richer in the mitochondria of
those neuronal sites onto which GABA might be liberated (for review
see ref. 104). Such regions would be expected to exist in pericarya
and dendrites that receive inhibitory inputs and possibly in the glial
and endothelial cells which are in the vicinity of inhibitory synapses
(104).
Recent pharmacological findings suggest that DAergic neurons can
control GABA neurons in the striatum. Thus, the DA receptor agonist
apomorphine can increase the GABA turnover in the striatum and this
effect can be counteracted by the DA receptor blocking agent pimozide
(105). DA has been demonstrated to have mainly an inhibitory action on
the cells in the striatum (90,92), and therefore the DA terminals may
not have a direct contact with the GABAergic cell bodies giving rise
to the descending striatonigral pathway, since an increase of GABA
turnover has been demonstrated following DA receptor stimulation.
Cholinergic intemeurons may be involved in the control of both the
descending GABA pathways and the GABA interneurons within the striatum
itself (106).
2.1.4 Lesions of the nigrostriatal pathway
It is possible to study the interactions between the various
neuronal systems and to elucidate the neuronal circuitry of a region
such as the striatum, by selectively manipulating one system and
- 43 -
examining the effect on the others. Lesioning of the substantia nigra,
where the cell-bodies of the DAergic neurons terminating in the stria¬
tum are located, has been frequently employed in the study of the fun¬
ctional importance of the nigrostriatal DAergic pathway in the control
of behaviour. Unilateral intracerebral injection of the neurotoxin
6-hydroxydopamine (6-OH-DA) directly into the DAergic cell-body region
of the substantia nigra of a rat induces a selective degeneration of
the entire nigrostriatal DAergic neuronal system and disappearance of
DA from the striatum (107). The lesion causes deviation in the animal's
movements and posture towards the lesioned side (107,108)| this has
been attributed to the imbalance in DA neurotransmission in the two
sides of the brain (8). DA releasing drugs, e.g. amphetamine, induce
a dose-dependent rotation of the rat towards the side with the lesion,
whereas DA receptor stimulating agents, such as apomorphine, induce
marked dose-dependent rotation towards the non-lesioned side (110).
The fact that the animal moves away from the side where the DA receptors
are most stimulated, demonstrated by local injections of DA into the
striatum (ill), indicates that the rdation after the administration of
apomorphine is due to an increased sensitivity of the striatal post¬
synaptic DA receptors ('supersensitivity') on the denervated side, where¬
as the amphetamine-induced rotation is due to the release of DA from
the intact side of the striatum only. Low doses of neuroleptic agents,
i.e. DA receptor blockers, inhibit the turning behaviour induced by
DAergic receptor agonists (l*0). Cholinergic receptor agonists block
the turning induced by DAergic agonists, whereas anticholinergic agents
induce turning towards the side with the lesion (112). These findings
suggest that the synaptic contacts of the nigrostriatal pathway
- 44 -
et the striatal or nigral level may play a part in the circling behaviour
of rats with specific lesions of the DAergic neurons.
2.1.5 'Supersensitivity* of DA receptors after denervation
If receptors in the peripheral nervous system are deprived of
their natural chemical transmitter for son® time, they develop super¬
sensitivity to this substance (113). The same reason has been advanced
to explain the 'supersensitivity* phenomena after lesioning of the nigro-
striatal pathway in the central nervous system, e.g. the supersensitivity
of striatal postsynaptic DA receptors of the denervated side to system-
ically administered DA receptor agonists or iontophoretically adminr-
istered DA (114)*
However, the increased responsiveness to DA receptor stimulants
after nigrostriatal lesions might result from changes distal to the DA
receptor or in other systems. Alternatively, it could reflect a true
alteration of the DA receptor itself. Activity of a striatal DA-
sensitive adenylate cyclase, which appears to be associated with the DA
receptor, has been reported to be unaffected by nigrostriatal lesions
(115) or to be enhanced (116). It should be mentioned that the adenylate
cyclase activity in the substantia nigra is not affected after 6-OH-DA
lesions of this structure but it disappears after lesions of the striato-
pallido-nigral GABAergic or substance P-containing connections (56,18).
Enhanced DA receptor binding of (^H)-haloperidol has been found in the
denervated striatum (119)* This increased number of DA receptors could
account for the behavioural supersensitivity to DA agonists which dev¬
elops after lesions of the substantia nigra. Electrophysiological exper¬
iments produced evidence that the striatal cells on the lesioned side
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show higher firing rates than those on the control side (120). In
addition, the cells of the lesioned side respond to DA receptor agonists
(apomorphine and L-dopa) with a much greater reduction in their firing
rate than the cells on the intact side (121).
The "biochemical, pharmacological and behavioural events observed
after nigrostriatal lesions should be interpreted with caution, for two
main reasons;
(a) A close anatomical relation seems to exist between the two nigro¬
striatal systems (in the two sides of the brain), probably through a
nigro-thalamo-cortical pathway, which in t\im may project to the con¬
tralateral striatum and indirectly to the nigra through the stri-
atonigral pathways. Thus, a lesion made in the left substantia nigra
of the cat blocks the release of (^H)-dopamine in the ipsilateral stri¬
atum, but an increase in the release of (%)—dopamine in the contralat¬
eral side is observed. The opposite effect is produced by the applica»-
tion of DA in the left substantia nigra4 (122).
(b) Remaining DAergic neurons after partial destruction of the nigro¬
striatal pathway are hyperactive, with increased DA synthesis and util¬
isation (123). This is probably caused by a compensatory mechanism
induced by the DA deficiency at some postsynaptic receptor sites.
I
2.1.6 'Supersensitivity* in Parkinson's disease
In addition to its usefulness in the study of the nigrostriatal
neuronal connections, in the screening of potential DA agonists and
antagonists and in the study of the involvement of DA in the motor be¬
haviour, the rat rotational model has been proposed as a model of
Parkinson's disease (8). It has been suggested that the progressive
death of the substantia nigra cells and degeneration of the nigrostriatal
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Mergic pathway that occurs in Parkinson's disease (117) niay cause
denervation supersensitivity of striatal DA receptors. The effective¬
ness of L-dopa in the treatment of this disease can thus he explained
hy the idea that the DA synthesised from Ir-dopa acts predominantly on
the supersensitive receptors of the denervated striatum (110).
2.1.7 Effect of DA receptor agonists and antagonists on other neuronal
systems
All available evidence seems to suggest that, in the striatum,
DA exerts an inhibitory action on cholinergic mechanisms, whereas
acetylcholine (Ach) has, possibly by way of a feedback, an enhancing
action on striatal DAergic mechanisms. Thus, drugs which are supposed
to selectively block DA receptors in the striatum (such as most of the
neuroleptic agents) as well as cholinergic agonists, increase the syn¬
thesis and release of DA in the striatum (54, 118) | the former drugs
also increase the Ach release or decrease its levels (124,125). Con¬
versely, compounds with DAergic agonist action (L-dopa, amphetamine,
apomorphine) decrease the Ach release in this region (124,125). In
addition, anticholinergic agents (in high doses) seem to cause a dec¬
rease in striatal DA turnover (126) and cholinergic agonists, such as
oxotremorine, to cause an increase (54).
As suggested by Kebabian and Greengard (127) for the peripheral
autonomic ganglion, stimulation of DA receptors produces post-synaptic
inhibition resulting in hyperpolarization ( 30 ) and decreased release
of Ach. This latter effect could lead to accumulation of transmitter
in striatal interneuronal cholinergic nerve terminals, and consequently
the levels of Ach would be higher. Similarly, blockade of DA receptors
produces disinhibition of the cholinergic interneurons, which leads to
their overactivity and a marked release of Ach, and consequently decreased
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levels of this transmitter.
Pharmacological evidence suggests the possibility of a DAr-GABA
interrelation at the level of the basal ^nglia (129). It has been shown
that drugs increasing ffABA concentrations in the brain reduce DA turn¬
over in the striatum (130,131). Conversely, prolonged administration
of Ir-dopa increases the activity of the GABA-synthesizing enzyme GAD
in the striatum (132), indicating an enhancing effect on the GABAergic
activity.
Prom these and other studies, the conclusion may be drawn that
the interactions between the neuronal systems play an important role in
the normal function of the basal ganglia and that disturbance of one of
these systems will frequently be followed by changes in the others,
which can be predicted.
2.1.8 GABA: post-mortem changes
GABA appears to increase rapidly in brain tissue after death.
Since Elliot and Florey, in 1956 (133) observed that the GABA content of
brain tissue increased after excision, there have been several confict-
ing studies dealing with the magnitude and time-constant of this inc¬
rease. Lovel and Elliot (134) observed increases of about 30 per cent,
2 min after decapitation, followed by a steady but slower increase.
Minard and Mushahwar (135) reported that GABA levels reached a plateau
within 1-2 min, without further increase. Shank and Aprison (136) rep¬
orted changes in several brain areas as early as 30 sec and lasting for
at least 10 min post-mortem. Alderman and Shellenberger (137) found
that a post-mortem increase in GABA levels begins at 60 sec, reaches a
maximum rate of increase between 60 and 120 sec and continues until the
4th min, and then shows a plateau. The post-mortem inorease found by
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the last two investigators was ahout 30 per cent of "basal levels.
Exposure to a microwave field has been proposed recently as a
means of killing animals in order to inactivate enzymatic processes
and prevent post—mortem changes (133). GAD appears to be totally inact¬
ivated after a 2 sec exposure of the brain to microwave irradiation,
while the GABA content and distribution in various brain nuclei is not
affeoted (86). Post-mortem increments during the first 3 min following
decapitation range up to 5 times the levels measured following micro¬
wave exposure.. This study (86) reported no correlation betiieen GAD
and endogenous GAM levels, but a significant correlation was found
when the rats were decapitated and the tissues dissected within 3 min.
Other investigators (139) also using microwave radiation, found
only 18 per cent post—mortem rise of GABA in brain tissues when the
rats were decapitated and the tissues excised at room temperature with¬
in about 2 min after death. They found, in addition, much lower levels
of GABA than those previously reported for brain regions, but a close
correlation of the distribution to the regional distribution reported
in the literature (assessed without the use of microwave fixation).
The controversy over the use of microwave irradiation as a means
of killing animals and the lack of sufficient evidence for the functional
importance (as well as the real extent) of the GABA formed post-mortem
make the interpretation of results involving this aminoacid difficult,
and its value questionable, unless other measures of the activity of
GABAergic neurons are included.
2.1.9 Purpose of the present study
The concept of a functional neuronal interaction that involves DA,
Ach and GABA in the substantia nigra and the corpus striatum initiated
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our interest in an investigation into the effects of interruption of
the nigrostriatal DAergic neuronal pathway upon the activity of neurons
utilising Ach and GABA within the two structures. Also, it was of inters
est to study and compare the effect of drugs which are known to act
primarily on DA receptors, upon DA metabolite levels (as an index of
DA neuronal activity) after destruction of the cell bodies of DAergic
neurons, in order to obtain some information about the site of their
action# The administration of the DA receptor agoniBt apomorphine, in
particular, known to elicit the •supersensitivity* phenomenon in rats
with lesions of the substantia nigra, was used as a tool for the bio¬
chemical characterisation of this phenomenon with regard to the DAergic
system or the cholinergic or GABAergic systems supposedly linked to it
functionally#
The elucidation, in particular, of the mechanism by which the
GABAergic and the cholinergic system may be affecting the function of the
nigrostriatal pathway, was tentatively considered and several proposed
alternatives assessed in the light of the findings of this study.
Although as has been consistently found by several investigators, uni¬
lateral destruction of DAergic cell bodies has a selective effect on
the DAergic system in the terminal area of the striatum, the cholinergic
and GABAergic systems may be in some way also affected. This secondary
effect may be seen on the enzymatic activities of choline acetyltrans-
ferase (CAT) and glutamic acid decarboxylase (GAD) as markers of the
activity of the respective neurons or on the GABA concentrations in the
striatum and the substantia nigra. In addition, further stimulation
of DA receptors by apomorphine or inhibition by haloperidol might yield
more information about the site and the nature of these interactions,
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as well as the site of action of these agents* This would provide
important clues to the overall actions of drugs thought to affect DA
neurotransmission, and could guide the search for new, more speoifio
drugs or for drugs without certain side effects*
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2.2 MATERIALS AMD METHODS
2.2.1 Intracerebral injection of 6-hydroxydopamine into the rat
substantia nigra
Albino Wistar male rats weighing 180-210 g were used. A rat
was placed in a plastic box and anaesthesia was induced by circulating
a mixture of fluothane-oxygen through the box. When anaesthetised,
the animal was transferred to the head-holder of a David Kopf No. 1530
stereotaxic instrument, where anaesthesia was maintained by circulating
the same gaseous mixture through a vinyl mantle over the animal's
nose and mouth. The concentration of anaesthetic (about 2 per cent)
was adjusted to give a moderately deep narcosis at this stage.
Blunt ear bars were used to fix the head position of the animal. A
sagittal cut was made in the skin over the skull of the rat and the
periosteum scraped off to expose the skull where the anterior suture
junction, i.e. the 'bregma', is located. With the aid of a
stereoscopic operation microscope (Carl-Zeiss) the injection needle was
adjusted to make contact with the bregma, the co-ordinates of this
point with reference to the stereotaxic instrument scales were
recorded and the needle was lifted up again. The needle was then moved
a predetermined distance (according to the co-ordinates chosen from
tiigerstedt (8) and Konig and Klippel (140)) in the antero-posterior
direction and in the lateral direction. A 2mm wide hole was drilled in
the skull with a dental drill and the tip of the needle was lowered to
a predetermined depth from the dural membrane. After the completion of
the injection, the hole in the skull was sealed with bone wax following
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the withdrawal of the needle and an antibiotic powder (puromycin
and neonycin mixture) applied locally before suturing the scalp
wound with a thread. After operation, the animals were kept warm
under an infra-red lamp.
The intracerebral injections of 6-hydroxydopamine (6-OE-DA)
were made routinely into the left side of the rat brain. 6-Hydroxy-
dopamine hydrochloride (Labkemi Ab,(Joteberg) was dissolved in
0.9?o (w/v) sodium chloride containing ascorbic acid (img/ml) to
prevent auto-oxidation. 8 jug of 6-OH-DA (calculated as the free
base) was delivered in a volume of 4 pi. The injections were made
through a 30 gauge needle which was connected to an 'Alga' micrometer
all—glass syringe (Wellcome Reagents) by PE 20 polythene tubing
(Portex). The 6-OH-DA solution was injected at a speed of 1 pl/min
by a motor drive. *Sham-operated' animals received an intracerebral
injection of the vehicle but without the 6-OH-DA.
The co-ordinates used for animals of about 200 g were:
antero-posterior (a-P)-4»2; lateral (l)-1.2} vertical (v)-7.6.
An ipsilateral spontaneous turning, as described by TJhgerstedt (8)
was observed on recovery from anaesthesia after the operation.
Ungerstedt (107) demonstrated that rats with a lesion of the
nigro-striatal DAergic pathway or of the substantia nigra by the
injection of 6-OH-DA showed anterograde and retrograde degeneration of
the terminals in the caudate-putamen and of cell bodies in the
substantia nigra. Animals with this type of degeneration in the
nigro-striatal DAergic system showed contralateral circling movements
when apomorphine was injected intraperitoneally, and ipsilateral
circuling movements when amphetamine was injected.
The intraperitoneal injection of apomorphine (0.25mg base/^g) into
rats, one week after the operation, was used as a reliable behavioural test
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for successful lesioning. Rats that performed more than 200
contralateral turns within the first 25 min after a single dose of
apomorphine were selected for the biochemical assays. Ungerstedt (8)
demonstrated that degeneration of the nigrostriatal pathway occurred
within 2 weeks after the intracerebral injection of 6-OH-DA.
Histological examination of the brains from a number of animals
injected with 6-OH-DA showed the production of a lesion in the desired
position. Sections of the brain were cut in a cryostat and stained by
the luxol fast blue-cresyl violet method (described in Section 5)* On
examination of the serial sections and by reference to the rat brain
atlas of Konig and Klippel (140 ) it was found that the lesion was
situated in the commencement of the nigrostriatal DAergic ascending
pathway and it avoided the majority of the noradrenergic ascending
axons (8).
2*2.2 Biochemical determinations
Rats were killed by decapitation and the brains quickly excised
and placed in the ice-cold saline solution. Left and right sides of
both striatum and substantia nigra were then carefully dissected out
(as described in Section 1, 1.2) and the tissues frozen in liquid
nitrogen within 2-3 min.
2.2.2a Determination of homovanillic acid (H7A) and
3,4-dihydroxyphenyl acetic acid (POPAC)
The concentrations of (HVA) and (DOPAC) in the striatum were
measured according to the gas chromatographic procedure described in the
Appendix.
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2.2.2b Measurement of y-aminQbutyric acid
The aminoacid ^-aminobutyric acid (GABA) was measured in the
corpus striatum and the substantia nigra of the rat brain, with a
sensitive gas chromatographic technique based on the method published
by Pearson and Sharman (141).
The method involves homogenisation of the tissue, precipitation
of proteins and isolation of GABA by passing the clear supernatant
through a column filled with an Araberlite CG120 resin on which the GABA
is retained, and elution of the aminoacid with ammonium hydroxide (NH^H).
The alkaline eluate is evaporated to dryness and the residue is reacted
with trifluoracetic anhydride and hexafluoroisopropanol. After
evaporation to dryness under nitrogen, the residue is reacted with
trifluoracetic anhydride and hexafluoroisopropanol. After evaporation
to dryness under nitrogen, the residue is redissolved in ethyl acetate
and injected into the gas chromatograph fitted with an electron capture
detector.
The assay procedure is outlined below: Brain tissues dissected on
ice as quickly as possible were immediately immersed in liquid nitrogen
where they could be kept until the day of the assay (up to one month).
For analyses, a tissue sample was weighed and homogenised in a 1.5 ml
plastic centrifuge tube ('Bppendorf*) with 800 pi of ice-cold 0.1 M HQL.
The proteins were precipitated with 50 pi of concentrated (72p v/y)
ice—cold perchloric acid (PCA) and following addition of a saturating
amount of potassium chloride (KCl) the mixtures were centrifuged for
4 rain at 14,000 g in a bench centrifuge (*Eppendorf»). The clear
supernatant tvas transferred to a fresh tube. A portion, 25 pi, was
diluted to 1 ml with cold 1 M HC1. (The remainder of the supernatant
fluid was used for the assay of HVA and DOPAC). 0.5 ml of the acidified
- 55 -
supernatant was allowed to flow through a paateur pipette filled to
a depth of 2 cm with the Amberlite CO 120 cation exchange resin
(100-120 mesh) (pretreated as described below) and fitted with cotton
wool at one end to retain the resin. The column was washed with 10 ml
of distilled water in 2 ml portions. The GABA was eluted from the
column with 2 ml 2 M NH4OH directly into a 3 ml reaction vial
('Reacti-vials*, Pierce Co). The eluate was then frozen at —40°C
(in a deep freeze) and freeze-dried (jigtool freeze-drier) overnight.
The dry residue was reacted at room temperature for 2 hours with
0.2 ml trifluoracetic anhydride (Aldrich Chem. Co.) and 0,1 ml
hexafluoroisopropanol (HIM). After the 2 hours, the solution in the
vial was evaporated to the point of dryness, at room temperature, under
a stTeam Df dry nitrogen and redissolved in 1 ml ethyl acetate
(Reeve Angels - CT grade).
Samples of 2 fii were injected into the gas chromatograph with
an automatic injector every 30 min, with column temperature 92°C and
gas flow at 60 ml/min (corresponding to a pressure of 40 p.s.i.). The
Hewlett-Packard model 7000 gas chromatograph was fitted with an electron
capture detector arranged at 220°C for this assay. The carrier gas was
a mixture of argon^S^-methane 9^. The glass column was 9ft long,
packed with 2% SE 52 coated on Diatomite CQ (100-200 mesh).
Before the application of the sample, the Amberlite resin was
treated as followBS An amount of resin sufficient for several assays
was suspended in 3 volumes of 2 M NH^OH and stirred for 5 min. The
NH.OH was decanted and the resin was washed five times with distilled
4
water by stirring and decantation and HC1 (3 vol. 2M) was added to the
resin and the suspension stirred for 5 min* The HC1 was removed by
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decantation and washing of the resin with 5 portions of distilled
water. The acid treatment and water wash were repeated twice. After
the last water wash a slurxy of the resin in water was poured into a
pasteur pipette, plugged with a small amount of cotton wool, to give a
resin column of 2 cm. The column was treated "by the passage, in
succession, of 2 ml NH^OH 2 M, 3 ml distilled water, 2 ml HC1 1 M
and finally 10 ml distilled water. The acidified tissue extract was
then applied to the column as already described.
Standard GABA solutions in NH^OH 2 M were added into reaction
vials at different concentrations (10-500 ng) and processed in
parallel with the column eluates of tissue samples. Standard curves
of peak area versus ng of standard GATSA were made with all assays and
the unknown samples determined accordingly. The peak area increased
linearly in proportion to amounts between 10-500 ng (the linearity was
not assessed beyond 500 ng). The recoveries of authentic GABA added to
brain homogenates was 80 + Tf0 (n ■ 14)» Results were not corrected for
recovery. The lowest limit of sensitivity of the method was about 1 ng.
2.2.2c Determination of glutamic acid decarboxylase activity
The activity of the enzyme glutamic acid decarboxylase (GAD)
in the corpus striatum and the substantia nigra of the rat brain was
measured with a combination of the radiochemical assay methods of
Urquhart et al (142) and Drummond and Phillips (143)• The method involves
the measurement of the amount of radioactive carbon dioxide evolved from
L — 11—-glutamic acid on incubation with a tissue homogenate in the
presence of pyridoxal phosphate, an essential cofactor of the enzyme.
Labelled carbon dioxide is trapped in protozol, a strong base-solubilizer,
and measured by liquid scintillation counting.
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Assays were carried out within two days of obtaining brain
samples which had been stored frozen. Homogenates (10 pl/jug tissue)
of brain tissue samples were prepared in 1.5ml plastic centrifuge tubes
(Eppendorf) using an electrically driven tissue horaogeniser (Griffin
and George) with teflon pestle (jencons) in 1 mM potassium phosphate
buffer, ice-cold, pH 6.5 (containing 0.1% V/y Triton X-100 and 0.1 mM
pyridoxal-^-phosphate).
The incubation medium contained (final concentration) 100 mM
potassium phosphate buffer pH 6.5, 0.5 mM pyridoxal-5-phosphate,
0.5nM dithiothreitol, 1.22 mM L -(1-^0^-glutamic acid (specific
activity 55 mCi/„_„^ Amersham), 0.5 mM unlabelled glutamic acid,
0.1 raM Triton X-100,, sodium arsenite and distilled water (10% V/^).
Tbe homogenate (10 pi) and the incubation mixture (10 pi) were
placed in an 1.5 ml plastic centrifuge tube (Eppendorf), which was in
turn placed uncapped in a scintillation vial continaing 25O pi of
protozol solubilizer. The scintillation vial was closed with a rubber
seal (*Suba seal1) to give a gas tight closure. After incubation
accompanied by shaking for 20 min at 37°C in a water bath, the reaction
was terminated by the injection of 100 pi 3 M HgSO^ into the plastic
tube through the rubber seal. The vial was left in the water bath at
37°C for 1 hour, in order to allow complete absorption of the released
^C02 by the protozol. The £ppendorf tube was removed and the
outside washed with 2 ml ethanol, the washing being added to the
protozol. Toluene scintillant (10 ml) was then added to the fluid in
the vial, the contents mixed and the vial was placed in the scintillation
counter (Nuclear Chicago Mark II) and the radioactivity measured for
1 min.
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GAD enzyme assays were carried out in duplicate. The counting
efficiency was 68 per cent. Results of the enzyme assays were averaged
and corrected for any radioactivity observed in assay blanks. Protein
content of tissues was determined by the method of Lowry et al (144)
in duplicate 5 ^1 aliquots of the homogenates with bovine serum albumin
as the standard, using a Gilford 250 spectrophotometer. The results
were expressed as n moles ^C02 formed per mg of protein in the tissue
sample per hour of incubation. Assay blanks, consisting of tissue
homogenates (10 pi) without radioactive glutamate or of reaction mixtures
without homogenates, were processed in parallel with the tissue samples.
Both blanks gave about the same number of counts, which were subtracted
from the counts obtained from the tissue samples in the calculation of
results.
Measurement of counting efficiency
f14 1
10 pi of a standard solution of toluene-/ C-methyl | with specific
activity was added in a vial, mixed with 10 ml of toluene
— 6
scintillation fluid and counted for 1 min. Since 1 pCiz.2.22 x 10 dpm,
0.01 pCi^2.22 x 10^" = 22,200 dpm. The efficiency is the ratio:




The number of cpm obtained from each sample, after subtraction of
the blank values, were corrected for the counting efficiency, the time of
incubation, the amount of protein present in the aliquot of the homogenate
used in every individual assay and the specific activity of the radioactive
glutamate in the assay. The following formula was used for the
calculation of the results:
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(cpm-"blarik:,,cpm) x 100 x 60roin 1 Inmole C0^
efficiency 20rain x ^protein/ xdpm liberated/ *
^tissue nmole^C02
n moles 1^C0? formed per mg of protein in the tissue sample per hour
of incubation.
Reagents
Dithiothreitol or CIsland's reagent (DTT), from Koch—Light;
pyridoxal-p-phosphate (PLP) and Lr-glutamic acid (potassium salt) from
Sigma Chem. Co.; Sodium arsenite from BDH; /l -1^'cJ -L-glutamic acid,
specific activity 23 mCi/j^g^ from Amersham Radiochemical Centre;
Protozol, from New England Nuclear; 2,5-diphenyloxazol (PPO) and
1,4-di-( 2-(4-methyl-5-phenyloxazolyl)-benzene] (P0P0P), from
Koch-Light. The toluene scintillation fluid contained 8.5 g PPO and
0.225 g POPOP in 2 1 toluene.
All other reagents and solvents were of analytical grade.
2.2.2d Determination of choline acetyltransferase activity
The activity of the enzyme choline acetyltransferase (CAT) in rat
brain areas (corpus striatum and substantia nigra) was measured with
the rapid radiochemical method of Fonnum (145)• The method involves
measurement of the radioactive acetylcholine (Ach) formed from 1-^C -
acetylcoenzyme A and excess choline, by an activated tissue preparation
at a pH of 74i in the presence of eserine (acetylcholinesterase
inhibitor) and a high concentration of NaCl. The labelled Ach formed
is then isolated by liquid cation exchange using sodium tetraphenylboron
(kalignost) in acetonitrile and toluene scintillation mixture, and the
extraction is carried out directly in the scintillation vial.
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Labelled Ach is then determined by liquid scintillation counting at
high efficiency in the biphasic aqueous toluene scintillation solution
mixture.
Homogenates (10 jul/mg tissue) of corpus striatum and substantia
nigra were prepared in 1 mM EDTA ice-cold, pE7.0 (containing
0.1 v/y Triton x-100 for the total activation of the enzyme). The
tissue samples were homogenised in 1.5 ml plastic eppendorf tubes
using an electrically driven tissue homogeniser (Griffin and George)
with teflon pestle (jencons). The homogenates were kept on ice until
the incubation.
The incubation mixture contained (final concentration). 0.2 aiM
Q~Ucj -acetyl-CoA, 20 mM EDTA pH 7«4» 20 mM choline chloride,
600 raM NaCl, 100 mM sodium phosphate buffer pH 7«4» 0.2 mM eserine
salicylate and 1 mg/mi bovine serum albumin. The labelled
acetyl-CoA (specific activity 58 raCi/mmol) was mixed- with the unlabelled
compound to give a final concentration of 2 mM.
The tissue homogenate (10 ^.l) was placed in a stoppered 15 ml
glass centrifuge tube with conical bottom and the incubation mixture
(10 pi) was added. The solution was mixed and incubated with shaking
for 15 min at 37°C in a water bath. At the end of the incubation, the
tubes were placed on ice, and the reaction was terminated by the
addition of 5 ml of ice-cold 10 mM sodium phosphate butter, pH 7»4,
containing 250 pg of acetylcholine chloride. 2 ml of acetonitrile
(containing 10 mg of kalignost) was then added to the tube and the
mixture was shaken and transferred to a scintillation vial, followed
by the addition of 10 ml of toluene scintillation fluid. The liquid
in the vial was vortex mixed for 1 min, during which the Ach was
extracted into the toluene phase, whereas the acetyl-CoA was left in
- 61 -
the aqueous phase. The scintillation vial was placed in the
scintillation counter and the two layers were allowed to separate
14.
for 30 min. The samples were counted for C for 10 min.
Enzyme assays were carried out in duplicate. The counting
efficiency was 67 per cent. Results of the assays were averaged and
corrected for any radioactivity observed in assay blanks. Protein
content of tissues was determined by the method of Lowry et al,(144)
in duplicate 5 ul aliquots of the homogenates, with bovine serum
albumin as the standard, using a Gilford 250 spectrophotometer.
The results were expressed as n moles 1-1^C-Ach formed per mg of
protein per hour of incubation. The counting efficiency was measured
as described for the GAD assay. The number of counts per min (cpra)
obtained from each sample, after subtraction of the blank values, were
corrected for the counting efficiency, the duration of the incubation,
the amount of protein present in the portion of the homogenate used
in every individual assay and the specific activity of the
radioactive acetyl-CoA in the assay. Blank samples were prepared
as in the GAD assay.
Reagents
1—14cj-acety1-CoA specific activity 58 mCi/mmol, fr°ra Amersham
Radiochemical Centre?
acety1-S-CoA and bovine serum albumin, from Sigma Chem. Co.;
choline chloride, acetylcholine chloride and eserine salicylate, from
BDH}
2,5-diphenyloxazol (PPO) and 1,4—di-^2-(4-methyl-5-phenyloxazol)-
benzenej (POPOP), from Koch-Light}
tetraphenylboron, sodium salt (kalignost) from Fluka.
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The toluene scintillation fluid contained 8.5 g FPO and 0.225 g
POPOP in 2 1 of toluene.
All other reagents and solvents were of analytical grade.
2.2.2e Estimation of dopamine and noradrenaline in the striatum
The estimation of dopamine (DA) and noradrenaline (NA) in the
striatum was carried out using a radiometric assay employing
methylation of endogenous DA and NA by catechol-O-methyl transferase
(COMT), with S-adenosyl—(methyl—^H)—methionine as methyl donorf
followed by extraction and measurement of the labelled 3-methoxytyraraine
and normetanephrine formed. The method used was derived from that
described by Palkovits et al. (147)* The assay procedure is outlined
be lows
Striatal tissue (about 20 rag) was homogenised in 0.1 M
perchloric acid (300 pi/10 mg tissue). The homogenate was centrifuged
at 10,000 g for 15 min and 300 pi of the supernatant fluid used for
the subsequent assay. 300 pi aliquots of 0.1 M perchloric acid were
used as blanks and standards of DA added to brain extracts were run
with all assays.
Standards, samples and blanks were reacted with labelled
&-adenoaylmethionine in the presence of COMT.300 pi of samples were
added to a mixture containing 500 p.g of dithiothreitol, 0.5 ^pmol
MgCl2» 140 pmol Tris-HCl buffer pH 9»6, 2.5 pi of rat liver COM1
(prepared as described by Axelrod and Torachick, 146) and 2.5 pCi of
S-adenoxyl-(methyl-^H)-raethionine. After incubation at 37»5°C for
1 hour, the reaction was stopped by the addition of 500 pi 0.5M
borate buffer, pH 10. After addition of non-radioactive carrier
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(7 jig methoxytyramine and 7 pg normetanephrine) and 1 pg EDTA in
a total volume of 50 pl» the O-raethylated reaction products were
extracted into 9 ml of waters-saturated ethyl acetate-methanol
(10:1 v/y) by shaking for 30 sec. The phases were separated by
centrifugation (1,000 g for 5 min) and 0.5 ml of the organic layer
transferred to another tube containing 0.5 ml of 0.5 M borate buffer
(pH 10). After vortex mixing for 15 sec and centrifuging for 5 min,
8 ml of the organic phase were transferred to another tube
containing 0.5 ml of 0.1 M HC1 into which the 0-methylated products
were extracted into the aqueous phase by mixing on a vortex for
30 sec. The tubes were centrifuged for 5 min and the organic phase
was aspirated and discarded. The acid aqueous phase was washed with
an additional 8 ml of water-saturated ethyl acetate by mixing for
15 sec and, after centrifugation, the ethyl acetate was aspirated and
discarded.
The procedure so far described results in the methylation of
both NA and DA and the extraction of their methylated derivatives.
In order to separate normetanephrine (NA derivative) from
methoxytyramine (DA derivative), the side-chain of normetanephrine
is cleaVed by metaperiodate at the fj-hydroxyl position to form
vanillin, which is then separated fromnethoxytyramine. To this aim,
the aoid aqueous phase described above was reacted with 50 pi of
3$ (w/y) sodium metaperiodate and 0.5 ml of 0.5 M sodium phosphate
buffer (pH 7*5) for 3 min at 0°C. The reaction was stopped by the
addition of 50 pi of 10$ (v/y) glycerol and 10 ml of toluene was
added. After vortex mixing for 30 sec and centrifugation, the toluene
layer was separated and used for NA estimation as it contained the
labelled vanillin. The aqueous phase contained labelled
- 64 -
methoxytyramine and was saved for the DA determination. 5 ml of
toluene was added to the aqueous layer and the mixture shaken and
centrifuged to separate the two phases. 0.5 ml of 1 M borate buffer
(pH 11)t and 6 ml of toluene-isoamyl alcohol (3:2) was added to the
aqueous layer. After mixing and centrifugation, 5 ml of the organic
layer was taken and added to 10 ml of NE 260 liquid scintillation fluid.
All samples were counted for 10 min.
To assay NA, the tubes containing 1 N NaOH and toluene (after
the periodate cleavage reaction) were mixed, the organic phase
removed and the aqueous phase containing the "H - methyl-vanillin
was acidified with 0.1 ml of glacial acetic acid. 10 ml of toluene
were added to each tube and the tubes were shaken for 30 sec. 9 ml
of the organic phase were transferred to a scintillation vial
containing 0,4 ml of Liquifluor (scintillation fluid) and counted
for 10 min. Blanks and control samples containing known amounts of
NA and DA were run in parallel with the unknown tissue samples.
Efficiency of radioactive counting
Efficiency of the counting of the tritiated products of the
DA-NA assays was 2>0fo* All samples were corrected for quenching by
the external standard channels ratio method.
Reagents
Dithiothreitol or Cleland's reagent (DTT), from Koch-Light;
S-adenosy1-(methyl-^H)-methionine, specific activity 5-15 Oi/.ii„,ni
from the Radiochemical Centre, Amersham; 3-methoxytyramine and
normetanephrine, from Sigma; NE 260, from Nuclear Enterprises Ltd;
Liquifluor, from New England Nuclear Corp.
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2.2.2f Statistical analysis
The significance of the difference between two independent
samples was determined by Student's t test. The differences between
arithmetic means were evaluated by the Student's t test for unpaired
data, whereas the difference between individual paired data was
evaluated by the Student's t test for paired samples. The
distribution of the results was sufficiently close to normal and
the number of results in each group usually greater than 5» thus
allowing the application of parametric statistics.
Results presented in the form:
X + sd(n)
represent a mean (X) plus or minus the standard deviation (sd) of
n observations. A two-tailed Student's t test was routinely applied.
The confidence limit used in assessing statistical significance
was that the probability (p) was less or equal to 0.05.
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2.3 RESULTS
2.3*1 Dopamine metabolism in the corpus striatum after 6-hydroxy-
dopamine leBions of the substantia nigra
Destruction of the catecholaminergic cell bodies in the
substantia nigra with 6-OH-DA caused degeneration of the
nigrostriatal DAergic pathway, including the axons and the nerve
terminals in the corpus striatum. This was evident in the DA levels
of the striatum, in the side ipsilateral to the lesion, which fell
hy 90/0 compared to the contralateral side (Table 2.1). This effect
of the lesion, which was observed 1-2 months after the operation,
confirmed similar results reported in the literature. Surprisingly,
the concentrations of HVA and DOPAC in the ipsilateral striatum were
only reduced by about 30$ of those of the intact side (Table 2.1).
When the destruction of the nigral DAergic cell bodies was
complete, as in another group of animals, the disappearance of DA
from the ipsilateral striatum was almost total (98^), but the HVA and
DOPAC concentrations were again reduced by only 40 and 43/S,
respectively, of those of the intact striatum (Table 2.1).
The lesion had no significant effect on the amine or on the
metabolite concentrations in the contralateral striatum, these being
not significantly different from those of control animals,' the
concentrations of DA or of the metabolites in the ipsilateral striatum
were significantly lower than in the contralateral side.
Table2.1
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2.3.2 Effect of treatment with apomorphine or haloperidol
on dopamine metabolism
Apomorphine, administered at a dose of 1 mg/kgi.p. 20 min
before decapitation of the animals, produced in the striatum
contralateral to the lesion a significant decrease in both HVA
and DOPAC (p<^0.05), but it failed to alter the levels of the two
metabolites in the ipsilateral striatum, compared to the same side
in lesioned animals injected with saline solution (Table 2.2).
Haloperidol, given at a dose of 1 mg/kgi.p. 30 min before
killing caused a significant rise to 247 and 245$ in HVA and
DOPAC, respectively, in the striatum ipsilateral to the lesion
compared to the same side in saline treated rats. The concentrations
of HVA and DOPAC in the striatum contralateral to the lesion were
329 and 333$» respectively, of those in the same side of saline-
treated rats (Table 2.2).
After treatment with haloperidol the concentrations of HVA and
DOPAC in the striatum ipsilateral to the lesion were significantly
lower than the concentrations in the contralateral side, i.e. 50$
of the contralateral side. On the contrary, after apomorphine there
was no significant difference between the levels of the metabolites
of the two sides (Table 2.2).
2.3.3 Changes in GABA levels of the striatum and the substantia nigra
The concentration of GABA in the denervated side of the
striatum (Table 2.3) was significantly higher than in the intact side
(p<^0.001, paired t test). Treatment of the animals with apomorphine
at a dose of 1 mg/1<gi.p. 30 min before killing led to a significant
increase of GABA in the striatum contralateral to the lesion,
Table2.2
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compared to the same side in lesioned animals treated only with saline
(pN0.05)t t>ut had no significant effect on the denervated side
compared to the same side of lesioned animals treated with saline.
Thus, the balance between the two sides with regard to GAM seems
to have been restored, as was found with the levels of HVA and
DOPAC after apomorphine administration (Table 2.2).
Treatment of rats with haloperidol (1 mg/fcgi.p.) 60 min
before killing, produced no significant effect on the GABA
concentration of the intact side of the striatum compared to control,
whereas a significant reduction was obtained in the denervated
striatum compared to the same side in saline treated animals
(p<^0.05). The concentration in the denervated side was significantly
lower than in the intact side following the administration of
haloperidol (p<fo.01, paired t test).
In the substantia nigra (Table 2.4), the lesion produced a
significant reduction of GAM concentration in the destroyed left
side compared to the right side which was not affected by the
6-0H-M injection (p<^0.01, paired t test). Administration of
apomorphine (1 mg/^i.p.) to successfully lesioned animals, 30 min
before decapitation, caused no significant effect on GAM in the
intact side of the substantia nigra compared to the same side in
lesioned animals treated with saline, but the reduction in the
lesioned side was restored by a significant increase of the GAM
levels in this side, compared to the lesioned side in animals treated
with saline (p<^0.01). A significant difference was found between
the lesioned and the intact side in rats treated with apomorphine
(p^0.01, paired t test).
Table2.U
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Administration of haloperidol (1 mg/^gi.p.), 60 min before
decapitation, caused no significant effect on GABA concentration in
the intact side of the substantia nigra compared to the same side in
animals treated with saline, but it restored the balance between the
two sides by a significant increase of the GABA levels in the
lesioned side compared to the same side in animals treated with
saline (p-^0.05).
2.3.4 Lesion-induced changes in enzyme activities (Fig. 2.1.)
Choline acetyltransferase (CAT) (Tables 2.3 and 2.4.)
6-hydroxydopamine lesions successfully placed in the substantia
nigra caused a significant fall in the activity of the enzyme CAT
in the lesioned side compared to the intact side of this region.
In the corpus striatum a significant rise of the enzyme was
observed in the ipsilateral compared to the side contralateral to
the lesion (p<^0.005 and p<(0.001, paired t test, respectively).
Administration of apomorphine at a dose of 2 mg/kgi.p.,
30 min before killing, caused no significant effect on either side
of the striatum, the side ipsilateral to the lesion still having
higher CAT activity compared to the contralateral side (p<^ 0.001,
paired t test). In the substantia nigra, apomorphine produced a
further decrease in the lesioned side, and the imbalance of CAT between
the two sides remained (p<C,0.05, paired t test).
Administration of haloperidol (1 mg/^gi.p.), 1 hour before
decapitation, produced no significant effect on CAT activity of
either side of the substantia nigra, and, therefore, the lesioned
side was still lower than the intact side with regard to the CAT
enzymatic activity (p<^0.05» paired t test). In the striatum,
haloperidol did not alter the lesion-induced imbalance; the
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ipsilateral side was still higher than the side contralateral to the
lesion (p ^0.001).
Groups of sham-operated animals were subjected to the same
treatment (i.e. saline, apomorphine, haloperidol) and showed no
imbalance in CAT between the two sides of the striatum cr the
substantia nigra.
Glutamic acid decarboxylase (GAP) (Tables 2.3 and 2.4)
Similarly to CAT, GAD activity was higher in the ipsilateral
compared to the contralateral striatum (p<^0.05, paired t test) in
successfully lesioned animals, but it was significantly lower in the
lesioned compared to the intact side of the substantia nigra
(p<0.05» paired t test).
Apomorphine (2 mg/, i.p.), given 1 hour before killing, had a
to
stimulating effect on the activity of GAD in the intact side of the
substantia nigra (p<^0.0l) but no significant effect on the activity
in the lesioned side, so that an imbalance between the two sides was
produced (lesioned side lower than the intact side) (p<0.00f;,
paired t test).
Haloperidol (1 mg/^gi.p.), given 1 hour before killing, had no
significant effect on the GAD in the intact side, but it caused a
marked increase of GAD in the lesioned side of the substantia nigra,
which thus became significantly higher than the intact side
(p<^0.05, paired t test) and than the lesioned side of saline-
treated animals (p<(0.005).
In the striatum, apomorphine had no significant effect on either
side's GAD activity compared to the same side of saline-treated
lesioned animals, but the imbalance between the two sides with regard
to the GAD was eliminated to the extent that no significant difference
was any longer observed between them. In the same region,
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haloperidol produced a significant reduction of GAD activity in the
side contralateral to the lesion hut had no significant effect on
the enzyme activity in the side ipsilateral to the lesion, thus
leading to an imbalance similar to that observed in saline-treated
animals•
Sham-operated animals, treated with saline or apomorphine or
haloperidol showed no difference in GAD between the two sides in the
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2.4 DISCUSSION
2.4*1 The primary effect of the lesion; degeneration of the dopaminergic
pathway
It is well known that lesions of the substantia nigra, which con¬
tains the cell bodies of DAergic neurons, innervating the striatum,
cause orthograde degeneration of the axons and nerve terminals of these
neurons (8). This is reflected in a significant depletion of DA from
the denervated striatum (107)• Due to the high specificity of the
6-OH-DA-induced lesion (l49)» the deviation in movements and posture of
the animal towards the lesioned side (8,107) is in all probability an
expression of the imbalance in DA transmission induced by the lesion.
Total DA loss in the striatum is not usually achieved by the nigral
6-OIKDA lesion; the extent of the lesion (loss of cells from the sub¬
stantia nigra) determines the extent of DA loss in the ipsilateral stri¬
atum in the case of almost complete lesions (150).
In the present study, the changes in the DA levels of the striatum
were found to be comparable to those reported in the literature. Les¬
ions of the substantia nigra produced, in separate groups of animals,
reduction of DA concentrations by 98 and by 90 per cent. Since the
substantia nigra seems to be the exclusive source of striatal DAergic
innervation (8) the reduction of the DA levels in the striatum probably
mirrors the extent of the lesion damage, -unless compensatory changes
occur. Increased activity of the remaining intact neurons in the les¬
ioned side would result in increase in the synthesis and utilisation of
DA. Indeed, an increase in DA synthesis and turnover was found by Agid
-11-
eX al.(l23) to result from a partial degeneration of the nigrostriatal
DAergic pathway, probably mediated through an unidentified feedback
process. The same process may be responsible for the discrepancy obser¬
ved in the present study between the changes in striatal DA concentrar-
tions and in the striatal concentrations of its main metabolites HVA
and DOPAC. Thus, disappearance of 98 per cent of DA in the denervated
striatum was accompanied by a fall in HVA and DOPAC concentrations of
only about 40 per cent. Similarly, a lesion which caused a 90 per cent
reduction in striatal DA levels (compared to the side contralateral to
the lesion) produced only a 30 per cent reduction in HVA and DOPAC
(Tables 2.1 and 2.2). A hyperactivity of the remaining intact neurons,
induced, perhaps, by the DA deficiency at some postsynaptic receptor
sites, and mediated through an unknown feedback mechanism, probably
induced a markedly accelerated turnover of DA in the partially dener¬
vated side.
The finding that the extent of DA deficiency is not proportional
to the extent of the deficiency in the metabolite concentrations, may
indicate that a large number of remaining intact neurons are hyperactive,
and that this number may be inversely correlated to the extent of the
damage. This interpretation is in agreement with the demonstrated
correlation between changes in NAergic neuronal activity and NA turnover,
both in central (27) and peripheral (26) neurons. The central DAergic
neurons also seem to behave in the same way, but a paradoxical increase
of DA synthesis as a result of tyrosine hydroxylase activation follows
cessation of impulse flow (25). The latter phenomenon, which occurs
after lesions of the nigrostriatal DAergic pathway, could explain the
finding of smaller percentage decrease in the concentrations of the
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metabolites of DA than in the concentrations of the amine. A reduction
of DA at the terminal area may result in a decrease of the end-product
inhibitory effect of DA on tyrosine hydroxylase, thus leading to increased
Synthesis and turnover.
2.4*2 Pre-and postsynaptic effects of apomorphine and haloperidol
The direct DA receptor stimulant apomorphine (109) had no signif¬
icant effect on DA metabolite concentrations in the denervated striatum,
although it caused a significant reduction in the striatum contralateral
to the lesion. Thus, the lesion-induced difference between the two
sides of the striatum with regard to HVA and DOPAC disappeared when the
rats were treated with apomorphine} the two sides seemed to have balanced
concentrations of the two metabolites, indicating equal turnover or met¬
abolism. The destruction of the majority of the fibres of the nigro-
striatal DAergic pathway appeared to prevent the reduction of DA turn¬
over that probably follows stimulation of DA receptors by apomorphine.
The presence of presynaptic DA receptors, which are involved in
the control of the rate of DA synthesis in the terminals of DA-contain-
ing neurons has been demonstrated (63). The presence of postsynaptic
DA receptors, probably located on cholinergic or GABAergic neurons of
the striatum (94»127) is well established.
Supersensitivity of postsynaptic DA receptors in the striatum
following lesions of the nigrostriatal pathway, manifested either in
increased number of DA receptor sites (119) or in increased activity of
DA-sensitive adenylate cyclase (116), or in the well known behavioural
supersensitivity (8), does not seem to be reflected in a change in DA
turnover following DA reoeptor stimulation. If the 'supersensitive' DA
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receptors were mediating the effects of apom °*bhine on DA turnover, an
increased effect would he seen in the denervated ♦supersensitive'side.
The lack of effect of apomorphine on DA metabolite levels in the den¬
ervated striatum would either indicate a subsensitivity of the presyn¬
aptic DA receptor population thought to be located on the remaining intact
neurons, or inactivation of the mechanism by which DA receptor stiraular-
tion results in decreased DA turnover in the intact striatum.
The finding that the lesion did not markedly prevent the effect
of the DA receptor blocker haloperidol on striatal HVA and DOPAC does
not exclude the possibility that the postsynaptic 'supersensitive' DA
receptors mediate the effect of this drug on DA turnover. The blockade
of the 'supersensitive' postsynaptic DA receptors in the striatum by
haloperidol does not appear to produce a 'supersensitive? response with
reference to DA metabolism. Additive effects may occur. The email
number of intact DAergic neurons may over-react in compensation for the
extensive denervation, and the effect of haloperidol is an increased
activity of the DAergic neurons. The unknown compensatory mechanisms,
induced by interruption of DA neurotransmission (by haloperidol) and
by the lesion, might be of similar nature.
In the light of the observations made by Seeman and Lee(l63), that
with electrically stimulated slices of brain tissue the stimulus-induced
release of DA was reduced by neuroleptic drugs (such as haloperidol),
whereas the spontaneous efflux of the catecholamines was increased, it
was suggested that neuroleptic drugs inhibit the coupling between the
nerve impulse and DA release from the nerve ending. The results of
the present experiments suggest, however, that the contribution of this
mechanism to the neuroleptio-induced increase in the striatal levels of
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HVA and DOPAC is a minor one. As Table 2.2 shows, i.p. administration
of haloperidol to rats lesioned in the substantia nigra with 6-OB-DA,
produced a 250$ increase of the metabolite concentrations in the ipsi-
lateral striatum, whereas in the contralateral side the increase was
not markedly higher, i.e. only 330$. Thus, the lesion and the consequent
destruction of the vast majority of the ascending DAergic fibres con¬
taining the presynaptic DA receptor sites, prevented the effect of
haloperidol on DA metabolism by only a small degree. This supports the
predominance of postsynaptic effects of haloperidol on DA turnover,
compared to the presynaptic ones. Cn the contrary, stimulation of the
presynaptic DA receptors seems to mediate the effect of apomorphine on
striatal DA metabolism.
The integrity of the nigrostriatal DAergic pathway, which appears
to be critical for the effect of apomorphine on striatal DA metabolism,
does not seem to be necessaxy for the increase in striatal DA turnover
induced by haloperidol. The exact mechanism or site of this action of
neuroleptics is not clear, yet. Although destruction of the nigrostriatal
DAergic fibres reduced to some limited extent the effect of neuroleptic
agents on DA-containing nerve terminals in the striatum, as the present
and previous studies by Bedard and Larochelle (164) have shown, destruc¬
tion of the descending striatonigral fibres did not suppress the accel¬
erated DA turnover in the striatum following haloperidol treatment (164,
165). Thus, the activation of DA-containing neurons in the striatum in
response to neuroleptic drugs does not seem to depend significantly on
the integrity of the known nigrostriatal or striatonigral fibres. There¬
fore, other mechanisms must be responsible for the observed increase
in striatal DA turnover• A local phenomenon or other unknown neuronal
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pathways might he involved in this effect. The postsynaptic DA reo-
eptor blockade seems to be the most probable process, activating as a
result the DA turnover in the striatum by a local feedback mechanism,
as suggested by ICehr et al„(63).
Recent reports concerning the site of action of DA receptor blockers
and DA receptor agonists eliminate the number of possibilities for the
regulation of DA metabolism in the striatum. Thus, the complete loss
of striatal adenylate cyclase after intrastriatal injection of kainic
acid, thought to be accompanied by destruction of postsynaptic DA rec¬
eptors (166) did not prevent the effect of these drugs on DA metabolism.
Consequently, these results indicate that an action at the level of the
postsynaptic DA receptors is not a pre-requisite for the in vivo eff¬
ects of DA receptor blockers and stimulants on DA metabolism. Location
of the mechanism which exerts an inhibitory influence on DAergic neur¬
ons at a prejunctional level, being mediated by DA released from DAergic
nerve terminals onto presynaptic DA receptors regulating tyrosine hyd¬
roxylase (168) or DA release (167) might explain the lack of effect of
DA receptor stimulation on HVA and DOPAC in the denervated striatum,
but cannot explain the increase in striatal metabolite levels by 250
per cent, induced by haloperidol in the denervated striatum (demonstrated
in the present study).
Alternatively, assuming that there is hyperactivity of the remain¬
ing neurons, then, presumably, any presynaptic feedback inhibition of
the release of DA is working maximally and, therefore, one might esroect
direct DA receptor agonists (e.g. apomorphine) not to affect the rel¬
ease of (and consequently the metabolite concentrations of) DA in the
denervated striatum by acting on presynaptic DA receptors (as it would
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in the intact side). However, receptor blockers (e.g. haloperidol)
can still show a presynaptic action, preventing the presynaptic self-
inhibition of DA release. Therefore, they cause an increase in DA
release and consequently an increase in the concentrations of the met¬
abolites in the denervated as well as in the intact striatum.
The results of the present study also do not support the location
of the mechanism of regulation of striatal DA metabolism in the substantia
nigra and the idea that it is mediated by DA released from DAergic den¬
drites on to DA receptors (autoreceptors) thought to be located on nigral
DAergic neurons (53). The results of Garciai-Munoz et al«(l65) alBO seem
to exclude the possibility of a post-junctional location of this mech¬
anism, mediated through a GABAergic striatonigral neuronal feedback
loop.
Thus, local regulatory mechanisms which function in both corpus
striatum and substantia nigra could be postulated to exist. The involve¬
ment of GABA or 5-HT inputs to the substantia nigra, and the known syn¬
aptic contacts of these neurons with the DAergic neurons in this reg¬
ion (73)t combined with the known inhibitory effects of local applicar-
tion of these Bubstances on cell firing (64) may be part of the post¬
ulated process of local dendritic control of DA release. The exist¬
ence of a similar mechanism at the DAergic nerve terminal area of the
striatum remains to be evaluated, but we could hypothesise that there
is a local feedback system which connects the postsynaptic with the
presynaptic sites of the DAergic neurons at the striatal level. Sub¬
sequent experiments seem to support this concept.
It has been suggested by Kehr et al(63) that receptor-mediated
feedback mechanisms exist, which control the rate of synthesis and
- 83 -
turnover of DA in the striatum. These investigators suggested that
the synthesis rate can be influenced by DA receptor stimulation or
blockade, even in the absence of impulse flow, but tiat the turnover
rate seems to depend to a considerable extent on impulse flow, as it
was proposed by earlier work (169). The different experimental condi¬
tions might explain the disagreement of part of the above findings with
the results of the present study. The fact that the above mentioned
workers measured the DA synthesis and turnover immediately after the
complete section of the nigrostriatal DAergic pathway contrasts with
the present study, where the animals were sacrificed 1-2 months after
a, probably, not complete lesion of the same pathway and by which time
the compensatory processes may be activated.
Other more complex processes might occur in the denervated stri¬
atum in view of the fact that part of the DAergic nigrostriatal fibres
seem to be intact and, probably, hyperactive, compared to the fibres
in the ccntrar-lateral side. The alteration of DA receptor sensitivity
by the lesion (121) and, probably, the increase of the number of DA
receptor sites in the lesioned striatum (119)» make the deduction of
any concrete conclusions from the study of the effect of haloperidol on DA
metabolism difficult. The proposed complex modes of action of this
agent on DA metabolism allow several interpretations of the findings.
2.4*3 The striatal dopamine-acetylcholine functional link
The complexity of the effects of the lesion would be expected, in
view of the known synaptic contacts of DAergic nerve terminals with
cholinergic neurons in the striatum (93,103). The cells of these stri¬
atal cholinergic neurons appear to receive an inhibitory influence from
the nigrostriatal pathway (90,91,92). Postsynaptic DA receptors, probebly
- 84 -
9
located on these neurons, mediate this influence. Therefore, changes
in the sensitivity (121) or the number (119) of the striatal DA rec¬
eptors (both phenomena seemingly resulting from the lesion of the nigro-
striatal DAergic pathway) could exert an indirect effect on the funct¬
ional state of the striatal cholinergic neurons. Interruption of the
inhibitory DAergic fibres would largely release the cholinergic neurons
from the inhibitory influence they receive and would be expected to
result in neuronal hyperactivity.
This may be the mechanism underlying the finding that lesions of
the substantia nigra produced in the denervated striatum a significant
increase of choline acetyltransferase activity (CAT) compared to the
contralateral side.
The enzyme CAT, synthesizing the neurotransmitter Ach, was chosen
for examination, because, in addition to its role in catalysing the syn¬
thesis of the transmitter, which makes it a good marker of the activity
of the cholinergic neuron, it also represents a specific protein pro¬
duced by identifiable nerve cells. Long term effects of treatments,
such as the 6-OH-DA lesion, might be manifested in an increase in enzyme
activity secondary to an increase in enzyme-protein synthesis. Changes
in protein turnover in the reactive cells might be reflected by changes
in the accumulation in response to surgical manipulations of the nigro-
striatal pathway. The increased bio synthesis of CAT in the denervated
striatum suggests a rearrangement of priorities in enzyme biosynthesis
favouring this enzyme, perhaps at the expense of the aizymes related to
DA synthesis or turnover. Otherwise, it could result from a compens¬
atory increase in biosynthesis of CAT presynaptically, in cholinergic
neurons impinging on the intact and hyperactive DAergic neurons of the
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denervated striatum, or at a postsynaptic level in the target neurons
deprived of their normal DA innervation. These arguments are, however,
weakened by the finding that the opposite pattern of change in CAT
biosynthesis seems to occur during axonal injury: the proteins required
for reconstitution of the axonal surface accumulate at the expense of
those required for neurotransmission (l?0) and the accumulation corr¬
elates with the regenerative sprouting of the neurons (171) •
The increased enzyme activity may well be mediated through an
ionic or electrical mechanism. Such a mechanism could act through loo-
al changes in ion concentrations near the nerve-ending membrane.
Depolarising agents such as ouabain or potassium ions have been found
to increase the activites of tyrosine hydroxylase in the vas deferens
(158) and adenylate cyclase in the brain (159)• The Supersensitive•
DA receptors in the denervated striatum, probably located on cholinergic
neurons, may modulate the activity of the enzyme CAT through membrane
hyperpolarisation or depolarisation. Similarly, these receptors may
alter the fluxes of specific ions (e.g. CA++) critical for the activ¬
ation of the neurotransmitter-synthesising enzymes present in the same
neurons. Alternatively, there might be a direct allosteric interaction
between the enzyme and molecules in the nerve ending membrane at the
site of transmitter release.
Whatever the mechanism of the lesion-induced dynamic changes in
enzyme biosynthesis might be, their functional importance could be
assessed by considering the proposed cholinergic link mechanism at the
axon terminals of the nigrostriatal DAergic neurons (172). In this
formulation, impulse-induced presynaptic release of Ach from cholin¬
ergic neurons impinging on DAergic nerve terminals in the striatum would
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act upon postsynaptic cholinergic receptors (located on DAergic term¬
inals) to facilitate the sutsequent release of DA. The enzyme acetyl¬
cholinesterase would be present in the vicinity of DA-containing term¬
inals to inactivate the initially released Ach. Compatible with the
hypothesis that Ach is a presynaptic neuromodulator of striatal DAergic
nerve endings are the observations of Georguief et al.(l74)i who found
that Ach at concentrations of 10"^ and 10"5 jj enhanced the release of
^B-DA from cat oaudate nucleus and rat striatal slices. This scheme
of neuronal interrelation is depicted in Pig. 2.2.
The data from the present experiments do not exclude prejunctional
contacts of the two neuronal systems but totally discount the possib¬
ility that the lesions affect directly cholinergic neurons in the stri¬
atum, since lesion and degeneration of these neurons would be expected
to reduce the enzyme activity or concentration. On the contrary, the
increased CAT activity (and, probably, concentration) would result from
an indirect effect of the lesion, and is indicative of increased activ¬
ity of cholinergic neurons. Both Ach and CAT appear to be present with¬
in intrinsic striatal neurons (interaeurons)f since lesions destroying
the majority of afferent pathways to this region do not cause a reduc¬
tion of either Ach content or the CAT activity of the striatum (97»175)*
It has been demonstrated that certain striatal neurons respond in
an opposite fashion to iontophoretic application of Ach and DA: Ach
enhances the firing of cells in the striatum, whereas DA depresses the
majority of these cells (176). Therefore, it seems possible that some
striatal cells could receive antagonistic neuronal inputs, i.e. excitatory
cholinergic and inhibitory dopaminergic input. These antagonistic in¬














A diagrammatic representation of some neuronal connections between the
corpus striatum and the substantia nigra.
The signs + or - indicate excitatory or inhibitory, respectively,
influence of the released transmitter on the postsynaptic neuron.
p.r. - pars reticulata
p.c. - pars compacta
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determines the efferent neuronal outflow from the striatum, such as
the striatonigral GABA-containing neurons (177)*
Using various pharmacological and lesioning techniques, many
investigatore have noted that the activity of the striatal cholinergic
system appears to be inversely correlated with the activity of the
DAergic system, e.g. an increase in DAergic activity appears to coincide
with a decrease in cholinergic activity and vice-versa (124,125).
Lesions of the medial forebrain bundle, which destroyed the nigrostriatal
DAergic neurons produced a decrease in the striatal steady-state levels
of Ach and a postulated increase in striatal cholinergic neuronal activ¬
ity (l8l). The present study, using a different approach, confirmed
this hypothesis. Lesions of the nigrostriatal pathway were shown to
lead to a long-lasting or, possibly, permanent increase of CAT activity
in the denervated striatum.
Additional experimental evidence supports the concept of a ohol-
inergio-DAergic balance in the striatum. Experiments by Sourkes and
Poirier (17&) demonstrated that a reduction of neuronal activity in the
nigrostriatal pathway produced by either placing lesions (i.e. a proc¬
edure similar to the one employed in the present study) or blocking the
postsynaptic effect of activity in this pathway (by administering DA
receptor blockers) results in symptoms similar to those of Parkinson's
disease, such as akinesia, rigidity, tremor. These symptoms are impr¬
oved by anticholinergic drugs, whereas acetylcholinesterase inhibitors
exacerbate them inboth man and animals (179). Thus, evidence for the
postulated functional balance between antagonistic striatal DAergic
and cholinergic systems continues to grow. The exact nature and the
anatomical arrangement of the systems involved is still unclear. Such
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a functional balance implies antagonistic DAergic and cholinergic inputs
on certain striatal cells or an interconnection between striatal DAergic
and cholinergic neurons, as suggested by experiments mentioned above
and by the present experiments (as illustratated in the diagram of
Pig. 2.2). An imbalance of these systems towards a cholinergic pre¬
ponderance, because of, for example, impaired DAergic function (following
lesions of the substantia nigra or administration of DA receptor block¬
ers) or enhanced cholinergic activity (secondary to administration of
cholinomimetic drugs), leads to parkinsonian symptoms.
Acute treatment of rats with apomorphine or haloperidol did not
change the striatal cholinergic imbalance induced by the lesion in the
present study (Table 2.3). The CAT activity of the denervated striatum
was significantly higher than the activity of the intact side following
the administration of either of the two drugs. Similarly Cfuyenet et al.
(93) following the same experimental procedure, found that these drugs
affected the concentration of Ach on the intact and the denervated side
of the striatum to the same extent.
The postsynaptic DA receptors^ located on cholinergic or other
interneurons of the striatum (94) did not seem to give a 'supersensitive*
response to DA receptor stimulants. Therefore, the biochemical events,
such as the activity of the cholinergic neurons, which are probably
influenced by the DAergic neurons through these receptors, do not coir-
elate with the phenomenon of 'supersensitivity*. The effect of dener¬
vation on CAT was probably due to the disinhibition of the cholinergic
neurons, following the destruction of the vast majority of the DAergic
fibres. Increased number of postsynaptic DA receptors (119) or increased
activity of DA-sensitive adenylate cyclase (116), probably associated
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with DA receptors or hyperactivity of the remaining intact DAergic neur¬
ons (123) do not seem to be responsible for the increase in CAT, since
the DA receptor blocker haloperidol seemed to produce in the intact
side a similar increase but had no effect in the denervated side (Fig.
2.1)
The suggestion - that the changes in Ach turnover and levels and
in CAT activity induced by administration of DA receptor agonists and
antagonists are due to the ability of these drugs to alter DAergic influ¬
ence and are not mediated by a direct effect on the cholinergic system -
gains support from the observation that these drugs, although producing
marked effects in the striatum, have no effect on Ach concentration or
turnover in areas not innervated by the DAergic system (184). These
and the present experiments thus provide strong evidence for the concept
that cholinergic neurons in the striatum are under the influence of a
tonic inhibitory input from the DAergic neurons which have their cells
of origin in the pars compacta of the substantia nigra.
Additional evidence comes from the work of Marco et al.(l84), who
found that haloperidol increased the Ach turnover rate in the rat striatum.
This further supports the current belief that nigrostriatal DAergic syn¬
apses inhibit the metabolism of Ach in cholinergic postsynaptic inter-
neurons. When the DAergic receptors are blocked by a neuroleptic, the
metabolism of Ach in the striatum is increased, suggesting an increase
of the activity of the intrinsic cholinergic interneurons. The increased
CAT in the intact striatum after haloperidol probably involves an increased
activity of existing CAT, rather than induction of new 6nzyme, because
of the change in response to the treatment. On the contrary, the lesion-
induced increase is more likely to rtfLect induction of new enzyme and
increased concentration in the denervated striatum.
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The discrepancy found by Guyenet et al,(93)j when surgical and
pharmacological interruption of the nigrostriatal DAergic pathway were
compared does not rule out an inhibitory influence of DAergic neurons
on the cholinergic system. Their results suggest, however, that the
physiiogical release of DA exerts a modulation of the activity of chol¬
inergic neurons much less pronounced than the effects induced by large
doses of a neuroleptic drug or apomorphine. The slight but not signif¬
icant decrease of Ach concentration observed by these investigators after
degeneration of the nigrostriatal DAergic pathway contrasts with the
marked reduction found by other workers (l8l) and does not explain the
results of the present study. The completeness of the lesion, the time
elapsed after the lesion and other methodological points could be the
reason for this disagreement of the data. Failure to detect changes in
the CAT activity of the striatum after various treatments, however, may
be due to the fact that the levels of the enzyme in the striatum are
very high, and a small but definite enzyme change due to severing the
nigrostriatal projection might go undetected.
Other complementary approaches, such as autoradiographic or
immunohistochemical studies, have to be used to establish the occurrence
of direct interactions of cholinergic neurons with the DAergic terminals
in the striatum and their possible importance as local regulatory pro¬
cesses. If, in addition to the cholinergic interneurons whose activity
seems to be controlled (partly at least) by the nigrostriatal DAergic
pathway at a postsynaptic level, other cholinergic neurons impinge at
a preterminal level on this pathway, a more complex system might evolve.
Indeed, Ach and other cholinergic agonists induce important changes in
the release of DA from DAergic terminals, as has been shown in striatal
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slices in vitro (174)• The striatum is devoid of DAergic cell todies.
Therefore, it can "be assumed that Ach and cholinergic agonists exert
their effects on DAergic terminals by acting directly on these terminals
or through local interneuronal processes. The changes in DA release
induced by these drugs could be prevented by nicotinic or muscarinic
blockers at low concentrations, indicating that these effects were med¬
iated by nicotinic and/or muscarinic receptors. Therefore, it could be
postulated that there are nicotinic and muscarinic presynaptic receptors
on DAergic terminals in the striatum. Interactions mediated through
these receptors could play an important physiological role, contribut¬
ing to local regulatory processes. The activation of intrastriatal
cholinergic neurons induced by the blockade of DAergic transmission
(following lesions or neuroleptic treatment) may be hypothesised to trig¬
ger a stimulation of DA release, finally resulting in a reduction of the
cholinergic neuronal activity. The impairment of this mechanism by an
almost complete lesion of the nigrostriatal pathway may remove this
process (which seems to control the cholinergic activity in the striatum)
and lead to the observed increase in CAT, the marker of activity of
cholinergic neurons.
Several questions remain unanswered, however, with regard to the
sites and the mechanism of these interactions. The lack of evidence
concerning the number of cholinergic receptors in the denervated stri¬
atum, the completeness of the lesion, the possible change in the sens¬
itivity of striatal cholinergic receptors induced by the lesion, and the
separation of cholinergic receptors located at pre- or postsynaptic level,
does not allow the elucidation of the exact mechanism of DA-Ach interaction
in the striatum. Further experiments are needed in order to clarify these
points.
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2.4*4 Dopamine-GABA interrelation in the striatum
A similar pattern of changes in GAD enzyme activity was found in
the striatum after 6-OB-DA lesions of the nigrostriatal DAergic pathway.
Thus, the activity of the enzyme was signigicantly elevated in the den-
ervated, compared to the intact side of the striatum. A high dose of
apomorphine (2 mg/kg i.p.) had no significant effect on either side of
the striatum, but the GAD activity became not significantly different
between the two sides after this treatment. A relatively high dose of
haloperidol (l mg/kg i.p.) produced a significant decrease of the enzyme
activity only in the intact side, thus increasing the lesion-induced
imbalance.
Although the mechanism of the enzyme protein induction may be
the same for both CAT and GAD, the effect of the lesion and the various
drug treatments on their activities is not the same. TMs is not surpris¬
ing, in view of the known different neuronal links between the DAergic
and the cholinergic or the GABAergic system in the striatum. In contrast
to the well established direct synaptic link between the nigrostriatal
DAergic nerve terminals and the striatal cholinergic intemeurons, there
is no anatomical or other evidence for a direct contact of the DAergic
pathway with the striatal GABA-containing cells which give rise to the
descending striatonigral or striatopallidal pathways. If the suggestion
that DAergic terminals do not have functionally important direct links
with GABAergic neurons in the striatum (106) is accepted, then the GAD
changes after lesions cf the substantia nigra might be a consequence of
a disturbance of the cholinergic system. This would suggest the inter¬
esting possibility of a DA-Ach-GABA chain in the striatum (Fig. 2.2).
Recent pharmacological evidence, however, suggest that DAergic
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neurons may have a 'trophic* influence on the GABA-containing neurons
in the striatum. DA receptor agonists and antagonists have been shown to
increase or decrease, respectively, the activity of striatal GABAergic neur¬
ons (105,129fl84)• Whether this stimulatory effect is direct or indirect
(mediated through cholinergic interneurons) is still a matter of speculation.
The possible neuronal links are depicted in Fig. 2.2.
Other evidence, in addition, suggests that GABA may have a regulatory
influence on the DAergic pathway, either in the striatum (at a preterminal
level) or in the substantia nigra. Thus, unilateral intranigral injection
of picrotoxin, a presumed GABA receptor blocker, produced a reversible contrar-
lateral turning syndrome (l9l)» similar to that seen after nigrostriatal
pathway lesions. Furthermore, intranigral GABA administration caused a red¬
uction of DA turnover in the striatum (130), whereas bicuculline, a GABA
receptor blocker, enhanced the release of striatal DA (192). The presented
evidence for an effect of GABA on DA release in the striatum (192,194) adds
further support to the wealth of data suggesting a DA-GABA interaction in
the striatum and the substantia nigra.
The sites of interaction may be: the substantia nigra, where descending
GABAergic striatonigral and pallidonigral fibres terminate; the striatum, where
the DAergic fibres may have postjunctional contacts with GABAergic neurons
(either directly, or indirectly through cholinergic interneurons) or pre¬
junctional contacts with GABAergic neurons impinging on them. With regard
to the proposed ooncept of presynaptic control of DA release by GABA, the
available evidence probably favours the inhibitory effect of the GABA neurons
(192), although a stimulatoiy effeot has also been suggested (194)* Through
their intrastriatal terminals, GABA neurons (probably axon collaterals of the
striatonigral pathway) could influence directly or indirectly DA release from
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DAergic terminals. GA3A could act as an excitatory or an inhibitory
transmitter and would induce a deoolarisation or a hyperpolarisation,
depending on the intracellular chloride concentration (l95)» These,
and other possible sites and mechanisms of interaction of DA and GABA
have to be borne in mind, in attempting to interpret the results of les¬
ions of the nigrostriatal pathway on the GABA Bystera.
The results of the present study indicate that GABA- or GAD-contain-
ing neurons of the striatum are not damaged by the lesion and subsequent
degeneration of the nigroetriatal Mergic pathway. On the contrary,
the demonstrated increase in GAD activity and in GABA concentration (if
one oan rely on this parameter, despite the reservations mentioned in
the Introduction, 2.1.3) support an inhibitory influence of DAergic neur¬
ons on the striatal GABA activity. Whether this influence is direct or
indirect cannot be decided from the present experiments, but there is
evidence against a direct synaptic contact at the striatal level (106).
Permanent interruption of the nigrostriatal pathway and elimination of
the DAergic neuronal transmission seemed to diainhibit the GABA neurons
of the striatum and cause increased synthesis and accumulation of GABA.
Apomorphine had no effect on the GAD activity or the GABA concentration
in the denervated side of the striatum, whereas it appeared to increase
significantly the GABA concentration in the intact side. This finding
gives further suoport to the belief that presynaptic DA receptors med¬
iate the biochemical effects of apomorphine and is in agreement with
the lack of effect of this agent on DA metabolism in the denervated
striatum (Table 2.2). Haloperidol, which is believed to act mainly by
inhibiting the postsynaptic DA receptors did not have a significant
effect on GAD activity or GABA concentration on the denervated side,
although it decreased significantly these parameters on the intact side.
2*4*5 Dopamine-acetylcholine-OABA link (Fig 2.2)
Thus, it seems that the activation or blockade of postsynaptic
DA receptors in the striatum leads to •supersensitive* behavioural res¬
ponses, which are not accompanied by any 'supersensitive1 biochemical
responses. These biochemical effects, which involve the DAergic, the
cholinergic and the GABAergic neuronal systems would be rather mediated
through stimulation of the presynaptic DA receptors, as their eliminai-
tion after degeneration of the presynaptic sites indicates. Alternar-
tively, the prejunctional (presynaptic) links of cholinergic or GABA¬
ergic neurons with the DAergic pathway at the striatal level may exist
in addition to the postjunctional (postsynaptic) contacts of the DAergic
nerve terminals with the other two systems. The demonstrated release
of DA by Ach in the striatum (174) and the stimulation (194) or inhibi¬
tion (192) of release of DA by GABA, suggested by other investigators,
point to the existence of prejunctional links, probably capable of
modulating the function of the DAergic terminals in the striatum.
Furthermore, unilateral 6-OH-DA lesion of the substantia nigra resulted
in a significant reduction of the GABA receptor binding in the ipsilat¬
eral striatum (196), suggesting that some of the GABA receptor binding
sites are located on DAergic axons. On the other hand,'f'finding that
adenylate cyclase, thought to be associated with the postsynaptic DA
receptor, is located on intrinsic striatal neurons and destruction of
this enzyme with kainic acid leads to significant decrease of 70$ of
the neurochemical markers for the cholinergic (CAT, Ach, Ach uptake)
and GABAergic (GAD, GABA, GABA uptake) neurons in the striatum (94)
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suggests that there are direct postsynaptic contacts of DAergic nerve
terminals with hoth GABAergic and cholinergic neurons in the striatum.
Cin the basis of the available evidence, it could be postulated
that DAergic terminals in the striatum form synapses with intrinsic
cholinergic and GABAergic neurons and that these neurons in turn form
synapses with the DAergic axons at a preterminal level, thus regulating
the synthesis and release of DA. Degeneration of the DAergic pathway
disinhibits the two systems, causing an increase in their neuronal
activity, as implied by the increased CAT and GAD activities in the
denervated striatum. Therefore, a local feedback control system seems
to be indirectly activated to modulate the activity of the remaining
intact DAergic nerve terminals. However, this control system might be
inactivated as a result of the destruction of the vast majority of the
DAergic fibres and the degeneration of the Ach or GABA presynaptic bind¬
ing sites, or it might be maximally activated as a result of DA receptor
supersensitivity. This could be particularly true for a cholinergic
presynaptic control of DA release. The activated after the lesion cho¬
linergic neurons would increase the DA release from the intact DAergic
nerve terminals, thus leading to the observed marked increase of DA
turnover and the disproportional reduction in the concentrations of DA
metabolites and DA in the lesioned striatum. The demonstrated reduction
of GABA receptor binding sites in the striatum after 6-OH-DA lesions of
the substantia nigra (196) also seems to support this scheme. Assess¬
ment of any changes in the number of other properties of cholinergic
receptors in the striatum after 6-OH-DA lesions of the substantia nigra
could clarify further the extent of cholinergic participation in this
postulated local feedback system.
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2.4*6 Ihe functional interactions in the substantia nigra (Fig. 2.2)
However, an integrated picture of the neuronal interconnections
could "be obtained only if the substantia nigra was included in the bio¬
chemical studies and the findings examined in the light of the known
anatomical connections of the substantia nigra and the striatum.
The complexity of the nigral processes involved in interactions
with the DAergic neurons is obvious from the numerous reports based on
anatomical, physiological, biochemical, pharmacological and lesion stud¬
ies. The present study confirmed the' interdependence of the DAergic,
GABAergic and cholinergic mechanisms in the substantia nigra. Lesion
of the left side of this region with 6-OH-DA caused a significant fall
in CAT, GAD and GABA compared to the right side (Table 2.4, Pig. 2.1).
Administration of the DA receptor blocker haloperidol did not alter the
CAT activity of any side, but it increased signif icantly the GABA con¬
centration and the GAD activity of the lesioned side (compared to the
same side in saline treated animals) whereas it had no significant effect
on GABA and GAD in the intact side of the substantia nigra. Thus,
haloperidol appeared to stimulate preferentially the activity of the GABA¬
ergic neurons in the lesioned side of the substantia nigra, and to
asverse the lesion-induced imbalance of the two sides.
Apomorphine reduced equally the CAT activities in both sides and,
therefore, did not alter the cholinergic imbalance induced by the lesion.
A disagreement between the GAD and GABA changes was noted after admin¬
istration of apomorphine: The GAD activity was increased in the intact
side but not in the lesioned side (compared to the same sides in saline
treated animals), resulting in an even bigger difference between the
two sides; the GABA concentration, however, was not changed by this
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treatment in the intact side, but was significantly elevated in the
lesioned side, resulting in an imbalance opposite to that seen in GAD
i.e. the GABA concentration of the left became significantly higher than
that of the right side. Thus, apomorphine appeared to reverse the
lesion-induced imbalance of the two sides of the substantia nigra in
relation Id GABA, but to increase the imbalance even further in relation
to GAD.
The evidence from the effects of apomorphine and haloperidol on
GABAergic activity in the substantia nigra offers a close biochemical
correlate of the ♦supersensitivity' phenomenon. The finding of dec¬
reased GAD and accumulated GABA in the lesioned side (compared to the
intact side) after apomorphine, i.e. the reverse of the lesion-induced
changes, and the contralateral turning of the rats, induced by the same
drug, are reminiscent of the contralateral turning induced by unilat¬
eral intranigral injection of the GABA receptor antagonist picrotoxin
(191) . The reversal of the effect of apomorphine on nigral GAD by
haloperidol (which can induce ipsilateral turning of the lesioned rats),
also supports the same contention, i.e. that apomorphine acts as a
GABAmimetic and haloperidol as an anti-GABAmimetic agent in the substantia
nigra.
The assumption could be made that an increase in GABA concentration
not followed by a change in GAD activity (or GABA transaminase activ¬
ity) might imply an increase in GABA release, whereas a parallel increase
or decrease of GABA and GAD might suggest an effect on the turnover of
GABA. Similarly, an increase in GAD activity not accompanied by a
change in GABA concentration might mean an increase of turnover. Parallel
changes in the activities of the synthesising and the degradative enzymes
may not have any effect on GABA concentration.
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It has been demonstrated that intranigral 6-OH-DA injections may
have non-specific toxic effects on other neurons at the injection site,
in addition to the effect on the DAergic neurons (198#199)- A non¬
specific effect could, therefore, contribute to the observed in the
present study reduction of cholinergic and GABAergic activity in the
lesioned side of the substantia nigra. However, the finding that the
DA receptor agonist apomorphine and the DA receptor blocker haloperidol
can influence in a predicted manner the markers of cholinergic and
GABAergic neurons in the lesioned side indicates that, at least some of
these changes, result indirectly through the primarily lesioned DAergic
neurons. The finding that 6-OH-DA lesions of the substantia nigra did
not affect the activity of the DA-sensitive adenylate cyclase, thought
to be located on GABA- or substance P- containing neurons (56, 46)
also supports the proposition that the effects on the GABAergic and
cholinergic neurons of the substantia nigra may result indirectly,
following a primary destruction of the DAergic neurons.
The already proposed model of DA-GABA interrelation in the
substantia nigra (Section 1) may be again recalled and examined in the
light of the findings described in this Section. The evidence for the
existence of close synaptic contacts between GABAergic terminals and
DAergic dendrites (32), the strong evidence for the inhibitory effect
of GABA on nigral DAergic neurons (64) and the demonstrated GABA release
by DA in vitro from slices of rat substantia nigra (57) suggest that
DA released from the dendrites may interact with DA receptors located
on terminals containing GABA, and the consequent selective release of
GABA may cause the observed inhibition of DAergic neurons. The
inhibitory effects of DA on DAergic cells when applied microionto-
phoretically into the substantia nigra (67) may, at least in part, be
mediated by this releasing action of DA on GABA-containing nerve "terminals.
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Furthermore, the occurrence of GABA receptors on DA cell bodies or
dendrites was suggested by the loss of ^H-GABA binding specifically
in the substantia nigra of Parkinsonian patients (202). This might
be the postulated site of inhibitory action of the released GABA on
the DA-containing neurons.
The concept of an inhibitory GABAergic input on DAergic cell
bodies, which regulates the activity of the nigrostriatal DAergic
pathway (44) has been strongly disputed as a result of the finding
that lesions of the striatonigral GABAergic pathway do not affect the
striatal DA turnover, either in control or in haloperidol or
apomorphine treated animals (165, 164)• The evidence that post¬
synaptic DA receptors are not a prerequisite for the effects of DA
receptor stimulants and blockers on striatal DA metabolism (166) casts
further doubt on the idea of a neuronal striatonigral feedback path¬
way regulating the activity of the nigrostriatal DAergic pathway. The
proposed local autoregulatory mechanisms (203) seem to participate in
the control of the activity of DA-containing neurons in the striatum and
the substantia nigra.
Degeneration of the vast majority of the DAergic neurons in the
substantia nigra, e.g. by 6-OH-DA injection, would be expected,
according to the proposed model, to lead to inactivity of the GABAergic
nerve terminals which have close synaptic contacts with them. This
might explain the decrease in both markers of GABAergic neurons in the
lesioned substantia nigra (i.e. GAD activity and GABA levels) found in
the present study, which indicates a decreased GABA activity. Systematic
administration of apomorphine produced, probably, an increase of the
GABA turnover in the intact side of the substantia nigra (increased GAD
activity, no significant effect on GABA concentration), further
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supporting the stimulating effect of DA and DA receptor agonists on
GABAergic neuronal activity in this structure (i.e. GABA mimetic action).
On the lesioned side, however, there was an acutely-induced increase
in GABA concentration hut no effect on GAD, suggesting a •super¬
sensitive* response of the DA receptors thought to he located on GABA
terminals resulting prohahly in increased release of GABA (assuming a
loss of GABA-transaminase due to the lesion). Thus, the •super¬
sensitivity1 phenomenon may not he only a mechanism which involves the
DA receptors of the denervated striatum, hut also the DA receptors of
the lesioned substantia nigra. Further studies are needed in order to
support this hypothesis and elucidate the mechanism of •supersensitivity*.
Various other parameters, such as DA metabolism, adenylate cyclase
activity and GABA release from the substantia nigra lesioned with
6-OH-DA and following DA receptor stimulation, may he necessary for
the understanding of the proposed nigral DA receptor •supersensitivity1.
Haloperidol, given systemically, had no effect on GAD or GABA in
the intact side, hut it produced an increase in GAD activity and GABA
concentration in the lesioned side. The latter suggests an increase in
synthesis and accumulation of GABA as a consequence of DA receptor
blockade in the lesioned substantia nigra. The paradoxical similarity
of the effects of DA receptor stimulation and of DA receptor blockade
on GABA levels in the lesioned substantia nigra cannot be readily
explained, although it emphasises the complexity of the mechanisms
involved. Haloperidol, by blocking the nigral DA receptors, probably
located on GABA terminals (as the increase in nigral DA turnover
indicates, Section 1} also, ref. 54) might be inducing a secondary
activation of GABA synthesis, resulting in accumulation of GABA but not
release (due to the lack of DA receptor stimulation).
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The proposed model does not, however, take into account the
possible involvement of substance P, (as speculated in Section 1),
probably released by DA from the terminals of its striatonigral
projections (46). Since substance P has been proposed as an
excitatoiy neurotransmitter of the striatonigral projection (58),
and other neurotransmitters such as Ach and 5-HT are believed to
function in the substantia nigra, more work to study the integration
ofthe various neurotransmitter systems is necessary for the under¬
standing of the proposed local regulation of DA neuronal activity.
Since dendro-dendritic connections have been reported in the
substantia nigra (73) and since some of these synapses may involve
DAergic dendrites, it is possible that a cholinergic link may operate
at some synapses (172). An initial, probably electrotonically induced,
release of Ach would facilitate in turn the release of DA from
presynaptic sites, and the released DA would act postsynaptically as
a neurotransmitter, probably to release GABA or 5-HT from their
neurons. The acetylcholinesterase found within or in the vicinity of
dendrites of nigral DAergic neurons (205) might serve the important
t
function of inactivating the initially released Ach. A similar
function may be served by acetylcholinesterase found within or in the
vicinity of the DAergic cell bodies in the pars compacta (205), i«e. to
inactivate a cholinergic input. This scheme of Ach-DA functional link
in the substantia nigra is supported by the finding of the present study
that CAT activity is significantly lowered in the lesioned side of this
structure, presumably as a result of inactivity of cholinergic neurons
due to the degeneration of the target DAergic neurons. Observations
that CAT in the substantia nigra (pars compacta) was significantly
lowered in parkinsonian patients with characteristic degeneration of
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nigral DAergic cells (206) also support this hypothesis.
Thus, the 6-OH-DA lesion of the substantia nigra had different
biochemical effects on neuronal systems other than the DAergic system,
in both substantia nigra and striatum. The difference could be
explained by the different anatomical location and the functional
interrelation of these systems. The idea of local presynaptic regulatory
interrelations of the DAergic, cholinergic and GABAergic systems in the
two areas seemsto explain various findings of this and other studies
and avoids the controversial neuronal feedback loop hypothesis or the
drawbacks of the exclusiveness of the *DA autoreceptor* theory for the
regulation of DA neurotransmission.
The finding that changes in GABA concentration and GAD activity
in the substantia nigra, both in control and in apomorphine and
haloperidol treated lesionad animals, do not correlate with changes in
DA metabolism in the striatum, may be another piece of evidence against
the neuronal feedback loop hypothesis which is based on the influence
of the inhibitory, descending GABAergic striatonigral pathway on the
ascending nigrostriatal DAergic pathway.
Finally, the possibility exists that glial cells modulate
neuronal excitability via release of GABA (207, 208). through their
contacts with nerve terminals and dendrites containing other neuro¬
transmitters. The fact that there is almost no GAD present in the glial
fractions of striatal homogenates (209) and the close correlation
between GAD and GABA found in the present study suggest that mainly
neuronal GABA is participating in the interactions with other neuronal
systems. However, glial cells do seem also to have a DA-sensitive
adenylate cyclase, probably linked with GABA release (209)» indicating
that glial GABA might also be involved in the regulation of neuronal activity.
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2.4*7 Conclusions
1. Unilateral 6-hydroxydopamine lesions of the rat substantia
nigra were effective in reducing by over 30%o the concentration of DA
in the corpus striatum, indicating a proportional degeneration of
nerve terminals belonging to the nigrostriatal pathway.
2. Reduction of striatal DA by 30% was accompanied by
reduction of striatal DA metabolite concentrations to only 7Of%\ more
complete lesions also resulted in non-proportional, higher reduction
of HVA and DOPAC. These data may be indicative of an increased
activity of the remaining intact neurons, which results in a marked
increase of striatal DA turnover.
3. Administration of apomorphine had no effect on HVA or
DOPAC in the partially (approx. 90%j) denervated striatum, whereas it
reduced both metabolites in the intact striatum. Haloperidol was
capable of increasing the metabolite concentrations of both sides, with
only a small deficit in the lesioned side.
The suggestion that apomorphine stimulates predominantly the
presynaptic and haloperidol blocks the postsynaptic DA receptors in
the striatum seems to be supported by these results. It appears that
there is no supersensitivity of the presynaptic DA receptors located
on the intact nerve terminals. The effects of haloperidol seem to
suggest that the increased number and the increased responsiveness of
the postsynaptic DA receptors may increase the activity of a local
feedback system, probably resulting in an increase of DA release, even
in the lesioned striatum. This feedback system may be cholinergic
or GABAergic or utilising some other neurotransmitter.
4. Increased activity of the enzymes GAD and CAT, the neuro¬
chemical markers for the GABAergic and cholinergic neurons, respectively,
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was found" the denervated (by approx. 90striatum, indicating a
normally inhibitory influence of the nigrostriatal pathway on these
neurons. No correlation was observed between the behavioural
'supersensitivity' phenomenon that follows the administration of
apomorphine, and any postsynaptic biochemical changes. The data
indicate a hyperactivity of the cholinergic and GABAergic neurons
in the lesioned striatum, and support the concept of presynaptic
modulation of DA neuronal activity by collaterals of cholinergic or
GABAergic neurons impinging at a preterminal level on the nigro¬
striatal pathway.
5. The enzyme activities of GAD and CAT in the substantia nigra
were reduced, indicating a possible dependence of the respective
neurons on DA innervation. The data are consistent with a DA-GABA
interrelation as proposed in Section 1 and may suggest a DA-Ach
interaction at the nigral level.
6. The demonstrated reversal of GABAergic activity in the
lesioned substantia nigra following the administration of apomorphine
correlates with the behavioural supersensitivity phenomenon and the
contralateral turning of rats with a 6-hydroxydopamine lesion.
7. The DA receptor agonist apomorphine appeared
to have a GABAmimetic action in the substantia nigra, whereas the DA
receptor antagonist haloperidol seemed to act as a GABA antagonist.
These results indicate that DA may also be a GABA stimulant, probably
acting by stimulation of DA receptors located on GABAergic neurons
(terminals of striato- or pallido-nigral projections) to release GABA
which in turn may bind to its specific receptors on DA cell bodies or
dendrites to inhibit the cell firing rate and consequently the DA
nueronal activity in the substantia nigra.
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This model avoids the complexities of the 'striatonigral feed¬
back loop* hypothesis for the regulation of DAergic activity and its
ineffectiveness to explain certain experimental data. The 'DA auto-
receptor* theory is also in doubt, as a result, since it does not
sufficiently answer the questions concerning the association of
adenylate cyclase and DA receptors in the substantia nigra and the
interrelation of DA with other neurotransmitters.
SECTION 3
SOME BIOCHEMICAL EFFECTS OF CHRONIC TREATMENT OF RATS
WITH NEUROLEPTICS ON DOPAMINERGIC, CHOLINERGIC AND




3.1.1 Therapeutic and side effects of neuroleptics
The short- and long-term effects of neuroleptic drugs differ
both clinically and biochemically. In 1967 Schelkunov reported that,
following chronic administration of a variety of classical
neuroleptics (drugs which in animals induce catalepsy, antagonise
apomorphine-induced stereotypy , and accelerate striatal DA
turnover)(148) mice and rats showed increased and prolonged
responses to amphetamine and apomorphine (70). The increased
sensitivity to DAergic receptor stimulation persisted for several
weeks after withdrawal of the neuroleptic agent. These findings
have since been confirmed by other workers (72,78,80) and have been
attributed to "chemical denervation" supersensitivity of the
striatal DA receptors (74). Further it has been suggested that
this mechanism could be responsible for the persistent and
irreversible tardive dyskinesias appearing after prolonged
administration of classical neuroleptic drugs (for several weeks
or months but usually after several years of treatment) on
reduction of dosage or on cessation of treatment (128).
There are two types of theories explaining the effect of
neuroleptic drugs on DA metabolism. The receptor blockade
hypothesis states that the neuroleptic drugs specifically attach to
post-synaptic DA receptors in the nervous system (79) thus
inhibiting activation of DA-sensitive adenylate cyclase (168),
increasing the firing rate of DA neurons (67) accelerating DA
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turnover (44) and blocking the effects of amphetamine and
apomorphine (108). The coupling-blockade hypothesis states that
neuroleptics act on presynaptic DA receptors to block the impulse-
coupled release of DA thereby activating a feedback mechanism which
increases DA turnover (163)»
The neuroleptic drugs are widely used as antipsychotic agents.
One characteristic of these drugs is their therapeutic latency.
The drugs must be administered to patients for at least 2-3 weeks
before the specific antipsychotic effects are seen} on the other
hand, tardive dyskinesia and other side effects appear on chronic
treatment with neuroleptic drugs (128). Many neurochemical changes
are evident with short—term treatment with such drugs, particularly
in DAergic systems in the brain, but the changes occuring with long-
term treatment are probably less relevant to the therapeutic effects
of these drugs. The neurochemical effects of long-term treatment with
neuroleptic drugs have not been studied extensively. Those studies
that have been made reveal striking differences between the
biochemical effects of long-term and short-term drug treatment
(e.g. 143,71).
Various attempts have been made to correlate the biochemical
effects of chronic neuroleptic treatment with the clinical findings
of antipsychotic effects and tardive dyskinesia, a syndrome
characterised by abnormal movements of facial muscles and extremities,
which is a major complication of long-term treatment with neuroleptic
drugs (128). Lowering the dose or terminating the treatment
frequently worsens these symptoms, while increasing the dose may
alleviate the symptoms. Since a major action of neuroleptics is
blockade of DA receptors in the brain, tardive dyskinesia is thought
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to be linked to the phenomenon of 'supersensitivity* of DA receptors
which develops after prolonged blockade by chronic neuroleptic
treatment. This would explain why a reduction of dose worsens
symptoms, while a dose increase temporarily reverses motor abnormalities.
Studies in animals suggest that the increased motor activity reflects
'supersensitivity* of DA receptors. Rats or mice treated
chronically with neuroleptic drugs show an increased sensitivity to
the motor stimulant effects of apomorphine, a direct DA receptor
agonist, after the treatment is terminated (72,78,80). A similar
motor 'supersensitivity' to DA receptor stimulation is apparent when
DA neurotransmission is reduced by inhibiting synthesis of DA with
/
CX-methyl-p-tyrosine or depleting DA stores with reserpine ("J2) or
lesioning the nigrostriatal DAergic pathway (8,110).
Other neurological syndromes, such as acute dystonias,
akathisias and drug^-induced Parkinsonism, have also been associated
with the use of neuroleptic drugs. These syndromes, which develop
early in treatment and tend to diminish with time (128) are known as
extrapyramidal side effects (EPS). They seem to be more relevant to
the antipsychotic effects, since both appear early in treatment
contrary to tardive dyskinesia which develops usually after several
years of treatment (128). Tolerance develops to these EPS but not
to the antipsychotic action of haloperidol (83). Thus one might
assume that any biochemical change elicited by haloperidol, which shows
tolerance may be related to the EPS and changes which persist after
prolonged administration of haloperidol may reflect synaptic
mechanisms related to its therapeutic action.
Both the clinical motor abnormalities seen after prolonged
administration of neuroleptics in man (tardive dyskinesia) and the
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increased response to apomorphine seen after such treatment in rats
suggest that DA receptor sites may he supersensitive. However,
behavioural supersensitivity to DA could be produced by a variety of
other mechanisms, such as effects on non-dopamine neuronal systems,
metabolic changes in cells at sites post-synaptic to DA neurons, or
behavioural conditioning phenomena.
Various attempts have been made to correlate biochemically the
phenomenon of tolerance to Eps produced after prolonged administration
of neuroleptics, to distinguish EPS and therapeutic effects with
regard to their biochemical correlates, to localize these effects,
to define the neuronal system (or systems) affected and finally
to elucidate the mechanisms of the EPS and the therapeutio-antipsychotic
effects.
3.1.2 Aim of the study
It is well established that one of the major actions of
neuroleptics is the blockade of DA receptors in brain, and that the
EPS are also probably related to the blockade of DA receptors in the
striatum. Therefore the effects of acute and chronic treatment with
the neuroleptic agents haloperidol and Oc-flupenthixol (168) on the
activity of the nigrostriatal DAergic pathway were investigated. The
effects of chronic treatment with these agents on the activity of the
cholinergic and GABAergic systems in the striatum and in the substantia
nigra were Btudied and compared to the effects of acute treatment in
order to define the involvement of these systems in the EPS and the
therapeutic effects. Conversely, the nature of the neuronal inter¬
relations was examined and, particularly, the role of the cholinergic
and GABAergic systems in the regulation of the activity of the
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nigrostriatal pathway. Finally, a comparison of the
•supersensitivity* phenomena demonstrated after lesions of the
nigrostriatal DAergic pathway and after prolonged neuroleptic
treatment was attempted, aiming at defining the interconnection of
the DAergic with the cholinergic and the GABAergic neuronal systems
in the striatum and the substantia nigra. The possible rearrangement
of the neuronal interrelations after prolonged treatment with
neuroleptic agents was assessed.
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3.2 MATERIALS AWD METHODS
3.2.1 Drug treatments
Male albino wistar rats (150-250 g) were used. In the acute
experiments they were injected i.p. with haloperidol (1 mg/^g),
«>(-flupenthixol hydrochloride (1 mg/kg), apomorphine hydrochloride
(1 mg/vg or 2 mg/jj-g), DL-amphetamine sulphate (5 mg/^g) or saline
solution (0.9$ MaCl). The animals were killed 30 or 60 min after
haloperidol, 180 min after o(-flupenthixol, 30 min after apomorphine
and 30 min after DL-amphetamine administration.
For chronic treatments, groups of animals were injected with
haloperidol or o(-flupenthixol at the dosage of 1 mg/^g i.p. daily
between 10 and 11am for 15 days. Appropriate controls were injected
daily with saline solution. All the animals were housed in groups of
4 — 5 under controlled temperature and had access to food and water ad
libitum. After the final (15th) injection, the animals were killed as
follows: The haloperidol-treated groups at 1 hour, 1, 3 and 6 days
after the last injection; the 0(-flupenthixol-treated groups at 3 hours
after the last injection.
The rats were killed by deoapitation, the brains rapidly removed
and the corpus striatum and the substantia nigra were quickly dissected
out (within about 3 min) as described in Section 1, immediately
immersed into liquid nitrogen and stored frozen until the biochemical
analyses.
Apomorphine hydrochloride was purchased in solid form from
Macfarlane Smith Ltd; haloperidol in ampoules as a commercially
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available solution ("Serenece") from Janssen Pharmaoeuticaj
0(~fTupenthixol hydrochloride in solid form from Lundbeck Ltd}
DL-amphetamine sulphate in solid form from Sigma Chem. Co.
3.2.2 Biochemical determinations
The concentrations of homovanillic acid (HVA),
3,4-dihydroxy-phenylacetic acid (DOPAC) and ^-aminobutyric acid
(GABA) and the activities of the enzymes choline acetyltransferase
(CAT) and glutamic acid decarboxylase (GAD) were determined in
pooled tissues from both sides of the substantia nigra and the corpus
striatum, according to the methods described elsewhere in this Thesis
(Appendix for HVA-DOPAC, Section 2 for GABA, CAT, GAD).
Protein content of brain tissues was estimated in duplicate




3.3.1 Striatal DA metabolism after acute and chronic neuroleptic
treatment
Acute treatment of rats with haloperidol (1 mg/kgi.p.)
30 min before sacrifice produced a highly significant increase in
the concentrations of HVA and DOPAC in the corpus striatum to 363
and 278 per cent, respectively, of the concentrations in the striatum
of saline-treated controls (Table 3.1)» Similarly, the neuroleptic
agent o(—flupenthixol, given at a dose of 1 mg/^gi.p. 3 hours before
sacrifice, caused a significant rise in both HVA and DOPAC, the
concentration being, respectively, 190 and 202 per cent of the
concentrations in the saline treated animals (p^0.01 and p<^0.0025,
respectively) (Table 3.1).
The increase in the striatal concentrations of HVA and DOPAC
Been after acute treatment tends to disappear after chronic treatment
with these neuroleptics. Thus, when rats were treated chronically for
15 days with a daily i.p. dose of 1 mg/vg haloperidol or oC-flupenthixol,
the initial increase observed after acute treatment was reduced
(Table 3.1). The striatal HVA concentrations at 30 min, 1, 3 and 6
days after the last (15th) injection of haloperidol were 157> 145»
89 and 76 per cent, respectively, of those of saline-treated controls.
All these HVA concentrations were significantly lower than that of
this metabolite at 30 min following a single administration of
haloperidol at the same dose level (p^0.0025)• The DOPAC
concentrations showed a similar pattern to the changes in the HVA
Table3.1
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concentrations in "both the acute and chronic treatments (Table 3.1).
Similaxly, the increase to 190^ for HVA and 202f0 for DOPAC of the
concentrations in the striata from saline controls produced by a
single administration of o<-flupenthixol, was reduced to 139 and 123
per cent respectively when the animals were decapitated 3 hours after
the last of 15 daily injections of this neuroleptic. Again, there was
significant difference between the extent of the changes in the
concentrations of both metabolites (p/0.025) under the two conditions
of drug administration (Table 3.1).
3.3.2 Nigral DA metabolism after acute and chronic neuroleptic
treatment
In the same experiments, in parallel with the investigation of
striatal DA metabolism, HVA and DOPAC were also estimated in the
substantia nigra. As described in Section 1, 30 min after administration
of haloperidol (1 mg/^i.p.) there was an initial significant decrease
in the concentrations of HVA and DOPAC, which was then followed by an
increase which persisted for about 2 hours before declining to normal
levels within 5 hours after the injection (Fig.1.3). This pattern of
the earlier changes was confirmed in the present series of experiments.
Haloperidol given acutely (l mg/^gi.p.) produced within 30 min a
decrease of both HVA and DOPAC to about two-thirds of the control
concentrations. One hour after the injection, the concentrations of
both HVA and DOPAC were significantly elevated to about 2 times the
saline control levels (Table 3.2).
After chronic treatment with haloperidol (1 mg/^gi.p.) for 15
days, the HVA and DOPAC concentrations in the substantia nigra were
significantly higher than those from controls similarly chronically
Table3.2
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injected with saline (Table 3.2). Elevated levels were still
apparent for at least 6 days after the last injection. The HVA
concentration, compared to control, was 136$, 30 min after the last
injection and 155$ 24 hours later. By 3 and 6 days after the last
injection, it had declined to 123 and 113 per cent, neither value
being significantly different (p<0.05) from the control. The
DOPAC concentration was 175$ of the control value 30 min after the
last injection and rose somewhat higher to 200$ by 24 hours, at which
level it was maintained to at leaBt the third day after the last
injection. By three days later the concentration of DOPAC had
declined to 155$ but was still significantly higher than the control
(p <0.025).
Three hours after 0(-flupenthixol given acutely (1 mg/^i.p.)
there was no significant change in either the HVA or DOPAC concentrat¬
ions. After chronic of-flupenthixol administration (1 mg/^gi.p.),
in contrast to the lack of any acute effect, the concentration of HVA
was 136$ of control (p<0.05) and that of DOPAC 147$ of control
(p^0.05), 3 hours after the 15th injection (Table 3.2).
3.3.3 Effects of acute and chronic neuroleptic treatment on GABA
concentration and glutamic acid decarboxylase (GAD) activity
in corpus striatum and substantia nigra
Acute administration of haloperidol (1 mg/i^gi.p.) 30 min before
sacrifice of the rats did not produce any significant change in the
concentration of GABA in the striatum (Table 3.3).Three hours after
an acute injection of oc-flupenthixol (1 mg/^gi.p.) there was a
significant fall in GABA concentration in the same brain area
(p<<3.0025). In the substantia nigra, neither of the two neuroleptics
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Table 3«3
Acute and chronic effects of neuroleptics on GABA concentrations in
~
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The rats were killed at the indicated time after an acute or after the
last of 15 daily injections of the neuroleptic drugs.
Control animals were injected saline solution.
Values represent means t s.d.j the number of animals in each group is
in parentheses.
Significance of difference from saline-control values (Student's t test^
two tailed):
* p <0.025>J ** p<0.0025.
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caused, any significant change, given at the above dosage and time
schedule (Table 3.3)•
Chronic administration of haloperidol (1 rag/^gi.p. daily) for
15 days, produced a statistically significant fall in the striatal
GAM concentration (p 0.025, compared to control) and a significant
rise in the concentration of GAM in the substantia nigra (p/0.025,
compared to control) when the rats were sacrificed 30 min after the
15th injection. <*-Flupenthixol, given chronically at a dose of
1 mg/kgi.p. daily, did not produce any significant change in either the
striatum or the substantia nigra, when the rats were sacrificed 3 hours
after the last (15th) injection.
The activity of glutamic acid decarboxylase (GAD), the GAM—
synthesising enzyme, was measured in the corpus striatum and the
substantia nigra after acute and chronic treatment with haloperidol
(Table 3.4)• Acute administration of haloperidol (1 mg/kgi.p.) 1 hour
before decapitation caused a significant reduction of GAD activity in
the striatum (p^0.005). Repeated administration of haloperidol at a
dose of 1 mg/kg daily for 15 days, produced (in contrast to the acute
administration) a significant increase in the striatal activity of
GAD. The increase of activity was observed at 1 hour (p^0.05) and at
24 hours (p<^0.01) after the last (15th) injection, and disappeared at
3 days. Acute administration of haloperidol (1 mg/kgi.p.) had no effect
on GAD activity in the substantia nigra, but chronic administration for
15 days produced a significant increase when the rats were killed 1 hour,
1 day and 3 days after the 15th injection (p/0.005, p <^0.025 and
p^O.01, respectively). By 6 days after the 15th injection the nigral
GAD activity was normalised (Table 3»4)»
Table3-h
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3.3.4 Effects of acute and chronic neuroleptic treatment on choline
aoetyltransferase (CAT) activity in corpus striatum and,
substantia nigra
Acute administration of haloperidol at doses of 1, 5 and
10 rag/kg 1 hour before sacrifice, produced changes in the enzyme
activity which were not dose-dependent (Table 3«4)• A single
injection of 1 mg/^gi.p. caused a significant increase in the striatal
CAT activity (p^/0.025) but it had no significant effect on the nigral
CAT. Doses of 5 and- 10 mg/kgi.p. produced lower but not significantly
different than the control mean enzyme activities in the substantia
nigra, and higher but not significantly different activities in the
corpus striatum.
There was a significant reduction of CAT activity in the corpus
striatum of rats killed 1 hour after the last of 15 daily injections of
haloperidol (1 mg/^gi.p.) (p^0.05). No difference from control
activities was evident when estimated in animals at 24 hours - 6 days
after the last injection.
In the substantia nigra enzyme activity appeared to be slightly
lower than the control at 1 hour after the last injection; by 24
hours after the last injection the activity of CAT appeared to be higher
than the control (p<{0.01). The difference in activities at these two
times (i.e. 1 hour and 24 haul's after the final injection) was
significant (p^0.005). The tendency towards a higher activity
appeared to persist for at least 6 days after haloperidol treatment
was terminated (Table 3*4)•
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3.3*5 Effects of acute apomorphine and amphetamine on GAM
concentration and on GAD and CAT activities in corpus
striatum and substantia nigra
Acute administration of apomorphine (1 mg/^gi .p^) 30 min
before sacrifice produced a highly significant increase in GAM
concentration in the corpus striatum (p/^0.0005) and a highly
significant decrease in the substantia nigra (p ^0.0005).
DLr-amphetamine, on the contrary, at a dose of 5 mg/^i .p.
given 60 min before decapitation, produced a significant decrease
of GAM in the corpus striatum (p<(0.0l) and a significant increase
in the substantia nigra (p-^0.05) (Table 3*5).
Acute apomorphine or DLr-amphetamine administration at the same
dosage had no significant effect on GAD activity in the corpus striatum,
but both drugs produced significant increases in GAD in the substantia
nigra (p<^0.05).
Apomorphine had no significant effect on striatal CAT activity
whereas DL-emphetamine produced a significant reduction (p/0.025).
In the substantia nigra both drugs caused significant reductions of the
enzyme activity (p<^0.05) (Table 3»5)«
Table3»5
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3.4 DISCUSSION
3.4.1 Striatal DA metabolism after chronic treatment with neuroleptics
The present study confirmed that tolerance to the effects of
neuroleptic agents (or antipsychotic agents) on DA turnover in the
corpus striatum develops after prolonged administration. Both
haloperidol and Of-flupenthixol produced effects on HVA and DOPAC
concentrations which were significantly smaller than the effects they
produced after a single administration, although they were still
higher than the controls immediately after the last injection} 24 hours
later and up to 6 days after the last injection the HVA and DOPAC
concentrations in the striatum became normal (Fig. 3.1). This
phenomenon of tolerance has been demonstrated in cats and monkeys
(126), in rabbits (71) and in rats (143) by several other
investigators.
By acting on postsynaptic or presynaptic DA receptors,
neuroleptics elicit marked changes in the synthesis and the release
of DA in the nerve terminal area of the striatum. In great part, these
effects are related to fluctuations in nerve impulse flow and are
reflected in changes in the concentrations of the DA metabolites HVA
and DOPAC. Therefore, estimation of these metabolites can be vised
as an index of the activity of the nigr^striatal DAergic pathway.
Changes in their concentrations in the striatum after prolonged
administration of DA reoeptor blockers could reflect changes in the
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Several workers have shown that a series of biochemical changes
in the DAergic system occur after prolonged treatment with neuroleptics.
The activity in the striatum of the enzyme tyrosine hydroxylase (the
rate limiting step in DA biosynthesis) returned to baseline level
24 hours after the last in a series of daily injections of haloperidol,
contrary to the significant increase seen after aoute treatment (151)•
The synthesis of ^B-DA from ^H-tyrosine in striatal slices was
markedly reduced 24 hours after the last in a series of daily
injections of various neuroleptics (152).
In addition to these presynaptic effects of blockade of DA
receptors in the striatum, an increase in the number of striatal DA
receptors following chronio treatment of rats with neuroleptics (as
evidenced by the increase in the number of ^H-haloperidol binding
sites) (153) suggests that postsynaptic changes may contribute to the
observed tolerance. Thus the reactivity of the postsynaptic DA
reoeptors in the striatum to acute or repeated administration of
neuroleptics may be different. Dopaminergic neurons in this structure
seem to adapt to repeated doses of neuroleptics, and this adaptation
may represent a tolerance phenomenon which may actually be involved in
the onset of the desired therapeutic effects or the disappearance of
certain extrapyramidal side effects or both (78,83). The loss of
sensitivity of striatal DA receptors to neuroleptics after prolonged
administration is accompanied by the development of hypersensitivity to
DA receptor stimulants, suggesting a functional modification of striatal
DA receptors. However, the activity of a DA-sensitive adenylate cyclase
in the striatum is not altered in ratB treated chronioally with
neuroleptics (80). Moreover, the ability of apomorphine to increase
striatal cyclic AMP concentrations in vivo is unaffected by the
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treatment (80). Data indicating a differentiation of receptor binding
sites and associated adenylate cyclase may explain this discrepancy (153)*
It has been suggested that the inhibition of DA synthesis seen in
striatal DAergic terminals after repeated injections of neuroleptics
could be related to the presence of a second interneuronal regulatory
process distinct from that involved in the activation of DA synthesis
classically observed after acute treatment (152). Further experiments
are needed in order to define whether this alternative mechanism is
totally or partially associated with the DA receptor supersensitivity,
or with the effects on non-DA neuronal systems, or with changes post¬
junctional to DA neurons in the striatum or even with behavioural
conditioning phenomena. Our subsequent experiments attempted to clarify
some of these points.
It has been shown repeatedly that a state of increased
responsiveness to DA develops when the DAergic transmission has been
impaired by denervation (8), by decreased transmitter release (157) or
by receptor blockade (78). It has also been reported by several
investigators that animals of different species become tolerant to
sedative (154)» adrenolytic (70) and cataleptic (148) effects of
neuroleptics, in addition to the tolerance to the increase in DA
turnover and HVA-DOPAC seen in the striatum (148, 126), Bowers and
Roxitis (71)» however, have found development of tolerance to the drug-
induced increase in HVA concentration only in the striatum and not in
the limbic and hypothalamic areas after chronic treatment with
neuroleptics. Similarly, Julou et al„(152) have demonstrated that
the synthesis of DA is markedly enhanced in the mesolimbic and
mesocortical (frontal and cingular cerebral cortex) DAergic systems
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shortly after the termination of chronic treatment, but no effect could
be seen at this time in the nigrostriatal DAergic terminals. This
observation is quite distinct from that seen after acute treatment,
when the maximal effect on DA synthesis was seen in the striatum.
The disappearance of the EPS induced by neuroleptics after the initial
period of treatment or the onset of the therapeutio-antipsychotic
effects could probably be related to the regional differences with
regard to DA metabolism. The EPS may thus involve an effect at the
striatal level, since their disappearance correlates with a decreased
responsiveness of striatal DA receptors to neuroleptics and an increased
sensitivity to DA receptor stimulants (80, 72). The antipsychotic
effects may be related to DA receptor blockade in the mesolimbic or
mesocortical areas, as suggested by Julou et al.(l52), since the
neuroleptics exert their blocking effect on cortical or mesolimbic
DAergic receptors for long periods of time.
Finally, the phenomenon of tolerance (with regard to DA
metabolism) does not seem to result from any direct action of the
neuroleptics on enzymesof the catecholamine metabolism (catechol-0-
methyltransferase or monoamine oxidase) (148) or from induction of
microsomal oxygenases metabolising the drugs (197)t since a
reduction of DA turnover is not observed in most brain areas.
3.4.2 Nigral DA metabolism after chronic treatment with neuroleptics
A single dose of a neuroleptic drug to rats causes an increase in
the firing rate of nigrostriatal DAergic neurons (67) and an increase
in striatal DA turnover (44)• Repeated administration has convincingly
been found to cause a tolerance to the effect on DA turnover, and this
was confirmed by the present study. It was of interest, therefore, to
investigate the effects of chronic neuroleptic treatment on DA turnover
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in the substantia nigra. Earlier studies (reported in Section 1) had
shown biphasic effects of haloperidol on HVA and DOPAC in the rat
substantia nigra, i.e. an initial reduction followed by a sharp increase
and finally a return to baseline levels. Similarly, high doses of
haloperidol (5-10 mg/kg) produced no significant effect, whereas low
doses (0.4-1 mg/kg) produced an increase in the levels of the DA
metabolites in this brain region. These fluctuations were not
observed in the corpus striatum with the various doses and at various
times (Fig. 1.2 and 1.3). The present experiments confirmed the
and
initial fall in HVa/dOPAC in the substantia nigra following a single
injection of haloperidol. The finding that the other neuroleptic
used, (X-flupenthixol, did not cause any effect on the metabolite levels
when it was injected 3 hours before decapitation of the animals,
although it produced an effect in the striatum .similar (but lower) to
haloperidol, indicates that the effects of haloperidol are time- and
dose-dependent. Prolonged administration (for 15 days) of both drugs
resulted in no tolerance to the increase in DA metabolism in the
substantia nigra. The HVA and DOPAC concentrations were markedly
enhanced shortly after the last injection of the drugs and persisted
for at least 24 hours, and even for 6 days with regard to DOPAC after
the last injection of haloperidol (Fig. 3«1)»
Thus, a discrepancy arises from the comparison of the changes in
the corpus striatum and the substantia nigra. The increase in DA
synthesis or turnover in the DA nerve terminal area of corpus striatum
is thought to result from an increase in the firing rate of the DA cell
bodies in the substantia nigra (25). Despite the demonstrated dose-
and time-dependent deviations from this rule, a parallel increase in
DA turnover seems to occur in the two ends of the nigrostriatal pathway
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after acute haloperidol administration. The results of chronic
administration, however, deviate from the rule. Although further
experiments are needed, such as electrophysiological and receptor
studies on the substantia nigra, one could hypothesise that the
persistent increase in DA cell activity and firing rate, implied by the
elevated levels of HVA and DOPAC in this region, was not followed by
an increase in DA turnover or synthesis in the nerve terminal area of
the striatum. Several recent reports suggest a reciprocity between
the effects of DA release at the two ends of the nigrostriatal
pathway. Using a push-pull cannula technique, Cherany et al„(52)
have shown that substantia nigra and corpus striatum react in opposite
directions to sensory stimulation and to local stimulation. Prom
electrophysiological studies it has been suggested that DA release in
the substantia nigra may inhibit the firing rate of DA cells (53)•
Thus an increase in DA release in the substantia nigra would be
associated with a decrease in the corpus striatum. Biochemical
studies in rats treated with haloperidol (Section 1) suggested that
the reverse may also be true, that is: an increase in DA release in
the corpus striatum is associated with a decrease in DA release in the
substantia nigra. The suggestion that the diminished activity of
the nigrostriatal pathway after chronic neuroleptic treatment results
from an increased activity of the 'feedback* striatonigral loop which
exerts its inhibitory influence on the nigral DA cells (189) does not
seem to explain the findings of the present study, since such an
effect would rather reduce DA turnover in the substantia nigra as
well as DA turnover in the striatum.
The proposed local feedback regulation of DA metabolism,
mediated by the nigral DA 'autoreceptors' or by the release of
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inhibitory neuromodulators, such as GABA, may offer an alternative
interpretation. The prolonged blockade of nigral DA receptors, which
are probably associated with the DAr-sensitive adenylate cyclase found
in this region (16,18), seems to result in an increase of the DA cell
firing rate and consequently in an increase of synthesis and release
of DA from the dendritic processes in the pars reticulata. The fact
that the changes induced by the repeated neuroleptic treatment are
not higher than the maximal effect induced by a single injection of
haloperidol, may indicate that some kind of homeostatic mechanism
exists in the substantia nigra, which adapts the sensitivity of the
target DA cells to the inhibitory or excitatory inputs. Such a
compensatory mechanism could be a supersensitivity of the DA~
containing cells in the substantia nigra to DA receptor stimulation
following long-term treatment with neuroleptics; this was suggested
by recent reports, on the basis of electrophysiological experiments
(183,186). The same phenomenon has been suggested with reference to
postsynaptic DA receptors in the striatum, in order to explain the
tolerance to the effect of neuroleptics on DA metabolism in this brain
area (78,83).
The compensatory mechanism could also well be a DA •auto-
receptor* hyposensitivity, resulting from the repeated stimulation
by DA released from the nigral dendrites. A similar phenomenon of
hyposensitivity has been demonstrated with reference to striatal DA
metabolism, following repeated administration of DA receptor stimulants(156).
Alternatively, a tolerance to the effect of the inhibitory transmitter
(e.g. GABA) probably released by DA from non-DAergic nerve terminals
in the pars reticulata (57) "lay result in a disinhibition of the
DAergic cells and the observed increased concentrations of HVA and
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DOPAC. Thus, it would appear that the DAergic neurons of the
substantia nigra might be self-inhibited under certain circumstances,
such as the chronic neuroleptic treatment.
Finally, a rather remote possibility should be borne in mind in
relation to the increased HVA and DOPAC in the substantia nigra
following chronic treatment with haloperidol, i.e. that the results
were misled by the inclusion in the »substantia nigra1 tissue of the
DA cell body area A10 which gives rise to the mesolimbic DAergic
system (8,9). Since it has been repeatedly shown that no tolerance
to the acute effects of neuroleptics on DA turnover develops in the
mesolimbic areas of the brain after chronic treatment (71,152), the
effects seen in the tissue thought to represent substantia nigra might
be partly due to changes in the A10 cell body area.
Further studies are needed in order to clarify the precise
mechanisms involved. Measurements of the number of DA receptors, of
the activity of DA-sensitive adenylate cyclase, of GABA-receptor
binding sites, or of tyrosine hydroxylase activity in the substantia
nigra after chronic treatment with neuroleptics, and parallel study
of these parameters in the corpus striatum could contribute to
elucidation of the specific, functional characteristics of the processes
involved in the regulation of DAergic neuronal activity in the nigro-
striatal system. Furthermore, inhibition of DA synthesis, e.g. by
ex.—methyl—p—tyrosine, could be a useful procedure for the different¬
iation of possible pre- or post—synaptic effects of chronic neuroleptic
treatment on DA metabolism.
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3.4*3 Effects of chronic treatment with neuroleptics on the
cholinergic system
In addition to the possibility that tolerance to the prolonged
administration of neuroleptics results from changes in the
dopaminergic system itself (adaptation phenomena, such as receptor
supersensitivity) other neuronal systems which may control or
interact with the Mergic system might be involved. Several
investigators found that repeated administration of haloperidol
produced effects on the cholinergic and GABAergic systemsin both
striatum and nigra, which were markedly different from those
obtained after a single injection (173» 202, 155). These neuronal
systems are believed to have synaptic contacts with the nigro-
striatal DAergic pathway, at a pre- or post-synaptic level, in both
corpus striatum and substantia nigra (Section 2, 2.1.3 and Pig. 2.2).
The present study demonstrated that after prolonged administration
of neuroleptics, changes at a pre- or post-synaptic level in the
DAergic nigrostriatal neurons may occur, which are distinct from the
effects of acute administration. Thus, in agreement with reports in
the literature, the cholinergic and the GABAergic systems were
found to be affected in a manner frequently correlating with the
changes in the DAergic system.
A single injection of 1mg/kg i.p. haloperidol probably increased
the activity of the cholinergic neurons in the striatum, as the
increase in CAT activity indicates. Doses of 5 or 10 mg/kg of this
neuroleptic had no significant effect on CAT activity. In the
substantia nigra, a single dose of 1 mg/kg of haloperidol did not
change the activity of the enzyme, although higher doses marginally
decreased it (Fig. 3.1).
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A similar response of the cholinergic system to a single
administration of haloperidol was obtained by other investigators
using other parameters as indices of cholinergic activity, e.g. Aeh
turnover time (173) or Ach concentrations (155)• Conversely, acute
amphetamine decreased the CAT activity in the striatum (Table 3.5)
From these and from the results of the present study (as well as the
results of Section 2, Fig. 2.1) it can be inferred that the DAergic
pathway is inhibitory on striatal cholinergic neurons. Acute
blockade of the postsynaptic DA receptors in the striatum may release
these neurons from the inhibitory influence and cause an increase in
their activity. The known anatomical or biochemical data do not seem
to offer a simple explanation of the effects on the CAT activity in the
substantia nigra, which were probably not statistically significant.
The finding that higher doses of the neuroleptic did not enhance the
effect of the moderate dose (1 mg/kg) in either of the two structures,
could be due to inhibition of the enzyme by higher concentrations of
haloperidol; this was suggested by the results of in vitro experiments
(Nicolaou, unpublished), which showed that haloperidol may significantly
reduce the activity of CAT in striatal homogenates at concentration
4 x 10""^M. Therefore, the possibility that the effects of chronic
haloperidol on the cholinergic system are merely effects of cumulative
amounts of this drug should not be totally discounted.
The effects of acute administration appeared to be different or
were reversed by the chronic treatment with haloperidol (Fig. 3*1)•
Thus, after 15 daily injections, a slight but not statistically
significant decrease, compared to the control levels, was obtained
in striatal CAT activity. The CAT activity in chronically treated
animals was, however, significantly lower than the activity in animals
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treated acutely. The activity of CAT in the substantia nigra was
not different from control 1 hour after the last daily injection of
haloperidol. However, a marked increase in the nigral CAT activity
was found 1 day after the termination of treatment with haloperidol,
which slowly returned to normal values. These results are consistent
with previous studies which showed a normalisation of Aoh concentrat¬
ions in the striatum (155) or of Ach turnover time in the striatum
and the substantia nigra (173) following chronic administration of
various neuroleptics, contrary to the acutely—induced marked effects.
The normalisation of CAT activity in the striatum following
sustained blockade of DAergio transmission by haloperidol correlates
with the tendency of the DA metabolite concentrations to return to
baseline level and it is compatible with the DAergic neurons being
inhibitory on striatal cholinergic interneurons* Similarly, the
elevation of CAT aotivity in the substantia nigra, which coincides
with an increase in the DA metabolite concentrations following chronic
administration of haloperidol, is compatible with the proposed
excitatory - modulatory influence of cholinergic interneurons on DA
cell activity in the substantia nigra. The same conclusion oould
be drawn from the finding that apomorphine and amphetamine, two drugs
known to cause a reduction of DAergio cell firing rate, produced
significant inhibition of the CAT activity in the substantia nigra
(Table 3.5).
The diminution of the effeots of acute treatment on CAT
activity after chronic treatment with neuroleptic drugs suggests
that tolerance to these effects may develop. Tolerance to the effects
of neuroleptics on striatal cholinergic aotivity also suggests that
certain EPS may be related to altered Aoh synthesis, release and
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metabolism, since these effects (which are thought to he due to
excessive striatal cholinergic activity) (188) gradually disappear
during prolonged treatment (83). Support for this hypothesis comes
from studies with neuroleptics, such as clozapine, which does not
elicit EPS in man (193) or catalepsy in rats (78) and is a potent
cholinergic (muscarinic) receptor blocker (188). The haloperidol-
induced EPS disappear on prolonged neuroleptic administration (128).
Furthermore, it has been suggested that there is an inverse
relationship between the in vitro affinity of antipsychotic drugs
for central muscarinic Ach receptors and their propensity to cause
extrapyramidal disturbances in man (188). The findings that the
antirauscarinic action of clozapine was preserved after chronic treat¬
ment, and chronic administration of haloperidol induced an anti¬
cholinergic action (173) or resulted in a different effect on
cholinergic activity compared to a single injection (present study,
(155))1 support the hypothesis that cholinergic hyperactivity in the
striatum may be responsible for certain EPS. Whether the changes
induced in the striatal cholinergic activity are due to changes in
the cholinergic neurons themselves or are due to changes in the
dopaminergic neurons synapsing on them needs to be further investigated.
The mechanisms of induction or inhibition of enzyme activity by
the neuroleptics in particular needs to be studied using different
approaches such as in vitro studies. The various possibilities were
mentioned in Section 2 (2.4»3)» Our finding (unpublished) that
haloperidol at doses 4 x 10% causes marked inhibition of CAT activity
in striatal homogenates may also explain the inhibition caused by
chronic treatment with this drug. Continued exposure of the cholinergic
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cells in the striatum, which probably contain part of the DA receptor
population, to the neuroleptic may lead to neuronal adaptation,
finally resulting in altered synthesis of enzyme (CAT) or simply in
altered activity of existing enzyme.
3»4«4» Effect of chronic treatment with neuroleptics on the
GABAergic system
The marked differences between the acute and the chronic
effects of neuroleptics on GABA concentration or GAD activity found
in this study indicate that the state of functional interaction
between the DAergic and the GABAergic system may be differently
altered by these two treatments. The GABAergic systems in the
striatum and in the substantia nigra seem to be involved in the
phenomenon of tolerance elicited by the chronic treatment with
haloperidol or £X~flupenthixol.
A single injection of haloperidol lowered GAD activity in the
striatum but not in the substantia nigra, in agreement with a recent
report (202). Chronic haloperidol administration significantly
increased the GAD activity in both brain regions, as it was found by
the same research team (202). The increase of GAD activity
persisted after termination of treatment for 3 days in the substantia
nigra and for 1 day in the striatum (Fig. 3*1)* The finding that
GABA concentration in the striatum was not altered after acute
haloperidol but was decreased after chronic administration, compared
to the corresponding effects on GAD activity, indicates that the turn¬
over of GABA was probably altered by the chronic neuroleptic treatment.
Thus acute treatment appeared to decrease the turnover rate of GABA
in the striatum and chronic treatment seemed to reverse this effect,
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in agreement with other reports (173» 202).
The GABA concentration in the substantia nigra was not changed
after acute treatment but significantly increased after prolonged
haloperidol administration. This result conflicts with reports
showing that neuroleptics administered acutely reduce the nigral
GABA concentration (202, 204). Although the disagreement may be due
to the different dosage and time-course or even due to post-mortem
changes or dissection procedure differences, a second neuroleptic
( oi—flupenthixol) produced a similar effect and the DA receptor agonist
apomorphine produced the opposite effect. The marked increase of
GABA concentration and GAD activity in the substantia nigra after
chronic haloperidol administration indicates a persistent increase in
the turnover of this aminoacid,as it was found by other investigators
(202).
Thus, definite changes in the GABAergic neuronal activity are
elicited by chronic neuroleptic treatment. These changes may be
related to the onset of the antipsychotic effects or to the dis¬
appearance of certain EPS. A comparison of the changes in the DA-
ergic^cholinergic and GABAergic system in the striatum and the
substantia nigra shows no correlation and indicates that alternative
mechanisms may be initiated during prolonged treatment with neuro¬
leptics. Routes of interaction of the DAergic system with the other
two systems, other than those normally functioning, may be triggered
by the chronic impairement of DAergic transmission.
The acute reduction of GAD activity in the striatum due to
haloperidol does not seem to be critically related to the extent of the
anticholinergic properties of this neuroleptic, since clozapine, an
antipsychotic with a strong anticholinergic action, produced a similar
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effect on GAD (202). Therefore, DA released from nigrostriatal
neurons may directly stimulate striatal GABA neurons, probably cell
bodies of the striato-nigral GABAergic pathway. Blockade of DA
receptors on the GABAergic neurons would result in an inhibition of
the activity of these neurons, reflected in a decrease of GAD
activity. According to the original 'feedback loop' hypothesis of
Carlsson and Lindquist (44)« the reduction of the activity of the
striatonigral inhibitory neurons leads to an increase in DA cell firing
in the substantia nigra and an increase in DA turnover in the striatum.
Although this sequence has been disputed (164, 165, 166) a direct
contact of the DAergic nerve terminals with the GABAergic neurons may
be postulated to exist, alongside the indirect link through cholinergic
interneurons. The nature of the direct DA-GABA link in the striatum
seems to be stimulatory, as shown by the increase in striatal GAD
induced by L-dopa administration (202) or the highly significant
increase of striatal GABA concentration by apomorphine (Table 3.5),
whereas the inhibitory DA-Ach may be followed by a stimulatory Ach—GABA
connection, as shown by changes in GABA levels induced by cholinergic
agonists and antagonists (105,106), resulting in an overall inhibitory
influence (as depicted in Pig. 2.2).
Bearing in mind these two alternative routes for the inter¬
action of the nigrostriatal DAergic pathway with the GABA-containing
neurons in the striatum, we could hypothesise that under certain
conditions one of the two meohanisms predominates. Acute blockade of
postsynaptic DA receptors may open up the direct link, whereas
chronic treatment and the demonstrated tolerance to the effects on DA
turnover and Ach turnover may proceed through the indirect route.
Therefore, a reversal of the acute inhibition of GAD would be
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expected, i.e. an increase of GAD activity. The decrease in GABA
concentration after chronic haloperidol might indicate an increase
in turnover (release and utilisation of GABA) or an increase in GABA
output from the striatum. The latter possibility is supported by the
finding that both GAD activity and GABA concentration were increased
in the substantia nigra, indicating possible increased GABAergic
neuronal activity. The finding that DA metabolite levels were still
significantly higher than control in the substantia nigra, while
GABAergic activity in this region appeared to be increased, argues
against the postulated feedback regulation of the DAergic nigro-
striatal pathway by the descending striatonigral GABAergic pathway.
In addition, the diminished effects of neuroleptics on DA turnover in
the striatum after chronic administration support the existence of local
independent mechanisms for the regulation of DAergic activity in the
DA cell-body area of substantia nigra and the DA nerve terminal area
of corpus striatum. A •chemical1 denervation appears to result from
the chronic blockade of DA receptors, and a dissociation of the DA
cell-bodies and the DA nerve terminals seems to operate with regard
to the regulation of DA metabolism. The effects of chronic neuroleptic
treatment on DA turnover in the striatum could simply result from the
activation of the intrastriatal GABAergic neurons, postulated to
impinge on (and regulate the activity of) the DAergic nerve terminals
at a prejunctional level (Fig. 2.2).
The finding that amphetamine significantly increased GAD activity
and GABA concentration in the substantia nigra is in agreement with the
GABA-releasing properties of this agent, found in nigral slices in
vitro (57) and suggests that the neuroleptio-sensitive release of DA
from dendrites in the substantia nigra may stimulate in turn the
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release of GAM, which could then act to inhibit the DA cell-bodies
or the dendrites.
The stimulatory effect of apomorphine on GAD activity in the
substantia nigra (Table 3»5) ®ay also support the idea that DA and
DA receptor agonists act in this area as GAMraimetics. The reduction
of nigral GAM accompanying the increase of GAD activity following
this treatment may indicate an increase in release and degradation of
GADA.
However, chronic blockade of nigral DA receptors by haloperidol
does not lead to a maximum activation of DAergic activity (as the
elevated HVAr-DOPAC concentrations indicate). The increase in GAD
activity and GAM concentration in the substantia nigra after chronic
haloperidol may indicate an enhancement of DA receptor stimulation
(probably on GABAergic neurons) and consequently of GABAergic activity,
which in turn causes an increased inhibition of DA neuronal
activity. The latter effect, however, does not seem to explain the
finding that DA turnover is still high in the substantia nigra,
whereas it could explain the normalisation or the reduction of
turnover observed in the striatum. Alternatively, changes in the
nature of GABA receptors in the substantia nigra (probably located on
DAergic neurons), such as subsensitivity, may result from the continuous
stimulation by released GAM leading to a reduced inhibition of the DA
neurons and a consequent increase in DA turnover.
3.4»5 Conclusions
In conclusion, comparison of the effects of chronic neuroleptic
treatment on the three neuronal systems demonstrates that functional
links may operate between the three systems in both substantia nigra
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and striatum. The development of tolerance to the effects of
neuroleptics on DAergic activity in the striatum does not seem to he
accompanied by a readjustment of the firing rate of the DAergic cells
in the substantia nigra. Tolerance t© the effects of neuroleptics on
the cholinergic activity in the striatum (which are normally
excitatory) seems to follow, probably as a secondary phenomenon,
after the chronic blockade of DA receptors. Changes in the DA receptor
itself or in the number of striatal DA receptors (as has been reported)
may be the primary stage in the development of tolerance. Otherwise,
the effects of neuroleptics on the cholinergic or the GABAergic
system subsequent to the DA receptor blockade may, in the form of
local feedback regulatory processes, contribute to the readjustment of
the DAergic activity. Chronic indirect activation or deactivation of
the GABAergic or cholinergic interneurons, thought to impinge on
DAergic terminals at a prejunctional level, may result in adaptation
of DAergic neuronal activity, in changes of the DA receptor itself or
of the number of receptors and in the demonstrated increase of the
sensitivity of DA receptors to direct stimulants. The links probably
existing at physiological states between the DAergic terminals and the
GABAergic neurons (excitatory), between the DAergic terminals and the
cholinergic neurons (inhibitory), and between the cholinergic and the
GABAergic neurons (excitatory (Fig. 2.2) do not seem to operate in the
same way after acute and chronic treatment with neuroleptics.
The chronic treatment provided further evidence for the
reciprocal relation of DA turnover between the striatum and the
substantia nigra. In contrast to the tolerance observed in the
striatum, the activity of the DAergic neurons in the substantia nigra
and the consequent increase of HVA and DOPAC in this area did not show
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any adaptive response after chronic neuroleptic administration.
Moreover, the proposed DA-GABA interaction in the substantia nigra,
as evidenced by the GABAmimetic action of apomorphine and amphetamine
and the anti-GABAmimetic action of acute haloperidol (Section 1,
1.4*2.5) did not appear to occur after chronic blockade of DAergic
transmission.
Further experiments are needed in order to establish the
nature of the primary effects of chronic neuroleptic treatment in the
substantia nigra. An investigation of the effects on the characteristics
of the DA receptor and the DAr-sensitive adenylate cyclase associated
with it (which has been found in substantia nigra), an evaluation of
any changes in the number of DA receptors (as it has been found in the
striatum) and any consequent DA receptor supersensitivity phenomena,
could further help in elucidating the mechanism of tolerance to the
chronic administration of neuroleptics.
3.4*6 Lesion- and drug-induced 'supersensitivity' and relevance
to Parkinsonism
Animals treated chronically with neuroleptic drugs displayed
an enhanced sensitivity to DA receptor stimulants (72,78). A
similar 'supersensitivity* was apparent when DAergic transmission
along the nigrostriatal neuronal pathway was interrupted by lesions
of the substantia nigra (8,110). The common feature in these
phenomena, i.e. the prolonged blockade of DA neurotransmission along
the nigrostriatal pathway, is present in certain pathological states
in humans, such as Parkinson's disease. The characteristic substantial
loss of DA cells in the substantia nigra of Parkinsonian patients (117)
and the specific destruction by 6-OHDA of the DA-containing cells in
the same structure in rats (150) have been postulated to represent a
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similar phenomenon (110). Several biochemical and behavioural
findings elicited by the various states of chronic blockade of
DAergic transmission, those involving the cholinergic and the
GABAergic system in particular, demonstrate profound similarities.
A comparative study of these findings may be useful in defining the
interrelation of the various neuronal systems.
Degeneration of the DA cells in the substantia nigra of
Parkinsonian patients and in the substantia nigra of rats injected
with 6-OHDA directly into this area, is characterised by a marked
decrease in the concentration of DA and its synthesizing enzymes in
the substantia nigra (117,8). In addition to this main neurochemical
effect, there are other consistent alterations of other neurotrans¬
mitter systems in the substantia nigra (Table 3.6). Among these, the
alterations related to the GABA-containing neurons are of particular
interest. A decreased functional state of the nigral GABA neurons is
implied by the reduction in the concentration of GABA and the GAD
activity in animals with 6-OHDA-lesions (Section 2) and by the
diminution of GAD activity in Parkinson's disease (202,206). This
might be interpreted as meaning that an atrophy or degeneration of the
GABAergic nerve terminals in the substantia nigra follows the DA cell
degeneration. The proposed synaptic contacts and the mutual
regulation of neuronal activity are consistent with these data. A
biochemical inactivity of GABA neurons subsequent to an impaired
DAergic influence is also manifested in the reduction of the DA-
sensitive adenylate cyclase activity in the substantia nigra after
lesions of the striatonigral GABAergic neurons (56,58) and by the
reduction of GABA—binding sites in Parkinsonian patients specifically
in the substantia nigra (202). Chronic neuroleptic treatment, however,
Table 3.6
Changes in glutamic acid decarboxylase (GAD) and Choline acetyl-
transferase (CAT) activities and GABA concentration in the corpus
striatum and the substantia nigra of parkinsonian patients and of
rats with 6-hydroxydopamine (6-^OHDA)-induced lesions in the sub¬
stantia nigra or treated for 15 days with the neuroleptic drug
haloperidol.
substantia nigra corpus striatum
CAT GAD GABA DA turnover CAT GAD GABA DA turnover
Parkinson's 1 1 >|/
6-ohda >i \L i' t t t
Chronic neurol. t f f T 'til
Data for parkinsonian brains are from refs. 202,206,117.
Data for animal experiments are from Sections 2 and 3 of the present Ifcesis.
The arrows indicate the direction of change, i.e.^: significant decrease;
^ : significant increase; — : no significant change.
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did not lead to DAergic inactivity in the substantia nigra, but to
an increase in turnover (Fig. 3«1). The same concept of DA-GABA inter¬
action seems to explain the consequent increase in nigral GABA turn¬
over (Table 3.6, 173).
Similarly, the cholinergic neurons in the substantia nigra seem
to receive a DAergio •trophic* influence, since reduction of DA results
in a reduction of CAT activity in both Parkinson's disease (206) and
in 6-OHDA lesions (Section 2). On the contrary, the increase in DA
turnover after chronic neuroleptic treatment, probably results in an
increase in CAT activity (Table 3.6).
In the striatum, a reduction of DA is the common feature in
Parkinsonian patients (117) and- in rats lesioned with 6-OHDA in the
substantia nigra (Section 2). Chronic neuroleptic treatment also leads
to a reduction of DA turnover compared to the acute treatment (Fig. 3.1).
The reduction of the known inhibitory influence of DAergic nerve
terminals on the striatal cholinergic interneurons after 6-OHDA lesions
results in an increase in striatal cholinergic activity. The normal¬
isation of DA turnover is followed by a normalisation of the CAT
enzyme activity (Table 3.6). In Parkinsonian brains, however, a
yy/o reduction of CAT activity in the striatum was found (206) probably
indicating biochemical inactivity of the cholinergic neurons following
the degeneration of the DAergic neurons which directly synapse with
them. In this respect, an important difference is noted between
Parkinson's disease and the proposed animal model for this disease.
The possible importance of GABA and GAD in Parkinson's disease
is not clearly known. However, areas such as substantia nigra and
globus pallidus, which show characteristic pathological changes in
brains of Parkinsonian patients, were found to have selectively
decreased GAD enzyme activities (202,206). The striatal GAD activity
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was also found to be reduced (202,206) whereas the GAM concentration
did not show any apparent change (202). Thus, there might be a
decrease of GAM turnover or a decrease of synthesis and also of
release of GABA in the striatum, subsequent to the chronic degener¬
ation of DAergic neurons. Acute treatment with neuroleptics was also
found to produce a reduction of GAD activity but prolonged blockade of
DAergic neuro-transmission by these agents increased GAD activity and
reduced GABA concentration (Table 3-6).
The difference between the effect of acute and chronic neuro¬
leptic treatment and Parkinson's disease, indicate that an alternative
functional interrelation of DAergic and GAMergic neurons in the
striatum may be unmasked after prolonged impairment of DAergic neuro¬
transmission. Indeed, as it has been discussed in detail in Section
2, more than one way seems to exist in which the DAergic and the
GAMergic neurons influence each other's activity. Therefore,
degeneration of the DAergic terminals may have different effect on
GAMergic neurons synapsing with them in the striatum than the pro¬
longed blockade of DA neurotransmission by chronic treatment with DA
receptor antagonists.
Lesions with 6-0HDA in the substantia nigra of rats also seem to
produce effects on striatal GAD and GABA which do not appear to be
comparable to the effects of Parkinson's disease. Thus, an increase
in GAD activity and GABA concentration in the striatum of rats
lesioned in the substantia nigra with 6-0HDA was found, in contrast
to the decrease in GAD and lack of effect on GABA found in Parkinson's
disease or the increase in GAD but decrease in GABA that results from
chronic neuroleptic treatment (Table 3.6). The involvement of
cholinergic interneurons between the DAergic terminals and some GABA-
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ergic neurons in the striatum (105,106) and the different effect
of the three syndromes under study on CAT activity (Table 3.6)
indicate that these cholinergic interneurons may mediate part of the
effects of DA on GABA neurons. A comparison of the effects of
6-OHDA and Parkinson's disease, in particular, shows that a positive
correlation exists between CAT and GAD activity in the striatum,
which suggests that the cholinergic neurons may exert a trophic
influence on the GABAergic neurons, perhaps mediated by a stimulatory
action of Ach at receptor sites located on GABAergic neurons.
The major neurological manifestations of Parkinsonism are
akinesia, tremor at rest, rigidity and loss of postural reflexes
(177)• A relationship between central cholinergic overactivity and
Parkinsonian tremor has been demonstrated in patients (179) and in
laboratory animals (210). The tremorgenic action of cholinemimetics
in rats wan increased by treatment with neuroleptics (211). In dogs
destruction of catecholamine-containing neurons by 6-OH-DA produced
Parkinsonian signs which were aggravated by doses of cholinomimetbs
that had no effect on control animals (212). Tardive dyskinesia
resulting from chronic treatment with neuroleptics has been postulated
to be due to striatal DA receptor supersensitivity (78)• Stimulation
of these receptors by DA receptor agonists also resulted in dyskinesias
in animals pretreated with 6-OHDA (213) as it did in patients with
Parkinson's disease (212). Treatment of tardive dyskinesia is based
on the hypothesis that DAergic hypersensitivity and resultant
cholinergic hypoactivity in the striatum is responsible for the sympto¬
matology.
These pharmacological and clinical data demonstrate the
involvement of striatal cholinergic activity in certain extrapyramidal
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side effects and offer clues to possible therapies. However, the
alterations in the GABAergic activity, their importance in the
manifestation of these symptoms and possible treatments aiming directly
at restoring the normal GABAergic function have not been studied.
The evaluation of the activity of GABAergic neurons following DAergic
deficiency may enable the elucidation of the mechanism of the under¬
lying neurological disorders and suggest alternative or supplementary
treatments to those currently employed.
SECTION 4
EFFECT OF L-TRYPTOFHAN AND MONOAMINE OXIDASE INHIBITORS ON
CATECHOLAMINE METABOLISM IN THE RAT BRAIN
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4.1 INTRODUCTION
4.1.1 5-Hydroxytryptamine metabolism and storage in brain
The principal metabolic pathway of 5-hydroxytryptamine (5-HT)
is shown in Pig. 4»1« As the blood-brain barrier is impermeable to
the amine (214), it must either be synthesised from tryptophan in the
brain or from 5-hydroxytryptophan (5-HTP) taken up from the blood.
5-HTP however is normally undetectable in rat plasma (215), therefore
the hydroxylation of tryptophan possibly takes place in the brain itself.
As the evidence described below shows, the amine could be synthesised
in the nerves where it is found.
Tryptophan is converted to 5-HTP by the enzyme tryptophan-5-
hydroxylase; its presence in brain has been shown by several groups
(216,217). The regional distribution of the enzyme was shown by
Peters et al.(2l8) to parallel the distribution of both 5-HT and 5-HT-
containing nerve terminals (as described by Dahlstrom and Fuxe, ref 5).
5-HTP is decarboxylated to 5-HT by 5-HTP decarboxylase, an enzyme widely
distributed in the brain (219). The hydroxylation is the rate limiting
step in the synthesis of 5-HT; Ichiyama et al.(217) have shown that,
in vitro, the decarboxylase activity is far in excess of the
hydroxylase, and, in vivo, Moir and Eccleston (220) reached the same
conclusion from studies on the administration of 5-HTP or L-tryptophan.
The latter report, as well as several others also indicate that the
rate of hydroxylation is highly dependent on the concentration of
tryptophan in the brain (215), which in turn depends on the plasma
unbound tryptophan level (221).
■CHXH<NH2 tryptophan2 COOH
jtryptophan hydroxylase
HO-r^X rCHXH(NH2 5-hydroxy-tryptophan2 COOH
Fig, 4.1


























Principal metabolic pathways of dopamine and noradrenaline in brain.
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Theoretically, 5-HT could also "be synthesised "by decarboxylation
of tryptophan to tryptamine and then hydroxylation. However, due to
the relative affinities of the alternative substrates for the enzymes
(217), this pathway is not important.
5-HT is catabolised by monoamine oxidase (MAO) to 5-hydroxy-
indole acetaldehyde and then mostly to 5-hydroxyindol-3-yl acetic
acid (5-HIAA) by aldehyde dehydrogenase. Some of the aldehyde may
be converted to 5-hydroxytryptophol by alcohol dehydrogenase, as has
been shown in brain slices in vitro (222).
By the use of fluorescence microscopy, Dahlstrom and Fuxe
have shown that 5-HT in brain is largely concentrated in norve
endings (5). Subcellular fractionation of brain homogenates by
Michaelson and Whittaker (223) showed that a substantial fraction of
the 5-HT in brain is associated with pinched-off nerve endings or
•synaptosomes*. This was confirmed by Aghajanian and Bloom (224),
who used autoradiography to localise intraventricularly injected
(^H)-5HT} they found most of the radioactivity in nerve terminals and
unmyelinated axons. In addition, they noted that most of the terminals
which showed activity contained so-called dense-core vesicles, which
suggests that 5-HT may be stored in such vesicles in the nerve endings.
Subcellular fractionation studies by Green and Sawyer (216) showed
that 40 to 60 per cent of the tryptophan hydroxylase was present in
the 'crude mitochondrial* fraction. Further fractionation into synapt¬
osomal and mitochondrial, fractions (217) indicated that most of the
activity of the crude mitochondrial fraction wan contained in the
synaptosomes rather than in the mitochrondria. 5-HTP decarboxylase
is a soluble enzyme and its activity is distributed throughout the
different subcellular fractions (217). Monoamine oxidase is thought
- 152 -
to be located exclusively in the mitochondria (225).
4»1*2 Catabolism of catecholamines in brain
The principal metabolic pathways of DA and NA are shown in
Pig. 4.2.
Mannarino et al.(226) in 1963 described the formation of
normetanephrine, 3-methoxy-4^hydroxyphenylethylene glycol (MHPG) and
a small quanitity of vanillyl mandelic acid (VMA) in the brain of the
cat after the intraventricular administration of (^C)-NA. In the rat
brain, Glowinski et al,(227) found that (^H)-NA injected into the
lateral ventricle is metabolised to normetanephrine, is deaminated and,
also, forms O-methylated deaminated metabolites. Studies with slices
of rabbit brain in vitro (228) showed that NA is metabolised mainly
to the two glycols MHPG and dihydroxyphenyl glycol (DHPG). Much less
is known of the metabolism of endogenous cerebral NA. The two glycol
metabolites MHPG and DHPG have been shown to be present in brain
tissue (229). In some species, such as rat and man, MHPG is further
metabolised in the brain to its sulphate conjugate (229).
Studies with slices of rabbit brain in vitro (228) showed that
radioactive DA is converted mainly to DOPAC and HVA, as well as to
a small amount of 3-methoxytyramine. DOPAC (2jp), HVA (231,232) and
also 3-methoxytyramine (233) were identified as being present in normal
brain tissue. A more detailed reference to DA metabolism is made in
Section 1.
4.1.3a Tryptophan leading
Tryptophan loading has been used as a means of determining the
rate of >-HT metabolism. It consists of injecting the animal with a
large dose of L-tryptophan, so that tryptophan hydroxylase becomes
saturated by its substrate, and the resultant increases in 5~HT and
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5-HIAA can be measured. The pattern of metabolites is the same as
under normal conditions (220).
Ashcroft et al.(215) showed that after rats had received a
large dose of L-tryptophan (800 mg/^gi.p.), 5-HT increased to a
maximum after 1 hour, and 5-HIAA was maximal after 4 hours. Grahame-
Smith (234) demonstrated that with doses of L-tryptophan up to
120 rag/kgi.p. the amount of 5-HT accumulating in the rat brain
within 1 hour was dependent upon the brain tryptophan concentration.
Tryptophan loading can give a dynamic profile of the whole
metabolic pathway, i.e. it indicates whether a certain experimental
situation is acting on the synthesis or breakdown of 5-HT or on the
excretion of 5-HIAA from the brain. The disadvantage is that a
rather unphysiological situation is produced. The level of
tryptophan in the brain is many times normal (234) and the saturation
of the pathway may upset the regulatory mechanisms, e.g. Aghajanian
(235) has found a reduction in the firing rates of 5-HT-containing
cells in the raphe area after administration of L-tryptophanj as
with MAO inhibition (236), the reduced firing rate is probably linked
to the elevated 5-HT concentration.
4.1.3b Monoamine oxidase inhibition
The rate of accumulation of 5-HT after inhibition of MAO has
been used to measure its rate of synthesis. After administration of
a MAO inhibitor, 5HT in the brain builds up linearly for about an
hour and eventually plateaus at around three times the normal level
(237). That plateau is reached probably indicates either a loss of
the amine by diffusion, or a feedback inhibition of its synthesis
(end-product inhibition). Aghajanian et al.(236) found that a variety
of MAO inhibitors depress the firing rates of raphe cells, the effect
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appearing gradually over a period of about 30 min. This was
possibly due to the accumulation of 5HT, as there was no depression
of firing after previous depletion of 5-HT with p-chlorophenylalanine.
No marked hyperactivity was observed after MO inhibition (234).
4.1.3c Combination of tryptophan loading with monoamine oxidase
inhibition
When L-tryptophan was administered to rats, there was a small
increase in brain 5-HT concentration, but a large increase in the
concentration of the 5-HT metabolite, 5-HIM, indicating an increase
in the rate of synthesis of the amine, which was then broken down by
intraneuronal MAO; no gross behavioural changes occurred. When the
rats were treated with a MAO inhibitor followed by Ir-tryptophan at a
dose level which produced submaximal increases in brain 5-HT, motor
behaviour was strikingly increased (234)> probably due to a spillover
of 'active* 5-HT on to postsynaptic receptors. Appearance of this
'5-HT-induced* hyperactivity syndrome depends on MAO inhibition,
tryptophan administration and tryphophan hydroxylase and
5-hydroxytryptophan decarboxylase activity (since inhibition of either
of these two enzymes abolished the hyperactivity) (234) but the precise
mode of action of this combination is not clear. There is a positive
correlation between the rate of accumulation of brain 5-HT and the
rate of development of the hyperactivity, which suggests that the
syndrome could be produced by 5-HT receptor stimulation (238).
However, it is probably not just the excess 5-HT which is responsible
for hyperactivity, as there was no behavioural change after the
administration of a MAO inhibitor or tryptophan alone (234). It has
been also suggested that even in normal conditions 5-HT is in excess
of that required to fulfill the functional needs of the brain (239)»
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the excess 5-HT being contained by the intraneuronal pools (one of
which is identified as vesicular binding) or metabolised by intra¬
neuronal MAO. When MAO was uninhibited, L-tryptophan did not produce
hyperactivity, suggesting that normally both the granular and the
cytoplasmic MAO act together to regulate the size of the prefunctional
pools (240).
4.1.4 Interaction of 5-hydroxytryptamine with the catecholamines
There have been several reports that 5-HT can be taken up into
catecholamine-containing neurons. ("^h)-5-HT is taken up at very low
O
concentrations (4*4 x 10"" M) not only by serotonergic (i.e. 5-HT-
containing) but also by DAergic terminals, as haB been shown in an
in vitro preparation of rat striatal homogenates (241). Amphetamine
has been shown in vitro to release ^H-5-HT from rat striatal or
cortical slices, but at concentrations higher than those required for
the release of (^H)-DA or ("^H)-NA, e.g. ED 50 for catecholamines
1CT6 - 10"5 and for 5-HT ICf^M (242).
Administration of L-dopa (the precursor of both NA and DA)
to rats (plus a peripheral decarboxylase inhibitor) induced a
decrease in brain 5-HT and an increase in 5-H1AA, due possibly to
displacement of endogenous 5-HT from its stores (243,244,245)*
However, the depleting action of L-dopa on 5-HT storage is present,
regardless of whether the catecholaminergic neurons are damaged (246),
indicating an indirect action of L-dopa on the metabolism and/or storage
of brain 5-HT. A similar phenomenon was found with regard to the
effect of L-dopa on brain tryptophan (246). The decarboxylation of
5-HTP and L-dopa is apparently performed by the same enzyme (247)
and loading with L-dopa may cause competitive inhibition of the
enzyme. Conversely, loading doses of 5-HTP resulted in 5-HT-
- 156 -
derived fluorescence in catecholamine neurons previously depleted
of their transmitters (248,267) • Therefore, administration of
either the precursor of 5-HT or of the catecholamines could result
in non-specific stimulation of the other system, due probably to
displacement from the neuron and release into the synaptic cleft.
It has been observed in many studies with psychotropic drugs
that both DA and 5-HT metabolism may be affected; chlorpromazine, for
example, which is believed to block DA receptors (30), inhibited the
tryptophan-induced hyperactivity without altering the rate of 5-HT
accumulation (249)• Depletion of brain DA inhibited the hyperactivity
resulting from the administration of a MAO inhibitor together with
either tryptophan or 5-methoxy-N,lT-dimethyltryptamine, a 5-HT
receptor agonist (25$. Administration of L-tryptophan, on the
other hand, caused a large rise in the concentration of HVA in the
cerebrospinal fluid of the dog (251).
All the above evidence points to the existence of an interaction
between the cerebral metabolism of 5-HT and DA or MA. It has been
postulated that either a group of DAergic neurons lies between the
5-HT neurons responsible for initiating the hyperactivity response
and those mechanisms responsible for its behavioural expression (250),
or a group of DAergic neurons regulates the magnitude of the behavioural
response after the activation of postsynaptic 5-HT receptors (252).
The postulated interaction of DA and 5-HT in the production of
the hyperactivity syndrome in rats (250*256) and in a variety of
psychological and neurological disorders (255) poses the question
whether in certain psychiatric states some kind of imbalance exists
between neuronal systems containing these neurotransmitters.
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4.1 »5 Statement of the problem - purpose of "the study
The experiments described in this Section were designed to
determine the effects of tryptophan loading on neuronal systems
containing DA or NA in brain. The experiments were based on the
hypothesis that tryptophan loading results in displacement of the
catecholamines from their neurons and consequently elicits bio¬
chemical and behavioural responses similar to those obtained after
the administration of the monoamine-releasing agent amphetamine.
Acute and chronic administration of monoamine oxidase inhibitors
were combined to tryptophan loading and the effects on the DA and NA
metabolite concentrations assessed and compared to the effects of
acute administration of amphetamine.
The investigation of the pharmacological profile of the
combination of L-tryptophan plus a MAO inhibitor could offer an
explanation of the reported beneficial effect of this treatment in
human depression (254) and offer clues to possible improved therapies
for affective disorders.
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4.2 MATERIALS AND METHODS
4«2.1 Reagents - Drugs
All reagents and solvents were of analytical grade.
Distilled water was used throughout. The following drugs were
used: L-tryptophan, 5-hydroxytryptamine (serotonin creatinine
sulphate) and 5-hydroxyindoleacetic acid, purchased from Koch-Light
Lab.} phenelzine sulphate (-phenylethyl hydrazine) from William
Warner and Co.} Amberlite CG50 resin, type 1, 100-200 mesh and
benzene hexachloride from BDH; 3,4-dihydroxyphenylacetic acid
(DOPAC), bis-(3-methoxy-4-hydroxy-phenyl glycol) piperazine salt
(MHPG), tryptamine hydrochloride and DL-amphetamine sulphate from
Sigma Chem. Co.} 3-methoxy-4-hydroxyphenylacetic acid (homovanillic
acid, HVA) and trifluoracetic anhydride from Aldrich Chem. Co.}
pargyline hydrochloride from Abbott Lab.} helicase enzyme from Micro-
Bio Labs.
Before use, the Amberlite CG50 resin was treated as follows:
It was first stirred for 30 min with 3 vol. 1M HC1, the acid was
decanted off and the resin washed by decantation with distilled water
until no chloride could be detected in the supernatant fluid on
addition of a few drops of 2.5% (w/y) silver nitrate solution. The
resin was stirred twice with 3 vol. 3M NH^OH for 30 min. The NH^OH
was decanted off and the resin washed repeatedly with distilled water
until the pH of the supernatant fluid was 9» The resin was finally
treated with 0.215 ammonium acetate buffer pH7»5j until the buffer pH
remained unchanged after standing in contact with the resin for at
- 159 -
least 12 hours. The resin was stored under this buffer solution.
4*2.2 Animals
Male Albino Wistar rats, weighing between 200-250 g were used,
housed in groups of 3-4 and fed with their normal diet.
4*2.3 Drug treatments
Acute treatment. Phenelzine sulphate (20 mg/kgi.p.) was injected
1 hour prior to the administration of L-tryptophan (100 mg/kgi.p.)
and the rats were killed 1 hour after the latter injection. Saline
solution (0.9 g/^NaCl) was administered in both cases to the control
animals or instead of one of the two drugs when the animals were
injeoted with either L-tryptophan or phenelzine alone.
A suspension of L-tryptophan was administered, prepared as
described by Ashcroft et al.(215): the L-tryptophan powder was mixed
and ground in a mortar with 3-4 drops of Tween 80 and the saline
solution was added drop by drop with continuous grinding, until a
homogeneous white suspension was obtained.
Phenelzine sulphate was dissolved in sodium phosphate buffer
pH 7»0 for injections, because its aqueous solutions were acidic
(pH 2.3) and the injections painful to the animals.
DL-Amphetamine sulphate (16 mg/^^i.p.) was administered to the
animals acutely 1 hour before killing.
Pargyline hydrochloride (50 mg/ko.i.p.) was injected 2 hours before
killing.
Chronic treatment. Phenelzine sulphate (10 mg/v^i.p.) was administered
daily, at about 10am., for 15 days. One hour after the last injection,
L-tryptophan (100 mg/kg i.p.) or saline solution was injected and the
animals killed 1 hour later. Saline solution was administereddaily
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to animals that served as controls.
4.2.4 Dissection of brain regions
The rats were killed by a blow on the head, and after
decapitation, the brains (including cerebellum) were quickly
removed, weighed and placed on dry ice (for whole brain biochemical
analyses) or on a cold plate for dissection of the brain regions,
according to the technique described in Section 1 (1.2.1). The
areas corpus striatum, nucleus accurabens and olfactory tubercle
were dissected out and analysed on some occasions in the present
study.
4.2.5 Biochemical determinations
For biochemical analyses each brain was homogenised in an
all—glass homogeniser in 10 ml of 0.4M perchloric acid. The
precipitated proteins were sedimented by centrifugation at 2,500 XQ
for 15 min- at 4°C. The supernatant fluid was transferred to a
beaker and the pH adjusted to 7«5 (glass electrode) by dropwise
addition with constant stirring, of 5M and then 0.2M KOH. The contents
of the beaker were transferred into large (20 ml) centrifuge tubes
and centrifuged at 2,300 xg for 5 min at 4°C. The super¬
natant fluid was separated from the precipitated potassium per-
chlorate and passed through a weak cation exchange resin (Amberlite
CG50» type 1» 100-200 mesh) which had been previously washed with
5 ml of 0.02M ammonium acetate buffer pH 7»5» (Before use the resin
was treated as described in 4.2.1).
The procedure of separation of the amines, the metabolites,
etc. to be analysed is outlined in Fig. 4.3.
A pasteur pipette (0.5 cm internal diameter) was used as
Supernatant, pH 75
























Flow diagram for the separation of tryptophan^acid metabolites and
amines from the, supernatant fluid obtained after homogenisation of
the rat brain and precipitation of proteins.
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column, filled with resin (7 cm) and the narrow end was fitted with
a plastic tube and a clip in order to control the flow rate through the
column. Under the conditions employed, i.e. the pH of the sample
solution and the previous treatment of the resin, the amines were
absorbed on the resin{ the acidic products were not absorbed} the
neutral products (such as tryptophan) were either not or were loosely
absorbed, and hence easily eluted.
The supernatant was passed through the oolumn at approximate
flow rate 10 drops/min and the effluent kept for the assays of
tryptophan and the aoidio metabolites of 3-HT, DA and NA. Then
15 ml of 0.02 M ammonium acetate (NH^Ac) buffer, pH 7»5» followed by
4 ml of 0.1M HgSO^ were passed through the column at approximately
10 drops/min and the effluent discarded. The amines were eluted from
the column with 5 ml of a®2s04 a* a flow rate of 5 drops/min, all of
the eluate being collected.
The effluent (10-11 ml) was collected, the volume measured
accurately and divided for the assays of the acidic or neutral
products* Tryptophan, 5-HIAA, HVA, DOPAC and MHFG. The eluate
(5 ml) was measured accurately and divided for the determination of
>HT and tryptamine.
a. Estimation of tryptophan in the column effluent
Tryptophan was determined in less than 1 ml of the column eluate
by the »!torharmn* procedure (257)* 0.1-0.5 ml of the effluent was
diluted to 2.8 ml with 2M HgSO^, mixed with 0.1 ml of 10/ (w/y)
formaldehyde and 0.1 ml of % (w/v) hydrogen peroxide, and the
mixture was heated in a boiling water bath in a tightly covered
test tube for 20 rain. The tubes were then cooled down with running
water and the fluorescence intensity of the norliarman derivative
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formed from tryptophan was determined using a Perkin-Elmer MPF3
spectrophotofluorimeter. The norhartaan derivative showed maximum
fluorescence at 440 mp, with two activation maxima at 310 mp and
360 mp.. The tryptophan content of the effluent was determined from
the fluorescence intensity reading at 360 mp (activation): 440 mp.
(fluorescence) by comparison with the intensity reading of different
amounts of tryptophan (50-500 ng) processed according to the norharman
procedure. The mean recovery of 10 pg tryptophan added in brain
homogenates and carried through the procedure was 71+7 ( n = 6).
b. Determination of 5-hydroxyindole acetic acid (5HIAA)
5-HIAA was determined by a modification of the spectrophotofluori-
metric method of Udenfriend et al,(258). 3-4 ml of the effluent were
acidified (pH 1-2) with 100 pi of concentrated HC1, containing ascorbic
acid (about 3 rag/mi)* followed by the addition of KC1 to slight
saturation, and 4 ml of ethyl acetate before mixing vigorously. After
centrifugation at 3,000 xg for 10 min at 4°C, 3»5 ml of ethyl
acetate were removed, mixed with 2 ml of 0.5M sodium phosphate buffer
pH 7*3 and after centrifugation at 3,000 xg for 10 min at 4°0,
the ethyl acetate layer was discarded by aspiration. 0.5 ml of
concentrated HC1 (containing ascorbic acid, 3 mg/ml) was then added
and the fluorescence intensity measured with a Perkin-Elmer MPF3
spectrophotofluorimeter at activation 295 mp and fluorescence
wavelength 550 mp.
The mean recovery of standard 5-HIAA added in brain homogenates
and carried through the procedure, compared to pure solutions of
standards mixed with 0.5 ml of concentrated HC1 (plus ascorbic acid),
in respect of their fluorescence intensity, was 74+4 (n = 13)«
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o. Determination of 3-metho:.iy-4-hydroxy-p.iienyleth.ylene glycol (MHPG)
The assay procedure used was that of Walter and Eccleston (259)»
which, basically involves hydrolysis of MHPG-sulphate complex by
using helicase enzyme, extraction of the glycols into ethyl acetate at
pH 5t acetylation and extraction of the derivatives formed into
dichloromethane and finally, trifluoracetylation and gas-liquid
chromatographic determination with a Perkin-Elmer 900 glc fitted
with an electron Capture detector.
The assay procedure is detailed below: After addition of
0.2 ml of 0.5M sodium acetate buffer (pB 5) "to 2-3 ml of the
column effluent, helicase was added to give a final concentration
of 1.8 mg/ml. Finally 2 drops of chloroform were added as anti¬
bacterial agent, the tubes stoppered, and placed in a water bath at
37°0, and left overnight (17 hours) for hydrolysis of the conjugated
MHPG-sulphate.
After the enzymatic hydrolysis, the pH was adjusted to 5*0 with
0.5 ml of 0.5M sodium acetate buffer. Following addition of 4 ml of
ethyl acetate, mixing and centrifugation at 3,000 xg for 10 min^
3.5 ml of ethyl acetate were removed and taken into a test tube. The
extraction from acetate buffer was repeated and the combined ethyl
acetate extracts evaporated to dryness under nitrogen in a heated
block at 56°C. The residue was resuspended in 0.4 ml of water and
acetylated by the addition of 50 acetic anhydride (redistilled)
and 0.6 ml l6.5g/^QQm^ KHCO^. The solution was gently shaken and the
reaction allowed to proceed for 30 min. The sample was then
whirlmixed for 1 min with 1.6 ml dichloromethane and centrifuged.
1.3 ml of the lower, organic layer (containing the acetylated
derivatives of the glycols) was shaken in a plastic 'Eppendorf• tube
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with, a little anhydrous NagSO^. The dichloromethane extract was
decanted into a glass test tube and evaporated to dryness under
nitrogen at 56°C. The residue was resuspended in 0.6ml trifluoracetic
anhydride mixture (1 paid; trifluoracetic anhydride plus 5 parts ethyl
acetate, prepared feesh) and the test tube stoppered and heated at
56°0 for 15 rain. The solution was then evaporated to dryness under
nitrogen at 56°C and the residue was taken up in 0.2 ml of re¬
distilled ethyl acetate, containing 15 ns/ml benzene hexachloride as
internal standard. The solution was transferred into a microvial for
injection into the glc.
Conditions for the gas—liquid chromatography
A Perkin-Elmer 900 gas —liquid chromatograph was used, fitted
with a Pefckin-Elmer column (6ft long, 4mm diameter) which was
packed with stationary phase 2.5$ silicone gum rubber E301 on a
support of chromosorb GAW-DMCS, 80-100 mesh. The carrier gas was
argon-methane (90 + 10$) set at flow rate 60 ml/min (pressure 70 p.s.i.)
The column temperature was 165°C, the injection port 220-260°C, the
Electron Capture Detector temperature 290-315°C.
4pl of sample were injected each time, with an automatic
injection device and the retention time was 1.8 min for MHPG and
2.8 min for the internal standard. The ratio of the height of each
MHPG peak to the peak height of the internal standard was calculated
and the amount of MHPG in the sample was determined by comparing the
sample ratio with the ratio obtained from amounts of MHPG taken through
the procedure.
d. Determination of HVA and DOPAC
HVA and DOPAC were determined in 2—3 ml of the effluent which
was acidified (pH 1-2) and the procedure continued according to the
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method of Pearson and Sharman (41)» described in the Appendix.
e. Determination of 5~hydroy)rtryptaniine
5-HT was determined in 2 ml of the column eluate (see flow
diagram in Pig. 4*3). After addition of 0.5 ml cone. HC1
(containing 3 ™g/mi ascorbic acid), the fluorescence intensity of
the sample was measured at 300 my. activation and 530 ray
fluorescence wavelengths, using a Perkin Elmer MPF3 spectrophoto-
fluorimeter.
Standard amounts of 5-HT in 21 HgSO^ (the solvent used to
elute the amine from the cation exchange resin) were mixed with
0.5 ml conc. HC1 (containing ascorbic acid) and the fluorescence
intensity was read immediately. The standard curve (arbitrary units
of intensity versus ng of 5-HT) served to calculate the amount of
5-HT in the sample solution, which was subsequently corrected for
dilution factors, to give the concentration in brain tissue.
Recoveries of 5-HT added in brain homogenates and carried through
the entire procedure were 87+7 (n = 13).
f. Determination of tryptamine
Attempts were made to measure tryptamine in 3 ml of the column
eluate (i.e. of the eluate). The norharman procedure, applied
directly on this solution gave a product which had the fluorescence
characteristics of the norharman derivative (fluorescence at 440 my,
activation at 310 and 360 my). But after extraction of the eluate
into butanol (4 ml) and back extraction into aqueous solution, followed
by the norharman procedure, no derivative was formed, which suggests
that the fluorescence observed in the first place was due to
tryptophan, as it was found by Eccleston et al.(246).
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The recovery of standards added in brain homogenates and
carried through the procedure was 82+9 (n = 5).
The finding that the tryptamine content of the rat brain does
not exceed the limits of sensitivity of the above procedure (about
50 ng) is in agreement with studies of other workers who measured
tryptamine in rat brain using various methods and found it to be at
the level of 20—40 ng/ tissue (260,261).
o
g. Determination of normetanephrine
Normetanephrine was measured in whole brain by the radio-
enzymatic method of Molinoff et al,(262). The assay cbpends on the
conversion of norraetanephrine to the U-methyl derivative of
phenylethanolamine N-methyl-transferase (FNMT) with ^O-S-adeno-
sylmethionine (1^0-SAM) as a methyl donor. The radioactive product
is separated from the 1^0-SAM and the other N-methylated amines (such
as HA and DA) by the use of alumina resin and by solvent extraction
into a mixture of toluene and isoamyl alcohol. The assay procedure is
outlined below: The animals were killed by decapitation and the brains
removed and immediately frozen on dry ice. Brains were homogenised
in 20 pl/mg tissue of 0.4M perchloric acid, ice-cold, and the
homogenates centrifuged at 10,000 g for 20 rain. To the clear
supernatant, ^ volume of 4M KgCO^ was added, left at 0°C for
30 min and after centrifugation at 32,000 g for 15 min at 2-4°C
the protein-free supernatant was decanted into a clean test tube.
The volume was made up to 2.5 ml with 5mM of ice-cold tris-(hydroxy-
methy1)aminomethane (Tris) buffer, pH 8.6, and 400 mg of neutral
alumina resin was added. The mixture was left at room temperature
for 30 rain with occasional mixing, centrifuged at 2,000 g for 15 min.
The alumina sediment was kept for the assay of the absorbed NA and
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DA, whereas the supernatant contained mainly normetanephrine and
3-methojytjrramine.
25 }il of this supernatant were placed into a 15 ml centrifuge
tube and the enzyme assay initiated by the addition of 10 yil of
1 A
10 n moles O-SAM, 25 P-l of partially purified cow adrenal PNMT
and phosphate buffer pH 7*9 (50 >iM) to make a final volume of
300 p.1. The mixture was incubated for 1 hour at 37 °C and the
reaction was then terminated by the addition of 500 p.1 of 0.5M borate
buffer, pH 10. The radioactive N-methyl-metanephrine was extracted
into 6 ml of a mixture of toluene-isoanyl alcohol (3:2) by mixing
for 5 min, and centrifugation at 2,000 g for 15 min. 4 ml of the
toluene-isoamyl alcohol mixture were transferred into a scintillation
•vial, followed by 1 ml of ethanol and 10 ml of toluene scintillation
mixture (containing PPO and POPOP, as described for the GAD assay,
2.2.2c). The radioactivity of samples was determined by scintillation
14
spectroscopy at an efficiency for C of about 60$.
Known amounts of normetanephrine were added to homogenates and
carried through the procedure as internal standards.
4.2.6 Statistical analysis
As in previous Sections, Student's t test (two tailed) was
used for the determination of statistical significance of differences
between the mean values obtained from separate groups of animals.
The confidence limit vised in assessing statistical significance was
that the probability (p) value was less than or equal to 0.05»
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4.3 RESULTS
4.3.1 Effects of acute administration of L-tryptophan and
L-tiyotophan plus phenelzine
As shown in Tables 4«1 and. 4.2, administration of a single
dose of phenelzine (20 mg/ i.p.), 2 hours before decapitation, wasnig
effective in significantly increasing the concentration of 5-HT
and decreasing the concentrations of 5-HIAA, HVA
DOPAC and MHPG| this treatment had no significant effect on brain
tryptophan levels.
Administration of a single dose of L-tryptophan (100 mg/^i.p.),
1 hour before decapitation, produced a profound increase in brain
tryptophan concentration of more than 250 per cent, a significant
increase in 5-HT (Table 4.1) and significant increases in 5-HIAA.
HVA (p<0.05), DOPAC (p<0.025) and MHPG (p<0.05) (Table 4.2).
When a group of animals were pretreated with phenelzine
(20 mg/kgi.p.) 1 hour before injection of L-tryptophan (100 mg/j^i.p.)
and 2 hours before sacrifice, brain 5-HT was significantly higher
than the concentration of either saline-treated control animals or
animals subjected to a single dose of either phenelzine (p<0.025)
or L-tryptophan (p <0.025). Tryptophan concentration in brain was not
different than after administration of L-tryptophan alone (Table 4«1)«
After this drug combination, HVA and DOPAC concentrations were
significantly lower than control but still significantly higher than
after phenelzine alone (p<0.05 and p<0.025, respectively). MHPG
was still lower than control (p<0.0025) hut not different than after
TableU.l































Acutephenelzine(20mg/kgl.p.)wasgiv n1hourb foreL-tryptophan(100mg/kgi. .)a dhrats werekill d1hourlat r. Chronicphe elzine(10rag/kgi.p.)wasdministereddaily,fo5ys,follow dh urafterth finalinjection,byL-tryptopha(100mg/kgi. «)j^heratsw rekill durl ter.Saline solutionwasinjectedthappr priateont ols. Resultsrepresentm anst.d.jhnumberofanimalsi parenthe es. Statisticalsignif ance(Student'stest,tWo-t iled)*p<0.05;*p<.0.025j*p<, .01; **p<0.005j-fp<0.0 05,comparedt control.tHt' ap<0.025jbp<0.005comparedt phenelzinealone, cp<0.025jd. 005comparedtL-tryptophanalone.
TableH.2


























Amineetaboliteconce trat onsir twholeb ifollowingsingleadministrationf phenelzinea dL-tryptophan. Iheanimalswerefirstgivenphen lzine,follow d1h url tbyL-trypt0phana de sacrificed1hourft rt elattinjection. Salineinjectionswereg v nins adofthwdrugswh nothera0b administeredalon . Results(yg/gtis e)representm ans* .d.jnumberofanimalsiparenth ses. Statisticalsignificance(s udent'stes , wotail d);*p<0.05;*p .02 $*** p< .01j **p<0.0025j{.0005comparedt0ntrol ap<0.05Jb<o.025jcp<0 1compared^^s^n^le
- 171 -
phenelzine alone. Similarly, 5-HIAA was significantly lower than
control but still higher than after phenelzine alone (p<0.01)
(Table 4.2).
Paradoxically, normetanephrine, the amine metabolite of
noradrenaline did not rise after acute administration of phenelzine
or phenelzine plus L-tryptophan, although L-tryptophan alone increased
significantly the concentration of this amine (p<0.025).
Pargyline (50 mg/^i.p.) (a MAO inhibitor) on the other hand, after
acute administration, did give a significant rise in normetanephrine
(p <0.025) (Table 4.4).
4.3.2 Effects of chronic administration of phenelzine
The results obtained after administration of phenelzine for
15 days are detailed in Tables 4*1 and 4.3.
Treatment of rats with phenelzine (10 mg/^i.p. daily)
produced highly significant increases in 5-HT and in txyptophan
(Table 4»1) and. significant reductions in 5-HIAA, HVA, DOPAC and
MHPG (Table 4«3)» L-tiyptophan (100 mg/^i.p.), given acutely
1 hour after the last (I5"fch) injection of phenelzine gave results
comparable to its administration after acute phenelzine, that is
significant increases in tryptophan and 5-HT and significant
decreases in 5-HIAA, HVA, DOPAC and MHPG, compared to saline treated
control animals.
Compared to chronic phenelzine treatment, without L-tryptophan
administration after the 15th injection, the combination of the two
drugs produced highly significant increases in 5-HT and tryptophan
(Table 4»1) and significant increases in the concentrations of the
metabolites, 5-HIAA (p <0.025), HVA (p<0.05), DOPAC (p<^0.0025)
and MHPG (p<0.05) (Table 4«3)» At this point it should be noted that
Table4.3
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Table i;. U
Effect of acute or chronic MAO inhibition on the concentration of
normetanephrine in the rat whole brairu
Treatment Normetanephrine
ng/g tissue
Control (saline) 50.2* 1 8.9(13)
Acute phenelzine (20 mg/kg i.p.) 2*9.7 1 10.6(5)
Acute phenelzine (20 mg/kg i.p.)
plus
L-tryptophan (100 mg/kg i.p.)
2*1.9 1 8.U(6)
L-tiyptophan (100 mg/kg i.p.) 69.9 t 7.1(5) *
Acute pargyline (50 mg/kg i.p.) 62.8 + 6.0(8) *
Chronic phenelzine
(10 mg/kg i.p., 15 days) 63.5 - 3.2(8) **
Normetanephrine was measured as described in the text (1*.2.5 g),
following acute or chronic (for 15 days) administration of phenel¬
zine, acute administration of pargyline or L-tryptophan and acute
administration of the combination phenelzine plus L-tryptophan.
Control rats were injected saline solution.
The animals were killed 2 hours after acute phenelzine or pargyline,
1 hour after acute L-tryptophan and 2 hours after the last of 15
daily injections of phenelzine.
Values represent means 1 s.d., number of animals is in parentheses.
Statistical significance (Student's t test^two tailed):
* p<0.025j ** p<0.005 compared to control
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MHPG had not risen after acute administration of phenelzine plus
L-tryptophan compared to acute phenelzine administration (Table 4*2).
Chronic treatment of rats with phenelzine (10 mg/,_gi.p., for 15 days),
in contrast to a single injection of this MAO inhibitor, produced a
significant elevation of normetanephrine (p<(0.005) (Table 4*4)*
4.3.3 Effect of L-tryptophan on DA and HA concentrations
A single administration of L-tryptophan (100 mg/kgi.p.),
1 hour before sacrifice, produced a significant increase in brain
DA concentration (p<(0.025) but had no significant effect on the
concentration of HA (Table 4*5)•
4.3.4 Effect of L-tryptophan on HVA and DOPAC in various brain areas
As shown in Table 4.6, administration of a single dose of
L-tryptophan (100 mg/v i.p.), 1 hour before sacrifice, producedKg
significant increases in both HVA and DOPAC in the corpus striatum
(p <(0.005 and p <(0.025, respectively), the nucleus accumbens
(p<^0.025) and the olfactory tubercle (p<(0.05 and p<(0.005, respect¬
ively) as has been found in the rat whole brain (Table 4»2).
4.3.5 Effect of DL-amphetamine administration on 5-HT, DA and HA
metabolism
A high dose of DL-amphet amine (16 mg/^i.p.), 1 hour before
sacrifice, produced no significant effect on 5-HT concentration in the
whole brain, but significant increases in tryptophan (p <(0.025),
5-HIAA (p<0.01) and MHPG (p(0.005). On the other hand, DOPAC
concentration was significantly lowered (p<(0.0005) but HVA
concentration was significantly increased (p^0.05) (Table 4«7)«
Table 1|.5
Effect of L-tryptophan on rat whole brain concentrations






Control 1380 t UU(5) 651 1 52(5)
L-tryptophan 1690 t 209(5) * 700 1 75(5)
L-tryptophan (100 mgAg i.e.) was administered 1 hour before
sacrifice.
Control animals received o.5 ml of saline solution.
Values represent means - s.d.j number of animals is in
parentheses.
* p<0.02^ compared to control values (Student's t test)
Table 1+.6
Effects of L-tryptophan loading of rats on regional DA metabolism
Control (saline) L-Tryptonhan
Brain Area HVA . DOPAC HVA DOPAC
Corpus















L-tryptophan (100 mg/kg i.p.) was administered 1 hour before sacrifice and
the concentrations of HVA and DOPAC in regions of rat brain were measured.
Control animals were treated with saline solution.
Values/represent means 1 s.d.j number of animals is in parentheses.
Statistical significance (Student's t test; two-tailed):
# p<0.05; *» p<0.025; ^ p<0.005, compared to control.
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Table U.7
Effect of dl-amphetamine on rat whole brain concentrations of 5-HT







323 + 72(8) 395 1 83(8) n.s.
5-hiaa
ng/g tissue 192 - 30(8) 25U ! 1*1(8) p<0.01
Tryptophan
fig/g tissue
5.98 + 1.18(8) 7.96 i 1.0ii(8) p< 0.025
hya
ng/g tissue 1U3 - 16(9) 158 i 1U(9) p<0.05
DOPAC






or- 92 + 11(8) p <0.005
A dose of 16 mg/kg i.p. of the drug was given to rats 1 hour before
sacrifice^ saline solution was injected to animals that served as con¬
trols »
Yalues represent means i s.d.j the number of animals is in parentheses.
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4*3*5 Behavioural effects of L-tryptophan plus phenelzine
In addition to the behavioural effects described in
Section 5 (5*3.4c), of which hyperactivity is the most obvious,
this drug combination induced in rats with a unilateral 6-OB-DA
lesion of the nigrostriatal DAergic pathway (performed as described
in Section 2) circling behaviour ipsilateral to the lesioned side.
The turning was slow (about 2 turns/min) and persisted for about
1 hour. It was only observed after the drug combination and not
after any one of the two drugs alone. The direction of turning was
the same as with amphetamine, i.e. ipsilateral to the lesion (8,110).
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4.4 DISCUSSION
4»4«1 Effects of MAO inhibition plus L-tryptophan loading on
monoamine metabolism
Earlier "biochemical studies showed that treatment of animals
with a MAO inhibitor such as phenelzine, resulted in an apparent
decrease in the concentrations of the deaminated metabolites of
5-HT, DA and NA and an increase in the concentrations of the parent
amines in the brain (264,237). Acute treatment with b-tryptophan, on
the other hand resulted in a marked increase in the concentrations of
tryptophan, 5-HT and 5-HIAA in the rat brain (220). The data from
this study are in agreement with these findings and provide further
evidence for the predicted effects of the drugs. Thus, single
administration of the MAO inhibitor phenelzine reduced significantly
the concentrations of 5-HIAA, HVA, DOPAC and MHPG. A single
administration of L-tryptophan (100 mg/^i.p.) increased the concentrat¬
ions of tryptophan, 5-HT and 5-HIAA in brain.
Combination of phenelzine with the precurser of 5-HT tryptophan
resulted in an increased synthesis and turnover of 5-HT compared to
the administration of the inhibitor alone. Despite the inhibition of
MAO, loading with L-tryptophan resulted in an increase in 5-HIAA
(compared to MAO inhibition alone) and in 5-HT one hour after the
injection. The increased rate of synthesis of 5-HT after acute
or chronic treatment with phenelzine (Table 4*1) niay be a result of
an increased concentration of total tryptophan or an altered
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compartmentalisation of tryptophan in brain. An increased availability
of tryptophan may lead to an increased synthesis and turnover of the
functional pool of 5-HT, since tryptophan hydroxylase is not saturated
at normal physiological levels of tryptophan. These results of
L-tryptophan loading on 5-HT parameters again confirm findings of
similar studies (264) and suggest that the treatment with the
precursor was effective in increasing the synthesis and turnover
of 5-HT, regardless of whether MAO was inhibited or not. The reason
for this effect of L-tiyptophan on rats treated with a MO inhibitor
could be either the existence of two or more forms of MAO (265), one
of which may not be inhibited by phenelzine, or the non complete
inhibition of MAO at this dosage of phenelzine (20 mg/, i.p.).Kg
Phenelzine, however, is probably a non—selective MAO inhibitor
(263) and is effective in blocking the MAOs responsible for oxidising
both 5-HT and catecholamines. The concentrations of the amine
metabolites were reduced to approximately the same extent, but not
completely. Our finding (Hicolaou, unpublished) that a higher dose
of phenelzine (30 mg/, i.p.) caused even higher percentage reductions
of the metabolites, indicates that MO was not completely inhibited
and, therefore, the increased availability of the substrate (5-HT)
activated the enzyme to produce the observed increase of 5-HIAA and
HVA, DOPAC.
In addition to the effects on 5-HT synthesis and metabolism,
tiyptophan loading, with or without MO inhibition, produced effects
on synthesis and metabolism of other monoamines, such as DA and
HA. b-tryptophan alone produced a significant increase in HVA and
DOPAC concentrations in the striatum and the limbic system, which was
probably reflected in an elevation of the concentration of DA and its
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major metabolites in the rat whole "brain. Similarly, the concentration
of total MHPG, the major brain metabolite of NA (228), was increased
significantly following tryptophan administration; the concentration
of normetanephrine, the intermediate amine metabolite of NA, was also
increased, but there was no effect on NA concentration.
The increase in catecholamine metabolite concentrations could
be a result of an increased release, synthesis, turnover or of
impairment of transport of the metabolites out of the brain due to
competition with the abundantly formed 5-HIAA.
In all probability, the brain monoamines as well as noraetane-
phrine, cannot be transported out of the brains The finding, there¬
fore, that normetanephrine is increased after L-tryptophan, in
parallel with the acid metabolites, seriously weakens the possibility
that competition for a transport mechanism is responsible for the
increase of the deaminated metabolites in brain. The finding that
administration of L-tryptophan to dogs pretreated with phenelzine
caused a significant increase in the concentration of HVA in the
CSP (251,264) also argues against this possibility. The active
transport system which is sensitive to probenecid, removes the acid
metabolic products of the amines from the brain to plasma (266,38) and,
the suggestion that tryptophan loading may block this system, could be
considered. However, although most of the HVA formed in brain is
transferred by this mechanism, DOPAC is only partially transported by
the probenecid-sensitive active transport system (42). Therefore,
the almost equal degree of increase in the concentrations of HVA and
DOPAC after L-tiyptophan administration eliminates the possibility of
involvement of this mechanism in the observed changes in DA
metabolism. For the same reason, the possibility that the increase
in HVA and DOPAC is caused by interference with the DA reuptake into
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its nerve terminals by tryptophan, (or 5-HTP or 5-HT) seems unlikely,
considering the proposed concept of DOPAC formed intraneuronally and
HVA formed extraneuronally (38,39»40)»
A simple, reserpine-like increase in the release of DA and NA,
probably due to displacement from their neurons by newly synthesised
5-HT should result in a reduction in the amine levels of the brain.
The lack of effect on NA and the increase in DA (shown in Table 4*5)
do not support this very simple interpretation. On the other hand,
the increased synthesis or turnover of DA and NA, suggested by these
data could be a secondary result of displacement of these amines from
granular storage sites by the 5-HT which 'spills over' the neurons.
An acute injection of the non-selective MAO inhibitor pargyline
(265) produced a rise in normetanephrine, as well as a fall in MHPG,
whereas the other MAO inhibitor, phenelzine, caused a similar change
only after it was administered chronically. The difference between
the two drugs could be due to a different degree of MAO inhibition or
to the possibility that pargyline is a specific inhibitor of the MAO
which is metabolising normetanephrine. However, this possibility seems
unlikely, since both drugs are known to be non-selective MO inhibitors
(263,265)* Therefore, the difference may be due to the different
degree of MO inhibition they produced, which is known to be dose-
dependent (242).
Chronic administration of the MO inhibitor phenelzine did not
alter the profile of the acute effects of this drug. A relatively
higher degree of inhibition is indicated by the lower acid metabolite
levels. However, tryptophan loading of rats, after acute or chronio
administration of phenelzine, was capable of increasing significantly
the concentrations of the metabolites (5-HIAA, HVA, DOPAC, MHPG). An
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increase of the catecholamine synthesis or turnover seems to be
suggested by these results, rather than an effect on the probenecid-
sensitive active transport system.
4*4*2 Release of catecholamines by 5-hydroxytryptamine
The release process is more probably the system affected by
L-tryptophan loading. The neuroanatomical background is available
for such interpretation. Following the administration of 5-HTP to
rats, the accumulation of 5-HT in catecholaminergic neurons has been
demonstratedusinghistofluorescencetechniqu.es (267,248,268), pre¬
sumably arising through the decarboxylation of 5-HTP in the
catecholaminergic neurons. In vitro studies by various investigators
presented evidence supporting the above in vivo results. Ng et al.
(269) showed that both 5-HT and the precursor 5-HTP at concentrations
are able to increase the efflux of labelled DA from striatal
slices. In this system, the decarboxylation of 5-HTP was found to be
necessary for the 5-HTP-induced efflux of DA, a point implicating
5-HT as the stimulatory agent for this effect of 5-HTP. Furthermore,
it was found by other workers that both 5-HT and 5-HTP can increase the
efflux of endogenous DA from rat striatal synaptosomes (270). These
in vitro systems, i.e. slices and synaptosomes, are believed to be
devoid of intact interneuronal or transynaptic processes; this makes
the possibility of an indirect effect of increased 5-HT neuronal
activity onto catecholaminergic neurons with subsequent changes in the
metabolism of DA or NA, as a very unlikely interpretation of the
findings of the present study. Thus, it seems likely that increases
in 5-HT may produce alterations in catecholamine functioning, by
way of effects within the catecholamine neuron.
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5-HT has been found to inhibit catecholamine accumulation in
storage vesioles from the adrenal medulla (279) and also DA
accumulation in storage vesicles from the striatum (280)* These
findings are consistent with the concept of intraneuronal dis¬
placement of catecholamines by 5-HT, but they also imply an inhibition
of synthesis of the catecholamines accompanying the stimulatory effect
(270). Thus, despite the differences, the findings of the present
study are compatible with the idea of intraneuronal displacement of
DA and NA from their vesicular storage sites and release into the
intra- and extra-neuronal cytoplasm where they are metabolised by
the oxidative and methylating enzymes.
However, the inhibition of DA synthesis by 5-HT and 5-HTP in
rat striatal synaptosoraes in vitro at concentrations 5HT
(30$ inhibition) and 2 x 5-HTP (7Of0 inhibition) (270), thought
to result from the release of DA and the consequent increase in DA-
induced feedback inhibition of the enzyme tyrosine hydroxylase or
from a direct inhibition of dopa decarboxylation, does not seem to
agree with the finding of the present study, i.e. the increase in DA
or no change in NA levels following loading with the precursor of
5-HT. Both 5-HT and 5-HTP were able to release endogenous DA at
concentrations 2 x 10""S>1 (270). The different methodological
approach used in these in vitro experiments and the present in vivo
study impair any comparison of the results and may aocount for the
apparent discrepancy. However, the uptake system for 5-HT in brain
seems to be more complex. Shaskan and Snyder (271) demonstrated that
(^H)-5HT can accumulate in catecholamine neurons or in serotonergic
neurons depending on the concentration of 5-HT. Thus, striatal slices
could take up labelled
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concentrations a greater proportion of amine entered catecholamine
neurons by a low affinity uptake system ('uptake 2'), in contrast to
the high affinity uptake into serotonergic neurons ('uptake 1').
Subsequent experiments also support the finding that increased
5-HT caused an increase in catecholamine turnover. The combination of
MAO inhibition, either acute or chronic, and tryptophan loading caused
an increase in 5-HT concentration in brain, which was the sum of the
effects of the two treatments separately (Table 4*1)• Thus, MAO
inhibition together with tiyptophan loading might cause displacement
of catecholamines to a greater extent than a single dose of
L-tryptophan, if 5-HT induced displacement of catecholamines from
the nerve endings is proportional to the concentration of 5-HT.
The demonstrated uptake of 5-HT and 5-HTP into catecholamine neurons
in the brain, previously depleted of their catecholamines (267,268)
indicates that 5-HT (and probably 5-HTP) are located outside the
storage granules, possibly fixed to extragranular binding sites and
under the attack of intraneuronal MAO. Therefore, the enzyme has to
be inhibited in order to obtain an accumulation of 5-HT. However,
L-tryptophan alone produced significant increases in the turnover of
NA and the synthesis and turnover of DA in the rat whole brain, as
it probably did in the corpus striatum and the limbic areas
(nucleus accumbens, olfactory tubercle) of the brain with regard to OA,
This may be difficult to reconcile with the reported ineffect¬
iveness of L-tryptophan to produce marked hyperactivity in rats
(234) or turning behaviour in rats with nigrostriatal pathway lesions
(present study), in contrast to the effectiveness of the combination
with MAO inhibition. The DAergic and probably the NAergic component
of the effects of this drug combination seem to be present after a
simple increase of 5-HT in brain. This may indicate that the low
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affinity 'uptake 2* system for the entry of 5-HT into catecholaiaine
neurons proposed "by Shaskan and Snyder (271) is possibly functioning
-8
in vivo j their finding that as low as 10 1 5-HT could be taken up
by catecholamine neurons may not be incompatible with the lack of
obvious behavioural responses of rats at low doses of 5-HT precursors
or MAO inhibitors alone (234). A slight amount of released DA or
NA may not reach the appropriate receptors mediating their behavioural
effects because of degradation by intra- or extraneuronal MAO. The
fact that there is no increase of acid metabolites after the drug
combination compared to Lr-tryptophan alone, may be accounted for by
the inhibition of their formation by phenelzine. However, there is
some evidence of an increased turnover of DA after L-tryptophan plus
phenelzine, in that the reduction in the concentrations of HVA and
DOPAC after phenelzine alone was significantly diminished when
phenelzine was given together with L-tryptophan (Table 4«2).
4.4.3 Amphetamine-like action of L-tryptophan loading
Amphetamine and the combination of L-tryptophan with a MAO
inhibitor are known to present a common feature behaviourally, in
that they induce a hyperactivity syndrome in rats (272,234).
Amphetamine is known to influence all three monoamine systems, i.e.
DAergic, NAergic and serotonergic (273, and Table 4»7 of the present
study). It has also been demonstrated that the monoamine releasing
properties of amphetamine at low concentrations (10*"''' - 10~"^M) in
vitro (242) or at low doses after intraperitoneal administration
(43,275) are accompanied at higher concentrations (10~^M) by amine
reuptake inhibition and MAO inhibition (242). This oomplex effect
of amphetamine was demonstrated in vitro (242) and in vivo (274)•
The finding of Kuczenski (274), that the effect of amphetamine on
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striatal DA dynamics has, at least, two components, one resulting in
an increase and the second in a decrease in the conversion of
possible mediator of the observed effects on the levels of the
deaminated metabolites. Similar double effects of amphetamine have
been reported by Rutledge et al,(242) with regard to NA and 5-HT
release and reuptake in vitro.
The present study, as it is shown in Table 4»7«» confirmed some
of the earlier observations: amphetamine is indeed affecting the DA,
NA and 5-HT systems. Although in these experiments, the effects of
DL-amphetamine administered as a single high dose (16 mg/^i.p.) were
determined only in relation to the concentrations of the acid
metabolites HVA, DOPAC and MHPG and not of the amine levels in the
whole brain, the results could be interpreted in several ways. The
observed selective decrease of DOPAC, with an opposite effect on HVA,
could be due to DA reuptake inhibition and support the concept of
mainly intraneuronal formation of DOPAC and extraneuronal formation
of HVA| the same finding was reported by several investigators
estimating the same metabolites (22,40,38). The results obtained by
them referred to the striatum and the mesolimbic system, but the whole
brain picture with regard to DA metabolism should not be different, as
these brain structures are the richest in DA and its metabolites.
The finding that a high dose of amphetamine (known to be
effective at low doses in releasing DA and consequently increasing
HVA,) had significant effect on the whole brain concentration of this
metabolite, could be attributed to the MAO inhibition that may occur
at this dosage and act as a kind of homeostatic mechanism, to maintain
normal DA levels. The possibility that the effect of DL-amphetamine
exclude the uptake inhibition as a
loci
on DA metabolite concentrations is the result of an influence of
this drug on the system responsible for the active transport of
deaminated metabolites out of the brain (i.e. the probenecid-
sensitivesystem) could not explain these results. An inhibition of
this system would be expected to have no effect on DOPAC but to
increase the HVA concentration, as does probenecid (38,39)|
DLr-amphetamine, however, caused a significant reduction of DOPAC
concentration in brain, in addition to an increase in HVA.
The possibility that transynaptic interactions mediate the
effects of the amphetamine treatment on the various monoamine systems
would imply that the observed effects on the metabolism of the three
monoamines are not all resulting from a direct action; a primary
effect on the catecholamines, for example, might mediate some of the
effects on the 5-HT system. However, the complexity of these mono¬
amine interactions (as discussed in detail in Section 5) cannot be
simplified by whole brain studies, but can only be studied by the
use of other more direct approaches and by investigations restricted
to specific brain areas.
The increased tryptophan and 5-HIAA with unchanged 5-HT
concentrations in brain after DL-anrphetamine (shown in Table 4»7)
are indicative of an increase in the synthesis and turnover of 5-HT.
The increase in MKPG suggests that the turnover of NA is also
increased, but unlike DA, blockade of NA reuptake does not seem to
be a significant component of the action of DLr-amphetamine on this
amine (at this dosage). Such data seem to indicate that monoamine
release and inhibition of reuptake can lead to increased turnover,
probably due to homeostatic control of neuronal activity, mediated
by unknown feedback mechanisms.
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Tlie biochemical response to DL-araphetamine can. be summarised
as being constituted by an increased synthesis and metabolism of 5-HT,
following the stimulation of its release or the inhibition of its
reuptake and perhaps MO inhibition, in addition to the stimulation
of release of DA from its neurons and probably the release and
increased metabolism and/or turnover of HA. The changes in these
processes seem to present, in general, a close correlation with the
corresponding changes in the three monoamine systems following
chronic or acute administration of phenelzine together with
L-tryptophan.
The observed in the present study similarity between the
behavioural responses to DL-amphetamine and to L-tryptophan plus
phenelzine, i.e. hyperactivity and ipsilateral turning of rats with
a unilateral lesion of the nigrostriatal DAergic pathway, seem to
support the hypothesis that these treatments have a similar mode of
action.
The finding that the hyperactivity syndrome in the rat,
produced by MAO inhibition combined to L-tryptophan could be
abolished by pretreatment of the animal with «-methyi-p-tyrosine
(an inhibitor of catecholamine synthesis) or ohlorpromazine (a DA
receptor blocker) but was not affected by HA depletion with disulfiram
(a D-b-h inhibitor) (249*250), suggests that brain DA rather than HA
has an important role in the behavioural expression of the accumulation
of 5-HT in brain. Since pretreatment with c<-methy1-p-tyrosine did not
affect 5-HT synthesis, but inhibited the responses to the 5-HT
receptor agonist 5-methoxy-H,H-dimethyltryptamine (p-MDT), it appears
that DAergic neurons postsynaptic to the serotonergic neurons
mediate certain behavioural effects of 5-HT receptor stimulation (250).
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Thus, it seems that the effect on the DAergic system may he an
essential component of the behavioural response to the treatment
with a MAO inhibitor plus L-tryptophan. The involvement of the
NAergic system, although less clear, may be of minor importance.
Administration of L-dopa (the precursor of DA and NA) to rats
pretreated with a MAO inhibitor also resulted in hyperactivity (256),
thought to be partly due to displaced 5HT from serotonergic neurons
(245»256) and partly due to increased DA in brain (276). Although
both 5-HT and DA appear to be involved in the production of the
behavioural syndrome of hyperactivity, transynaptic contacts of the
respective neurons seem to mediate this response, with the DAergic
neurons in the dominant role (250,252).
Several questions related to the amphetamine-like effects of the
combination of phenelzine with L-tryptophan remain unanswered. Firstly,
it is not clear whether L-tryptophan is taken up by catecholamine-
containing neurons and subsequently converted to 5-HTP and finally
5-HT, which acts to release DA or NA} or, whether the conversion to
5-HT takes place in serotonergic neurons and then released 5-HT
enters catecholamine neurons to cause the displacement of DA and
NA from their nemrs terminals} or, finally, whether L-tryptophan is
converted to 5-HTP in serotonergic neurons and then 5-HTP is taken up
by catecholamine neurons and decarboxylated to form 5-HT, which
releases DA or NA. Secondly, it is possible that an intermediate
product of the conversion of L-tryptophan to 5-HT or
tryptamine or a 5-HT derivative, could act as a false transmitter
to cause the release of DA and NA from their neurons. The presence
of tryptamine in reserpine-resistant storage sites within cate¬
cholamine neurons was suggested by the work of Marsden and Curzon (260).
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The possibility that this amine contributes to the biochemical and
behavioural effects of the combination phenelzine plus L-tryptophan,
either by catecholamine release or by interaction with 5-HT receptors,
cannot be discounted, although 5-HT rather than tryptamine appears to
be responsible for the hyperactivity syndrome (234)•
Several experimental and clinical data indicate that an increase
of 5-HT at the functional sites of the brain may not be the total
explanation for the effectiveness of the combination tryptophan plus
phenelzine in some patients suffering from affective disorders.
From the studies detailed here, it seems possible that this drug
combination may act by increasing the activity of other than the
5-HT monoaminergic systems in a manner similar to amphetamine.
Administration of high doses of L-tryptophan or 5-hydroxytryptophan
has been used in an attempt to alter the functioning of serotonergic
neurons in the brain of psychiatric or neurological patients (254)*
Failure to improve the depressive state may be due to the fact that
a simple deficiency of brain 5-HT does not seem to be the only
reason for the syndrome; precursor loading alone demonstrated little
beneficial effect in depression (277)> hut the ability of
L-tryptophan to potentiate MAO inhibitors in the treatment is widely
accepted (278).
The involvement of the catecholamines in the pharmacological
profile of this treatment may be another important point for the
interpretation of its therapeutic effectiveness, the elucidation of
the mechanism of action and the search for improved effective
treatments for affective disorders. Drugs like amphetamine, appearing
to have a similar pharmacological profile, could form the basis for
the replacement of this treatment. They could also clarify the
mechanism of the various forms of depressive illness by comparison of
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the biochemical and behavioural effects in laboratory animals to the
clinical symptoms in humans.
4*4*4 Conclusions
1. Treatment of rats with L-tryptophan, with or without a MAO
inhibitor, produced an increase in the synthesis and turnover of
5-HT in brain, but also in the synthesis and/or turnover of DA and
NA- Among the various possible mechanisms, displacement of the
catecholamines from their storage granules by 5-HT or 5-HTP or even
hy tryptamine that 'spills over' the catecholamine neurons, appears
to predominate.
2. The combination of MAO inhibition with tryptophan loading seems
to have similar but different effects on the three monoamines
(5-HT, NA, DA) in brain. The similarities, and especially the mono-
amine-releasing properties, lead to a possible interpretation of the
effectiveness of the combination MAO inhibitor plus L-tryptophan in
some cases of depression in humans and may indicate ways for
improved treatments of this syndrome.
3. Although the accumulation of 5-HT in brain and the consequent
effects on catecholamine metabolism present a rather unphysiological
situation, the amphetamine-like effects of increased 5-HT synthesis
and turnover on catecholamine function may occur in addition to the
intraneuronal, receptor mediated interaction of 5-HT and catecholamines.
The influence of 5-HT on DAergic neuronal activity, in particular,is
examined in Section 5.
SECTION <3
SOME BIOCHEMICAL AND BEHAVIOURAL OBSERVATIONS OP RATS WITH
ASYMMETRIC ELECTROLYTIC LESIONS IN THE MEDIAN RAPHE (MR) OR
IN THE DORSAL RAPHE (DR) NUCLEI
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5.1 INTRODUCTION
5.1.1 5-Hydroxytryptamine in brain
The presence of 5-hydroxytryptamine or serotonin (5-HT) in
the rat brain has been convincingly demonstrated by the use of
biological and chemical methods (282,281,247). It was found to be
unevenly distributed, with the highest concentrations being present
in hypothalamus, brain stem, striatum and some areas of the limbic
system (282,281). Further work showed tryptophan hydroxylase, the
rate—limiting step in 5-HT biosynthesis, to be present in the brain
(216,217) with its regional activity correlating with the
distribution of serotonergic nerve cells and their processes (218).
Evidence that 5-HT in brain fulfills the role of a neurotransmitter
was obtained from physiological (29,283), pharmacological (284) and
histochemical (5) studies. All these observations point to the
existence of specific monoaminergic neurons utilising 5-HT, which is
stored in vesicles and can be released from the nerve terminals by
the transmission of nerve impulses (286,283) to act on specific
receptors (287)•
The corpus striatum of the rat brain has a relatively high
concentration of 5-HT (282,281,288), unequally distributed in various
parts of this structure, but concentrated mainly in the ventro-
caudal part (289). High activities of tryptophan hydroxylase and
L-aromatic aminoacid decarboxylase, the biosynthetic enzymes for
5-HT, were found (282,218). A high affinity uptake and release
process for 5-HT has also been demonstrated in striatal slices in
vitro (271). The rat substantia nigra concentration of ^-HT and
the activity of tryptophan hydroxylase are among the highest in the
brain, almost equally distributed within the areas pars compacta and
pars reticulata (282). A high affinity uptake (73) and release (290)
process for exogenous 5-HT has been demonstrated.
5*1*2 Location of cell bodies of serotonergic neurons (Pig. 5*1)
Fluorescence histochemical studies have demonstrated that the
cell bodies of the 5-HT neurons are mainly localised in the raphe
nuclei of the lower brain stem (5,291), named B1 to B9 hy Dahlstrom
and Fuxe (5). Cell bodies in the medulla oblongada and the pons
(B1 to b6) generally give rise to descending bulbo-spinal pathways
(5,291), whereas ascending pathways generally originate in the caudal
raphe nuclei of the mesencephalon (5,292), named B7, B8,B9* The cell
bodies of group B7 are situated in the substantia grisea centralis.
The vast majority of cell bodies lie within the nucleus dorsalis raphe
(DR), especially in the part just above and medial to the fasciculus
longitudinalis (FL). The cells of group B8 are present from the caudal
end of the posterior colliculus to the end of the nucleus inter-
peduncularis, being situated mainly within the nucleus medianus
raphe (MR). Some cells are also present within the caudal portion
of the nucleus linearis, and a number of cells are found just lateral
to the MR within the formatio reticularis (reticular formation RF ).
Group B9 is present mainly within and around the lemniscus medialis
(LM) from the caudal end of the posterior collide to the caudal end
of the nucleus interpeduncularis. A number of cells are also present
dorsal to the lemniscus medialis within the mesencephalic reticular
formation. Fig. 5*1 depicts a transverse diagram of the rat midbrain,
showing the major raphe cell groups and the adjacent areas.
B9
Fig. 5»1
Diagrammatic transverse representation of the
midbrain showing the location of the major raphe
cell groups (dotted areas) and the adjacent
brain areas.
Abbreviations
AC : aqueductus cerebri
DR-B7: dorsal raphe (area B7 of Dahlstrom and Fuxe,5)
MR-B8: median raphe (area B8)
PCS : pedunculus cerebellaris superior
RF : formatio reticularis (reticular formation)
FLM : fasciculus longitudinalis medialis
CC : crus cerebri
FL : fasciculus longitudinalis
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High concentrations of 5-HT have been found in several of the
raphe nuclei where 5-HT containing cell bodies are located. The nucleus
raphe dorsalis has the highest concentration of 5-HT in the rat brain
(282). Tryptophan hydroxylase is especially concentrated in the raphe
nuclei, with the highest concentration among all the brain areas
being found in the nucleus raphe dorsalis (282).
The 5-HT nerve cells are thus found almost entirely in the raphe
nuclei. The importance of this is not clear, since the connections
and the functions of these nuclei are more or less unknown. According
to Taber et al.(293), the raphe complex seems to be *a primitive part
of the brain which shows relatively little differentiation during the
phylogenetic ascent of the vertebrates* and may thus have 'relatively
small but fundamental and important tasks in the function of the brain.*
Some of the nuclei send descending fibres to the spinal cord.
Brodal et al.(294» 295) have shown that all the raphe nuclei give rise
to ascending fibres and that these fibres appear to be part of links
in the ascending pathways from the spinal cord to higher levels.
5.1.3 Serotonergic nerve terminals in brain
5-HT-containing nerve terminals have been demonstrated, mainly
by the use of histochemical fluorescence, in the nucleus supra-
chiasmaticus, in the ventral part of the lateral geniculate body, in
the fornix, in the habenula and other thalamic nuclei (6,296), in
certain amygdaloid nuclei, in the hippocampus (6), in the globus
pallidus (6,296) and in the olfactory tubercle (297)• Also, very
fine 5-HT nerve terminal plexuses have been visualized in the septal
area, in the anterior colliculi of the preoptic area, in the hippo-
campal formation, in the neo- and mesocortex (6) and in the nucleus
caudatus-putamen (corpus striatum) (296,6). A cerebellar sero-
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tanergic innervation has also been demonstrated. (298) and strong
evidence exists that the substantia nigra receives a large number of
serotonergic fibres forming axo-dendritic synapses (73,5,297).
The presence of 5-HT binding sites, thought to be associated
or to be part of the 5~HT postsynaptic receptor, as well as the
presence of a 5-HT-sensitive adenylate cyclase linked to them, have
been demonstrated in close correlation with the distribution of
serotonergic nerve terminals in various brain areas, e.g. cerebellum,
cerebral cortex, striatum, hippocampus, colliculi, hypothalamus
(287,299,300).
5.1.4 Raphe-efferent projections
The majority of the ascending serotonergic raphe-efferents sweep
ventrally from the raphe nuclei, then curve rostrally to course through
the ventral tegmentum and into the medial forebrain bundle (MFB) (7).
Prom the MPB, fibres branch into the hypothalamus, preoptic area,
anterior amygdala and olfactory tubercle, while some fibres enter the
fornix or the stria terminalis and the hippocampal formation (301).
A well defined lateral mesencephalio-cortical serotonergic pathway has
been demonstrated, together with a medial subcortical pathway (301).
An ascending projection to the habenular nuclei through the fasciculus
retroflexus, as well as to the other thalamic nuclei (mediodorsal,
parafascicuius, reuniens), has been described (297). Descending
projections have been also noted to the dorsal tegmental nucleus and
locus coeruleus and diffusely to the pontine reticular formation and
caudal central grey (297).
The medial ascending pathway, which primarily innervates the
hypothalamus and the preoptic area, originates from the mesencephalic
raphe (B7, B8) and pontine raphe areas. The lateral ascending sero —
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tonergic pathway, which innervates the cortical areas, originates
mainly from the mesencephalic raphe cell groups (B7, B8, B9)• The
minor, far lateral pathway, which primarily innervates the extra¬
pyramidal motor system originates from groups B7» B3, B9 (301). The
cerebellar innervation originates mainly from the mesencephalic raphe
(B7i B8) and possibly from the pontine (B5» B6) raphe cell groups (298).
Biochemical and histochemical studies have clearly indicated the
existence of serotonergic pathways, innervating the globus pallidus and
the striatum (6,292,302,294). Although there are several reports that
lesions involving interruption of the fibres at the level of the ventro¬
medial tegmentum or of the median forebrain bundle result in extensive
reduction of striatal 5-HT and tryptophan hydroxylase (296,303)» in more
recent studies evidence has been obtained indicating that the MFB does
not contain the 5-HT afferents to the striatum (304). Instead, the
5-HT fibres reaching the striatum are postulated to course the area of
Tsai at the midbrain and caudal hypothalamic level and then projeot to
the striatum through the rostral part of the cerebellar peduncle and the
internal capsule (304).
5.1.5 Nigral and striatal serotonergic innervation
With regard to the particular origin of the serotonergic
innervation of the substantia nigra, recent evidence obtained from
lesion, autoradiographic and histochemical studies indicates that the
DR-B7 and not the MR-B8 is the origin of this projection (305)•
Furthermore, the area pars compacta of the substantia nigra is believed
to be primarily innervated, rather than the area pars reticulata
(305). Other workers, however, using electrophysiological and lesion
experiments have suggested that the substantia nigra receives a direct
monosynaptic inhibitory serotonergic pathway from the MR and not from
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DR nucleus (87). It has also been suggested that the 5-HT input to
the substantia nigra from the raphe is by way of axon collaterals from
a main projection to the striatum (306). Further evidence for a raphe-
nigra serotonergic projection comes from a recent report which states
that large lesions of the midbrain raphe, which destroy both MR and DR
nuclei, decrease significantly the 5-HT levels in the substantia nigra
and abolish the potassium-evoked release of endogenous 5-HT from rat
nigral slices, probably due to the loss of 5-HT terminals and the
resulting loss of tiyptophan hydroxylase activity (290).
There is also controversy about the distribution of 5-HT within the
substantia nigra. Histochemical studies (6,307), supported by electro¬
physiological studies (87) suggest that nigral 5-HT is localized
mainly in the pars reticulata, but autoradiographic studies using
transport of ^II-leucine from the raphe nuclei in the rat and cat
(308) indicate that the pars compacta is more heavily innervated than
the pars reticulata. Evidence that the pars reticulata has a higher
content of 5-HT than the pars compacta (290) is also challenged by
another report showing that the two regions have approximately equal
5-HT content (282).
The evidence about the origin of the serotonergic innervation of
the corpus striatum is similarly controversial. Although most of the
reports agree that the MR (B8) and/or the DR (B7) areas constitute the
origin of the main projection from the raphe to the striatum, on the
particular raphe cell group giving rise to thi3 projection the evidence
is divided. It has been suggested that the striatal serotonergic
innervation may originate partly from cells of the B7-B8 area and
partly from cells of the group B9 (301). Large electrolytic lesions
that destroyed both MR and DR resulted in substantial reduction of striatal
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5-HT content (296,289) and reduction in 5-HT synaptosomal uptake and
in tzyptophan hydroxylase activity (296). Other lesion studies,
involving extensive damage of the DR area have showed a reduction of
5-HT in the striatum, whereas lesions of the MR had no effect on
striatal 5-HT content (302,309). The same conclusion has been reached
from the results of experiments based on the transport of labelled
aminoacids, such as ^H-proline or "^H-leucine, by the axonal flow (310)
or by the use of the horseradish peroxidase retrograde transport method
(302.311). Electrical stimulation of the DR cell group has been found
to exert a strong inhibitory action on the firing of striatal cells
(302.312), whereas stimulation of the MR was found to inhibit a much
smaller percentage of these cells (312).
Contrary to these reports, evidence obtained from lesion
experiments indicates that the MR is the main origin of the serotonergic
innervation of the striatum. Lesions of the MR cause a fall in striatal
5-HT levels (313,296), in tryptophan hydroxylase activity and in the
uptake of 5-HT by synaptooomes prepared from the striatum (296).
Furthermore, Costallet al„(314) have reported a fall in 5-HT in the
ipsilateral striatum of rats with small electrolytic lesions confined
to one side only of the MR. These animals turned away from the side of
the lesion after parenteral administration of apomorphine or amphetamine.
5.1.6 Nature of striatal and nigral serotonergic afferents
Despite the controversy over the origin of the nigral and
striatal serotonergic innervation, several reports agree about the
inhibitory nature of these projections. Electrophysiological experiments
indicate that a monosynaptic pathway exists from the DR area to the
striatum, whose function is to produce long-lasting inhibition of cell
firing in the striatum (302). Inhibition of striatal cells, to a
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smaller extent than nigral cells, has also "been reported following MR
stimulation (312).
Stimulation or lesion of the raphe nuclei produce a marked release
or depletion, respectively, of 5-HT in the striatum (318,286,283),
suggesting that 5-HT may be a neurotransmitter in this pathway.
5-HT applied directly to cells in the substantia nigra by means
of microiontophoresis has little effect on pars reticulata neurons but
totally blocks glutamate excitation of pars compacts cells (315)• Such
evidence suggests that the Mergic neurons in the pars compacts may be
the ones primarily influenced by the serotonergic input. Other studies
have shown, in agreement with this, that in the substantia nigra the
predominant effect of 5-HT is depression of pars compacts cells and both
depression and excitation of pars reticulata neurons (64).
Behavioural observations, such as a state of general excitement
with increased locomotor activity after selective inhibition of 5-HT
synthesis by p-chlorophenylalanine (319»320) or destruction of
serotonergic neurons by electrolytic lesions placed in the midbrain raphe
(321), point to a participation of 5-HT in the motor function. In general,
the 5-HT system in the brain is thought to be an inhibitory one for the
locomotor stimulation caused by DA receptor stimulating agents, like
apomorphine, or DA releasing agents like amphetamine (272,323). This is
further supported by the finding that lesions of the raphe nuclei or
inhibition of 5-HT synthesis increase the locomotor activity induced by
apomorphine or amphetamine (324*323,322).
5*1.7 Afferents to the raphe: their possible importance
By means of the horseradish peroxidase retrograde transport method,
afferents to the midbrain DR and MR nuclei of the rat have been determined
by Aghajanian and Wang (325)• Only two areas were found to send afferents
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to 'both, raphe areas and not to the adjacent reticular formation, the
nuclei of the diagonal band and the lateral habenula. The latter area
also contained the highest density of afferent cells for both DR and
MR (325)« The solitary tract nucleus (caudal portion) was found by
these investigators to project exclusively to the DR and not to the
MR or adjacent reticular formation. The B9 area of serotonergic cells
has also been reported to project to the MR (325) whereas it seems that
more synaptic interconnections may exist between the raphe nuclei, such
as an afferent to the DR from the MR (326,325»327). There is no evidence
for the existence of cerebellar afferents to the raphe (325*294*295)•
The striatum is believed to project to the raphe (328), but another
report argues against this idea (325)• There is no evidence for
afferents from any other area of the basal ganglia or the amygdala
(325)j whereas there are several reports based on results using various
techniques such as horseradish peroxidase, degeneration and auto¬
radiography, for afferents from the preoptic nuclei and the medial
forebrain bundle (325*329,330).
Of the major areas that receive a serotonergic innervation from
the raphe, e.g. anygdala, hippocampus, septum, basal ganglie, substantia
nigra, ventral lateral geniculate, optic tectum and suprachiasmatic
nucleus (310,297*6,301), none appears to project directly back to the
raphe (325). Thus, there is no close correlation between the raphe
efferents and afferents. Among the nuclei projecting to the raphe, the
lateral habenula is hypothesized to be a relay nucleus, which, according
to Nauta (331) may serve a pivotal role within a 'dorsal pathway' to
the midbrain, receiving inputs from amygdala and hippocampus and pro¬
jecting to the 'limbic midbrain area' via a component of the fasciculus
retroflexus, thus regulating or modulating the 5-HT cell neuronal
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activity. There is very little evidence about the chemical transmitter
used by the described above afferents.
An inhibitory system has been postulated to exist in the raphe,
which may have a physiological role of maintaining the slow, regular
spontaneous firing of 5-HT neurons by means of 5-HT axon collaterals
(316). Also, the discovery that electrical stimulation of the
habenular nuclei markedly suppressed the firing of serotonergic
neurons in the raphe supports the idea that the habenula may have an
important role in regulating or modulating the neuronal activity of
serotonergic cells in the midbrain raphe nuclei (317)* Attempts to
biochemically test the suggestion of Wang and Aghajanian (317) that
GAM might be the inhibitory neurotransmitter contained within the
habenulo-raphe projection, led to the conclusion that neither GAM nor
Ach are likely to fulfill that role (362).
The possibility of a 5-HT axon collateral inhibitory system (316)
or 5-HT dendro-dendritic junctions (334) mediating directly inhibition
of midbrain raphe neurons after stimulation of the ventromedial
tegmentum has also been proposed (316,317), with unknown but perhaps
important physiological role in regulating the firing of 5-HT neurons.
In addition to the neuronal feedback mechanisms that may exist,
a local feedback system appears to function, in which increased 5-HT
availability induced by drugs or 5-HT precursors results in a compen¬
satory decrease of the firing of 5-HT neurons (332). This is not
surprising, knowing the high sensitivity of the firing rate of raphe




Feedback mechanisms triggered by specific receptors control,
partly at least, the biosynthesis and release of monoamines in the
rat brain. In 1963 for the first time Carlsson and Lindquist (44)
observed an increase in the turnover of dopamine in the brain
following the administration of dopamine antagonists, i.e. neuroleptics.
Similar observations were made later for the other monoamines, such as
5-HT. Thus, stimulation of central 5-HT receptors by LSD (335,344),
by 5-methoxy-N,N-dimethyltryptamine (336), by ergocornine (337) and
by some hallucinogenic phenylethylamines (338) probably initiates a
compensatory negative feedback mechanism which decreases the turnover
of 5-HT in brain. In contrast, the blockade of central 5-HT receptors
by methysergide (339)» 6y methergoline (34$ and by methiothepin (341)
induces an increase in the turnover of 5-HT, probably due to the
activation of a positive feedback mechanism (342). These feedback
mechanisms are still operating in brain slices to control the release
of (^1$ - 5-HT induced by potassium or electrical field stimulation
(343,344).
5.1.9 Catecholamine - serotonin interactions
The presence of nerve terminals and relatively high amounts of
5-HT and tryptophan hydroxylase in areas of the rat brain rich in DA or
NA (6,73,282,8) and the existence of catecholamine-containing cells, as
well as DA, NA and their synthesizing enzymes in the raphe region in close
contact with the 5-HT cells (5,6,282) effer grounds for the postulation
of the existence of a physiological interaction between the catecholamines
and 5-HT in specific brain structures. Also, fibre bundles belonging to
both catecholamines and 5-HT neurons have intimate contacts in the medial
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forebrain bundle (8,345)* NAergic terminals originating in the
locus coeruleus have been observed in the raphe region (348,347)>
supporting the suggestion that NA may serve as neurotransmitter in
the raphe nuclei, with a probable inhibitory function on anterior
raphe units, as revealed after electrophysiological experiments (348).
On the basis of biochemical or lesion studies many workers
have postulated that for normal motor activity a critical balance
should exist between serotonergic and catecholaminergic neurons
(350»349)* In addition, the cataleptogenic action of various
neuroleptics, known to interfere with DAergic transmission, is
suppressed by lesions of the raphe which markedly affect striatal
5-HT or by inhibition of 5-HT synthesis with p-chlorophenylalanine
(351»352). Increased locomotor response to amphetamine, a
catecholamine releasing agent (43f353) is obtained following lesions
specific to the MR (354»322) or to the medial forebrain bundle (355)
or following the administration of the inhibitor of 5-HT synthesis
p-chlorophenylalanine (321). Also, electrical stimulation of the
raphe nuclei in rats leads to a decrease in motor activity (321),
whereas lesions of these nuclei cause a temporary increase in
spontaneous activity (321,356). Apomorphine, a direct DA receptor
stimulant (109)* increases the brain 5-HT and 5-HIAA, and this
effect is antagonised by neuroleptics (357»358), suggesting that
this effect is a secondary one, resulting from DA receptor
stimulation. The increase in locomotor activity induced by apo¬
morphine is bigger in rats after lesions of the raphe nuclei and
after inhibition of 5-HT synthesis (324). The 5-HT system is also
thought to be an inhibitory one for the locomotor stimulation induced
by amphetamine (272,322,323).
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Data suggestive of an interaction between serotonergic neurons
of the raphe system and noradrenergic neurons originating in the locus
coeruleus are the changes in 5-HT synthesis and/or metabolism following
primary catecholamine changes (359,360) or lesions of the locus
coeruleus or of the ascending NAergic pathways (361). Electrolytic
lesions of the locus coeruleus destroying the NA-containing cell bodies
result in a significant increase of 5-HT metabolism in the forebrain
of rats (361). The serotonergic innervation of the locus coeruleus has
been postulated to have a modulatory influence on the NAergic cell
bodies (362).
It is thought that some effects of amphetamine,especially those
related to motor behaviour, are strictly related to dopaminergic
mechanisms in the striatum (363,353)} therefore, the possibility of
an interaction between DA and 5-HT should be considered when the
effect of this drug is examined in relation to the serotonergic
system in the brain. Several other findings point to a participation
of 5-HT in the function of the DAergic system. The amphetamine-
induced stereotyped behaviour, which is believed to result from an
increased availability of DA at striatal receptor sites (363,353) is
inhibited by low doses of tryptophan, the 5-HT precursor, and enhanced
by methysergide, a 5-HT antagonist (364), whereas neither of these
agents appears to affect the intensity or duration of apomorphine-
induced stereotypy (365). Moreover, the apomorphine or amphetamine-
induced stereotypy is not, probably, significantly affected by mid¬
brain raphe lesions (366), contrary to the potentiation of the
locomotor behaviour described by several investigators (322,354,
324,321).
Large doses of L-dopa produce a marked decrease of brain
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5-HT (243, 243) and large doses of >-hydroxyi;ryptophan produce a
reduction of DA in the brain (248,269)* These actions may be due to
displacement of DA by excess 5-HT and- vice-versa, or to competition
between the exogenous aminoacid and the endogenous counterpart for the
synthesising enzymes or for entry into the brain and the neurons
(243»248,244)* Some behavioural aspects observed after the
administration of D-dopa are specifically antagonised by drugs that
block serotonergic transmission in the brain (256). Also, agents which
are known to block dopaminergic transmission in the brain have been
shown to antagonise some behavioural effects of tryptophan (250).
A functional balance between DA and 5-HT in the striatum has been
proposed to explain some neurological and pharmacological aspects of
human parkinsonism (177)* In parallel to DA, 5-HT is reduced in the
striatum and substantia nigra of brains from parkinsonian patients,
but, unlike DA,levels of 5-HT are above normal after treatment of these
patients with MAO inhibitors (117,177)*
The available data from animal studies offer satisfactory
evidence for a large number of serotonergic fibres reaching the corpus
striatum and the substantia nigra. They also point to the idea that
these inputs may play an important role in modulating the nigral and
striatal function, and consequently may be involved in the regulation of
the nigrostriatal dopaminergic pathway. It is possible that 5-HT neurons
may impinge on nigrostriatal dopaminergic fibres and nerve terminals
or affect the activity of nigral cellB and dendrites or influence
striatal cells controlled by the dopaminergic input. This would have
important physiological and pharmacological significance, in view of
the fact that the nigrostriatal pathway has been implicated in very
important brain functions.
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5.1.10 Statement of the problem,purpose of the present study
The present study was undertaken in order to:
1. Clarify the anatomical origin of the serotonergic projections to
the substantia nigra and the corpus striatum of the rat brain. Asym¬
metric electrolytic lesions were made in specific raphe nuclei and the
concentrations of 5-HT and 5-HIAA were measured and compared in the
two sides of the substantia nigra and the striatum.
2. Investigate the physiological importance of these projections and,
in particular, their influence on the nigrostriatal DAergic pathway.
The levels of DA and its main metabolites HVA and DOPAC were determined
on each side of the substantia nigra and the striatum following the
asymmetric lesions of the raphe nuclei.
3. Investigate possible turning behaviour following asymmetric lesions
of the dorsal or the median raphe nuclei. Turning consistent with DA
receptor stimulation would indicate that the lesions produced striatal
DAergic asymmetry. Various pharmacological treatments were used in order
to find the aminergic system or systems responsible for the turning.
4. Examine the possibility of postsynaptic 5-HT receptor
*supersensitivity* induced by the lesion, following the analogy of a
similar phenomenon induced by lesions of the nigrostriatal DAergic
pathway. The extent of the involvement of the 5-HT and the DA system
in the turning behaviour was assessed by measuring the intensity of
turning following the treatment of rats with a combination of drugs
affecting specifically the individual systems.
5. Consider the hypothesis that the serotonergic projection to the
substantia nigra from the raphe nuclei may be part of an alternative
mechanism regulating the activity of the nigrostriatal DAergic path¬
way) to postulate a model for the 5-HT influence on this pathway.
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5.2. MATERIALS AND METHODS
5.2.1 Animals
Male albino Wistar rats, weighing 190-210 g at the time of the
operation were used throughout the studies. They were housed 3 or 4
to a cage, under automatically controlled temperature and lighting
conditions and had free access to food and water. Rats with lesions
in the DR were always housed in separate cages from those with MR
lesions. The weights of all the animals were regularly measured.
5.2.2 Stereotaxic techniques
Lesions of the median raphe (MR) and the dorsal raphe (PR) areas
Small asymmetric electrolytic lesions of the median or the dorsal
raphe area were made. For lesioning, bipolar electrodes, made of two
twisted wires 0.15mm in diameter and insulated except for the tip, were
used. Lesions were made by passing a DC current for the time necessary
for 3 m Coulomb electric charge to cause electrolytic coagulation (about
20-30 sec). The animal was kept anaesthetised with fluothane, circulating
through a vinyl mantle over the nose and mouth throughout the operation.
After positioning the rat in a David Kopf No. 1530 stereotaxic frame,
the head position of the animal was fixed with blunt ear bars, and
the electrode was lowered at an angle of 46° (laterally), either into
the MR nucleus to co-ordinates A-P 7.8mm, L 4-4mm and V 6.9mm, or into
the DR nucleus to co-ordinates A-P 7«8mm, L 5*9mm and V 6.9mm,
according to the atlas of Konig and Klippel (14) (A-Ps anterior-
posterior; L: lateral; V: vertical distance). The lesions were made
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routinely in the left side of the desired nucleus.
The bregma suture was used as the stereotaxic reference point
for the anterior-posterior and lateral co-ordinates, and the vertical
readings were taken from the cortical surface overlying the electrode
insertion site. A hole in the skull was opened in the appropriate
position, using an electrically driven dental drill. After the
completion of the operation, the hole in the skull was sealed with
bone wax following the withdrawal of the electrode and an antibiotic
powder (puromycin and neomycin mixture) applied locally before suturing
the scalp wound with thread.
After operation, the animals were kept warm under an infrar-red
lamp until they recovered from anaesthesia. They were tested for
turning behaviour at least one week and up to four months after the
operation. After completion of the behavioural experiments, randomly
selected animals were killed and the brains quickly removed. Sections
of each brain at the level of the brainstem were cut for histological
examination. The remainder of the brain was dissected into areas
required for the biochemical assays.
•Sham'—operated control animals (either in DR or in MR) were
treated in the same way except that no current was passed after insertion
of the electrode to the appropriate co-ordinates.
Positioning the electrode at an angle was found to be essential
in order to cause a selective lesion in one raphe cell group without
causing damage with the electrode to another group. For example,
vertical positioning of the electrode for lesioning the MR cell group
would also cause damage to the DR region. Also, when the electrode
was positioned vertically at the level of the midbrain area, the
sagittal sinus on the cerebral cortex was damaged and the bleeding that
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followed made the operation very difficult.
Mortalities among lesioned animals after the operation were very
low (less than 5 per cent), but they increased to about 10 per cent
after the first week increased the death rate. A higher frequency of
deaths occurred in rats with the lesion in the MR than in the DR, as
follows: MR,9j DR, 4»
5.2.3 Behavioural observations
Circling behaviour of lesioned and 'sham'-control animals was
measured as the number of complete turns per 30 min to the same
direction, performed by each animal after the injection of the
appropriate drug (unless otherwise stated). Experiments were always
carried out between 11a.m. and 4p.m. For the observation of circling
movements the rats were placed in individual plastic circular baths of
50 cm diameter. About 30 min was allowed for each rat to adapt to the
new environment and for the diminution of the 'handling effect1 (short-
lasting, intense ciroling, which appeared when the rats were handled for
the first time) before the test substance was injected. Lesioned animals
that did not exhibit at least 30 turns/30 min after a dose of 2 mg/^i.p.
apomorphine were considered as not turning and excluded from further
experiments. Only rats turning consistently in one direction were
taken into account.
The onset and the duration of turning were always recorded and
the intensity of circling behaviour was measured over consecutive
5 min periods. Complete turns to one side of the whole body of the
animal were counted. Rats were tested, when necessary, with different
drugs, but care was always taken to leave at least a week between
injections. Other behavioural observations were noted at the same
after the first postoperative week. Amphetamine-treatment
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time as the measurement of the circling behaviour.
5.2.4 Drugs
DL-Amphetamine sulphate (Sigma Chem. Co.), apomorphine
hydrochloride (Mcfarlane and Smith), propranolol hydrochloride
(•Inderal1, ICl), methysergide bimaleate (Sandoz), phenelzine
sulphate (William R. Warner), 5-methoxy-N,N-cLimethyl tryptamine
(Sigma Chem. Co.) and fusaric acid (Sigma Chem Co.) were dissolved
in sterile saline solution (0.9$ NaCl). 5-Methojqy-N,N—dimethyl
tryptamine was mixed with saline, 2-3 drops HCl 1M were added and
heated to 100°C to dissolve completely. Haloperidol (•Serenace1,
Searle) was commercially provided as a solution in ampoules of
5 mg/ml and the content was diluted with saline to the appropriate
concentration. ^Tryptophan was injected as a suspension, prepared
as described in Section 4*
All doses were calculated as the free base (or free acid, in the
case of acids) and were administered peripherally by the intraperitoneal
route (i.p.). All drug solutions were prepared immediately before use.
Control animals received the appropriate diluent of the corresponding'
drug. When two injections of different drugs were given to the same
animal, they were administered into opposite sides of the peritoneum.
Details of reagents for the biochemical determinations are given
in the description of the particular assay.
5*2.5 Histological assessment of lesion site
Histological analysis of speoified sections of brain was made
by using a modification of the Kluver and Barrera technique (367).
Serial frozen sections of the brain were made on a freezing microtome
as follows: After careful removal from the skull, the brain area around
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the expected position of the electrode tract was cut (a slice about
4 mm thick) and fixed onto the microtome chuck in a cryostat. The chuck
was kept in the cryostat at -40°C until the tissue was frozen and then
it was fixed onto the microtome. Coronal sections of 20 pathick were
taken, approximately every fifth one being collected on a glass cover-
slip.
Staining was done with luxol fast blue and cresyl violet as
follows: Sections were partially dehydrated using 70$ ethanol for a
few hours and 95$ ethanol for 4min. The sections were then stained with
luxol fast blue for 30 min (0.1$ luxol fast blue in absolute ethanol
containing 5 ml of 10$ acetic acid per litre). The stained sections were
further washed by immersing in distilled water and in 70$ ethanol for
1 min. If, after this stage, not only the fibres but the whole section
was stained blue, the sections were alternately immersed in 0.05$
lithium carbonate solution (1 min) and in 70$ ethanol (1 min) until
satisfactory differentiation could be observed. Counter-staining was
then carried out with 0.1$ cresyl violet in 70$ ethanol for about 5 min,
followed by washing with 95$ ethanol for 5-10 min, until satisfactory
staining was observed. The doubly stained sections were cleared in
xylene for at least 10 min and mounted on slides with Canada balsam in
xylene.
The fixed sections were observed under the microscope and were
compared with illustrations in the stereotaxic atlas of the rat brain
of Konig and Klippel (140). Photographs of sections were made by
conventional techniques. Localisation of the lesion site in the




a. Dissection of brain regions
Animals, 2-3 months post operation, were killed by decapitation
after a sharp blow on the head. The excised brain was rapidly
dissected on an ice-chilled glass plate into four brain regions, as
shown in Pig. 1.1.
In this study only the striatum, the substantia nigra and the
midbrain area were dissected out (as described in 1.2.1), a procedure
that lasted about 2—3 min. Thfc tissue samples of corpus striatum and
substantia nigra were frozen immediately in liquid nitrogen, with the
left and right side of these tissues immersed simultaneously. Part 4 of
the brain was vised for the histological examination of the lesioned
midbrain area; it included the midbrain area, the pons and the
cerebellum. The dissected substantia nigra tissue was about 8 mg from
each side and the corpus striatum 40-50 mg from each side. Dissected
tissues from turning animals were kept frozen (in liquid nitrogen) and
were analyzed within 14 days of dissection, for 5-HT, 5HIAA, DA and
HA, HVA and DOPAC.
i>* Determination of 5-HT and 5-HIAA
5-HT and 5-HIAA in corpus striatum and substantia nigra were
measured by the rapid and sensitive method of Curzon and Green (288).
Slight changes in the dilutions of some reagents were made in the
present study.
The weighed tissue samples were each homogenized in 3 ml of
cold acidified butanol, and, after centrifugation for 10 min at 3»000
revs/min , 2.5ml of the supernatant was pipetted into a glass test tube
and shaken mechanically (horizontally, with a Luckham shaker) for 10 min
- 214 -
with 5 ml n-heptane and 0.4 ml 0.1 M HCl containing 0.1$ L-cysteine.
The two phases were separated "by centrifugation for 10 min and 5 ml of
the organic phase were transferred into another test tube for the
5-HIAA estimation, and the aqueous phase was used for the 5-HT assay.
0.1 ml of the aqueous phase was mixed in a test tube with
0.6 ml 0.04?, o-phthalaldehyde (OPT) in 10 M HCl, vortex mixed and
heated in a boiling water bath for 15 min , after which the tubes were
cooled in running water. The fluorescence of the solution was measured
in microcuvettes using a Perkin-Elmer MPF3 fluorescence spectrophoto¬
meter. Activation and fluorescence wavelengths were respectively
360 rap and 470 rap. (both uncorrected) • Standards were prepared as
60 pg/ml solutions in distilled water, diluted 1:100 with 0.1 M HCl
(containing 0.1$ Ir-cysteine), and 0.1 ml of this solution was reacted
with 0.6 ml 0.04$ OPT in 10 M HCl in parallel with the tissue samples.
Blanks were prepared by reacting 0.6 ml 0.04$ OPT in 10 M HCl with
0.1 ml 0.1 M HCl (containing 0.1$ L-cysteine). The peak height was
taken as the fluorescence intensity (in arbitrary units).
To measure 5-HIAA, the 5 ml of organic phase, which had been
stored in a test tube in ice, was mixed with 0.6 ml 0.5 M phosphate
buffer (pH 7*0) and shaken mechanically for 15 min. After centrifug>-
ation for 10 min at 3,000 revs/min the organic layer was discarded
by aspiration and two 0.2 ml portions of the aqueous phase were
pipetted into two 1.5 ml plastic polypropylene (Eppendorf) tubes A and
B. To tube A 20 pi L-cysteine 1$ was added and to B 20 pi of 0.02$ W/y
sodium periodate solution. Then 0.4 ml 10 M HCl was added to both A and
B, after which 20 pi 0.1$ W/^. OPT in methanol were added to tube B.
The tubes were then mixed and placed in a boiling water-bath for 15 min ,
cooled in water and the fluorescence was read at activation 360 mp and
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fluorescence wavelength 470 rnji.
The peak height of the "blank (tube B) was subtracted from that
of the test sample (tube A) to give the net 5-HIAA fluorescence.
Standards were prepared as 15 pg/ral solutions in distilled water and
diluted 1:100 in phosphate buffer 7«0, 0.2 ml being added to tubes
A and B and processed in parallel with the tubes from tissue samples.
The 5-HT and 5-HIAA content of samples was calculated from curves
of fluorescence intensity (in arbitrary units, e.g. mm of peak height)
versus the amount of standard 5-HT and 5-HIAA added to tubes and proo-
essed in parallel with the samples. The relation between fluorescence
intensity and the amount of 5-HT and 5-HIAA present was linear over the
range 10-300 ng tested. About 10-15 ng of both 5-HT and 5-HIAA could
be detected by this method. Recoveries of both 5-HT and 5-HIAA added
to butanol and carried through the procedure were 90—100$. The method
was sensitive enough for measuring 5-HT and 5-HIAA in one side of the
striatum from one rat brain, but, in order to measure sufficiently both
substances in the substantia nigra, left or right sides of this tissue
from 2 or 3 brains had to be pooled.
All chemicals were of analytical grade, N-Butanol was acidified
by the addition of 0.85 ml concentrated HC1 to 1 litre of n-butanol.
Solid OPT and L-cysteine (from BEH and Sigma, respectively) were stored
at -25°C until use. 0.04/5 W/y. OPT in 10 M HC1, 0.1$ w/y. L-cysteine in
0.1 M HC1, 1$ W/v L-cysteine in distilled water, 0.1$ w/^. OPT in methanol
and 0.02$ w/v sodium periodate (BDH) solution in distilled water were all
prepared immediately before use.
c. Other biochemical determinations
The concentration of dopamine and noradrenaline in each side of
the striatum, and the concentration of homovanillio acid (HVA) and
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3,4-<31hy<iroxyphen3rl acetic acid (DOPAC) in each side of the striatum
and of the substantia nigra were measured as described in other
Sections of this Thesis.
5«2.7 Statistical analysis
As described in Section 2 (2.2.2. f),for the comparison of turning
rates of lesioned rats, paired t test was used, with the rats serving
as their own controls against different drug treatments. The turning
rate. in response to drugs was found to be the same up to 4 months after




The weights of the experimental animals, both lesioned and sham-
operated, were regularly recorded. As Fig 5*2 indicates, there was no
statistically significant difference between the weights of MR- and DR-
lesioned animals, or the DR-sham- and the MR-sham-operated animals, or
between the DR-lesioned and the DRsham-lesioned animals, up to 80 days
after the operation. Paradoxically, there was a significant fall in the
mean weight of MR-lesioned animals compared to the MR-shan>-lesioned
animals during the period of 80 and 100 postoperative days (p^O.Ol).
5*3.2 Histological assessment of lesion location
The location and the extent of damage in animals with asymmetric
electrolytic lesions in the MR and the DR cell body areas are shown in
Pig* 5*3* Histological examination of the lesions proved essential to
the success of the project. On several occasions the 46° approact had
led to the lesion being contralateral to the side of entry of the electrode
and a description of the lesion extent was vital in the interpretation of
behavioural and biochemical results. Most of the lesions were smaller
than the area represented and occasional extension of the lesion along
the needle track led to a minimal amount of damage outside the area in
some animals.
The extent of the lesioned area at the various planes of the Atlas
in about 20 rats with MR and 20 rats with DR lesion was superimposed and
Fig. 5.2
Postoperative development of animal body weight in rats with a lesion
in the median raphe (mr) or the dorsal raphe (dr) or sham-operated in
either of these nuclei.
Vertical bars represent s.d. of the mean weight obtained from 12-15 rats.
*p^0.01, compared to mr-sham lesioned (control) animals (Student's
t test, two-tailed)
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the schematic diagram of Fig 5*3 was constructed. Black shading in the
drawings represents an area part of which was damaged in all the animals
showing turning behaviour.
The extent of the lesions was found to vary slightly between animals,
but it was confined primarily 'between the levels A350 - Al60 of the Atlas
of KiJnig and Klippel (140). However, in most of the brains the damage
extended to posterior plane P290 and to anterior plane A620 of the Atlas.
The electrode, angled laterally at 46°, caused damage of approximately
one-third of the left side of either DR or MR area in each animal. In
the group of sham-lesioned animals only the electrode tract could occasion¬
ally be observed without any observable damage to the MR or DR nuclei.
Lesions of the dorsal raphe nucleus caused distortion of the
aqueductus cerebri (AC) and frequently damaged the fasciculus longitudinalis
mediaiis (FLM) and fasciculus longitudinalis dorsalis pars tegmentalis, the
substantia grisea pars ventralis, and very occasionally the pedunculus
cerebellaris superior (PCS), but the damage never extended to the areas
beneath or to the MR. Lesions of the median raphe nucleus also caused
damage to the pedunculus cerebellaris superior (PCS) and tractus tecto-
spinalis and occasionally to the mesencephalic formatio reticularis (FOR)
and the nuclei ventralis tegmenti. On rare occasions the lemniscus mediaiis
(LM) was also damaged. The area formatio reticularis (reticular formation
FOR) which contains the ascending from the locus coeruleus, dorsal
noradrenergic fibres (8) was always carefully examined for any damage.
As mentioned above, occasionally lesions of the MR nucleus damaged this
area, but there was no correlation between circling behaviour or biochemical
changes and the damage to the reticular formation.
Fig. 5.4 represents a diagrammatic representation of the extent
Fig. 5.3
Diagrammatic representation of the extent and localisation of damage
caused by lesions placed asymmetrically in A, the dorsal raphe, or B,
the median raphe nucleus. The diagrams and coordinates are based upon
those of Konig and Klippel (140). Black shading represents total tissue
destruction caused in consistently turning rats, compiled from about
20 rats for each type of lesion.
Abbreviations; AC: aqueductus cerebri; dr: dorsal raphe; PCS: pedunculus
cerebellaris superior; FLM: fasciculus longitudinalis medialis; mr: median
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and the localisation of the damage caused by asymmetric lesions placed in
A the dorsal raphe, or B, the median raphe nucleus. The shaded area in
the planes A350 - Al60 of the Konig and Klippel Atlas of the Rat Brain
(140) represents the area, large part of which was damaged by the lesion
in the 10 animals (of each type of lesion) that displayed the most intense
turning behaviour.
Pig* 5>5 - 5*11 represent photographs of tranverse histological
sections through the midbrain of rats lesioned in DR or MR, with lesions
either confined to these areas or damaging other areas adjacent to these
two nuclei. The sections were stained with luxol fast blue-cresyl vioLet,
as described in the Methods. Pig. 5*5 shows a photomicrograph of an
accurately placed DR lesion. Pig. 5.6 shows a small lesion in the MR
nucleus (indicated by the arrow); surrounding cell degeneration and gliosis
can be seen. Pig. 5*7 shews a photomicrograph of a DR-lesioned animal
the 46° angle approach led to this lesion being contralateral to the
side of entry of the electrode and the turning following the administration
of apomorphine or amphetamine being in opposite direction compared to
typical DB-lesioned animals. The damage due to the passage of the elect¬
rode is still visible, at over 80 days sifter the operation. In Pig. 5*8
a lesion is shown, which damaged the pedunculus cerebellaris superior and
part of the reticular formation but not the desired MR nucleus; this
atypical lesion did not elicit the behavioural response (circling) that
MR-lesioned rats displayed. Pig. 5*9 shows a photomicrograph of another
accurately placed DR lesion, and Pig 5*10 and represent photographs of
sections in posterior planes of the rat brain with small, localised MR
lesions (indicated by arrows).
250|iTn
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Fig. 5»6
ft photomicrograph showing a veil-localised
^symmetric lesion (arrow) of the median raphe
nucleus of the rat; gliosis and cell degeneration
in the area surrounding the lesion can be seen.
Section stained with cresyl violet-luxol fast
blue. (magnification x 80)
Abbreviations: DR - dorsal raphe
FLM - fasciculus longitudinalis medialis
Fig. 5-1
A photomicrograph of a lesion (arrow) in the
opposite than the desired side of the dorsal
raphe nucleus. The electrode tract can be seen
crossing the DR nucleus to the contralateral
side. The rat with this lesion responded to
apomorphine with turning in opposite direction









in the median raphe nucleus. The section
represents a posterior plane of the rat brain.
The cresyl violet-luxol fast blue method was used
for staining.
Fig. 5«1Q
A photograph of a small asymmetric lesion (arrow)
Fig. 5.11
A photograph of a small asymmetric lesion (arrow)
i >
2 mm
of the median raphe nucleus. The section
represents a posterior plane of the rat brain.




5*3 *3 Effect of lesions on brain monoamine content
5*3*3a Changes in 5-HT and 5-HIAA after lesions of the raphe nuclei
As shown in the Table 5*1> lesions of left side of MR caused a
decrease of 5-HT in the ipsilateral striatum of 34$ and a 32$ decrease
of 5-HIAA levels compared to the contralateral side, both reductions
being statistically significant (p<^0.01 and p<^0.025, respectively,
using paired t test). The same lesion resulted in no significant
change either in 5-HT or in 5-HIAA in the left substantia nigra when
compared to the right substantia nigra (-13$ and +10$, respectively).
Contrariwise, lesions of the left side of DR resulted in a 31$
reduction of 5-HT and 30$ reduction of 5-HIAA in the left substantia
nigra when compared to the levels of the right substantia nigra, both
changes found with the Students paired t test significant (p<^0.01).
In the corpus striatum, the changes in both 5-HT and 5-HIAA in the left
side as compared to the right side, ifere not statistically significant
being only -14$ and -9$ respectively.
The changes in 5-HT and 5-HIAA in the lesioned side of the
corpus striatum or the substantia nigra were always of about the same
percentage, as the ratios 5-HT/^_Hshow (Table 5*2).
Tryptophan loading of rats made the determination of 5-HT and
5-HIAA in small brain areas, like substantia nigra, possible without the
need to pool together 2 or 3 tissue pieces from different animals, due
to the problem of sensitivity of the assay. Thus an injection of a
suspension of L-tryptophan (prepared as described in Section 4) in a
dose of 100 mg/^o, of animal body weight was given i.p. 1 hour before
sacrifice to groups of animals lesioned in the DR or the MR. The
animals with asymmetric lesions of the left side of the MR cell group
had significantly lower concentrations of 5-HT and 5-HIAA in the left
Table5.1
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Table 5.2
Effect of raphe lesions on the ratio 5-HT/5-HIAA
Lesioned Treatment No. of Brain 5-HT/5-HIAA
area expts. region Left Right
MR saline 8 CS 2.14 + 0.49 2.00 + 0.37
-
5 SN 0.72 + 0.20 0.79 + 0 • 0
L-tryptophan 6 CS 1.38 + 0.49 1.04 + 0.22
100 mg/kg ip
6 SN 0.62 + 0.19 0.73 + 0.12
DR saline 5 CS 1.60 + 0.30 1.62 + 0.24
4 SN 0.85 + 0.23 O.87 + 0.18
L-tryptophan 6 CS 0.93 + 0.09 0.88 + 0.12
100 mg/kg ip
6 SN 0.44 + 0.18 O.69 + 0.28
Asymmetric electrolytic lesions in the median raphe (MR) or the dorsal
raphe (DR) were made and the ratio 5~HT/5-HIAA in the corpus striatum
(CS) and the substantia nigra (SN) of the rat brain was calculated.
The ratios 5~HT/5_HIAA were calculated from the data of Table
Results represent means + s.d.
*
Significance (Student's t test for paired data): p ^0.001 (compared to
the right side)
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side of the corpus striatum than in the right side (p<^0.05 and
p<$).01, respectively, paired t test). Both sides had significantly
higher concentrations of 5-HT and 5-HIAA than the corresponding sides
of saline-treated animals. The difference between the mean values of
the two sides was —24$ for 5-HT and -32$ for 5-HIAA. There was no
statistically significant difference between left and right substantia
nigra in either 5-HT or 5-HIAA concentration, the difference between
the mean values being -11$ and +7$, respectively (Table 5«1)«
An injection of L-tryptophan to rats with a lesion in the left
DR cell group resulted in a statistically significant rise in 5-HIAA
in both sides of the substantia nigra (left +157$• right +139$)»
whereas only the right (contralateral) side showed a significant rise
in 5-HT (+98$), the 23$ rise of the left (ipsilateral) subtantia nigra
not resulting in a significantly different concentration compared to the
corresponding side of saline-treated, lesioned animals. Therefore, the
concentration of 5-HT in the left substantia nigra was lower by 55$
.001, paired t test) whereas the concentration of 5-HIAA was only
lower by 26$ (p<^0.01, paired t test) compared to the contralateral
side.
In the corpus striatum (where 5-HT and 5-HIAA were reduced after
lesions of the MR and not of the DR) L-tryptophan treatment of rats with
an asymetric DR lesion caused a smaller increase in 5-HT and 5-HIAA in
the side ipsilateral to the lesion than in the contralateral side.
Thus, the concentration of 5-HT and 5-HIAA was significantly higher in
both sides of the corpus striatum, compared to the corresponding sides
in saline-treated animals with a DR lesion (Table 5«1)» taut the 5-HT
and 5-HIAA were lower in the ipsilateral compared to the contralateral
side (by 14$ and 19$» respectively)} the difference was statistically
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significant only with respect to 5-HIAA (p <^0.025, paired t test).
Sharo-lesioned animals, either in the DR or in the MR, showed no
statistically significant difference in 5-HT or 5-HIAA between the two
sides of the corpus striatum or the substantia nigra. Furthermore, there
was no significant difference between the 5-HT or 5-HIAA concentrations
in the side of the corpus striatum or the substantia nigra contra-
lateral to the lesion in the DR or MR and the concentrations in either
side of rats with sham-lesions (Table 5*1) •
A comparison of the ratios 5-HT~^e right
side of corpus striatum and substantia nigra (Table 5*2) shows that the
lesions, in general, did not cause any change, except on one occasion:
in the substantia nigra of rats with lesions in the Dfl, after treatment
with L-tryptophan. In this case, a significant reduction of the ratio
was found (p<^0.001, paired t test), due to the smaller increase of
5-HT in the lesioned side after L-tryptophan (+23/5) compared to the
98$ increase in the right side, whereas 5-HIAA concentrations increased
by approximately the same percentage in both sides (left: +157$t
right: +139$).
5.3.3b Effects of the lesions on catecholamine metabolism
There was no statistically significant change in the concentration
of either NA or DA in the left (ipsilateral) side of the striatum
compared to the right (contralateral) side of the same structure in rats
with lesions of the left DR or the left MR nucleus (Table 5«3)« The
sensitivity of the radiometric assay did not allow the measurement of
the two amines in the substantia nigra.
The concentrations of the main metabolites of DA in brain, i.e.
homovanillic acid (iWA) and 3,4-dihydroxypheny1 acetic acid (DOPAC) were
determined in the two sides of the corpus striatum and the substantia
Table3*3
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nigra lay the sensitive gas chromatographic technique described in the
Appendix. The results are shown in Table 5«3 •
An asymmetric electrolytic lesion of the MR which affected only
the left side of this nucleus and resulted in a significant reduction
of 5-HT and 5-HIAA in the ipsilateral striatum (Table 5*1)» also caused
statistically significant rises in HVA and DOPAC in the ipsilateral
striatum compared to the contralateral side (p <^0.001, paired t test).
No statistically significant difference in either HVA or DOPAC was
found lbetween the left and the right substantia nigra, in good
correlation with the 5-HT and 5-HIAA, which did not change in the left
compared to the right side of this structure after asymmetric MR
lesions.
The concentrations of HVA and DOPAC were determined in the left
and the right substantia nigra and in the left and the right striatum
in a group of successfully rotating animals with a lesion in the left
side of the DR nucleus. No significant difference was found between
the two sidfls of the corpus striatum in the concentrations of these
metabolites, whereas there was a highly significant rise in both HVA and
DOPAC in the left compared to the right substantia nigra (p 0.005,
paired t test). Thus, an inverse correlation was found in the substantia
nigra between the changes induced by DR lesions in 5-HT and 5-HIAA
(Table 5.1) and HVA and DOPAC (Table 5.3).
5«3»4 Circling behaviour and other behavioural observations
Both in the acute and the chronic postoperative period, the
electrolytically lesioned rats displayed slow spontaneous turning
lasting 1-2 min and a tendency to unilateral turning of the head
immediately after they were placed into the plastic circular bowl.
Rats with asymmetric lesions in the MR usually turned to the right
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(contralateral) side, whereas those with asymmetric lesions in the
DR turned to the left (ipsilateral) side; however, a number of
DR-lesioned animals did not exhibit any spontaneous turning. The
spontaneous behaviour (turning and postural asymmetries) was more
pronounced during the first postoperative week, becoming less obvious
and finally disappearing in the 3-4 months after the operation.
Spontaneous circling is common in other types of neurological lesions,
such as 6-hydroxy-dopamine - induced lesions of the substantia nigra
(8) and has been attributed to handling effect. In general, a gross
comparison with sham-operated control rats showed an increased
excitability and hyperactivity in both MR- and DR-lesioned animals,
in agreement with several published reports (368,321,356).
5.3.4a Apomorphine and amphetamine effects
Apomorphine, a drug thought to directly stimulate DA receptors
(109) enhanced the spontaneous turning and induced turning in rats not
turning spontaneously. The rate of turning was dose-related (as shown
in the Pig. 5»12) between 0.5 - 5 body weight. After a dose of
2 mg/, i.p. the turning started in 2-3 min , continued for about 30 minKg
at a constant rate and lasted usually 45 rain (with more than one complete
turn per minute). Not infrequently the turning lasted up to 2 hours,
especially in MR-lesioned rats. Pig. 5*13 shows a typical raphe
(MR or DR)-lesioned rat, turning after apomorphine administration.
In MR-lesioned animals apomorphine in doses 0.5 - 5 rag/ i»P«
kg
caused contralateral turning, as reported by Costall and Naylor (368),
which was alower than the turning reported by the above authors. It was
however, found consistently in rats which at the histological assess¬
ment showed that they had the lesion properlylocated in the left side
 
Fig.5«12
Turningbehaviourofr tswithlesionint emed arhdo salraphe. TotalnumberfturnsiJ>0minareplott dfortwogr upsfa imal .The solidcolumnsrepresentanimalsw thunila rallesi nofthMRa d opencolum sani alw thunilat rallesi nsftheDR.Tur stow rdt lesionedid(ipsiversive)arepresentedownwar s,a dcontrav rsiv turnsarerepresentedu wards.Ve ticalbrepreses.d.fothn mb ofanimalsshowni parentheses. t A-apomorphine2mg/kgi. . B-amphetamine5g/kgi.p. C-phenelzine20mg/kglusL-try topha10mg/kgi. . D-5-methoxy-N,N-dimethyltryptamine10g/kgi.p. A'-apomorphine,tdosesindicat d(mg/kgi.p.) B'-5-methoxy-N,,N-dimethyltryptamineados sindicat d(mg/kgi.p.)
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of the MR (as shown in Pig. 5*6,5»10,5*11)• A relatively slower
turning was obtained when apomorphine (0.5 - 5 mg/^i.p.) was given to
rats that had an asymmetric lesion in the DR nucleus, but the animals
turned consistently to the ipsilateral side. The rate of turning was
also dose-dependent, as Pig. ^>.12 illustrates.
In both types of lesion, the rats turned in tight circles,
(Pig. 5«13), frequently showing half turns to one side followed by
complete turns to the other. No difference could be observed in the
way the animals turned in the MR or DR type of lesion, apart from the
direction of turning and the difference in the rate of turning. In
both lesions, the rats responding to apomorphine were turning in the
centre of the circular bath, within a small radius, usually tending to
pivot round the hind limbs. About 80% of the lesioning operations were
successful in producing animals responding to apomorphine with circling
behaviour.
Sham-operated animals showed no consistent postural asymmetries or
spontaneous turning. They did not show any turning response to apo¬
morphine or amphetamine. During the first week after lesioning, mild
asymmetric postures of the head or the body, probably of neurological
nature, were observed, but subsequently disappeared.
Locomotor stimulation and body asymmetry were more pronounced after
apomorphine. Also hyperactivity, stereotyped movements (such as pacing
and padding of the forepaws, sniffing, licking, knawing), tail
stiffening or tail erection, clinging with the hindpaws on the walls
of the bath and even sidewards jumping were common characteristic
effects of apomorphine administration (0.5 - 5 rag/v i»p0» observedKg
in MR- and DR-lesioned rats and in the control sham-lesioned rats.
Appearance of these effects, especially the sniffing and the stereotyped
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movements were taken as an indication that the animals responded to
apomorphine, whereas in the absence of these symptoms the injection was
considered unsuccessful and was repeated.
When given in a dose of 5mg/v i.p., DL-amphetamine, an agentKg
believed to be acting indirectly on DA receptors in the brain by
releasing DA from the nerve terminals (43)» caused intense turning.
The turning started at 3-4 min after the injection and lasted for about
45 min at a constant rate, and continued at a slowering rate for as
long as 90 or 120 min. The intensity of turning was in general higher
in rats with a lesion in the MR than in rats with a lesion in the DR.
Rats with an asymmetric lesion in the MR responded to amphetamine with
intense turning contralateral to the side of the lesion. Rats with an
asymmetric lesion in the DR responded to the same treatment with
turning ipsilateral to the side of the lesion (Fig. 5*12). No turning
was apparent after amphetamine administration to sham-lesioned animals.
Both in sham-operated and in MR- or DR-lesioned rats, amphetamine
administration was followed by hyperactivity and increased locomotion,
as shown by the intense stereotyped and exploratory behaviour. Also,
piloerection, clinging on the walls of the circular bath, tail erection,
movements of the head, exploration of the air-space with the head,
sniffing, and, occasionally, jumping, backwards movements, standing on
the hindpaws were the behavioural effects consistently observed after
amphetamine.
5.3.4b Effect of haloperidol on apomorphine—» or amphetamine-
induced turning
The DA receptor blocking agent haloperidol, at doses of 0.5 or
1.0mg/kgi.p. given 1 hour before the injection of apomorphine or
amphetamine, inhibited the turning induced by these agents, in both
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MR- and DR-lesioned rats. When it was injected after the
administration of either of the two drugs, haloperidol inhibited
the rotation of the rats within 5 min. No turning was observed when
haloperidol alone was administered.
Mild to severe catalepsy with subsequent disappearance of the
spontaneous movements, proptosis of the head, sedation and flattening
of the body, with extended paws, squeaking (when the animals were
touched) were the characteristic behavioural effects of haloperidol.
Most of the previously described behavioural effects of apomorphine were
eliminated in rats pretreated with haloperidol. No sniffing or stereo¬
typed movements were observed, but the postural asymmetries of the rats
persisted even after haloperidol administration. Apomorphine (2mg/^
i.p.) administered after haloperidol did not alter the cataleptic effect
of this drug, whereas haloperidol given after apomorphine induced
catalepsy within 5 min (in addition to the interruption and inhibition
of turning).
Haloperidol (0. 5mg/^ or 1 mg/^i.p.) also caused catalepsy when
it was given to rats either 1 hour before or within the 30 min after the
administration of amphetamine (bmg/, i.p.), in addition to theKg
complete inhibition of turning. The rats were sedated, alert but not
moving and squeaking when touched. Complete disappearance of the stereo¬
typed movements were observed, but an interesting exploratory behaviour
was also noticed; the animals were only moving their heads, exploring
the aia>-space. The postural asymmetries induced or enhanced by
amphetamine also persisted when haloperidol was administered.
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5• 3 • 4.C.Effects of L-1ryptophan-phenelzine drug combination
L-tiyptophan, the 5-HT precursor, at a dose of 100mg/kgi.p. and
following the injection of the MAO inhibitor phenelzine sulphate given
at a dose of 20mg/, _i.p. 1 hour earlier, caused contralateral turning inKg
rats with a MR lesion and ipsilateral turning in rats with a DR lesion,
(Pig. 5*12). About 80^b of the MR- and DR—lesioned rats that turned with
apomorphine also turned in the same direction with this drug combination.
An even higher percentage (90y) of the rats that turned after amphetamine
responded with circling behaviour in the same direction after the
combination phenelzine-tryptophan (Table 5*4)* The turning was slow in
onset and rate; it was starting between 30-60 min after tryptophan
injection and lasting for about 2 hours. No circling was observed
with phenelzine or with tryptophan alone.
The typical behavioural symptoms of this drug combination were
always observed: Flattening of the body, compulsive sniffing, squeaking
and excitability, padding of the forepaws, movements of the head,
shivering, pilo-and penile-erection, salivation, proptosis of the
head. Postural asymmetries persisted throughout the duration of action
of this drug combination. Marked sedation was induced by phenelzine
alone, but most of the above effects appeared only after the administrar-
tion of tryptophan. The rats had periods of deep sedation and inter¬
ruption of turning, so that the actual intensity of turning after
subtraction of these dead-time intervals could be much higher than the
intensity shown in the Pig. 5•12.
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5.3«4d Effects of 5-methoxy-NtN-dimethyItryntamine
The drug 5—methoxy—N,N-dimethyltryptamine (5-MDT) thought to be
a central 5-HT receptor stimulant, was injected at a dose of 10mg/^i.p.
and caused ipsilateral turning in rats with an asymmetric lesion in the
ICR and contralateral turning in rats with an asymmetric lesion in the
DR, i.e. in the opposite direction than apomorphine or amphetamine
(Fig. 5«12). The turning rate was dose-dependent in the range
0.5-10mg/Vp,i.p. tested,as Fig. 5*12 illustrates. All rats that had
responded to apomorphine and amphetamine, responded also with circling
behaviour alter administration of this agent. A peculiar and very
characteristic way of turning was observed with this drug (Fig. 5*14)•
Two to three min after the injection, the body was flattened
completely and turning started, with great difficulty in moving. Instead
of turning actively about on one hind leg as they did after amphetamine
or apomorphine, the animals were turning with all their legs extended
laterally, and their abdomen close to the surface of the bowl.
Shivering and convulsions of the body were observed, with padding of
the forepaws and thebindpaws extended and also elongation of the body.
No exploration, stereotypy or marked hyperactivity was observed.
5.3.4e Correlations between circling responses
As shown in Table 5«4«» apomorphine (2mg/v^i.p.) andI)I?aiiiphetamine
(5mg/,„gi.p.) caused contralateral turning (away from the lesioned side)
in 22 out of 25 rats with an asymmetric lesion in the MR and in
opposite directions in the other 3 rats. Among the DR-lesioned rats,
these two drugs induced ipsilateral turning (towards the lesioned side)
in 18 out of 19, and in opposite directions in 1 rat.
DL-Amphetamine and the combination phenelzine plus L-tryptophan
induced turning in the same direction in 11 and in opposite direction in
Fig. 5.14
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Drugs were administered to rats at intervals of about 10 days,
at doses described in the text. The numbers of rats tested
are indicated.
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2 of the MR-lesioned rats; in the DR-lesioned rats, the direction of
turning was the same in all 19 rats tested, i.e. ipsilateral to the
side of the lesion.
Apomorphine and the combination phenelzine plus L-tryptophan
induced contralateral turning, in MR-lesioned rats, in 14 out of 16
animals, with the other 2 turning in opposite directions. In DR-
lesioned rats, the turning was ipsilateral in 15 out of 18 rats, with
the other 3 turning in opposite directions.
When compared with apomorphine, 5-MDT caused circling in the
opposite direction in all 5 rats tested that had an asymmetric lesion
in the MR. Of the 7 rats with an asymmetric lesion of the DR that were
tested, 1 turned in the same direction and 6 in opposite directions with
the two drugs.
All correlations of the directions of turning are shown in
Table 5»4»
5«3-4f Acute and chronic effects of haloperidol on circling
As mentioned above, pretreatment of rats with 0.5 or Img/^
haloperidol inhibited completely the turning induced by apomorphine
(2mg/jCgi«P») or amphetamine (pmg/^i.p.). However, when haloperidol
was administered chronically for 10 or 15 days, at a dose of 1mg/, i.p.Kg
daily, tolerance developed to the blocking effect of this drug on the
circling induced by apomorphine or amphetamine. Apomorphine (2mg/, i.p.Kg
administered 24 hours or 1 hour after the last (15th) injection of
haloperidol to rats lesintned in the MR elicited turning that was
significantly more intense (p<^0.05 and p <^0.025, respectively, paired
t test) and in the same direction, compared to the turning recorded
when the same animals were tested with apomorphine alone, without

























Modification of turning behaviour by chronic haloperidol treatment
S (f\ or
Open columns represent turning after S mg/kg amphetamine (C and D).
Filled columns represent turning after aponwrphine (A and B) or
amphetamine (C and D) given 1 hour after the last of 15 daily injections
of haloperidol (l mg/kg daily). Dashed columns represent the responses






when administered to MR-lesioned rats after pretreatment for 15 days
with haloperidol (Img/^i.p. daily), elicited turning which was of
about the same intensity and in the same direction as the turning
obtained when the same animals were injected with amphetamine alone
(without pretreatment).
In rats with an asymmetric lesion in the DR, apomorphine caused
significantly less intense turning (p<(0.05j paired t test) at 1 hour
but not at 24 hours after the last injection of haloperidol and always
in the same direction. Amphetamine caused turning of about the same
intensity and in the same direction in rats with a DR lesion, when it
was administered 1 hour or 24 hours after the last of 15 daily
injections of haloperidol, compared to the response obtained when it ifas
administered alone (without pretreatment). All the above results are
illustrated in Pig. 5.15.
With regard to the other behavioural effects of apomorphine
(2mg/jcgi.p.), both 1 hour and 24 hours after the last of a series of
10 or 15 daily injections of haloperidol (img/^i.p.) to rats lesioned
either in the MR or the DR, these were more intense than the effects
following a single apomorphine dose without the chronic pretreatment
with the DA receptor blocker. Stereotyped repetitive, apparently
purposeless movements (sniffing, gnawing, licking, padding of the
forepaws, clinging on the walls of the bath with the forelimbs),
postural asymmetries, tail erection, occasionally backwards movements
and general excitability were the behavioural symptoms common to all rats
that had undergone this treatment. The circling continued for about
45 min and was followed by sedation and mild catalepsy, with inter¬
ruption of turning and disappearance of the apomorphine effects
(sniffing, stereotyped movements, tail erection, etc). Catalepsy also
- 23 S -
developed if haloperidol (irag/, i.p.) was injected again 45 rain sifterKg
apomorphine, whereas injection of haloperidol (1mg/v i.p.) during theKg
first 30 min of the intense apomorphine effect did not stop the turning
or induce catalepsy in either MR- or DR-lesioned rats.
It should be noted that, although DR-lesioned animals tended to
turn in response to apomorphine following chronic haloperidol pretreat-
ment, the turning rate was just over the arbitrarily set limit of
30 turns/30min. In contrast to the MR-lesioned rats, not an increase
but a statistically significant decrease of the turning rate was
recorded 1 hour after the 15th haloperidol injection, compared to the
turning following a single apomorphine injection (p<^0.05f paired t test)
(Pig. 5.15). It should also be noted that all the other behavioural
symptoms of apomorphine administration were intensified in MR- and
DR-lesioned rats treated chronically with haloperidol. The behavioural
effects of amphetamine (apart from circling) were also more intense when
it was administered 1 hour or 24 hours after the last in a series of
15 daily haloperidol injections, than when it was administered to the
same animals without this pretreatment. Hyperactivity, exploration,
stereotypy (especially padding of the forepaws), piloerection, tail
erection, backwards or sidewards movements and jumping were the common
symptoms observed. The stereotypy was intensified after about 45 rain
when the turning stopped, and continued for about 1 hour with increased
sidewards jumping. Sedation and catalepsy followed the disappearance of
the effects of amphetamine.
5.3.4g Interaction of drugs acting on the dopaminergic and the
serotonergic systems
Haloperidol (img/^i.p.) administered 1 hour before the 5-HT
receptor agonist 5-MDT, (lOmgA i.p.) blocked the turning induced bykg
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the latter, in "both MR- and DR-lesioned animals. The catalepsy that
resulted from the haloperidol administration was followed and replaced
by the symptoms of 5-MDT, i.e. flattening and extension of the body,
tremor, convulsions, squeaking (when touched), shivering, padding of the
forepaws and extension of the hindpaws. Similarly, haloperidol pre-
treatment abolished the turning but not the other behavioural effects
of the combination phenelzine plus L-tiyptophan.
Simultaneous administration of aporaorphine (2mg/, i.p.) andKg
5-MDT (I0mg/, i.p.) resulted in no consistent or measurable turningKg
of the rats in either direction (Fig. 5*16.). The same response was
obtained from rats lesioned in the MR or the DR, in contrast to the
intense turning (but in opposite directions) induced by both agents
when they were administered alone (Fig. 5*12). The behavioural effects
of the 5-HT agonist were the predominant ones; the flattened body of the
animal was moving with difficulty, with tremor, shivering and even
convulsions dominating its posture, but with intermittent clinging on
the walls of the bowl and jumping. Characteristic movement of the head
to the left and to the right, with repetitive padding of the forepaws
were observed.
Simultaneous administration of amphetamine (5mg/,_ i.p.) andKg
5-MDT (lOmg/, i.p.) resulted in turning that was significantly moreKg
intense (p<^O.G25, paired t test) in both MR- and DR-lesioned rats
compared to the turning induced by amphetamine alone. The direction
of turning was determined by amphetamine, i.e. rats with^lesion in the
MR turned contralaterally (away from the lesioned side) and rats with a
lesion in the MR turned ipsilaterally (towards the lesioned side),
(Fig. 5*16). The behavioural response to this drug combination was
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Fig. 5.16
Turning behaviour of rats with MR or DR lesions
Bars represent s.d.^with the number of rats used in
parentheses.
A: 1 - 5 mg/kg amphetamine i.p.
2-5 mg/kg amphetamine plus 10 mg/kg 5-methoxy-N,
N-dimethyltryptamine i.p.
B: 3 - 2 mg/kg apomorphine i.p.






typed movements were coupled with hody flattening and difficulty in
moving, also tremor, shivering and convulsions, squeaking and hiding
of the hindpaws under the body. Turning continued over 45 min.
Methysergide bimaleate, a 5-HT receptor antagonist (339)> at a
dose of 0.5mg/, i.p. caused no turning in DR-lesioned rats, butKg
induced contralateral turning in rats lesioned asymmetrically in the
MR (Fig. 5.19). When injected it rendered the animals sedated but very
excitable. •
A drug combination which proved interesting wan the administration
of methysergide bimaleate (0.5nig/1, i.p.) followed 45 rain later by-xg
apomorphine (SJmg/^ i.p.). In all rats with an asymmetric lesion
either in the MR or the DR, the behavioural effects of apomorphine,
including circling, were apparent before the end of the first min after
the injection and frequently as soon as 30 sec. Hyperactivity and
stereotypy (sniffing, licking, clinging on the walls of the bath, etc.,)
appeared in less than 1 min , in contrast to the effects appearing in
about 3 min after the injection when apomorphine was given alone
(without pretreatment with methysergide). The intensity of turning,
measured in turns/30 min , was significantly higher after this drug
combination, compared to apomorphine administration alone, both in
MR- and DR-lesioned rats (p^O.Op, paired t test) (Fig. 5• 17) • The net
number of turns was also significantly higher during the first 5 and
10 min in both MR and DR lesioned rats, compared to the appropriate
controls (p<^0.05, paired t test), as shown in Fig. 5• 18• The
direction of circling after apomorphine was not altered by the pre¬
treatment with methysergide, i.e. it was contraversive in MR- and
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Fig. 5.17
Effect of acute administration of methysergide on
apomorphine- and amphetamine-induced turning.
Vertical bars represent s.d.^with the number of rats used
in parentheses.
A: 1-2 mg/kg apomorphine i.p.
2-0.5 nig/kg methysergide plus 2 mg/kg apomorphine i.p.
B: 3 ~ 5 rag/kg amphetamine i.p.









Effect of acute administra'tion^on the turning during
the first 5 or 10 min after apomorphine or amphetamine.
Vertical bars represent s.d.^with the number of rats
used shown in parentheses.
a,c (5 min): 1 - 5 mg/kg amphetamine i.p.
2-0.5 mg/kg methysergide plus 5 mg/kg
amphetamine i.p.
b,d(l0 min): 3 _ 5 mg/kg amphetamine i.p.
4-0.5 mg/kg methysergide plus 5 mg/kg
amphetamine i.p.
A,C (5 min): 5 - 2 mg/kg apomorphine i.p.
6-0.5 mg/kg methysergide plus 2 mg/kg
apomorphine i.p.
B,D(10 min): 7 ~ 2 mg/kg apomorphine i.p.
8 - 0.5 mg/kg methysergide plus 2 mg/kg
apomorphine i.p.

















Effect of chronic treatment of rats with methysergide on the turning
induced by 5-methoxy-N,N-dimethyltryptamine (5-MDT) given 45 min after
the last injection of methysergide.
Vertical bars represent s.d.; the number of rats used is in parentheses.
A - 10 mg/kg 5~MDT i.p.
B - 0.5 mg/kg methysergide (daily for 22 days) plus 10 mg/kg 5~MDT i.p.
(45 min after last injection of methysergide)
C - 0.5 mg/kg methysergide (daily for 24 days) plus 10 mg/kg 5~MDT
D - 0.5 mg/kg methysergide (daily for 27 days) plus 10 mg/kd 5-MDT
E - 0.5 mg methysergide (acute) plus 10 mg/kg 5-MDT i.p.







That the dose 0.5nig/, i.p. of methysergide was sufficient toKg
directly block some central 5-HT actions was demonstrated by the complete
inhibition of the turning induced by the central 5-HT receptor stimulant
5-MDT (lOmg/, i.p.) when the blocker was administered 45 min beforeKg
the agonist drug. It was observed that most of the behavioural effects
of the 5-HT agonist were apparent despite the blockade of 5-HT
receptors. These behavioural effects could not, possibly, be inhibited
by doses of 0.5 or 1mg/, i.p. of the antagonist, which, however, wereKg
effective in inhibiting circling completely. Thus, the animals were
sedated after methysergide (or were slowly turning in the case of MR
lesions) but showed a burst of activity immediately after the
injection of the 5-HT agonist, flattening of the body within about
2 min , shivering,tremor and convulsions, padding of the forepaws and
intermittent clinging on the walls of the bath.
Administration of methysergide (0.5mg/, i.p.) followed 45minKg
later by DIr-amphetamine (5mg/ i.p.) caused turning in the sameKg
direction as with DL-amphetamine alone, (i.e. contralateral in MR and
ipsilateral in PR lesions), but of lower intensity (measured as turns/
30min ) (Fig. 5«1T)* The intensity of turning in MR-lesioned rats was
significantly lower during the first 5 rain (p<^0.05, paired t test)
(Fig. 5*18), but not during the 10 or the 30 min of testing, compared
to a single administration of amphetamine. There was no significant
effect on the turning rate of DR-lesioned animals during the first
5 or 10 min (Fig. 5*18) but a significant reduction during the
30 rain period (Fig. 5•17)• The turning started in less than 60 sec
after the amphetamine injection and continued for up to 90 min.
Hyperactivity, exploration and stereotyped movements were not marked
during the first 20 min , but thereafter increased in the period of
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20-40 min , reaching the maximum at 40-45 min•
5.3.4h Tolerance to chronic treatment with methysergide
As described above and shown in Pig. 5«19» an acute dose of
0.5mg/k i.p. of methysergide bimaleate inhibited the turning induced by
lOmg/^^i.p. of 5-MDT when the latter was injected 45 rain later, When
the 5-HT receptor blocker, however, was administered daily at the dose
of 0.5 mg/, i.p.for 22 days to animals with a lesion in the MR or the—g
DR, an injection of the 5-HT receptor agonist at a dose of 10mg/,_ i.p.leg
45 rain after the last injection of the inhibitor, initiated intense
turning. The direction of turning induced by 5-MDT was the same as
that recorded in the absence of any chronic pretreatment with
methysergide, i.e. ipsilateral to the lesioned MR side and contra¬
lateral to the lesioned DR side. The intensity of turning was higher
in both MR and DR lesion and even reached the level of statistical
significance in rats with a lesion in the left side of the MR
(p</0.01, paired t test), as Pig. 5»19 illustrates. As the treatment
with methysergide continued, daily, for 24 or 27 days, the rats of both
MR and DR lesion type responded to a challenge with 5-MDT (10mg/, i.p.)leg
with a further increase in intensity of turning, which reached
statistical significance in both groups of animals (Fig. 5»19)« An
increase in the last dose of methysergide by two or four times (i.e.
img/^ or 2mg/^) did not inhibit the turning initiated by a single
dose of the 5-HT receptor stimulant (I0mg/Voi.p.) given 45 rain later.
A decrease in the intensity but not complete elimination of turning could
be obtained when, in addition to the last (27tb) injection of 0.5mg/v^i.p.
of methysergide, 4mg/^i.p. of the latter agent were injected into the
rats at the same time as 5-MDT. The turning rates obtained were
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significantly lower (about 50$) than in the absence of the additional
4mg/, _ of methysergide, in both MR- and DR-lesioned rats (p<^0.05»
paired t test), thus becoming approximately equal to the rates of
turning after a single injection of 5-MDT.
Chronic administration of methysergide for 15 days, at a daily
dose of 0.5mg/1 i.p., followed on the last day by apomorphine
(2mg/Voi.p.) 45 rain after the last methysergide injection, resulted in
no modification of the acute effect of this drug combination regarding
the intensity and direction of turning (Fig. 5«17)» The turning rates
recorded were significantly higher compared to those of apomorphine alone
in both MR- and DR-lesioned rats (p<(0.05, paired t test). There was no
change in the direction of turning and no statistically significant
difference in the intensity of turning after this drug combination,
either when methysergide was administered once (45 rain before
apomorphine) or when it was administered for 15 days (with the last
injection 45 rain before apomorphine).
5.3.4i Amphetamine-induced turning: effects of drugs
Pretreatment of rats with haloperidol (img/, i.p.) for 1 hourKg
prevented the amphetamine-initiated turning, as has been described
above, in both MR and DR type of lesion.
Propranolol, a centrally acting ^-adrenergic receptor blocker
(187), which recent reports indicate is active in central serotonergic
mechanisms (371) was administered at a dose of 10mg/^i.p. (effective
in blocking the central noradrenergic system) (187) 90 rain prior to the
administration of amphetamine (5mg/, i.p.) and the turning whichKg
resulted was compared to that recorded when amphetamine alone was given.
No change in the direction of turning was observed and no statistically
significant difference in the intensity of turning was recorded, either
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in MR- or DR-lesioned rats (Fig. 5«20). Similarly, injection of
phenoxybenzamine (a central a-adrenergic receptor blocker)(372)
at a dose of 30mg/, i.p. failed to alter the intensity or the directionKg
of the circling response of rats with MR or DR lesion to amphetamine,
3mg/kgi-p«
Furthermore, fusaric acid, a drug thought to act primarily by
inhibiting the enzyme which converts DA to HA (that is dopamine-|3-
hydroxylase) and hence decreases the central NA concentration (373) was
combined with amphetamine and the effect of this drug combination was
compared to the effect of amphetamine on circling behaviour. Although
amphetamine alone (pmg/, i.p.) induced circling that was of relativelyKg
higher intensity than the circling induced by the combination of this
drug with fusaric acid (75mg/, i.p.) given 90 min prior to itskg
administration, no statistically significant difference was found
between the two treatments in either MR or DR lesions (Fig. 5*20).
With regard to the other behavioural effects, propranolol caused
deep sedation of the animals, which was followed by hyperactivity,
exploration and stereotypy, clinging to the walls, uplifting of the
forelimbs and exploration of the air space, piloerection, etc., when
amphetamine was injected. The circling persisted for about 60-70 min.
Administration of fusaric acid also induced deep sedation followed by
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Fig. 5»20
Effect of fusaric acid and propranolol on the
turning induced by amphetamine
Vertical bars represent s.d.jwith the number of animals used in
parentheses.
A: 1 - 5 mg/kg amphetamine i.p.
2-75 m9/kg fusaric acid plus 5 mg/kg amphetamine i.p.
B: 3 - 5 nig/kg amphetamine i.p.
4-10 mg/kg propranolol plus 5 mg/kg amphetamine i.p.
- 243 -
5.4 DISCUSSION
5«4»1 Anatomical significance of the results
It is well established that when the cell bodies of central
neurons are destroyed, the axons and the nerve terminals of these
neurons degenerate within a few weeks, with a concomitant disappear¬
ance from the innervated areas, of the neurotransmitter substance
utilised by them. On the basis of this fact, lesioning of specific
raphe nuclei was performed and the brain areas thought to be
innervated by projections from these nuclei were examined for changes
in 5-HT, the neurotransmitter believed to be utilised by these
projections. Since the functional state of an aminergic neuronal
system is related to the metabolism of its neurotransmitter (25,
26,27), an assessment of the effects of lesions of the serotonergic
nerve cell bodies on the functional activity of the 5-HT neurons
could be primarily assisted with measurement of the concentrations
of 5-HT and its main metabolite, 5-HIAA, in certain brain structures
where the suspected serotonergic innervation terminates. Such areas
are the corpus striatum and the substantia nigra of the rat brain,
which, as mentioned in the Introduction, are believed to receive
serotonergic projections from the raphe area, and where 5-HT may act
as neurotransmitter.
The 5-HT content of the terminal area could be used as an index
of a successful lesion at the cell bodies of serotonergic neurons
innervating it. Therefore, the 5-HT levels, as well as the levels of
its main metabolite 5-HIAA, were measured in each side of corpus
striatum and substantia nigra after selective lesions of the raphe cell
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groups B7 (dorsal raphe, DR) and B8 (median raphe, MR). The lesions
were placed unilaterally, i.e. in one side of the raphe nucleus and
the left and right sides of the two suspected terminal areas were
separately dissected and analysed. This procedure was based on the
assumption that there is no important crossing of raphe-originating
ascending serotonergic fibres to the contralateral side of the brain.
To our knowledge there is no clear-cut anatomical information in the
literature about this point, although this was implied by the histo-
chemical fluorescence-based mapping of brain monoamine pathways by
Uhgerstedt (8) and by Fuxe and Jonsson (301). It was reasonable to
conclude that this was the case with regard to the striatal and
nigral innervation, since asymmetric lesions of the raphe nuclei had
an effect (if any) on only the 5-HT and 5-HIAA levels of the ipsi-
lateral side and not the contralateral side.
2-3 months after the asymmetric lesions, 5-HT and 5-HIAA were
reduced to about the same extent, i.e. about 3© per cent, in the
striatum ipsilateral to the MR lesion and in the substantia nigra
ipsilateral to the DR lesion. Lesions of the DR had no significant
effect on striatal 5-HT, and lesions of the MR did not alter the nigral
5-HT. These differential neurochemical effects of lesions of the two
raphe nuclei were supported by the histological assessment of the
lesion location and the distinct behavioural responses of the
lesioned animals. In addition, other biochemical results supported
this finding: lesions in the left side of MR had only an effect on
DA metabolite concentrations (HVA and DOPAC) in the left side of the
striatum but not in the substantia nigra, whereas lesions in the left
side of DR had an effect on HVA. and DOPAC in the left substantia nigra
but not in the striatum. Since it is known that there is no significant
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crossing of the DAergic fibres of the nigrostriatal pathway (8),
the effects of the unilateral lesion on DA metabolism may be seen
only unilaterally.
Treatment of lesioned animals with a large dose of L-tiyptophan
(lOOmg/^gi.p.), which is known to increase the 5-HT synthesis in the
brain (Section 4) did not in general alter the pattern of changes.
The predominantly differential projections of the two raphe nuclei
were again confirmed, but with an additional important point:
lesions of the DR resulted in a smaller increase in 5-HT and 5-HIAA
(which reached statistical significance)in the ipsilateral compared
to the contralateral side of the striatum, contrary to the lack of any
difference between the two sides in saline-treated rats. In addition,
\
a much smaller increase of 5-HT and 5-HIAA was found in the ipsilateral
substantia nigra compared to the contralateral side (p4)0.01, paired
t test), so that the concentrations of 5-HT and 5-HIAA in the
ipsilateral aide were 45$ and 74$» respectively, of the contralateral
side.
Tiro main points arise from these findings. Contrary to various
previous reports, these data suggest that the MR is the main origin
of the striatal serotonergic innervation and DR the main origin of
the serotonergic innervation of the substantia nigra.With regard to
the origin of the serotonergic afferents to the substantia nigra,
the results of the present study are in agreement with the finding of
Bunney and Aghajanian (305)» who demonstrated by the use of the
retrograde horseradish peroxidase technique, that the origin of these
fibres is the DR and not the MR; they are, however, contrary to the
results of the work of Dray et al.(87) which support the MR and not
the DR as the origin of the nigral serotonergic innervation.
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The evidence of Dray et al,(87) is weakened by the fact that they
approached the MR area vertically, possibly thereby damaging the DR
nucleus with the electrode; this casts some doubt on the specificity
of the lesions and the electrophysiological experiments they performed.
Furthermore, the fact that they performed large lesions of the MR
nucleus, which probably damaged other raphe cell groups and even the
DR nucleus (mainly by secondary gliosis and cell degeneration)
could be another reason for the different results of their study,
compared to the well localised, small lesions of the present study.
It seems difficult to explain the difference of the present
results from several previously published reports regarding the
striatal serotonergic afferent. The exclusiveness of the MR cell
group as the origin of this projection is indicated by the evidence
from the present experiments, although the tryptophan loading
revealed that some, perhaps limited, serotonergic innervation of
the striatum may originate from the DR. This disagrees, however,
with the results of several lesion studies (302,309) suggesting that
the DR is the major origin of the 5-HT projections to the striatum, or
with the evidence of experiments using the labelled amino-acid trans¬
port method (310) or the horseradish peroxidase technique (302,311)»
which point to the same conclusion. In support of the present study,
on the other hand, is the work of Costall and llaylor (314) • They made
small asymmetric electrolytic lesions of the DR and the MR, confined
to part of these cell groups (a methodology followed in the present
study) and obtained biochemical evidence suggesting that the MR and
not the DR sends serotonergic fibres to the striatum. The results of
Marsden and Guldberg (313) based on lesion studies, also give support
to the finding that the MR is the major origin of the serotonergic
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innervation of the striatum, as well as of the cerebral cortex and the
hippocampus. They demonstrated, however, that large lesions which
destroyed both the MR and the DR resulted in a bigger decrease of
striatal 5—HT compared to large MR lesions, indicating that the DR or
other nuclei located between MR and DR may also project to the striatum.
A common feature of the studies carried out in the past (302,297) that
involved lesions of the raphe nuclei, seems to be the extensive damage
of the whole nucleus and also some of the adjacent areas; in the case
of DR lesions, for example, the damage frequently extended as far as
the area pedunculus cerebellaris superior, (Fig. 5*1)» where 5-HT
cells also seem to exist (5)« In the present experiments it was
observed that lesions affecting these areas did not produce the same
consistent pattern of behavioural response (circling) after amphetamine
or apomorphine, which was produced by small lesions in a restricted
area of the DR. Therefore, these animals were discarded from further
experiments. This point could be a methodological reason for the
different results, if indeed the 5-HT cell bodies adjacent to the DR
send projections to the striatum.
It is also possible that, some of the cell bodies of the raphe
nuclei thought to be destroyed by the lesion contain another indoleal-
kylamine, e.g. tpyptamine (as it has been suggested by other
investigators, 369»301); damage to these cell bodies by one lesion
(present study) and not by others (previous work), and vice-versa,
could account for the different results of lesions seemingly affecting
the same brain area. Although the nature and the physiological role
of the raphe cells which contain indolealkylamine(s) other than 5-HT
is not known, the interpretations of the electrophysiological
experiments (302,312) could be seriously weakened if these cells had
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a different function and different response upon electrical stimul¬
ation than the 5-HT containing cells. Autoradiographic studies based
on the retrograde transport of labelled aminoacids, which indicate
that the DR nucleus innervates the striatum (302,311,310) could also
suffer from the reported limitations of the technique: non-specific
damage and diffusion, uptake of the labelled tracer by axons on
passage, orthodromic and antidromic transport of the lebelled material,
etc. (370). Similarly, electrophysiological experiments could be misled
by current spread to dorsal raphe axons during the recording. There¬
fore, in the raphe area where interconnections of the various nuclei
seem to exist (325,327)i misleading results could be obtained using
these techniques in order to identify projections originating from a
particular cell body area.
The discrepancy between saline-treated and tryptophan-treated
rats concerning the existence of a serotonergic projection from the
DR nucleus to the striatum may be important. The possibility that
this difference may be due to methodological difficulties also has
to be borne in mind. The employed method of Curzon and Green (288)
is sensitive for the measurement of 5-HT and 5-HIAA in a single
striatum in saline-treated rats, but it may not be sufficiently
discriminating subtle changes of the concentrations within the range
10-207&. Tryptophan loading increases significantly the concentrations
of 5-HT and 5-HIAA, and this might improve the accuracy of the assay
to the extent that changes otherwise not revealed become apparent.
Therefore it is possible that a minor serotonergic innervation of the
striatum originates from the DR nucleus, as the difference between the
two sides of the striatum after tryptophan loading indicates. Other¬
wise, a preferential effect of the lesion on the synthetic enzymes of
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5-HT could also be the reason for the discrepancy: when synthesis of
5-HT is increased by the administration of tryptophan, the difference
in the activity of 5-HT neurons between the denervated and the intact
side of the striatum may be amplified, resulting in a bigger difference
in the concentrations of the amine and of its metabolite between the
two sides.
Tryptophan loading, either alone or in combination with MAO
inhibition, is known to increase to a different degree both 5-HT and
5-HIAA concentrations in the rat brain (Section 4)• In the case of
the raphe lesions, a treatment that increases the synthesis and
metabolism of 5-HT to a different but known extent (such as tryptophan
loading) would be a useful tool in differentiating the metabolic stages
affected by the denervation of the brain structure under study. It
would also make the determination of 5-HT and 5-HIAA in small brain
areas, such as substantia nigra, possible without the need to pool
together 2 or 3 tissue pieces from different animals.
The demonstrated significant reduction of the ratio 5-HT/5-HIAA
in the substantia nigra ipsilateral to the DR lesion compared to the
contralateral side, following the administration of a large dose of
L-tryptophan, may indicate a deficit in 5-HT synthesis or an increase
in 5-HT metabolism caused by the lesion. A preferential, bigger
reduction of uptake of precursor (tryptophan or 5-HTP) by the sero¬
tonergic terminals in the denervated substantia nigra, or a reduction
of tryptophan hydroxylase, the rate-limiting step in 5-HT synthesis,
or an increase in 5-HT metabolism could be responsible for the
observed deficit. The presented evidence favours an effect on 5-HT
metabolism rather than on synthesis; the relatively higher increase of
5-HIAA in the denervated substantia nigra may result from increased
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release of 5-HT due to destruction of storage sites in serotonergic
nerve terminals.
Differences between the weight increase of rats with lesions in
the MR or the DR and the sham-operated controls were recorded and were
more profound during the period of 2-3 months after the lesion (Fig.
5.2). An even significant decrease of the weight of MR-lesioned rats
was found, 90 days after the lesion, compared to sham-lesioned
animals. These differences may be related to the observed bioohemical
deficits of the denervated side of the substantia nigra following
tryptophan loading of DR-lesioned rats, since the animals for biochemical
analyses were killed during this period. A change in the weight could
be of importance for the interpretation of changes in 5-HT metabolism,
since 5-HT availability and synthesis from its precursor tryptophan
is subject to dietary variation, as indicated by the work of Milson
and Pycock (374)• These workers also demonstrated a significant
alteration of the spontaneous locomotor activity and the arrrohetamine-
induced circling behaviour in mice with nigro-striatal dopaminergic
nerve terminal destruction by varying the protein content in the diet
of the animals. Therefore, changes in the weight of the rats could
result from changes in the dietary intake, which could also affect
the tryptophan and 5-HT concentrations in the brain, and possibly to
a different degree between the intact and the denervated side.
5*4*2 Evidence for functional interaction of 5-HT with dopamine
The examination of changes in amine metabolism induced in one
system by selectively manipulating another system provides some
information about their functional interaction in the brain. There¬
fore, the assessment of any changes in catecholamine metabolism in
specific brain areas after lesions of the serotonergic nerve cell
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bodies in the MR or DR would be of interest, especially in view of
the anatomical, biochemical and pharmacological—physiological evidence
for an interaction between these monoamines. The estimation of the
catecholamine concentrations, namely dopamine and noradrenaline, in
the striatum was of particular importance in order to establish the
neuronal system responsible for the circling behaviour of rats with
lesions in the MR or the DR. Some of the rats had the lesion in the
area between the MR or DR and the adjacent lateral reticular formation,
where ascending catecholaminergic fibres exist (3,8). Therefore, the
possibility had to be examined that damage to these fibres was a
contributing or even the main factor causing the turning of the
animals in response to various agents acting directly or indirectly
on catecholamine receptors. As the histological assessment of the
lesion location could not answer this question completely, the
concentrations of NA and DA in the striatum were determined. No
statistically significant difference in the concentration of either
of the two amines was found between the two sides of the striatum,
after MR or DR lesions.
Rats with unilateral electrolytic lesions of the nucleus locus
coeruleus, known to contain the bulk of the noradrenergic cell bodies
in brain (5), turned in tight circles away from the side of the lesion
after the administration of amphetamine or apomorphine (375)• This
circling in response to drugs was short lasting and usually disappeared
within about 30 days of surgery. Ascending dorsal noradrenergic fibres
from the locus coeruleus, located in close proximity to the MR
nucleus (in the area reticular formation) could be damaged by the
asymmetric lesions of this nucleus, and this could possibly result in
the transient circling behaviour as it has been shown by other workers
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(368)• The direction of turning induced by apomorphine and amphetamine
in rats with asymmetric electrolytic lesions of the MR or the locus
coeruleus was found to be the same (368,378), but the turning was
transient in the case of locus coeruleus lesions. Selective lesions
of one side of the MR (verified histologically) not affecting the
reticular formation area, were found by these workers to produce
persistent, contralateral turning following the administration of
DA receptor agonists (apomorphine, amphetamine); the concentration of
5-HT in the ipsilateral cortex, the limbic area and the striatum was
reduced, but no effect was found on DA or HA concentrations in these
areas (314,313).
The present study confirmed the above. As shorn histologically,
the area damaged by the lesion was small and confined to the MR or
DR areas in rats successfully rotating after apomorphine or ampheta¬
mine. The concentrations of DA and NA in the ipsi- or contralateral
side of the striatum were not affected by either of the two lesions.
These findings indicate that the lesions did not damage any ascending
DAergic or NAergic fibres and that the 5-HT system was selectively
damaged. Therefore, any changes in the metabolism of DA or HA in the
terminal areas could result from an indirect effect of the lesion,
through synaptic contacts of the 5-HT system (which is primarily
affected) with these amine systems.
However, functional variations are better indicated by changes
of amine metabolism and/or turnover rather than by changes in the
concentrations of the amines themselves. The fact that DA or NA
concentrations did not seem to change in the striatum after raphe
lesions, does not exclude the possibility of a functional link between
DA or NA and 5-HT in the striatum or elsewhere. Although the assays
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of the two catecholamines vfere performed 2-3 months after surgery,
when the degeneration of the lesioned neurons should have been
completed, and the resulting depletion of the amines should "become
obvious, the possibility exists that compensatory overactivity of the
remaining intact neurons may replace the amine loss. This, however,
does not seem to happen, as the changes in the metabolite concentrations
indicate; The HVA and DOPAC concentrations were selectively increased
in the side of the substantia nigra ipsilateral to the DR lesion or
in the side of the corpus striatum ipsilateral to the MR lesion
reflecting increased DA neuronal activity. Thus the data in Tables
5.1 and 5*3 demonstrate reciprocal changes in 5-HT and 5-HIAA on one
hand, and in HVA and DOPAC on the other hand in these brain areas.
The fact that the concentration of DA in the ipsilateral striatum did
not change after MR lesions, but the concentrations of the DA
metabolites increased significantly, indicates an increase in the
turnover of this amine in the denervated structure. Although the DA
concentration in the substantia nigra was not measured, because of the
low sensitivity of the method, the selective increase in HVA and
DOPAC in the substantia nigra ipsilateral to the DR lesion indicates
that probably a similar release or turnover effect occurs in this
area. It seems, therefore, that selective reduction of 5-HT in the
striatum or the substantia nigra is accompanied by an increase in the
turnover of DA in these brain structures.
Since the evidence from these experiments suggests that there is
no direct effect on DAergic neurons, the lesion seems to release an
inhibitory effect of the 5-HT neurons in the striatum and the substantia
nigra upon the turnover of DA in these areas. That a tonic inhibition
of DAergic neurons in the striatum is the normal function of 5-HT
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released from afferents to this structure, has been shown by several
investigators. Electrical stimulation of the DR and MR cell groups
has been found to result in release of 5~HT in the striatum (283)
and marked inhibition of striatal neurons (312). Microiontophoretic
application of 5-HT inhibited the striatal neurons (376)• Lesions
in the known ascending projections from the raphe area reduced the
inhibitory effect of raphe stimulation on striatal neurons (302),
Similarly, microiontophoretic application of 5-HT inhibited the DA
cells in the area pars compacta of the substantia nigra (315|87»64)»
This effect was blocked by methiothepin (64) which has been reported
to be an effective antagonist of 5-HT-induced depression of cell
firing in other areas of the brain (377)*
A functional balance between DA aid 5-HT in the striatum has been
proposed by Barbeau (177) i*1 relation to some neurological and
pharmacological aspects of human parkinsonism. Several findings
from animal experiments also point to a participation of 5-HT in
the function of the DAergic system. The biochemical data from this
study suggest that removal of the 5-HT innervation from the striatum
and the substantia nigra stimulates indirectly and independently the
activity of the DAergic neurons in the two structures. Therefore, a
possible role of the 5-HT input in controlling the activity of DA cell
bodies (in the substantia nigra) and DA nerve terminals (in the corpus
striatum) might be indicated by the demonstrated inverse correlation
betTveen 5-HT concentration and DA turnover.
5.4*3 Behavioural expression of the biochemical interactions
Differential behavioural and neurochemical effects following
DR or MR lesions in the rat have also been found by several other
investigators. Jacobs et al.(354) have demonstrated that a total MR
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lesion gives rise to increased locomotor activity, "but a DR lesion
has no effect on locomotor activity. Similarly, Srebro and Lorens
(378) have shown that MR lesions increase responsiveness to novel
stimuli or environmental change, whereas DR lesions do not produce
these effects, despite the fact that MR lesions produced a decrease
in forebrain 5-HT that was smaller (2&fo) than that produced by DR
lesions (65tf0). According to Geyer et al„(379)» it is the MR lesion,
and not the lateral (DR) lesion, which is responsible for the hyper¬
activity and hypersensitivity that follows combined raphe lesions.
The main difference in projections according to these authors (379) is
that the MR projects to the septum and the hippocampus, whereas the
DR does not. Both project to the hypothalamus and cortex. The MR is
considered by several authors to be the primary source of hippocampal
5-HT (309»354»379)• Further work of Jacobs et al. (380), however,
contrary to the above, indicates that the increased locomotor
activity following a DR lesion or depletion of 5-HT induced by
p-chlorophenylalanine is abolished by prior aspiration of the antero-
dorsal hippocampus in adult rats. A common finding of these studies
despite the controversy, is the increased locomotor activity of rats
following selective decrease of 5-HT in brain and, probably, a
differential behavioural expression of lesions in the MR or the DR.
A state of general behavioural excitation, with increased loco¬
motor activity was observed after the administration of drugs which are
known to increase the activity of catecholamine containing neurons
in the brain (363), whereas drugs that reduce central catecholamine
transmission produce behavioural states of sedation and inactivity.
Similarly, behavioural excitation with increased locomotor activity is
observed after pharmacological and neurological procedures which lower
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selectively brain 5-HT, e.g. inhibition of 5-HT synthesis by
p-chlorophenylalanine (319>320) or destruction of serotonergic neurons
by electrolytic lesions placed in the midbrain raphe (321), preferably
in the MR rather than in the DR nucleus (354»379)»
In the present study, in addition to the biochemical different¬
iation, the behavioural response of rats with an asymmetric electrolytic
lesion in the MR or the DR was different following the administration
of various drugs. Most characteristic of these responses is the
circling behaviour, as depicted in the diagram of Pig. 5»21.
Amphetamine and apomorphine induced contraversive circling in MR lesions
and ipsiversive in DR lesions. These responses were dose-dependent
and could be obtained up to 4 months after the operation. Other workers
have reported circling behaviour of raphe lesioned rats (321).
Moreover, selective asymmetric lesions of the MR were found to result
in consistent contraversive circling behaviour following the administ¬
ration of various doses of apomorphine or amphetamine (368,314)• There
was no consistent spontaneous rotation with either of the lesions,
perhaps because the survival of a relatively small number of neurone
may suffice for conditions where demand is within normal limits.
Ungerstedt et al.(38l) have suggested that the induction of
circling behaviour after lesions of the nigrostriatal neurons is almost
exclusively a DAergic phenomenon. Furthermore, Ungerstedt (8) and
Creese and Iversen (382) have suggested that the amphetamine—induced
locomotor and stereotyped behaviour are both dependent on the
functional integrity of the nigrostriatal system. When the nigro¬
striatal DAergic pathway is lesioned unilaterally, administration of
apomorphine induces contraversive circling, whereas amphetamine induces
ipsiversive circling. These responses have been interpreted, the former
Fig. 5.21
A schematic representation of the serotonergic innervation of the
substantia nigra (sn) and the corpus striatum (cs) by fibres arisinp
unilaterally from the dorsal raphe (dr) and the median raphe (mr)
respectively, as suggested by the present study. The degeneration of
5-IIT axons (broken line) after asymmetric lesions of the raphe nuclei
produced turning upon stimulation by various drugs in the direction
indicated by the arrows. The nigrostriatal pathway is also represented.
Abbreviations: apo: apomorphine, amph: amphetamine, trypt + phen:
tryptophan plus phenelzine, 5_M DT : 5~methoxy-N,N-dimethyltryptamine
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as being due to stimulation of the supersensitive DA receptors in
the denervated striatum, and the latter as being due to release of DA
from the intact striatum (8,110). In both cases, a striatal DAergic
deficit and an imbalance is involved.
In the present study, the amphetamine- and apomorphine-induced
turning seem to be, partly at least, DAergic phenomena. Amphetamine
is known to release both NA and DA from the presynaptic sites, but for
the circling behaviour of rats lesioned in the MR or the DR, it seems
that there is no NA involvement, at least at the striatal level. This
was suggested by the ineffectiveness of various drugs acting on NAergic
transmission to alter the rate of amphetamine-induced turning. These
drugs were: a p-adrenergic receptor blocker (propranolol), an
o;-adrenergic receptor blocker (phenoxybenzamine) and a DA-b-
hydroxylase inhibitor (fusaric acid ). Doses of these agents that had
been found effective in altering central NAergic transmission were
used (187,372,373)• Thus the amphetamine-induced circling behaviour
seems to be due to receptor stimulation by the released DA. Lowering
of striatal 5-HT after the asymmetric MR lesion appeared to release
the striatal DAergic neurons from an inhibitory influence, as the
increase in DA turnover indicates. This unilateral increase in DA¬
ergic transmission might have caused the spontaneous contraversive
turning which was enhanced by the postsynaptic DA receptor stimulant
apomorphine and the DA releasing drug amphetamine. The effects of both
drugs were completely blocked by haloperidol, a DA receptor blocker,
and this further supports the concept of a DAergic mechanism involved
in the turning.
A similar mechanism could exist in the DA cell body area of the
substantia nigra, where lowering of 5-HT (after lesions in the DR) was
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followed by an increase in the concentrations of HVA and DOPAC. The
nature of the 5-HT projection to the substantia nigra also seems to be
inhibitory, as several previous studies indicate, in agreement with the
increase in DA turnover suggested by the present experiments. Stimul¬
ation of the DA receptors, however, which are believed to exist on
DAergic cells or dendrites of the substantia nigra (53) or on non-
DAergic neurons (46,56), by apomorphine, or by amphetamine (indirectly)
produced circling ipsiversive to the lesioned side in rats with an
asymmetric lesion in the DR. Thus, removal of the inhibitory effect
of 5-HT neurons from DA cell bodies or DA terminals resulted in
turning in opposite directions upon stimulation with DA receptor
stimulants (Fig. 5*21).
If the integrity of the nigrostriatal DAergic system is necessary
for the amphetamine—induced locomotor activity and stereotyped behaviour,
as it has been proposed (8,382), then an effect on the DA cell bodies
in the area pars compacta of the substantia nigra should result in the
appropriate response of the striatal target cells or neurons. Thus an
inhibition of the DA neurons in the substantia nigra by 5-HT will
probably decrease the normal function of the nigrostriatal pathway which
is believed to be inhibitory on certain striatal neurons. Most
available evidence indicates that DA is indeed inhibitory in the
striatum. Iontophoretically applied DA inhibited striatal neurons
(176,92) and electrical stimulation of the substantia nigra had an
inhibitory effect, probably due to striatal release of DA, in the same
way as iontophoretically applied DA (30). Degeneration of the nigro¬
striatal DA system caused an increased spontaneous firing frequency
of certain striatal cells (120).
It could be assumed, therefore, that the behavioural excitation
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that follows increased, release of DA is due to an inhibition of certain
striatal neurons receiving a DAergic input. The behavioural depression
that follows a decrease in DAergic transmission may be due to a
stimulation of the same or other neurons receiving a DAergic input
from the substantia nigra. Although the mechanisms by which the
striatal neurons influence motor behaviour are far from understood,
the striatum seems to be an important centre of sensory-motor-
integrating mechanisms and important link of the nigrostriatal path¬
way to the thalamus, the motor cortex and finally the spinal cord, all
these being involved in the initiation of motor movement (383).
Lowering of the inhibitory nigral 5-HT influence, following
selective asymmetric electrolesions of the DR nucleus, results,
probably, to an indirect stimulation of the firing of the cell bodies
giving rise to the nigrostriatal DAergic pathway, leading to an
increased inhibition of the target neurons in the striatum.
Following the above assumption, behavioural excitation should follow
the increased release of DA and the resulting inhibition of the
target neurons in the striatum. Similarly, drug-induced release of
DA from the striatum (by amphetamine) should result in increased
inhibition of these neurons and behavioural excitation.
Thus, the lesion in one side of the DR nucleus, which reduced
selectively the 3-HT content of the ipsilateral substantia nigra, and
the administration of amphetamine or apomorphine could be expected to
be additive in their striatal effects; this might be manifested in the
circling behaviour (spontaneous and drug-induced) towards the side of
the lesion due to the biochemical deficit of some important neurons
in the striatum ipsilateral to the lesion, compared to the contrar-
lateral side, i.e. because the increased activity of the nigrostriatal
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DAergic pathway in the ipsilateral to the lesion side results in
inhibition of the striatal neurons which seem to be an important and
necessary link for induction of circling behaviour. The inhibitory
nature of the nigrostriatal DAergic pathway seems, therefore, to be
the reason why asymmetric lesions of the DR, which projects mainly to
the substantia nigra, and asymmetric lesions of the MR, which projects
to the striatum, resulted in spontaneous and apomorphine- or
amphetamine-induced circling in opposite directions. However, other
more elaborate interpretations of the circling behaviour should be
considered, integrating several recent pharmacological findings.
5.4.4 Alternative interpretation of turning response to dopamine
stimulants
It appears that an increase of DA turnover in the corpus striatum
in the lesioned side is associated with an action of apomorphine and
amphetamine on that side, which is greater than on the unoperated side
and results in contralateral turning of MR-lesioned animals. However,
the reverse is true of lesions affecting the substantia nigra (that
is, DR lesions). Although DA turnover was increased in the side of
the lesion in the substantia nigra, turning induced by apomorphine
and amphetamine was in the ipsilateral direction. Several recent
reports suggest a reciprocity between the effects of DA release at
the two ends of the nigrostriatal system. Using a push-pull cannula
technique, Niecullon et al. have shown that substantia nigra and corpus
striatum react in opposite directions to sensory stimulation (384) and
to local stimulation (385)• Prom electrophysiological studies it has
been suggested that DA release in the substantia nigra may inhibit the
firing rate of DA cells (53»67)• Thus, an increase in DA release in
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the substantia nigra would be associated with a decrease in release
in the corpus striatum. Biochemical studies in rats treated with
haloperidol (Section 1) suggested the reciprocal effect is also true,
that is; an increase in DA release in the corpus striatum is
associated with a decrease in release in the substantia nigra.
Bearing these results in mind, it is less surprising that
lesions which differentially affect one or the other of the ends of
the nigrostriatal pathway would have opposite effects on behaviour.
Increasing DA turnover in the substantia nigra specifically would be
expected to reduce DA release in the ipsilateral corpus striatum and
hence make the animal tend to turn in the opposite direction to one
with the DA turnover raised in the corpus striatum. Thus, when
stimulated with apomorphine or amphetamine, the observed turning
behaviour was in opposite directions with lesions specific to MR or
DR (Fig. 5.21). This concept could offer an interpretation of the
behavioural excitation that follows raphe lesions or inhibition of
5-HT synthesis (319»320,321) or of the enhancement of the amphetamine-
induced hyperactivity by these procedures (322,323,324). Furthermore,
the apparent contradiction between the proposed inhibitory influence
of 5-HT on DA release in the striatum and possibly the substantia
nigra on one hand, and the production of the hyperactivity syndrome
both by the DA releasing agent amphetamine and by the combination
phenelzine plus tryptophan (which increases brain 5-HT) on the other,
could be resolved by the demonstrated DA releasing properties of the
latter, as described in Section 4«
Tryptophan loading of rats lesioned in the raphe nuclei, pre—
treated with the MAO inhibitor phenelzine, induced turning that was not
in the direction one would expect from a precursor of 5-HT, but in the
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same direction as amphetamine and apomorphine (Fig. 5«21). This was
surprising, in view of the known fact that this drug combination
produces a marked increase of 5-HT concentration in brain. The
amphetamine-like biochemical effects of this drug combination and
especially the release of DA due probably to displacement by the
newly synthesised p-HT, as the results in Section 4 of the present
Thesis indicate, would explain a similarity in the effect of the two
treatments. The question why a small amount of released DA can pre¬
dominate over the massively formed >-HT in determining the direction
of fuming in both MR- and DR-lesioned animals cannot be answered from
the present experiments. A first interpretation could be that more
5-HT accumulates in the intact side of the striatum or the substantia
nigra (as it was found in the present study) and this produces greater
inhibition of the DAergic neurons in this side, resulting in the DAergic
asymmetry, an important step for the induction of turning. The
direction of turning would then be towards the side with the striatal
DAergic deficit (contralateral to the less inhibited striatal side), i.e.
contralateral to the lesion in the MR and ipsilateral to the lesion in
the DR-lesioned rats. A similar circling behaviour of rats with
lesions of the nigrostriatal DAergic pathway was also observed
following treatment with the combination phenelzine plus L-tryptophan
and amphetamine: the former induced rotation in the same direction as
the latter, i.e. ipsiversive (Section 4) •
5»4*5 Relation of turning to stereotyped behaviour
In both types of lesion, amphetamine administration was followed
by behavioural excitation and stereotyped behaviour, as described by
Randrup and MunkUad (363). Rotation has been considered by some
workers to be a facet of the amphetamine-induced stereotyped behaviour
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(313)• Evidence has suggested that the 5-HT innervation of the
striatum does not influence the amphetamine-induced stereotyped
behaviour (313) • Randrup and Munkuad (272) also concluded that 5-HT
receptors are not involved in amphetamine stereotyped behaviour.
These considerations, however, would contradict the described
behavioural effects of raphe lesions and the present experimental
results. Accordingly, if the amphetamine-induced rotation in inl¬
and DR-lesioned animals is considered as part of the stereotyped
behaviour produced by this drug, then the 5-HT receptors do not need
to be directly involved in this behaviour. The direct effect of
amphetamine on DA release, finally mediating the circling or
stereotyped behaviour, could explain the lack of apparent involvement
of 5-HT in amphetamine-induced stereotypy. This, however, does not
exclude the possibility that alterations of the 5-HT input may affect
behavioural syndromes mainly mediated by DA.
Obviously, the selectivity of the lesions is in no doubt, as it
was histologically and biochemically demonstrated. The involvement of
DA in the circling and other behavioural responses induced by
amphetamine or apomorphine has clearly been demonstrated, whereas
involvement of NA did not seem to be a factor contributing to the
circling behaviour. Furthermore, obvious changes in 5-HT and 5-IIIAA
in the striatum or the substantia nigra correlated with the successful
rotation after MR or DR lesions, respectively.
Additional evidence for involvement of 5-HT receptor stimulation
in the circling behaviour was obtained from behavioural experiments.
5-Methoxy—N,KF-dimethyItzyptamine (5-MDT), a drug considered to be a
specific central 5-HT receptor stimulant (336) produced in both types
of lesion a dose-dependent rotation that was in opposite direction to
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the rotation induced by apomorphine or amphetamine, i.e. ipsiversive
in MR and contraversive in DR lesions (Fig. 5*21). The rotation was
blocked by prior administration of methysergide, a 5-HT receptor
antagonist (339)• Thus, it is evident that the turning involves also
5-HT mechanisms which are distinct from the DAergic mechanisms and
result in different behavioural responses. The finding that methy¬
sergide blocked only the turning and not the other behavioural
effects of 5-MDT, could indicate that these effects are separated
from the turning response or that they could not be inhibited by the
doses of 0.5 or 1 mg/^ methysergide.
With regard to the circling behaviour in particular, the DA
receptor agonists and the 5-HT agonist seemed to produce the opposite
effect. When apomorphine and 5-MDT were administered simultaneously,
no consistent rotation in either direction appeared in both MR and DR
lesions. This finding provided further support for the proposed concept
of tonic inhibitory control of the DAergic neurons by the serotonergic
input to the substantia nigra and the corpus striatum. That this
sequence is involved in the initiation of rotation is indicated by
the finding that haloperidol, a DA receptor blocker, prevented the
circling induced by the 5-HT receptor stimulant. Ey analogy, the 5-HT
receptor blocker methysergide, presumably through temporary removal
of the serotonergic inhibition of DAergic neurons (which is added to
the surgical removal of this 5-HT influence from one side of the
substantia nigra or the corpus striatum and together result in a bigger
DAergic asymmetry in these areas) significantly speeded up the onset
of the apomorphine effect and increased the number of turns during
the first 5i 'the first 10 and during the total period of 45 min of
the test (Fig. 5*17 and 5«18). Hot only the circling, but also other
behavioural effects of apomorphine appeared, as early as 30 sec after
the i.p. administration of this drug, when it was given 45 min after
methysergide.
The facilitation of the auomomhine effect on turning by
methysergide is in close agreement with the reported enhancement of
apomorphine-induced locomotor activity (388) and stereotypy (389) and
also apomorphine-induced turning behaviour of rats with 6-hydroxydopamine
lesions (390), although absence of serotonergic influence on apo-
momhine-induced stereotypy has been proposed by other workers (365) •
These findings also seem to be in agreement with the reported
intensification of amphetamine-induced excitation by methysergide
(364) or the reported enhancement of amphetamine locomotor action after
surgical interruption of ascending serotonergic pathways (322,354) or
after depletion of 5-HT from the brain by p-chlorophenylalanine (321);
all this evidence points to a neuromodulatory influence of serotonergic
neurons on the DAergic neurons in brain.
Further support for the concept of DAergic neurons finally
mediating certain responses to various manipulations of the serotonergic
system (such as the motor response) came from the pharmacological
experiments of Green and Grahame-Smith (290); these investigators
demonstrated that the hyperactivity syndrome (a behavioural response
apparently dependent upon the release of 5-HT into the synaptic cleft)
was blocked by o(-methyl-p-tyrosine, a DA synthesis blocker.
The present study, however, suggests that methysergide does not
intensify the amphetamine-induced rotation, as it does to the apomorphine
effects, but it probably causes a reduction in the intensity of the
rotation. Methysergide alone induced rotation in MB- but not in DB-
lesioned rats, in the same direction as the DAergic stimulants, probably
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due to an indirect effect that follows inhibition of 5-HT
mechanisms. The demonstrated serotonergic asymmetry, which
resulted from the lesion, seemed to persist or to be enhanced
after 5-HT receptor blockade, at least with regard to the striatum.
Simultaneous administration of 5-MDT and apomorphine resulted in no
turning, whereas the amphetamine-induced turning was intensified by
simultaneous injection of 5-MDT, in both MR and DR lesioned rats.
The fact that the effect of apomorphine, a drug thought to stimulate
postsynaptic DA receptors, was inhibited by 5-HT receptor stimulation
probably at a presynaptic level of the DAergic neurons, tends to
suggest that the circling responses to these drugs can be mediated
by independent, different mechanisms.
The combination of amphetamine with the direct 5-HT receptor
agonist increased the intensity of amphetamine-induced turning in
both MR and DR-lesioned rats. Prior administration of methysergide
decreased the effect of amphetamine in both types of lesion. These
results contrast with the effects of apomorphine combined to a 5-HT
agonist or antagonist. This could mean that a component of the
amphetamine effect not common to that of apomorphine interacts with the
5-HT agonist and antagonist. This difference might be related to the
presynaptic action of amphetamine (compared to the postsynaptic action
of apomorphine), or to the 5-HT releasing properties of amphetamine
(242) additional to its DA and NA releasing properties. The finding
that 5-HT receptor stimulation significantly potentiates and 5-HT
receptor blockade partially decreases the intensity of turning
induced by amphetamine, implies that amphetamine has a direct or
indirect stimulant effect on 5-HT receptors, contributing to the
turning. This effect of amphetamine could be postulated to be on
— 257 -
the intact side of the striatum or the substantia nigra, since an effect
on the 5-HT system in the lesioned side would induce turning opposite
to the turning due to DA receptor stimulation; an action on the 5-HT
release or reuptake processes would probably be more effective in the
intact side than in the denervated side depleted of 5-HT. Therefore,
when amphetamine alone is administered, its effects on the DAergic
system predominate over the effects on the serotonergic system,
causing turning in the same direction as apomorphine. Another
possibility is that amphetamine is acting on the DAergic neuron at a
presynaptic level to release DA, which in turn may be taken up by
serotonergic neurons (244j245) to induce release of 5-HT which may
serve as the inhibitory neuromodulator. If the target 5-HT receptors
for the released 5-HT to exert its neuromodulatory effect (probably
located on DAergic neurons) are blocked by methysergide, the amphetamine
effect (mediated through the release of DA) will be more intense. Therefore,
lesions of the serotonergic projection from one side of the DR or the
MR leave the denervated afferent area deficient in 5-HT, or, perhaps,
the 5-HT receptors •supersensitive* and uninhibited by the dose of
0.5mg/lcg of methysergide.
Thus, the 5-HT agonist and the antagonist have the effects on the
response to amphetamine opposite to those on the response to apomor-
and inhibition
phine. Both 5-HT receptor stimulation/clearly affect the amphetamine-
induced turning. Furthermore, if stereotyped behaviour depends on the
integrity of the nigrostriatal DAergic pathway (8,382) and involves DA
receptor stimulation (272), the fact that turning is induced by drugs
acting specifically on 5-HT receptors opens other possibilities. The
present data indicate that both DAergic and serotonergic processes are
involved in the turning response, but the former may be the final
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mediator of this response and the latter the modulator of its function,
although the possibility of a direct 5-HT involvement in the initiation
of this syndrome independently of the DAergic mechanisms should be
considered.
If 5-HT is, in one or the other way, reducing the effect of
amphetamine on DA release and consequently on circling, several points
may arise with reference to this concept. 5-HT released from its nerve
terminals in brain, at physiological concentrations, acts probably on
its postsynaptic receptors in the striatum and the substantia nigra to
influence the DAergic neurons at a presynaptic level, by inhibiting
the release of DA. 5-HT receptors could, therefore, be located on DA
terminals. If circling is part of the stereotyped behaviour as has been
suggested (313)*the finding that 5-HT and DA receptor stimulation can
induce rotation of DR— and MR-lesioned rats is in agreement with the
demonstrated ability of both monoamines (5-HT and DA) to initiate a
stereotyped response of rats when they are administered intrastriatally
(386,111). Furthermore, the effectiveness of intrastriatal DA
application seems to be partially dependent upon an intact serotonergic
innervation, since raphe lesions reduced the stereotyped behaviour
induced by this treatment (368).
Therefore, the influence of 5-HT mechanisms upon stereotyped
behaviour appears to be facilitatory, in contrast with the inhibitory
nature of the serotonergic innervation of the striatum on locomotor
activity (380,321,322,313) and the lack of any effect on locomotor
behaviour following lesions of the DR nucleus (380), which seems to
innervate the substantia nigra (present study). Thus, the locomotor
behaviour seems to be related to striatal mechanisms mainly, whereas
stereotyped behaviour and circling behaviour seem to involve, to a
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different degree, both striatal and nigral mechanisms. Considering
the proposed relation of stereotyped and circling behaviour, the
direction of circling might involve a mechanism independent of both,
probably the nigrostriatal DAergic asymmetry.
5*4*6 Dopamine and 5-HT 'supersensitivity*
The rotation induced by both DA and 5-HT agonists needs further
investigation. The contraversive rotation of MB-lesioned rats and the
ipsiversive rotation of DR-lesioned rats following the administration
of apomorphine or amphetamine seem to result from ipsilateral DA
receptor stimulation. A state of •supersensitivity' of the DA receptors
could be postulated, similar to the denervation supersensitivity
phenomenon observed after interruption of the nigrostriatal DAergic
pathway (8,110). A 'supersensitive* response of the denervated DA¬
ergic neurons to direct or indirect stimulation of DA receptors is the
possible necessary step in the initiation of turning. A direct striatal
DA receptor stimulation by apomorphine and an indirect stimulation by
amphetamine (through release of DA) or even by methysergide (through
blockade of the remaining inhibitory 5-HT influence) may lead to the
demonstrated contraversive turning of rats with asymmetric MR lesions.
The preferential ipsilateral stimulation (causing the contraversive
turning) may result from the abolition of the mainly originating from
the MR nucleus inhibitory influence, and this might constitute the
most important feature of the 'supersensitivity' phenomenon presumably
occurring in MR-lesioned animals. A similar DA receptor 'superb-
sensitivity* could be postulated to occur in the substantia nigra. The
reciprocity of the two ends of the nigrostriatal pathway with refer¬
ence to DA release may be the reason why the turning due to DR lesions
is in opposite direction than the MR lesion-induced turning.
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The fact that there is no consistent spontaneous turning in MR-
or DR-lesioned rats, despite the increased DA release in the denervated
side of striatum or substantia nigra, respectively, may indicate either
that DA is inactivated before reaching its postsynaptic receptors or
that continuous stimulation of these receptors by the released DA has
caused decreased responsiveness to stimulation (subsensitivity), a
phenomenon appearing when DA receptors in brain have been stimulated in
a sustained manner (189). Subsensitivity of DA receptors, however,
could not explain the apomorphine- and amphetamine-induced contralateral
turning of MR-lesioned rats and the ipsilateral turning of DR-lesioned
rats. It is, therefore, possible that DA is released and rapidly
inactivated in the denervated side, thus leading to *supersensitivity'
of the postsynaptic DA receptors.
The fact that apomorphine and amphetamine induce rotation at
higher doses and with lower maximum intensity than in the case of
lesions of the nigrostriatal DAergic pathway (368,314) could be
partly attributed to the limited extent of the serotonergic denervation;
the remaining intact neurons are,probably, still functioning physio¬
logically, i.e. they exert an inhibitory influence on DAergic neurons.
Furthermore, the capability of DA to influence motor behaviour, by
acting as a neurotransmitter, seems to surmount much higher con¬
centrations of 5-HT, which could function either as a neurotransmitter
or as a neuromodulator in connection xfith motor behaviour. This is
suggested by the finding that the combination of MAO inhibition with
tryptophan loading may be expressed behaviourally as an indirect DA
receptor stimulant rather than a 5-HT receptor stimulant.
In addition to the hypothesised DA receptor 'supersensitivity'
resulting from raphe lesions, the intense rotation induced by the 5-HT
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receptor stimulant 5-MDT implies a distinct 5-HT postsynaptic receptor
•supersensitivity' mechanism functioning after denervation in both
corpus striatum and substantia nigra. The idea of a preferential
stimulation of the 5-HT receptors in the denervated side of the corpus
striatum or the substantia nigra vrould be compatible with the finding
of Bennett and Snyder (287) that raphe lesions did not reduce the 5-HT
and LSD binding in forebrain membranes, but 011 the contrary increased
it; the enhanced binding may reflect a depletion of endogenous 5-HT
bound to postsynaptic receptors rather than synthesis of new
•supersensitive' binding sites. The 5-HT-sensitive adenylate cyclase,
which seems to be associated with postsynaptic 5-HT receptors in brain
(299,300) might also be involved in the mechanism of the •supersensitive*
response to 5-HT stimulation. The increased stimulation of the post¬
synaptic sites ipsilateral to the lesion, either in the substantia
nigra or in the corpus striatum (probably located on Mergic cella or on DA-
ergic nerve terminals), due probably, to the reduced competition by
endogenous 5-HT, might result in an increased inhibition of DA release
which reverses the effect of DA receptor stimulants, producing turning
in the opposite direction (Fig. 5*21).
Chronic administration of neuroleptic drugs, which are known to
block DAergic transmission, probably by receptor blockade, led to
tolerance to the acute effects on striatal DA turnover (Section 3 of
this Thesis). Administration of a DA receptor stimulant, suoh as
apomorphine, after chronic neuroleptic treatment of normal rats,
produced a •supersensitive* response (148,80) whereas a single dose
of the neuroleptic could prevent the behavioural and biochemical
effects of DA receptor stimulation. Tolerance, and the 'super¬
sensitivity* stage that follows, have not yet been explained, and the
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mechanisms underlying these phenomena are far from clear. A common
feature of the •neuroleptic-induced supersensitivity* and the
'denervation-supersensitivity*f is the increased number of DA
receptors in the striatum or in the denervated area (t19*153) and
the increased responsiveness of striatal neurons to DA receptor
stimulation (120,80).
These phenomena, of the development of tolerance to the
blockade of DAergic neurotransmission and of *supersensitivity• to
DA receptor stimulation, were demonstrated in the present study.
Haloperidol given acutely blocked the turning induced by apomorphine or
amphetamine in both MR and DR lesions, indicating the direct involvement
of DAergic mechanisms in the circling behaviour induced by these drugs.
Chronic administration of haloperidol, for 15 days, did not prevent
the apomorphine- or amphetamine-induced turning, when these drugs were
administered 1 hour or 24 hours after the last daily injection of
haloperidol.
It seems from these observations that the hypothesised •denervation-
supersensitivity* of DA receptors, proposed as an important step in the
initiation of turning in both MR and DR lesions, could be inhibited by
an acute haloperidol injection but was unmasked after repeated adminis¬
tration of this neuroleptic. The *drug—induced supersensitivity* of
postsynaptic DA receptors was probably added to the •denervation-
supersensitivity', since the circling response of rats with MR lesions
to apomorphine was significantly higher than the response to administration
of apomorphine alone (without haloperidol pretreatment).
Rats with DR lesions also showed the phenomenon of tolerance to
the neuroleptic drug, but their response to apomorphine was, probably,
lower than the response to a single injection of apomorphine (without
pretreatment with haloperidol). The difference in the effect of chronic
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neuroleptic treatment on the MR- and the DR-lesioned animals cannot he
readily explained. The finding of this study that the MR innervates the
corpus striatum and the DR innervates the substantia nigra could probably
provide an answer, in view of the different effects of chronic neuro¬
leptic treatment on DA metabolism in the two areas reported in Section
3 of this Thesis; indeed, tolerance to the effect of haloperidol on the
concentrations of HVA and DOPAC did not seem to develop in the sub¬
stantia nigra on chronic treatment, but it did in the striatum.
Supersensitivity to amphetamine did not seem to develop in either
MR or DR lesions following chronic neuroleptic administration. How¬
ever, tolerance to the inhibitory effect of acute haloperidol on
amphetamine-induced turning was observed after chronic treatment: the
turning was of about the same intensity and in the same direction as
after the administration of amphetamine alone (without haloperidol pre-
treatment), both 1 hour and 24 hours after the last injection of halo¬
peridol. The same effect was noted in MR- and in DR-lesioned animals.
The complexity of the biochemical effects of amphetamine (the 5-HT and
DA releasing properties, in particular) could be the reason for the
difference in this circling response compared to the effect of apo-
morphine. The release of 5-HT by amphetamine, which has not been imp¬
licated by any direct or indirect evidence in the tolerance to neuro¬
leptic drugs, might counteract the 'supersensitivity* to the released
DA in the denervated side. This DA 'supersensitivity* could be a
reason for the grossly estimated 'supersensitive' behavioural response
to amphetamine with regard to locomotor and stereotyped behaviour
(5«3*4?)t which seem to be far more complex processes than circling.
Although the precise interpretation of these findings is not
possible from the present study, the close correlation between changes
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in DA metabolism and circling (reported in this Section) give further
support to the idea of a DAergic mechanism necessarily mediating the
turning of rats with asymmetric MR or DR lesions.
Chronic administration of the 5-HT receptor blocker methysergide
to rats with MR or DR lesions resulted in a phenomenon similar to the
above. The inhibition of the turning induced by 5-MDT when methysergide
was administered beforehand, was not seen on chronic administration of
methysergide; this finding indicates that tolerance to the 5-HT receptor
blockade had developed. The effect of the 5-HT receptor stimulant
could not bebLocked after 22-27 daily injections of methysergide; on
the contrary, the intensity of turning was increased and could not be
eliminated even with 2 or 4 times higher dose of the antagonist, given
before the injection of the 5-HT agonist.
Thus, a specific raphe lesion-induced and a 5-HT receptor
blockade-induced •supersensitivity* could be postulated to exist,
being additive in this rat-turning model, analogous to the same pheno¬
mena with reference to the DAergic system. The supersensitive response
to 5-HT receptor stimulation after chronic blockade did not change the
direction of turning and it did not prevent the imbalance produced
by the lesion. On the contrary, the increased turning rate might imply
an increase in the asymmetry between the two sides of the striatum or
the substantia nigra, indicating probably a further increase in the
sensitivity of the 5-HT receptors in the denervated side. Further
studies involving estimations of the 5-HT sensitive adenylate cyclase
and the number of p-HT receptors in the denervated areas could provide
more information about the effects induced by the lesion or the chronic
methysergide treatment and elucidate the mechanism of 5-HT receptor
'supersensitivity'.
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Available data on the acute effects of methysergide and 5-MDT
on 5-HT metabolism indicate some similarities to the effects of
neuroleptics and apomorphine on DA metabolism, respectively. Thus,
administration of methysergide produced an increase in the turnover
of 5-HT, reflected in an elevation of 5-HT and 5-HIAA in brain (339),
probably due to activation of a positive feedback mechanism which
increased the synthesis and utilisation of 5-HT. In contrast, stimu¬
lation of central 5-HT receptors by 5-MDT and by certain phenylethyl-
amines (338), probably initiated a compensatory negative feedback
mechanism which slowed down the turnover of 5-HT in brain. These
regulatory processes, triggered by 5-HT receptors were still function¬
ing in brain slices to control the release of labelled 5-HT induced by
potassium (30mM) or by electrical stimulation (344,343). The similarity
of these mechanisms with the regulatory mechanisms proposed for the
DAergic neurons in brain (44) tends to support a generally similar
process for the regulation of the biosynthesis and release of mono¬
amines in the central nervous system.
5.4«7 5-HT as a neuromodulator
The DA 'autoreceptors* in the substantia nigra (53,67), probably
mediating the effects of DA released from the dendrites (34) may
constitute part of a possible mechanism of local modulation of DAergic
cell activity. The demonstrated in vitro release of 5-HT (induced by
potassium, 30mM) from slices of the substantia nigra (290) and the known
ability of DA to enter serotonergic neurons (248) and displace under
certain circumstances the endogenous 5-HT from its neurons (244), could
possibly indicate an important neuromodulatory role of 5-HT in the
substantia nigra, where it is known to be of inhibitory nature (64,315)*
The demonstrated axo-dendritic synapses of the serotonergic afferents
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to the substantia nigra with other neurons of this area (73) offer
the anatomical background for the neuronal interrelation of the
serotonergic and the Mergic systems.
A similarity to the function of GABA in the substantia nigra,
which is believed to be released by dendritically released DA ( 7)»
to be inhibitory on nigral cells (64) and to be stored in neurons
originating outside of the substantia nigra (i.e. corpus striatum and
globus pallidus, 68,82) is evident from the findings of the present
study. The demonstrated ipsiversive circling behaviour of rats with
unilateral lesions of the GABAergic striato-pallido-nigral pathway
following the administration of apomorphine or amphetamine (45)» also
suggests that, perhaps, an additive or supplementary function could be
postulated for the 5-HT and the GABA inputs to the substantia nigra in
modulating the activity of the nigrostriatal DAergic pathway.
A presynaptic control of DA release in the striatum similar to
that proposed for GAPA could be postulated to exist, with 5-HT as the
neuromodulator. The serotonergic afferent to the striatum could
impinge on the DAergic nerve terminals at a preterminal level and
modulate the release of DA, probably by acting on 5-HT receptors
located on these terminals. Further experiments are needed in order to
assess these possibilities and establish the anatomical site and the
nature of the neuronal interactions of DA and 5-HT.
5.4*8 Conclusions
The asymmetric electrolytic lesions of the 5-HT-containing cell
bodies in the rat midbrain, described in this Section, suggested that:
1) The median raphe nucleus appears to project ■unilaterally to the
corpus striatum and not to the substantia nigra. The dorsal raphe
nucleus appears to project unilaterally to the substantia nigra; a
- 277 -
minor serotonergic afferent to the corpus striatum may also
originate from the dorsal raphe nucleus.
The lesions selectively damaged the 5-HT cells, without any
damage to DA- or NA-containing neurons terminating in the striatum.
2) DA turnover was selectively increased in the terminal area where
there was a reduction of 5-HT and 5-HIAA. These results indicate
that the serotonergic projections to the corpus striatum and the
substantia nigra have an inhibitory effect on DA metabolism in these
areas.
3) The DA receptor agonist apomorphine and the DA releasing drug
amphetamine induced turning in lesioned rats, which was contralateral
to MR lesions and ipsilateral to DR lesions. The 5-HT receptor agonist
5-methoxy-N,N-dimethyltrypt amine induced turning in opposite directions
to the DA receptor agonists. The combination phenelzine plus L-
tryptophan induced turning similar to that of DA receptor agonists.
Participation of NA in the amphetamine-induced turning was excluded.
4) Blockade of 5-HT receptors by methysergide appeared to facilitate
the circling response to apomorphine but rather reduced the amphetamine-
induced turning. Conversely, stimulation of 5-HT receptors by 5—
methoxy-N,N-dimethyltryptamine facilitated the amphetamine-induced
turning and blocked the apomorphine-induced turning. Haloperidol
blocked the response to 5-HT and to DA receptor agonists.
These results suggest that supersensitivity of the 5-HT
receptors in the denervated area may develop after the lesions, but
DA seems to be a necessary step in the initiation of turning. Apo¬
morphine and amphetamine seem to induce turning by a different mechan¬
ism. Since the DA asymmetry does not seem to induce consistent,
spontaneous turning, the response to DA receptor stimulation could be
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ascribed to DA receptor supersensitivity on the denervated side.
5) The demonstrated rat turning model could be useful in different¬
iating drugs acting as agonists or antagonists of 5-HT or DA. It
could also be used for the demonstration of tolerance to the effects
of chronic blockade of 5-HT or DA neurotransmission and for the
assessment of supersensitivity that follows.
6) The serotonergic projections to the corpus striatum and the
substantia nigra may be part of alternative mechanisms regulating the
activity of the nigrostriatal DAergic pathway by independently
influencing its two ends, the cell bodies and the nerve terminals.
GENERAL DISCUSSION
Present work — Proposed model - Future work
Despite the wealth of various experimental procedures employed,
limited and often inconsistent data were obtained relating to possible
functional relationships between the DA-containing nigrostriatal
pathway and other neuronal systems. Continued efforts to elucidate
the nature of these interactions would seem crucial to any comprehensive
view of sensory—motor integration and co-ordination of motor movement,
in which the nigrostriatal pathway seems to be an important link,
(383,394).
The work described in this Thesis suggests that several
neuronal systems function in a very interactive manner. The nigro¬
striatal pathway appears to have contacts and interactions crucial to
its function, both in the cell body area of the substantia nigra
(Pig. 5»22) and in the terminal area of the corpus striatum (Fig. 5*23).
Several procedures were employed in an effort to elucidate
certain interneuronal relationships which involve this pathway.
Primary lesions of the DA cell bodies and treatments with drugs
thought to act specifically on DA receptors provided evidence con¬
cerning the interaction of the DAergic with the cholinergic and the
GABAergic systems. Selective increase of 5-HT by precursor loading
or decrease by selective lesions of the raphe nuclei provided evidence
for the DA - 5-HT interactions. On the basis of the proposed neuronal
interactions, alternative interpretations of the action of drugs
primarily affecting the DAergic system might be obtained. Finally,
Fig. 5»22
Possible neuronal connections of a DAergic cell body
and a dendrite in the substantia nigra
Arrows indicate the presumed direction of synaptic transmission,
mediated through the respective receptors.
Possible neuronal connection with a glial cell, a 5-HT and a GABA-
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Summary of posBible neuronal connections in the corpus striatum
Arrows indicate the presumed direction of synaptic transmission mediated
through the corresponding receptors.
The DAergic nerve terminal is depicted to have post-synaptic contacts
with Ach- and GABA-containing cell bodies and presynaptic contacts with
neurons containing Ach, GABA or 5~HT and glial cells containing GABA.
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an attempt was made to formulate a comprehensive view of some neuronal
influences on the nigrostriatal pathway.
The homeostatic mechanisms, such as hypersensitivity or
tolerance of the DAergic system to certain experimentally-induced
changes, may represent nothing more than a special case of a general
biological phenomenon, that is, the capacity of the cell to compensate
for changes (within limits) by adaptation of its activity (cellular
adaptation). Even in these states, neuronal interactions might appear
to be involved.
A more concrete basis of adaptation would be through feedback
mechanisms. Such a mechanism for the control of the activity of the
nigrostriatal pathway has been postulated to exist, with the striato-
nigral GABAergic pathway as its morphological substrate (44,61).
Several other hypotheses have been made based on the intranigral DA-
DA interactions (*autoreceptor» theory, 53,34»33), the intranigral
neuronal interactions (57»56)f and the influence of the serotonergic
input to the substantia nigra (87). The experiments reported in this
Thesis were aimed at examining some aspects of these mechanisms.
A reciprocity of biochemical events related to DA neurotransmission
was found between the area of the DA cell bodies and the nerve terminal
area. Certain effects of haloperidol, the DA receptor blocker, and
apomorphine, the DA receptor stimulant, on DA metabolism in the
substantia nigra were contrary to those in the striatum (Section 1).
Chronic haloperidol treatment also resulted in different effects on
DA metabolism in the two areas (Section 3)« Selective lesions of the
5-HT containing cell bodies in either the median or the dorsal raphe
nuclei resulted in specific increases of DA metabolism in the corpus
striatum or the substantia nigra, respectively, without any effect on
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the other end of the nigrostriatal pathway (Section 5). Lesions
of the DA cell bodies and consequent degeneration of nerve terminals
in the striatum resulted in effects on cholinergic and GABAergic
neurons which were dissimilar or were even in opposite directions in
the two areas (Section 2). Some of these data could be taken as
evidence against the existence of a GABA-containing striatonigral
feedback pathway, since procedures affecting GABA in the striatum
or the substantia nigra did not have effects on striatal DA metabolism
consistent with such role. Strong evidence against the GABAergic
neuronal feedback loop has resulted from other experiments (165,166).
Similarly, the serotonergic projection from the DR to the substantia
nigra appeared to be inhibitory on DA metabolism in this area, but it
had no effect on DA metabolism in the striatum, suggesting that it is
probably not the alternative feedback control of the nigrostriatal
pathway.
The DA »autoreceptor» theory (53»34) implied that DA released
from the dendrites in the pars reticulata of the substantia nigra
(33f34) acts on DA receptors located on the cell bodies or the
dendrites to inhibit the cell firing rate. However, the finding
that changes in the concentrations of DA metabolites (implying parallel
changes in DA release) in the substantia nigra were not followed
consistently by reverse effects on DA release in the striatum
(Section 1) argues against this mechanism exclusively controlling the
nigrostriatal pathway. Further argument against the theory of auto-
receptor control comes from the reported lack of effect of 6-hydroxy-
doparnine lesions, which destroyed the nigral DA neurons, on the DAr-
sensitive adenylate cyclase (probably associated with DA receptors)
in the substantia nigra (18,56). On the contrary, location of this
adenylate cyclase in GABA- or substance P-containing nerve terminals,
as suggested by other experiments (46) may indicate that these or
other neurons are involved in the regulation of DA cell activity.
Release of GABA by DA and by the DA releasing agent, amphetamine,
has been demonstrated in the substantia nigra (57) t where the
inhibitory effect of GABA on DA cell firing is well documented (64,
82).
Feedback control by intranigral neuronal interactions could be
mediated by some of the substances known to be present in this area
of the brain. The finding that apomorphine and amphetamine appear to
increase and haloperidol to decrease GABAergic activity in the sub¬
stantia nigra (Section 3) might be in line with the proposed role of
GABA as neuromodulator. Further evidence that DA may act as GABA
mimetic, that is, to release GABA which in turn may inhibit the DA
cells (Fig. 5*22) was obtained from the findings that lesions of the
DA cell bodies resulted in reduction of GABA and GAD which could be
reversed by DA receptor stimulation with apomorphine (Section 2).
The latter finding is consistent with the hypothesised 'supersensitive'
response of the DA receptors in the lesioned side (to apomorphine) and
the resulting contralateral turning (8,110). It is also in agreement
with the reported contralateral turning of rats following elevation
of GABA in the substantia nigra (337) or ipsilateral turning following
reduction of GABA in the same area (45)• The chronic neuroleptic
treatment offered additional evidence for this concept, by demonstrating
a positive correlation between the changes in GABA or GAD and the con¬
centrations of the metabolites of DA (Section 3)« Although this
finding contradicts the known inhibitory effect of GABA on DA cell
activity, cellular adaptation to the effect of GABA might have resulted
from the chronic neuroleptic treatment.
In this context it is tempting to speculate that DA, by acting
on its receptors located on other neuronal systems, may induce the
release of inhibitory or excitatory neuromodulators of the DA cell
activity. Thus, release of substance P or Ach, which have been shown
to have excitatory effects in the substantia nigra (64,395), could
constitute part of a local positive feedback control (Fig. 5*22).
This has not been demonstrated yet. Further characterisation of this
interrelation would require evidence of the existence of a DA-
sensitive adenylate cyclase or DA receptors on nigral cholinergic
neurons, (as has been shown for substance P) as well as cholinergic
or substance P receptors on DA cells or dendrites. Furthermore, the
ability of DA to release substance P and Ach and, conversely, the
ability of Ach and substance P to release DA in the substantia nigra
need to be demonstrated. The finding that oxotremorine, a cholinergic
agonist, increases DA turnover in the substantia nigra (54) supports
this idea. The reduction of the enzyme CAT after lesions of the
substantia nigra (Section 2) also supports a •trophic* influence of
DA on nigral cholinergic neurons, in agreement with the proposed
interrelation. The reported increase of striatal release of DA by
substance P applied in the substantia nigra (396) provides further
evidence for this hypothetical relationship.
The finding that 5-HT, released by serotonergic neurons
originating in the raphe nucleus, may exert a tonic inhibition of DA
cells (87), thus inhibiting DA release (Section 5) may be yet another
influence on the nigrostriatal pathway, as depicted in the diagram¬
matic model of Fig. 5*22. 5-HT as well as GABA, could be released
from their nerve terminals in the substantia nigra (probably in the
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pars reticulata) to act as neuromodulators at some distance from the
release sites, probably on the DA cell bodies in the pars compacta,
or on the DA dendrites, thought to form synapses with these terminals
(73)« The release of these neuromodulators may, in turn, be controlled
by dendritically released DA, as has already been suggested for GABA
(57).
It is conceivable that a role for 5-HT similar to that of
GABA could be demonstrated if DA and DA receptor agonists could
release 5-HT in the substantia nigra, in a similar approach to that
of Reubi et al. (57). Furthermore, a DA sensitive adenylate cyclase
or DA receptors may be located on serotonergic terminals, similar to
the location of a DA-sensitive adenylate cyclase on GABAergic terminals
(18,46), to mediate the release of 5-HT by DA. 5-HT (and GABA)
receptor,binding sites may be located on DA cells. A unilateral
increase of 5-HT in the substantia nigra (e.g. by local application)
may be expected to have a similar effect on motor behaviour (turning
in particular) to the local application of GABA and GABA receptor
agonists (387). A study of the effects of such a unilateral increase
of 5-HT in the substantia nigra on the activity of the nigro-
striatal pathway and on DA metabolism in the corpus striatum could
test the hypothesis of Dray et al. (87) that the raphe projection
to the substantia nigra may be the inhibitory-modulatory influence
on the activity of the nigrostriatal pathway, as an alternative to the
GABA—mediated control.
The finding that lesions of the DR nucleus resulted in an
increase of DA metabolite concentrations in the substantia nigra but
not in the striatum, replicates similar findings after lesions of the
striatonigral GABA-containing pathways (45) and it is inconsistent with
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the role assigned to the serotonergic input. The fact that neither
of these lesions affected DA release from the striatum, "but probably
increased DA release in the substantia nigra may be suggestive of
other possibilities: (a) 5-HT (and GABA) may act directly on DA
dendrites to inhibit the release of DA in the substantia nigra and,
therefore, may not have an effect on DA cell firing rate, (b) The
release of DA may be regulated locally by serotonergic and GABAergic
afferents to the substantia nigra and by serotonergic afferents and
GABAergic axon collaterals impinging on DAergic neurons at a pre¬
terminal level in the corpus striatum. These mechanisms could be
similar but independent at the two ends of the nigrostriatal pathway,
(c) There might be a threshold of firing rate of the DA cells, below
which there is no observable change in DA release at the nerve
terminal. Therefore, reductions (even up to 50%) of the concentration
of the neuromodulator in the substantia nigra may not affect the DA
cell activity, because the 5-HT or GABA remaining after lesions of
the respective neurons, may suffice to fulfill the role of neuro¬
modulator designated to them, (d) If GABA and 5-HT have additive or
supplementary affects on the activity of the DA cells in the sub¬
stantia nigra, lesions affecting only the GABAergic or only the
serotonergic input may not impair significantly this activity due to
overfunctioning of the intact neuromodulatory neurons. The possibility
that both inputs act together to control the activity of the nigro¬
striatal pathway could be assessed by procedures (such as lesions)
that involve both GABA and 5-HT afferents to the substantia nigra,
(e) In view of the proposed existence of two or more compartments for
5-HT (240), of which the small*functional pool rather than the large
•storage* pool determines the functional state of the serotonergic
neurons, procedures which would prevent replenishment of the
functional pool would indicate more precisely the role of >-HT in
relation to the DA cell activity. Similarly, the functional
significance of alterations in the concentration of GABA needs to he
clarified before any conclusions can be drawn from experimentally-
induced changes in its total concentration in the substantia nigra.
The occurrence of high amounts of GABA in the glial cells (207) as
well as in the GABA nerve terminals may suggest that procedures
reducing only neuronal GABA are not necessarily valid methods for the
assessment of its functional significance in relation to the DA cell
bodies. GABA, of glial origin, may participate in the regulation of
DA cell activity, as speculated in Pig. 5.22
Further work is also needed for the elucidation of the nature
and the location of the proposed DA 'autoreceptor1 in the substantia
nigra, the possible existence of more than one DA receptor in this
structure, and the possible dissociation of DA-sensitive adenylate
cyclase from DA receptors. These points would clarify the postulated
DA-DA interactions, and the functional significance of the dendro-
dendritic synapses and the dendritic release and uptake of DA.
The diversity and often the reciprocity of changes induced
experimentally in the corpus striatum and the substantia nigra
concerning DA metabolism tend to suggest that local regulatory
mechanisms may be functioning independently in both areas. However,
the nature of the interactions in the striatum may be similar to
those postulated for the substantia nigra. Although reciprocity of
effects induced experimentally on DA release at the two ends of the
nigrostriatal pathway, without involvement of an intermediate feed¬
back pathway would contradict the generally accepted view that changes
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in cell activity and impulse flow are followed by similar changes
in transmitter synthesis and release from the nerve terminals (25,
26,27), "the proposed models (Fig. 5.22 and 5*23) may offer viable
alternatives.
According to the proposed scheme of neuronal interrelations
in the striatum (Fig. 5«23) the DAergic neurons originating in the
substantia nigra have both pre- and post—synaptic contacts with other
neurotransmitter systems. Although the functional substrate for these
contacts has been formulated, morphological evidence is still required
and remains an interesting subject for future work.
On the basis of in vitro experiments, presynaptic control of DA
release in the striatum by excitatory cholinergic (174) and by inhibitory
GABAergic neurons (192) impinging at a preterminal level on DA nerve
terminals have been proposed. A reduction of GABA receptor binding
sites in the striatum following lesions of the DA cells in the substantia
nigra with 6-hydroxydopainine, has been demonstrated (196), whereas
evidence concerning the cholinergic (muscarinic or nicotinic) receptors
after such lesions is needed in order to establish the existence of this
neuronal interrelationship.
Evidence obtained from the lesion experiments reported in
Section 5» suggests that 5-HT released from serotonergic terminals
originating in the MR may have an inhibitory effect on DA release,
probably at a preterminal level. Although the inhibitory nature of this
projection on behavioural phenomena that in all probability involve
striatal DA receptor stimulation appears to have strongly dooumented
support (present study, 322,388,250), its presynaptic contact with the
DAergic nerve terminals awaits further morphological and biochemical
evidence. Primarily, location of postsynaptic 5-HT receptors (or
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5-HT sensitive adenylate cyclase, thought to he aseociated with them,
299,287) on DA neurons has to be demonstrated, to form the basis of
the 5-HT-DA neuronal interactions. It is premature, however, to
speculate on the relative importance of the nigral and the striatal
serotonergic inputs (which the present study demonstrates to have
distinct origin), despite the finding that selective lesions of these
pathways resulted in reciprocal biochemical and behavioural effects
(Section 5)« The ability of accumulated 5-HT to enter DA and HA
containing neurons and displace these monoamines as observed after
tryptophan loading (Section 4)» does not appear in physiological states,
and probably represents a different interrelation, not mediated through
receptors.
The functional importance of the presynaptic contacts of the
various neurons thought to impinge on DA nerve terminals as neuro¬
modulators could be elucidated if a link could be shown between the
activity of these neurons and the activity of DAergic nerve terminals,
i.e. DA synthesis or release in the striatum. With reference to 5-HT,
there is no such concrete evidence. The ability of DA to release 5-HT
at low concentrations in vitro (397)- may suggest that the abundantly
released DA from the striatal nerve terminals is capable of inducing
in turn the release of 5-HT from serotonergic nerve terminals.
Alternatively, the reported finding of a projection from the caudate
nucleus to the area of the median raphe in the cat (328) may be
hypothesised to form the basis of a feedback loop, an attractive
possibility awaiting experimental evidence. The existence of such
feedback loops related to the serotonergic system has already been
proposed (332), even implicating the habenula as an intermediate nucleus
feeding back to the raphe cells information from the 5-HT nerve terminals
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(317,327,331).
The postsynaptic contacts of the DAergic nerve terminals appear
to be less obscure. Postsynaptic DA receptors (and DA-sensitive adeny¬
late cyclase) seem to be located in Ach and GA3A—containing cells in
the striatum (94,95) and to mediate respectively a direct inhibition
(Sestions 2 and 3, also 90,91,93) and, probably, a stimulation
(Sections 2 and 3). In addition, an indirect contact of DAergic with
GABAergic neurons, through short cholinergic interneurons has been
proposed (106,105) and is also supported by data reported in Section 3.
Thus •trophic* influences of DAergic neurons seem to exist on cholin¬
ergic or GABAergic neurons, in parallel, or in consecutive arrange¬
ment, as deduced from the results of this Thesis and the work of
others. The parallel existence of a DA-Ach-GABA and a DA-GABA synaptic
link, of which one would be inactivated during development of tolerance
to continuous exposure to a drug (such as haloperidol, Section 3) may
be an example of the general 'redundancy theory' of neuronal adaptation
(398). The excitatory indirect influence of DA on GABA-containing
cells (through short cholinergic interneurons, Pig. 5*23) may be
(jtactivated after prolonged blockade of DA neurotransmission by haloperidol.
The GABA- and Ach-containing striatal cells seem to be the origin
of the neurons imoinging on DAergic nerve terminals (174,192). It
might be speculated that these neurons form part of a local feedback
mechanism, activated through stimulation of DA receptors located on
their cell bodies. Such an effect would be predicted, on the basis of
the finding that activation of the striatal cholinergic system is
associated with an increased release of DA (increase of the metabolite
concentrations, Sections 2 and 3), the reverse, probably being also
true. Similarly increases or decreases of GABAergic activity in the
striatum generally correlate with reciprocal changes in DA release, as
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acute and chronic haloperidol treatment has indicated (Sections 3).
The reported increase of DA receptor binding sites in the striatum after
degeneration of DAergic neurons (119) and after chronic neuroleptic
treatment (153) may also be in agreement with this scheme® Definite
conclusions cannot be drawn, however, until this concept has been
further elucidated.
In a manner seemingly incompatible with the above scheme, lesions
of the DA cell bodies and the resulting •supersensitivity1 of post¬
synaptic DA receptors to stimulation by apomorphine did not result in
a 'supersensitive1 change in the DA metabolite concentrations. An
alternative explanation would be that apomorphine acts on presynaptic
DA receptors (on intact nerve terminals) to exert an influence on DA
synthesis and release, as suggested by other investigators (63,163).
The ability of haloperidol to induce an increase in the striatal DA
turnover, even in a 90% degenerated DAergic system, supports a
predominantly postsynaptic effect which is probably mediated through a
local feedback mechanism. These neuronal interactions may help to
explain the hyperactivity of DAergic neurons remaining intact after
lesions, a phenomenon appearing to represent an •intrinsic1 DA neuron¬
al adaptation mechanism. Use of other procedures is needed, however,
in order to establish a conceptual framework of these ♦feedback1
mechanisms.
APPENDIX
A SENSITIVE GAS LIQUID CHROMATOGRAPHIC ASSAY FOR HOMOVANILLIC ACID
(HVA) AND 3,4-DIHYDROXYPHENYLACETIC ACID (DOPAC) IN BRAIN TISSUE
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INTRODUCTION
In order to study the regional distribution of the metabolites
of DA in discrete areas of the rat brain and the effect of various
treatments on their concentration, it was found necessary to have
a reliable and sensitive assay procedure. The development of gas
liquid chromatographic (glc) methods for the estimation of 4-
hydroxy—3-methoxyphenyl acetic acid (homovanillic acid, HVA) and
3,4-dihydroxyphenyl acetic acid (DOPAC) was an important advance in
the study of DA metabolism in brain. The greater sensitivity and
specificity of these methods, compared to the existing fluorimetric
techniques made them much more useful, especially in the study of
changes in the concentrations of these metabolites in small, discrete
regions of the brain of small laboratory animals, such as rats and
mice, and enabled assays to be made without pooling tissues from
several animals.
The method used in the present study is a modification of the
method of Pearson and Sharman (41) with considerable improvements and
is based on the formation of the hexafluoro-isopropyl esters of the
trifluoroacetyl derivatives of HVA and DOPAC and their estimation by
glc. Such a technique was first described by Dziedzic et al. (391) and
was applied to the estimation of HVA in human urine and CSP. Their
method involved the extraction of the HVA into ethyl acetate, evar-
poration of the organic solvent and the formation of the hexar-
fluoroisopropyl (HFIP) derivative of trifluoroacetylated (TFA) HVA
which could be reliably measured at submicrogram amounts by glc fitted
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with an Electron Capture Detector (ECD). The presumed reaction (391)
is illustrated in Pig. A1.
Pearson and Sharman (41) extended the method to include the
estimation of DOPAC in the same sample of brain tissue or CSF. Their
method, slightly modified, was used in some of the experiments









The presumed reaction for the formation of the
trifluoracetyl-hexa-fluoroisopropyl (TFA-HFIP)
derivatives of HVA and DOPAC
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A.1 Examination of the method of Pearson and Sharman (41)
A.1.1 METHODOLOGY
The assay procedure was as follows:
Homogenisation and removal of protein from tissue sample. Brain tissue
(up to 2D0mg) was dissected out, weighed and placed on dry ice.
It was then homogenised in an all glass homogeniser (jencons 5ml model)
with 1ml 0.1M HC1, and the pestle was finally washed with another 1ml
0.1M HC1 which was added to the homogenate. Perchloric acid (25 pi of
72/) was added to the homogenate and mixed thoroughly by vortex-
mixing for 5 sec. The homogenate was then transferred to a 15ml
centrifuge tube with washing with 2 x 1ml 0.1M HC1, approximately
100mg KC1 (Analar) were added and the tube contents vortex-mixed for
15 sec. After centrifugation for 15 min at 3»000 revs/min, the
supernatant was transferred into a pml cellulose nitrate tube
containing a saturating amount of solid KC1 and mixed well by suction
into and expulsion from a teat pipette. The mixture was frozen in
liquid nitrogen, and allowed to thaw sufficiently for the formation of
a layer of water between the ice and the walls of the tube, before
centrifuging at 10,000 revs/min for 15 min at 10°C, using a high speed
head.
Extraction of HVA and DOPAC. The supernatant after centrifugation was
transferred to a centrifuge tube and more solid KC1 was added (about
100mg) with mixing. Ice-cold ethyl acetate (CT grade, 4ml) was added
and the two layers vortex-mixed for 1 min. After centrifugation at
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3,000 revs/min for 3 min, 3*5ml of the ethyl acetate layer was
transferred to another test tube. Another 2ml of ethyl acetate was
added to the first tube, vortex-mixed and centrifuged as before. Two
ml of the ethyl acetate layer was removed and combined with the 3«5ml
of the first extraction. The combined ethyl acetate extracts were
evaporated under a jet of dry oxygen-free nitrogen at 55°C until the
volume was reduced to about 0.2ml. The evaporated extract was
transferred to a reaction vial (1ml 'Reacti* vial, Pierce Chem. Co.)
with washing with 0.3ml of ethyl acetate. The solution in the vial
was evaporated to dryness under a jet of oxygen-free dry nitrogen at
room temperature.
Derivatisation of HVA and POPAC. To the residue in the reaction vial
0.2ml of trifluoracetic anhydride (TFA, Aldrich Chem. Co.) and 0.1ml of
% boron trifluoride etherate (BDH) in 1,1,1,3,3,3-hexafluoroisopro-
panol (HFIP,BDH) were added and mixed. The vial was then tightly closed
with a screw-on cap with a teflon liner and heated for 1 hour at 100°C
in a heating block. After cooling to room temperature, the vial was
opened and the contents evaporated under a gentle jet of oxygen-
free nitrogen to give an oily residue. The residue was dissolved in
1.0ml CT grade ethyl acetate containing lOOng/^ pentafluorophenyl-
benzoate (PFPB)• The PPPB served as an internal standard for the
subsequent glc. The HVA and D0PAC derivatives were 'separated and
estimated by glc.
Gas liquid chromatography. The solution of the derivatives (1 or
2 p.1) was chromatographed -under the following conditions:
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Column 2$ SE52 on Diatomite CQ in 9ft glass
column (4mm i.d.)
Carrier gas 5$ methane - 95$ argon






The recoveries of DOPAC and HVA (25-50 ng) added to homo-
genates of rat brain tissue and estimated by this procedure were
60+8$ (n = 12) and 58 + 10$ (n = 9)» respectively. The retention
times of TFA - HFIP derivatives of HVA and DOPAC relative to the
internal standard were 0.52 and 0.35 respectively, as reported by
Pearson and Sharman (41)•
A.1.3 DISCUSSION
Although the method theoretically offers great advantages over
the previously used fluorimetric or gas chromatographic methods, such
as increased sensitivity and specificity, it proved to be unreliable for
routine assays. Also, the preparatory work needed (redistillations of
reagents and solvents) made the procedure even lengthier. In extracts
from brain tissue, unidentified peaks were often observed over¬
lapping to a greater or lesser extent the peaks of HVA or DOPAC, thus
decreasing the specificity. The reproducibility was also unsatisfactory,
probably because of the fact that the procedure was complicated and
involved too many stages at which variable losses could oocur. The stage
at which insertion of the supernatant into liquid nitrogen in cell¬
ulose nitrate tubes was done was not satisfactory, because breakages
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of tubes with loss of frozen samples irere very frequent. The
extraction into ethyl acetate and then the transfer of the reduced
volume of ethyl acetate into the reaction vial was time consuming.
The recoveries of both HVA and DOPAC were low and the estimation of
these metabolites in tissues not very rich in DA would not be possible
unless tissues from several animals were pooled together. The 5$
boron trifluoride (BF^) etherate in EFIP, used with TFA for the
derivatisation of HVA and DOPAC was found to give a chromatogram with
many unidentified peaks. Very often the DOPAC peak was covered by an
unknown peak which disappeared when 3F^ was omitted. The loss of HVA
derivative, thought to form a complex of high b.p. with BFy was pre¬
vented when evaporation under nitrogen was carefully performed until
an oily residue remained in the vial.
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A.2 Detailed procedure for the estimation of HVA and DOPAC in
small portions of brain tissue
A.2.1 INTRODUCTION
The need to improve the method so as to increase its sensitivity
and reproducibility and decrease its complexity led to the introduction
of a number of modifications. The whole procedure was scaled down.
Small plastic centrifuge tubes (Eppendorf) of 1.5ml were used throughout
in the modified method, with smaller volumes being used both for
homogenisation and for extraction with organic solvents. Extraction
manipulations were carried out in 1.5ml Eppendorf tubes with snap
closures. These modifications enabled a larger number of samples to
be worked up simultaneously. Though the basic procedure of extraction
of the acidic metabolites from acidified supernatant into ethyl acetate
and subsequent derivatisation was retained, certain stages were found
to be unnecessary or even to cause additional problems rather than
aid. It was found that the introduction of an extraction of the home-
genate with toluene before extraction of the acids with ethyl acetate
proved useful. The additional toluene extraction step was found not
to affect the recovery of HVA and DOPAC, but removed much material
interfering with the assay, so that 'cleaner1 chroraatograms were
obtained. In some of the later experiments, additional purification of
the samples was obtained by freezing the aqueous extract, after the
toluene extraction, in liquid nitrogen. Centrifugation after thawing
gave separation of a clear supernatant from a small amount of precipitate.
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Three extractions into ethyl acetate were carried out and the extracts
combined in a reaction vial and evaporated to dryness. This step
increased the recovery of the method. BP^ etherate was omitted from
the reaction mixture to give a 'cleaner* chromatogram. One or two
toluene extractions could be carried out, depending on how clean the
supernatant was after the first extraction. Usually, one extraction
and subsequent insertion of the tube into liquid nitrogen was used.
A.2.2 METHODOLOGY
Hie improved method finally employed for the estimation of
HVA and DOPAC in brain tissue is detailed below:
Homogenisation of brain tissue and preliminary purification. Rat brain
tissue of known weight not exceeding 100mg and previously stored in
liquid nitrogen was thawed and transferred into a 1.5ml centrifuge tube
with a plastic snap—closure (Eppendorf tube). Ice-cold perchlorid acid,
200 pi 0.4M, was added and the tissue was homogenised for 1 min with
an electrically driven (6pOQr.p.m.) teflon tipped pestle. Another
600 pi of cold 0.4 M perchloric acid was added, the tube contents were
mixed and centrifuged for 4 min at room temperature at 14,000 revs/min
in a bench (Eppendorf) centrifuge. Hie supernatant was transferred into
an Eppendorf tube and a saturating amount of powdered KCl was added.
Hie contents were vortex—mixed for 15 sec and centrifuged for 4 min
at 14,000 revs/min. Hie clear supernatant, transferred to another
Eppendorf tube, was extracted with 500 pi of ice-cold toluene by
vortex-mi ing for 30 sec and separating by centrifugation for 4 min
at 14,000 revs/min. Hie organic layer was aspirated off and disoarded.
If a thick layer of lipid remained on the surface of the aqueous phase,
then either the extraction with 500 p.1 toluene was repeated or the tube
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contents were kept frozen in liquid nitrogen for 30 min or longer,
thawed and centrifuged, a clear supernatant then being separated from
the precipitated lipids.
Extraction of HVA and POPAC. The HVA and DOPAC were extracted from
the aqueous layer into O.pml of ice-cold ethyl acetate CT grade
Reeve-Angels) by vortex-mixing for 1 min. The layers were separated
by centrifugation for 4 min at 14,000 revs/min. The organic layer
was transferred into a 1 ml reaction vial ('Reacti vial1, Pierce Chem.
Co.), care being taken not to transfer any of the aqueous phase, since
this might prevent the trifluoroacetylation reaction that follows.
The extractions with 0.5 ml ethyl acetate were repeated twice more,
the extracts being combined in the reaction vial and then evaporated
to dryness under a stream of nitrogen at room temperature.
Derivatisation of the extracted IIVA and POPAC. To the residue in the
vial, 0.2 ml of redistilled TFA (Gold Label, Aldrich) and 0.1 ml of
redistilled HPIP ('special for spectroscopy*, 3DH) were added (from
ampoules kept sealed since the distillation) and the reaction vial
closed tightly with a screw-cap fitted with teflon liners. The vial
contents were vortex-mixed and heated for 1 hour at 100°C in a
thermostatically controlled heating block. After it had cooled to
room temperature, the vial was opened and the contents evaporated under
a gentle stream of nitrogen at room temperature to remove the excess
reagents. Evaporation was continued until a brawn or yellow oily
residue remained for the glc.
Gas liquid chromatography. This residue in the vial was dissolved in
1 ml of redistilled ethyl acetate, CT grade, containing 100 Bg of PFPB
which served as the internal standard. The contents of the vial were
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vortex-mixed and pipetted into a 2 ml hypovial which was closed with
a rubber cap held secure with an aluminium seal. The hypovial was
placed in the rack of an automatic injection system attached to a
Hewlett-Packard glc. About 2 yl were injected automatically with a
70111 Hamilton microsyringe, usually every 60 min. The injection volume
was constant, with + 1$ repeatable accuracy.
Conditions of gas liquid chromatography. A Hewlett-Packard 5700
series glc fitted with an auto-sampler and a 15 roCi ^Ni BCD was
employed. Operating conditions were the same sis in the original method
described above.
Recoveries of HVA and POPAC through the procedure. The recovery of the
acids through the method was determined as follows: Homogenates were
divided into two equal portions. One portion, to which known amounts
of HVA and DOPAC (usually 25, 50, 100 ng) were added, was carried
through the procedure in parallel with the other portion of homogenate.
The peak areas of the HVA and DOPAC in the homogenate with the standards
minus the peak areas of these metabolites in the homogenate without the
standards represent the net HVA and DOPAC recovered through the
procedure. The recoveries were then calculated by comparison with the
peak areas obtained from standards of HVA and DOPAC dissolved in ethyl
acetate, which liere added to reaction vials (usually the same amounts
as above, i.e. 25, 50, 100 ng), evaporated to dryness and derivatised.
Calculations. The peak area method (393) was used for the claculation
of the metabolite content of every sample. After triangulation of
the peak, the area was taken as the height x half the base of the
triangle. Standard curves were constructed from a series of HVA
and DOPAC (10 - 100 ng) dissolved in ethyl acetate, which had been
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evaporated to dryness under nitrogen, incubated for 1 hour at 100°C
with TFA and HFIP and then blown down under nitrogen, dissolved in
1 ml of ethyl acetate containing 100 ng/^ FFPB and injected into the
glc. A series of standards was injected in every assay. The peak
areas of these standards were calculated as well as the peak area of
the internal standard. A standard curve was constructed as ratio of
HVA or DOPAC derivative peak area to the peak area of PFPB against ng
of HVA or DOPAC present in the sample. The relation was linear over
a wide range of HVA and DOPAC tested, i.e. 5-200 ng. Best-fit straight
lines for graphs, evaluated by the method of least squares (using an
Olivetti computer programme), were always used for the calculation of
the amount of HVA and DOPAC in the unknown samples. A typical
chromatogram of brain tissue sample is shown in Pig. A2.
Preparation of pentafluorophenylbenzoate (PFPB) used as internal standard
for the glc. This substance was prepared by a method described by
Pearson and Sharman (41)• Pentafluorophenal (BDH) was redistilled
under reduced pressure (b.p. 264°C at about 15 ram Hg, water pump).
The pentafluorephenol (1 g) was dissolved in approximately 15 nil of
10$ UaOH, the glass stoppered tube being kept ice—cold. Excess
benzqyl chloride (BDH) (about 2 ml) was added and the mixture shaken
for 10 min during which time an oily precipitate appeared. This
precipitate was extracted into 10 ml dichloromethane. The dichloro-
methane extract was then dried over anhydrous sodium sulphate and the
solvent removed by evaporating under a stream of nitrogen. The residue
of PPPB was dissolved with warming in a minimum of redistilled hexane,
the solution rapidly filtered and cooled to 0°C. The crystals formed
were pure PPPB. After they were dried overnight at room temperature,
until no smell of benzoyl chloride remained, they were stored in a
Fig. A.2
Chromatograms of (a) 0«5 nil of cerebrospinal fluid, (HVA) ,
(b) brain tissue (HVA, DOPAC) and (c) brain tissue (GABA).
The peaks corresponding to the trifluoroacetyl-hexa-
fluoroisopropyl (TFA-HFIP) derivatives and to the internal
standard pentafluorophenyl benzoate (PFPB) are indicated.
The column was 9 ft long packed with 2°/i SE52 coated on
Diatomite CQ. Oven temperature was 115 C for (a) and (b)
and 92 C for (c). Detector temperature was 230 C.
Carrier gas was argon with y/o methane, at flow rate
60 ml/min (pressure 40 p.s.i.)
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desiccator. Solutions containing 100 ns/mj_ were prepared in ethyl
acetate as required for use as an internal standard.
Distillation of reagents. The reagents for the derivatisation of HVA
and DOPAC were redistilled at atmospheric pressure. TFA boiled at
39«5°c, HFIP at 57-58°C. Ethyl acetate (b.p. ■jj-j8°g) for the final
injection into the glc was redistilled and was also the hexane (BDH)
that was used for the preparation of PFPB. Small fractionation columns
(Quik-fit) were used for all the redistillations.
Column for glo-choice of packing material. In most of the experiments
the glc column vias packed with a methyl silicone gum (SE52) coated on
a diatomaceous earth support (Diatomite CQ or Chromosorb Q). A 2fo
loading of the liquid phase SE52 on the solid support of Diatomite CQ
100-200 mesh was used. Several liquid phases coated on Diatomite CQ
were tested and the relative retention times of the HVA and DOPAC
derivatives are given in Table A1. The stationary liquid phase SE52
and a similar non-polar silicone gum liquid phase, SE30, with yfo
loading were tried, as was a polarfluorinated silicone,QF1» with ¥jo
loading. The solid support, coated with the liquid phase, was
purchased from Hewlett-Packard (SE52), Pye-Unicam (SE30) and Analabs
(QF1). The linearity of the response and the sensitivity of the
fluorinated derivatives were also the same, so either of the SE52 or
SE30 stationary phases cotild be used effectively. On the other hand,
the QF1 due to its polarity tended to retain the oolar HVA and DOPAC
derivatives in preference to the less polar PPPB, so that the relative
retention times were 1.29 and 1•50, respectively. Though this liquid
phase offered the advantage of giving HVA and DOPAC derivative peaks
at a safe distance from most of the unidentified peaks that could
interfere, it had low efficiency and resolution, because the two peaks
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were wide and often overlapping, compared to the sharp and separated
peaks obtained when the SE52 and SE30 were used. A problem of
inconsistent linearity of the responses was another reason for
discarding the QF1 liquid phase. As can be seen in Table A1, the
relative retention times for the 2^ SE52 and the 3^ SE30 liquid phase
coating were about the same.
Amounts of the derivatives corresponding to as little as 1 ng
of DOPAC or HVA could be detected using the above assay and glc
conditions, provided the column packing was of a high enough quality
to provide good efficiency and resolution.
The column was filled with the packing material according to the
standard simple technique: The coated support was added in small
amounts into the column from the free end, while at the other end a
water aspirator was connected to the column which was plugged with
glass-wool to assist the packing. An electric vibrator was used to
speed up the settling of the packing material into the column.
Conditioning of the column. Conditioning is the process used to remove
from the raw column absorbed air and also impurities in the liquid phase,
residual solvent from the coating operation and other undesirable
impurities and to make it ready for analytical use. A special no—flow
conditioning procedure was used for the above silicone gum liquid phase
columns and it was carried out only once for a new column. The
column was installed in the instrument with the detector and unconnected
and it was heated at 100°C for 30 min with a normal flow rate of
carrier gas. The carrier gas flow was stopped and the column was
heated at 310°C for 90 min. The column was afterwards allowed to cool
to about 100°C, the carrier gas was turned on again and the regular
conditioning was continued for about 16 hours at 120°C, after which
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the detector end was connected again. The column was then ready for
use. Regular conditioning with normal flow rate and at a temperature
higher than the one used in the routine assays (usually 150°C) was
performed in order to remove accumulated trash from the column.
Modified method for cerebrospinal fluid (CSF) and amniotic fluid (AF).
The method described above for the estimation of HVA and DOPAC in
brain tissues was found suitable, with some slight modifications,
for the determination of these metabolites in CSF and AF from human
subjects. The final version of the method used for the CSF assays is
as follows: Ice-cold CSF (O.pml) was mixed with 0.4 ml of 1M HC1 in
a 1.5 ml plastic centrifuge tube (Eppendorf) with attached snap
closure. A few crystals of KC1 were added and the mixture vortex-
mixed for 30 sec. After centrifugation for 4 min at 14»000 revs/
min., the clear supernatant was transferred into another Eppendorf tube,
0.5 ml ice-cold toluene was added, and the assay continued as described
for brain tissue samples.
The recoveries of 25-100 ng of HVA and DOPAC added in the CSF
and carried through the procedure were 76+11$ (n = 18) and
75 + 10$ (n = 13) respectively. A peak with relative retsntion time
0.35 was wrongly taken as DOPAC in some samples, contrary to many reports
that DOPAC exists in subnanogram amounts per 1 ml of CSF, which cannot
be measured by this technique. After careful assessment this peak
was ignored as non-specific. A typical CSF chromatogram is shown in
Fig. A2.
The same procedure was applied to AF (0.2-0.5 nil), but with
the additional step of precipitation of proteins with 25 p.1 of
concentrated perchloric acid (72$ w/v). Values obtained from human




Recoveries of standards were 60+9$ (n = 7) for HVA and
59 + 4$ (n = 7) for DOPAC.
Incorporation of GABA assay in the glc procedure. In parallel with
the assay of the DA metabolites, the assay of the amino acid GABA by
glc could also be carried out on a portion of the same brain extract.
After precipitation of proteins, 25 or 50 ^u.1 aliquots were taken from
the clear supernatant and assayed as described in Section 2. Since
GABA is a relatively stable compound, the aliquots could be safely
kept at -20°C until it was convenient to perform the assays. A
typical GABA chromatogram is shown in Pig. A2.
Attempts to identify unknown peaks of the chromatogram. Various attempts
were made to identify some of the unknown peaks appearing frequently on
chromatographic tracings. It was of particular interest to discover
whether any of the other acidic metabolites of catecholamines or even
of 5-HT were among these peaks. The TFA-HFIP derivatives of potential
metabolites were prepared from the pure substances. Known amounts of
such standards were dissolved in ethyl acetate and a suitable volume
evaporated to dryness in a 'Reacti vial* under a stream of nitrogen at
room temperature. The compound was reacted with 0.2 ml TPA and 0.1 ml
HFIP at 100°G for 1 hour in a metal heating block. After evaporation
of the excess reagents, the oily residue was dissolved in ethyl
acetate and portions injected into the gas chromatography
Vanillyl mandelic acid (VMA), a minor metabolite of NA in the
rat brain (21) gave a derivative showing a sharp peak, with the peak
area increasing linearly up to 200 ng VMA on the SE30 and SE52 liquid
phase columns. Like HVA and DOPAC, the limit of detection was about
1 ng VMA. The relative retention time (with PFPB as internal standard)
was 0.425» so it would appear on a chromatogram between the peaks of
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the HVA and the DOPAC derivative. No such peak was detected in "brain
samples, indicating that the concentration of VMA in brain tissues is
below the limit of sensitivity of this method and in consequence is
very low. This is in agreement with the findings of other workers
(226,21).
The estimation of 5-HIAA was attempted by the same procedure, but
no peak could be obtained, either in brain tissues rich in this meta-
bolite or in pure standards added in reaction vials, probably because
the b.p. of the TFA-HFIP derivative of 5-HIAA is much higher than 115°C.
The compound p-hydroxyphenylacetic acid, a potential metabolite
of p-hydroxyphenylethylamine (tyramine) was another acidic agent
forming fluorinated derivatives with low b.p. Standards of this
phenolic acid gave linearly increasing peak sixes when reached in the
same way as the HVA and DOPAC. The standard curve was linear up to
200 ng with a retention time of 0.198, relative to PFPB. Standards
added to brain extracts were recovered at the end of the procedure, but
brain extracts failed to give consistently any peak with this retention
time, indicating that this compound does not exist in the rat brain in
amounts measurable by this method.
The derivatisation of the phenolic compounds m-hydroxyphenyl-
acetic acid, 3,4-dihydroxymandelic acid and dihydroxyphenylethyl
alcohol was attempted, but no peak could be consistently obtained at
column temperature 115°C, after they were reacted for 1 hour at 100°C
with 0.2 ml TFA and 0.1 ml HFIP.
A.2.3 RESULTS AND DISCUSSION
Recoveries. The modified method showed remarkably higher recoveries
from brain tissues than did the Pearson-Sharman method. For HVA it
was 97 + 1% (n = 9) compared to 58 + 10$ (n = 9) and for DOPAC it
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was 93 + 10$ (n = 7) compared to 60 + 8$ (n = 12) with the original
method. Since the recoveries were almost complete, quoted estimates
of HVA and DOPAC in tissues have not heen corrected for the small
loss (unless otherwise stated).
Retention times. The glc conditions employed in this method produced
satisfactory separation of the peaks corresponding to HVA and DOPAC,
both from each other and from other unidentified peaks (Fig. A2).
The relative retention times under operating conditions (2$ SE52,
column temp. 115°C, flow rate 50 ml/min) were 0.52 for HVA and 0.35
for DOPAC, the PFPB appearing at about 40 min. There was no detect¬
able variation in the relative retention times under the constant glc
conditions and, therefore, during the routine assays, the peaks
appearing at these retention times were assumed to be due to the
derivatives of HVA and DOPAC without any further test of specificity.
The available means of testing the specificity of the method were
randomly applied, as will be described below. When interfering
unidentified peaks made the recognition of the HVA and DOPAC peaks
difficult, the sample was run under different glc conditions and it
was discarded if that was not successful. There was no peak inter¬
fering with the internal standard in any of the experiments.
Precautions during the assay procedure.
1. There are reports of post-mortem rises of DA metabolites, especially
DOPAC (392); therefore, dissection of the tissues should be rapid and
the tissues frozen in liquid nitrogen as quickly as possible. For the
analyses the thawed tissue should be homogenised without delay, with
care being taken to keep the temperature as low as possible. The homo-
genates and the subsequent brain extracts should be kept on ice through¬
out the procedure.
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2. For a quantitative extraction of the acidic metabolites into ethyl
acetate with no loss into the prior toluene extracts, the pH of the
supernatant should be betvreen 1 and 2. With amounts of tissue greater
than 100 mg, the pH of the supernatant may be insufficiently low.
3. The extraction with ethyl acetate should not be proceeded unless a
clear aqueous solution is obtained, with no layer of lipids on the
surface. If a second toluene extraction is not effective in removing
such a lipid layer, then freezing in liquid nitrogen and subsequent
centrifugation after partial thawing may be effective. Finally, careful
aspiration of the lipid layer will provide a clear aqueous solution.
4. Cold ethyl acetate must be used for the extractions. As much of the
organic layer as possible is transferred into the reaction vial, but
usually it was found not advisable to try to take off more than 0.4 ml,
since any trace of water in the reaction vial would prevent the
trifluoroacetylation by inactivating the TFA.
5. The screw-cap vials must be tightly closed for the reaction. A
fresh teflon liner should be used each time to ensure a complete seal.
The reaction should take place in a fume-cupboard because the reagents
are corrosive and poiaonous. After the incubation the vials must be
left for about 10 min to cool down to room temperature before the
evaporation under nitrogen is started. A gentle jet of nitrogen should
be used, to avoid evaporation of the TFA-HFIP derivatives of HVA and
DOPAC (which occurs at relatively low temperatures). Complete eva¬
poration gives no consistent recoveries.
6. The derivatives, dissolved in ethyl acetate containing the internal
standard, must be injected into the glc apparatus not later than 48
hours after they have been prepared. The closed vials containing these
solutions for injection must be kept in a refrigerator until use.
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Assessment of specificity of the glc procedure. Various ways of
assessing the specificity of the glc method were used. The observation
that a few unidentified peaks appeared regularly on the chromatogram
with relative retention times in close proximity to those of HVA and
DOPAC derivatives raised the question of possible interference of other
unknown peaks with the peaks of HVA and DOPAC derivatives. Overlapping
of peaks is very common in glc and this possibility was examined. Since
the standard and most effective way of identifying and analysing
unknown peaks, that is mass fragmentography (combined glc-mass spectro¬
metry), was not available, other techniques were used.
The first approach was through a simple decrease of the operating
column temperature of 115° to 110° or 105°C. This procedure, which
could separate overlapping peaks, did not change the appearance of the
HVA or DOPAC peaks. Single symmetrical peaks were obtained, indicating
that they represent a single HVA or DOPAC derivative, as assumed from
the fact that the relative retention times of both remained constant at
temperatures 105°, 110°C and 115°C. In practice, this procedure was the
most reliable way of answering questions of specificity in routine assays
of brain tissues. When a similar problem arose and persisted for
relatively long time and in more tissue samples, further steps were
taken in order to separate overlapping peaks (if any) and ensure the
specificity of the assay.
First, several columns of different length and different packing
material were used. A column with a polar liquid phase, such as QF1,
may separate two overlapping peaks representing derivatives of different
polarity. As shown in Table A1, the HVA and DOPAC derivatives, which
are highly polar compounds (Fig. A1), were retained strongly by the
polar liquid phase, and their absolute retention times were higher than
that of PFPB, as one would expect because of their difference in
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fluoro-groups and hence the difference in polarity. Again, examination
of brain samples with a 3ft column loaded with 3$ QP1 on Chromosorb Q
did not reveal any peak: consistently accompanying and interfering with
the peaks of HVA or DOPAC derivatives® The relative retention times for
the HVA and DOPAC derivatives were 1.29 and 1.50, respectively. Other
columns with a silicone gum liquid phase, such as 0V1 and SE30 were used,
and in all cases there was no indication of non—specificity of the peaks
corresponding to HVA and DOPAC. The relative retention times of the
two derivaties, obtained using columns of different length or liquid
phase and also for different column temperatures are shown in Table
A1.
Second, the specificity of the peaks appearing on chromatograms
from brain samples was tested by a different approach, a pharmacological
treatment. A group of 3 rats was injected with a large dose of the MAO
inhibitor phenelzine sulphate (75 mg/^i'P*) and killed 2 hours later.
The HVA and DOPAC were determined in the corpus striatum of these rats
in parallel with tissue from 3 rats treated with saline. Since MAO
activity is a necessary step in the metabolism of DA leading to
formation of HVA and DOPAC, its inhibition should lead to a marked
reduction or even dissappearance of the two metabolites from the brain.
Indeed, in the glc tracing there was no apparent peak, either in the
position of the HVA or of the DOPAC derivative and hence no detectable
levels of these metabolites were present in the striata of the
phenelzine-treated animals. Extracts from the saline-treated controls
showed sharp peaks, with relative retention times of 0.52-—that oi the
HVA derivative - and of 0.35 - that of the DOPAC derivative. It should
be borne in mind that if an interfering peak represented an acidic
metabolite of some unidentified monoamine, this should have also dis-
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Table A.l
The retention times of the trifluoroacetyl-hexafluoro-isopropyl
(TFA-HFIP) derivatives of HVA and DOPAC




9 ft SE 52 2% 0.52 0.35 115
9 ft SE 30 3% 0.55 0.37 115
3 ft and 9 ft QF 1 3% 1.29 1.50 115
3 ft 0V 1 3% 0.525 0.37 115
3 ft SE 30 3% 0.53 0.35 110
3 ft OV 1 3% 0.53 0.37 110
The retention times (RT) of the HVA and DOPAC derivatives relative to that of
the internal standard (pentafluorophenyl benzoate, PFPB) were estimated using
columns with various packing materials and at different column temperatures
RT = retention time of HVA (or DOPAC) derivative
retention time of PFPB
The carrier gas was argon containing 5% methane with a flow rate of 60 ml/min
(pressure of 40 p.s.i.) The detector temperature was 230 C.
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appeared after MO inhibition. Various ways of causing increase in DA
metabolism were also used in subsequent studies, and selective effects
on HVA and DOPAC were demonstrated. The regional distribution of the
metabolites using the glc method was in agreement with other studies,
providing additional evidence for the specificity of the method.
Third, an additional stage of purification was added to the method.
That was an extraction of HVA and DOPAC from the ethyl acetate extracts
into borate buffer pH 8.6, adjustment of the pH of the buffer to about
1 with conc. HC1 and finally back extraction into ethyl acetate and
evaporation to dryness, as described above. This tedious procedure
did not produce any change in the chromatogram related to the size or
shape of the peaks corresponding to HVA and DOPAC.
All the ways presented above of testing the specificity of the
definitive version of the assay procedure led to the conclusion that
there was no substance consistently present in brain tissue interfering
with the HVA or DOPAC assay and, therefore, the peaks with relative
retention times 0.52 and 0.35 were due only to the HVA and the DOPAC
derivative, respectively. In conclusion, the evidence that the
definitive version of the method was specific, sensitive, uncomplicated
but reliable and allowed for the assay of as many as 36 samples in one
day (up to the stage of injection in the glc), was a satisfactory
indication that one could use this technique to study DA metabolism is
discrete, small areas of the rat brain with accuracy and reproducibility.
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